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Abstract 
 
Reversible protein phosphorylation plays a key role in cell signalling during neural 
development and thus controls cell proliferation, survival, differentiation and function. 
Kinases and their counter-partners the phosphatases tightly regulate protein 
phosphorylation. In the developing nervous system the neurotrophin receptor family of 
protein tyrosine kinases (TrkA, B and C) are major players in this signalling network 
during normal neuron development and also in several diseases such as neuropathies, 
degenerative disorders and cancers. Recently, receptor-type protein tyrosine 
phosphatases (RPTPs) were suggested to be possible regulators of Trks. Thus 
understanding the relationships between RPTPs and Trks may help to develop new 
therapeutics to control aberrant neurotrophin signalling in disease. In this study I 
investigated the relationship between RPTPs and Trks in murine embryonic sensory 
neurons from dorsal root ganglia (DRGs), a primary cell model. The expression and 
coexpression of RPTPs and Trks was extensively studied during critical stages of DRG 
maturation using qPCR arrays at Merck-Serono, Geneva, and fluorescent in-situ 
hybridization and immunohistochemical techniques. This revealed a relatively high 
expression of several candidate RPTPs, which were expressed in particular TrkA+, 
TrkB+ and/or TrkC+ subpopulations of sensory neurons, indicating a potential 
relationship in their signalling functions. To further analyze a potential direct interaction 
between candidate RPTPs with Trk proteins, a bimolecular-fluorescent 
complementation assay (BiFc) was tested. However, this particular assay, when used 
with type I transmembrane proteins, suffered from high, unspecific protein interactions. 
In the main experimental approach, a lentiviral-mediated shRNAi-induced knockdown 
system in primary cell cultures was set-up and the effects of the knockdowns of Ptprf, 
Ptprs and Ptpro on endogenous Trk gene expression and Trk phosphorylation and 
activation were analysed. These results suggest a potential role of the encoded proteins 
LAR and RPTPσ in Trk function and of RPTP-BK in the differentiation and 
specification of Trk+ neurons.  
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1.1. Introduction 
The nervous system is the most complex system in the animal kingdom. It consists of 
the central and peripheral nervous systems (CNS and PNS), which are built up by many 
different types of neurons and glia cells. The developmental processes that create this 
elaborate structure are even more complex. Like in any other tissue each individual cell 
decides throughout its lifespan upon the fundamental processes survival or death, 
proliferation, differentiation, function and aging, and reacts to environmental signals 
and interacts with other cells. All of these processes are governed on the molecular level 
by a complex and highly coordinated network of signalling cascades that finally result 
in the down- or upregulation of specific genes and cellular changes. These signalling 
cascades are interactions of biochemical molecules such as lipids, carbohydrates and 
above all proteins. The interactions between these molecules are especially governed by 
their post-translational modification such as glycosylation, methylation, ubiquitination, 
acetylation and reversible phosphorylation. These transient protein modifications create 
new recognition motifs for interactions with other molecules, direct their cellular 
localisation, affect the stability and thus lifespan of the proteins and regulate enzyme 
activity, by altering their conformation and electrical charge.  
 But what controls these transient protein modifications such as reversible protein 
phosphorylation? In the 1950’s Krebs and Fischer described for the first time that two 
specific enzymes, the kinases and phosphatases, regulate the phosphorylation state of a 
crucial enzyme in the initial step of glycogenolysis in muscle and thus control its 
function (Krebs et al., 1959, Graves et al., 1960). Nowadays it is known that kinases, 
which phosphorylate proteins, and their counter partners the phosphatases, which 
dephosphorylate them, tightly control and balance the phosphorylation state of proteins 
in virtually any type of tissue and system. It is also clear that a misbalance in the 
phosphorylation state consequently leads to cell malfunction or even death and results 
in the onset of many severe diseases. Whereas much is already known about protein 
kinases, phosphatases remain more mysterious as their study has been technically much 
more challenging. 
 In my thesis I was investigating the reversible protein phosphorylation in the 
developing PNS of the mouse. In this respect I have analysed the expression and 
function of receptor protein tyrosine phosphatases (RPTPs) and neurotrophin tyrosine 
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kinase receptors (Trks) in the cell model of sensory neurons from murine embryonic 
dorsal root ganglia (DRGs). The main focus of this thesis was to decipher a potential 
regulation of Trks by RPTPs.  
 
1.2. Protein tyrosine kinase (PTK) family 
Protein kinases are a family of enzymes, which transfer a phosphate group from  
high-energy donor molecules such as ATP mostly to the amino acid residues threonine 
(Thr), serine (Ser) or tyrosine (Tyr). This biochemical process is called reversible 
protein phosphorylation.  
 Whereas threonine and serine phosphorylation of proteins was known for over 
40 years, tyrosine phosphorylation was discovered later in the 1980s. Tony Hunter 
demonstrated that v-Src, a retroviral proto-oncogene, phosphorylates tyrosine residues 
and not threonines as previously falsely assumed (Hunter and Sefton, 1980). This  
break-through discovery was followed by the demonstration that epidermal growth 
factor receptor (EGFR) is as well a tyrosine kinase (Ushiro and Cohen, 1980) and many 
more followed. Protein tyrosine phosphorylation is a relatively rare post-translational 
modification (1% of total phosphoamino acids) in comparison to serine or threonine 
phosphorylation. Nevertheless, it is of immense importance in the context of signal 
transduction especially via growth factor receptors. 
 Among the 522 known protein kinases in the human and mouse genome, 90 are 
protein tyrosine kinases (PTKs) of which 58 are transmembrane receptor kinases 
(RPTKs) and 32 are non-receptor or cytoplasmic (NRPTKs) protein tyrosine kinases. 
RPTKs have been categorized into 20 subfamilies based on their extracellular structure. 
Some of the most famous subfamilies and essential kinases are the previously 
mentioned EGFRs, insulin receptors, platelet-derived growth factor (PDGF) receptors, 
vascular endothelial cell growth factor (VEGF) receptor, fibroblast growth factor (FGF) 
receptors, hepatocyte growth factor (HGF) receptors, ephrin (EPH) receptors, the Ret 
receptor and the family of nerve growth factor (NGF) receptors (Robinson et al., 2000, 
Blume-Jensen and Hunter, 2001). The latter are of major importance in the nervous 
system and were the focus of this thesis. 
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1.2.1. Neurotrophin protein tyrosine kinases (Trks) 
The family of nerve growth factor (NGF) receptors consists of three neurotrophin 
protein tyrosine kinases (Trks), TrkA, B and C. These single-pass type I membrane 
proteins are high-affinity receptors for their ligands the neurotrophins. Upon ligand 
binding Trk receptors become activated and trigger a plethora of downstream signal 
transduction mechanisms (described in section 1.2.3). The first Trk receptor identified 
was TrkA. In the late 1980’s trk (later referred to as TrkA) was discovered as a  
proto-oncogene in a colon carcinoma biopsy of a patient. Generated by a somatic 
rearrangement it consisted of the first seven out of eight exons of non-muscle 
tropomyosin fused to the transmembrane and cytoplasmic domains of a tyrosine kinase, 
which is reflected in its name tropomyosin (t)-receptor(r)-kinase (k), trk (Martin-Zanca 
et al., 1986). Several years later the putative form of TrkA was identified and 
characterised as a cell surface receptor with a kinase activity specific for tyrosine 
residues (Martin-Zanca et al., 1989). Subsequently TrkB (Klein et al., 1989, Middlemas 
et al., 1991) and TrkC (Lamballe et al., 1991) were discovered due to their 66-68% 
sequence homology with TrkA. However, their role as neurotrophin receptors was not 
recognized until Kaplan et al. (Kaplan et al., 1991a, Kaplan et al., 1991b) and Klein et 
al. (Klein et al., 1991a) have convincingly demonstrated in several binding studies 
using different cell types, that TrkA is a specific high-affinity receptor for NGF. 
Following these discoveries, TrkB and TrkC were also recognized as high-affinity 
neurotrophin receptors (Klein et al., 1991b, Lamballe et al., 1991). 
 Trks like all other members of the RTK family show a rather uniform pattern of 
structural motifs (Figure 1.1). They contain a signal peptide, which is required for 
trafficking to the cell surface, an extracellular domain (ECD), a transmembrane domain 
(TMD) consisting of 25-38 amino acids and an intracellular domain (ICD) and 
regulatory sequences, which are located near the COOH end. The ECD is involved in 
ligand recognition, whereas the ICD contains the catalytic kinase domain (Huang and 
Reichardt, 2003). The ECD of all three Trks show high homology, but their ICD have 
the greatest sequence similarity. The ECD consists of leucine-rich repeats (LRR) 
flanked by one cysteine cluster on each side. Its juxtamembrane region contains two 
immunoglobulin-like (Ig-like) domains, which represent the actual binding sites for the 
neurotrophin ligands (Urfer et al., 1995). Additionally to the mature highly glycosylated 
Trk receptors unglycosylated forms exist. However, only the fully glycosylated mature 
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form is targeted to the plasma membrane and interacts with the neurotrophins (Watson 
et al., 1999). Importantly, each Trk receptor has several different isoforms due to 
alternative splicing and alternative promoters and also protein cleavage. Most of these 
isoforms show different expression patterns, signalling properties and substrate 
specificity, as I will describe later in more detail.  
 In addition to the high-affinity Trk receptors, a low-affinity pan-neurotrophin 
receptor, the p75NTR receptor, exists. In fact it was the first neurotrophin receptor 
discovered, but unlike Trks it binds all NTs with much lower affinity (Johnson et al., 
1986). This 80kDa glycoprotein is a member of the tumour necrosis factor (TNF) 
receptor superfamily. It contains four highly glycosylated and cysteine-rich motifs in its 
ECD, a single transmembrane domain and a short cytoplasmic domain, which instead of 
a catalytic domain like in Trk receptors contains a “death” domain (Liepinsh et al., 
1997) (Figure 1.1).   
1.2.2. Neurotrophins (NTs) 
Neurotrophins (NTs) are a family of polypeptide growth factors, which exert their 
function upon binding and activation of Trk receptors. NTs were discovered and their 
function was analyzed decades before their receptors were identified. In the early 1950s 
Rita Levi-Montalcini and Viktor Hamburger showed for the first time that growth, 
development and survival of peripheral neurons is controlled by specific target-derived 
survival factors. They demonstrated, that neurons are produced in a surplus and that 
limiting quantities of NTs in the target-tissues of these neurons control their survival 
and thus establish a specific innervation density of the target tissue, known as the 
“neurotrophic hypothesis” (Hamburger and Levi-Montalcini, 1949, Davies, 1996). 
Further, Rita Levi-Montalcini together with Stanley Cohen identified a diffusible nerve 
growth factor (NGF) from sarcoma tissue and showed that it promotes the survival and 
neurite outgrowth of sympathetic and neural crest-derived sensory neurons. They 
produced an antibody against NGF and demonstrated that it inhibits the survival of 
these neurons during the time of target innervation (Levi-Montalcini, 1952, Levi-
Montalcini et al., 1954, Cohen and Levi-Montalcini, 1956, Levi-Montalcini and Cohen, 
1956, Cohen and Levi-Montalcini, 1957, Marx, 1986). Decades later in the 1980s a 
further NT, the brain-derived neurotrophic factor (BDNF), was isolated from porcine 
brain (Barde et al., 1982, Leibrock et al., 1989) and homology cloning using NGF and 
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Figure 1.1. Schematic representation of Trks and NTs.  
Neurotrophins interact with highest affinity with specific Trk receptors, whereby NGF binds to 
TrkA, BDNF and NT-4 bind to TrkB and NT-3 binds to TrkC and with lower affinity to TrkA 
and TrkB. All neurotrophins bind with lower affinity (dashed lines) to p75NTR, which binds 
with highest affinity the proneurotrophins. Displayed are only the full-length isoforms of the 
neurotrophin receptors. Gene names are displayed in italic, protein names in bold letters.  
CR1-CR4, cysteine-rich motifs; C1/C2, cysteine-rich clusters; LRR1-3, leucine-rich repeats; 
Ig1/Ig2, immunoglobulin-like domains (adapted after (Reichardt, 2006)). 
  
 
BDNF sequences lead to the discovery of the remaining members of the NT family 
neurotrophin 3 (NT-3) (Hohn et al., 1990, Maisonpierre et al., 1990b) and neurotrophin 
4 (NT-4) also known as NT-4/5 or NT-5 (Hallbook et al., 1991) and the fish-specific 
neurotrophin-6 (NT-6) (Gotz et al., 1994) and neurotrophin-7 (NT-7) (Lai et al., 1998). 
 NTs are homodimers, which are generated from immature precursor proteins, 
the proneurotrophins, by proteolytic cleavage. However, not only mature NTs but also 
proneurotrophins are biologically active (Teng et al., 2010). All NTs share 
approximately 50-60% amino acid identity and have similar structures. However, they 
differ in their expression patterns and the affinities to specific Trk receptors and hence 
perform distinct biological activities. NGF binds exclusively to TrkA (Cordon-Cardo et 
al., 1991, Kaplan et al., 1991b, Klein et al., 1991a, Loeb et al., 1991, Bibel and Barde, 
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2000), BDNF and NT-4 bind to TrkB (Klein et al., 1991b) and NT-3 binds with highest 
affinity to TrkC (Lamballe et al., 1991) and with lower affinity also to TrkA and TrkB 
(Squinto et al., 1991, Tsoulfas et al., 1993). The pan-neurotrophin receptor p75NTR binds 
any of the neurotrophins but with a 1000-fold lower affinity than Trk receptors 
(Raffioni et al., 1993). Instead, p75NTR binds proneurotrophins, the precursor NTs, with 
highest affinity (Lee et al., 2001). 
1.2.3. Expression and function of Trks and NTs in the nervous system  
NTs were first described as neurotrophic factors, but nowadays it is also known that 
they have additional immunotrophic and metabotrophic effects and thus play a role in 
cardiac development, neovascularisation and the immune system (Lin et al., 2000, Vega 
et al., 2003, Nockher and Renz, 2006, Caporali and Emanueli, 2009). In this review I 
will focus, however, primarily on their expression and function in the nervous system. 
 Expression patterns of all Trk receptors and NTs are dynamic and show distinct 
but also overlapping patterns during development and in adult organisms. Some neurons 
also switch from the expression of one Trk receptor to the other. Whereas TrkA and 
TrkC and their ligands are primarily expressed in the PNS, TrkB and BDNF are mostly 
found in the CNS. In the PNS, TrkB and TrkC are expressed in almost all sensory 
ganglia, but TrkA expression is limited only to neural crest-derived ganglia (Lindsay, 
1996). NTs can be found in the nervous system in a variety of specific target organs of 
Trk+ neurons during development and in adult organisms. Within the organs they are 
primarily produced and secreted by neurons but also by glia cells and different types of 
cells of the connective tissue. The picture of Trk expression is further complicated by 
the presence of different splice variants and isoforms, which all have specific expression 
patterns and functions. For instance apart from full-length catalytically active isoforms, 
truncated isoforms of TrkB and TrkC receptors lacking the catalytic kinase domain also 
exist. Different functions were attributed to the catalytically inactive splice variants 
such as inhibition of dimerization and hence inactivation of full-length Trks and even 
active but different roles in signalling than their full-length counterparts such as an 
implication in synaptogenesis (Barbacid, 1995a, Barbacid, 1995b, Eide et al., 1996, 
Baxter et al., 1997, Haapasalo et al., 2001, Takahashi et al., 2011). Interestingly, the 
expression of the non-catalytic relative to kinase-active Trk isoforms is increased during 
the peak period of synaptogenesis in the second and third postnatal weeks (Valenzuela 
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et al., 1993). Importantly some transcript variants appear to be also species-specific. In 
this review I will mostly concentrate on transcript variants found in rodents. 
 The importance of Trk receptors or NTs became evident, when it was realized 
that mice lacking either of these proteins die postnatally, whereas mice with reduced 
levels are viable but show impaired brain function, behaviour and sensory deficits 
(Lindsay, 1996, Chao, 2003). In general in the developing PNS Trks are especially 
important for neuronal survival upon ligand binding. Limiting quantities of NTs 
secreted from peripheral non-neuronal target tissues of neurons control the numbers of 
these neurons to achieve a specific innervation density of their target tissues. This is 
known as the classical “neurotrophic hypothesis” as mentioned earlier (Hamburger and 
Levi-Montalcini, 1949, Davies, 1996). However, it was realized early on that this 
hypothesis might be specific for the developing PNS but not the CNS, as unlike neurons 
of the PNS, most neurons from the CNS do not depend solely on one NT. This was 
supported by reports that mice lacking a specific NT do not display any loss of a 
particular cell population in the CNS (Tessarollo, 1998). In a more elaborate study it 
was also shown that TrkB and TrkC promote together but not alone the survival of 
hippocampal and cerebellar granule neurons (Minichiello and Klein, 1996). Another 
interesting insight into Trk signalling has disproven former assumptions that in the 
absence of NTs Trks are inactive and promote apoptosis by not activating survival 
pathways. As of late many studies have provided evidence that Trk receptors are  
so-called “dependence receptors” and can actively induce apoptosis by “negative signal 
transduction” in the absence of their ligands (Harel et al., 2010). For instance 
Nikoletopoulou et al. used engineered mouse embryonic stem cells and embryos to 
demonstrate that TrkA and TrkC but not TrkB can induce apoptosis in the absence of 
their ligands. In addition they suggested that cell death was not mediated by the activity 
of the kinase itself but partially through initiation of p75NTR cleavage (Nikoletopoulou 
et al., 2010). They also provided further evidence for the differences in NT dependence 
in PNS and CNS neurons. Based on their recent findings and the knowledge that TrkB 
is the evolutionary ancestor of TrkA and TrkC, these scientists hypothesized that the 
expansion of the Trk gene family accompanied by the separation of CNS and PNS 
during evolution generated new mechanisms to control neuronal numbers. This is 
supported by the predominant expression of TrkB in the CNS, but TrkA and TrkC in the 
PNS. This study is also well in agreement with the previously mentioned hypothesis, 
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that NTs have different effects on neuronal survival in PNS and CNS as described 
above.  
 In addition to cell survival Trk receptors and NTs are responsible for precursor 
proliferation, commitment, and axon and dendrite growth and guidance of neurons in 
the developing PNS and CNS. Moreover they play an important role in synapse 
formation, function and plasticity (Thoenen, 1995, Chao, 2003, Huang and Reichardt, 
2003, Lu et al., 2005, Takahashi et al., 2011). Finally in the adult organism Trks 
regulate the expression of ion channels and neurotransmitters and thus direct the 
differentiation, maturation and function of neurons (Bibel and Barde, 2000). 
1.2.3.1. TrkA and NGF 
The TrkA gene Ntrk1 is transcribed into a single 3.2 kb transcript, which encodes two 
different isoforms. Both isoforms are catalytically active but one of them (TrkA-II) 
contains an 18 bp insert (exon 9) in the extracellular domain, which enhances its 
responsiveness to NT-3 (Clary and Reichardt, 1994). The two isoforms are expressed in 
a tissue-specific manner. Neuronal cells express predominantly the isoform TrkA-II, 
whereas non-neuronal tissues such as kidney express both isoforms (Barker et al., 
1993). Further, TrkA shedding produces a soluble ECD and an active membrane-bound 
ICD (Diaz-Rodriguez et al., 1999). In the PNS, TrkA receptors are preferentially 
expressed in sympathoadrenal neurons, such as sympathetic neurons, chromaffin cells 
etc. and peptidergic nociceptive, thermoceptive and puriceptive sensory neurons in 
DRGs and the TG (Martin-Zanca et al., 1990). The TrkA ligand NGF is produced by 
non-neuronal tissues such as skin, vascular and smooth muscle cells, and various 
endocrine tissues, such as the testis and ovary, pituitary, thyroid and parathyroid glands 
(Davies, 1987, Sofroniew et al., 2001). In addition PNS glia such as immature Schwann 
cells and SGCs produce NGF (Mirsky and Jessen, 1999). In the CNS TrkA receptors 
and NGF can be found in cholinergic neurons of many structures of the basal forebrain 
such as the cerebral cortex, cerebellum, hippocampus and hypothalamus and 
additionally in the corpus striatum, which are degenerated in Alzheimer’s and 
Huntington’s Diseases respectively. Interestingly, TrkA expression is absent in the 
spinal cord (Martin-Zanca et al., 1990, Fagan et al., 1997), whereas NGF was detected 
in the spinal cord, pons and medulla (Shelton and Reichardt, 1984). Transgenic mice 
with reduced levels of NGF suffer from a loss of nociceptors in DRGs by increased 
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apoptosis at around E13.5 in mouse embryos and NGF- or TrkA-null mutants lose more 
than 70-90% of their sensory neurons embryonically. Additionally these mice suffer 
from decreased cholinergic innervation of the hippocampus, deficiency in memory 
acquisition and retention at postnatal stages (Lindsay, 1996).  
1.2.3.2. TrkB, BDNF and NT-4 
The expression of Ntrk2 gene, which encodes TrkB, is more complex. Seven TrkB 
mRNA transcripts of different sizes ranging from 0.7-9 kb were detected in rodent brain 
as early as E 9.5 (Klein et al., 1989, Klein et al., 1990b). However, only four transcripts 
are translated into a full-length isoform and the three truncated isoforms T1, the rodent 
specific T2, and T4, also called T-Shc, which all lack the catalytic domain. The 
transcripts T1 and T2 differ from each other solely in their C-terminus that, however, 
lacks homology to any known protein motif (Klein et al., 1990a, Middlemas et al., 
1991, Baxter et al., 1997, Haapasalo et al., 2001). The T-Shc isoform contains an Shc-
binding site in the juxtamembrane domain similar to the full-length form but lacks the 
catalytic domain (Forooghian et al., 2001, Stoilov et al., 2002). The full-length and 
truncated isoforms differ not only in their function but also in their expression patterns. 
During development the full-length isoform is the most abundant form. Transcripts 
were found as early as E9.5 in the neuroepithelium and in the neural crest and later on 
in their derivatives the neurons of the CNS and PNS (Klein et al., 1990a). In the CNS it 
was detected for example in the cerebral cortex, thalamus, hippocampus, in the Purkinje 
cells, granular layer caudal peduncle of the cerebellum, brain stem and the mantle zone 
and ventral horn of the spinal cord, where motor neurons reside (Armanini et al., 1995). 
In the PNS its expression was observed during development in cranial ganglia, the 
ophthalmic nerve, the vestibular system, in facial structures, the sub maxillary glands, 
and in large proprioceptive neurons in DRGs (Klein et al., 1989). Interestingly, in the 
mature nervous system the amount of the truncated TrkB isoforms is tenfold higher than 
of the full-length forms (Lindsay, 1996). The non-catalytic transcripts were found in the 
developing and adult NS mostly in non-neuronal cells, but also colocalized with  
full-length TrkB in neurons including motor neurons and hippocampal cells (Tessarollo, 
1998). In the PNS they were detected in SGCs in DRGs and TG and in the CNS in the 
cerebellar granule cell layer, where astrocytes reside, in the ventricular zone (VZ) and 
the medial mantle zone of midbrain and the spinal cord and the roof plate of the spinal  
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cord, where neural crest cells (NCCs) are generated at earlier stages (Valenzuela et al., 
1993, Armanini et al., 1995, Ninkina et al., 1996, Kumanogoh et al., 2008).  
 The TrkB and its ligands BDNF and NT-4/5 are known to participate in axon 
growth and targeting and synaptic plasticity (Bibel and Barde, 2000). BDNF and  
NT-4/5 mRNA and protein are expressed in many different neural structures of the CNS 
and PNS, which also contain TrkB transcripts, and their expression levels peak upon 
maturity (Leibrock et al., 1989, Hofer et al., 1990, Maisonpierre et al., 1990a, Katoh-
Semba et al., 1997). BDNF expression is highest in the CNS, where it can be found next 
to NT-4/5 for example in the spinal cord, and in septal cholinergic and dopaminergic 
neurons in the brain that are known to degenerate in Alzheimer’s Disease and 
Parkinson’s Disease (Alderson et al., 1990, Hyman et al., 1991). Further it was 
identified in granule cells and retinal glia cells (RGCs) (Hyman et al., 1994, Gao et al., 
1995, Studer et al., 1995). Although the expression and function of BDNF and NT-4/5 
are mostly overlapping, they differ in their concentrations and some structures do not 
express both neurotrophins. For instance BDNF but not NT-4 was detected in the 
thalamus and hypothalamus and in certain areas of the pons, and NT-4 but not BDNF is 
present in the putamen (Zhang et al., 2007a). In the PNS, BDNF is expressed in neurons 
and glia cells in cranial and dorsal root ganglia and also in non-neuronal tissues such as 
the trunk epidermis, spleen and heart (Wetmore and Olson, 1995, Yamamoto et al., 
1996). NT-4/5 is additionally expressed in all of these tissues apart from the heart 
(Hiltunen et al., 1996).  
 The phenotype of TrkB knockout mice is similar to BDNF deficient animals. 
Both transgenic mice are three times smaller than their wild type littermates due to 
disturbed feeding behaviour, they show impaired movement, coordination and balance 
due to cell loss in vestibular ganglia, breathing difficulties and impaired development of 
rod photoreceptors and die shortly after birth (Klein et al., 1993, Jones et al., 1994). 
TrkB conditional knockout mice with ablated TrkB expression in the brain lose specific 
populations of CNS neurons such as in the cerebellum and show inhibited synapse 
formation and plasticity (Lei and Parada, 2007). Mice with BDNF deficiency in the 
CNS show enhanced aggressiveness, hyperactivity and hyperphagia and have impaired 
memory, which can be reversed by local administration of BDNF (Erickson et al., 1996, 
Lyons et al., 1999, Rios et al., 2001). Reduced levels of BDNF in the PNS lead to a loss 
of mechanosensitivity (Ernfors et al., 1994a). Interestingly, although NT-4 and BDNF 
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show similar effects in vitro, knockout mice do not have the same phenotypes. In 
contrast to BDNF- and TrkB-deficient mice NT-4-/- animals do not die postnatally and 
show only mild sensory deficits (Liu et al., 1995, Conover et al., 1995, Erickson et al., 
1996, Roosen et al., 2001). A knock-in study of NT-4 into the BDNF gene has 
demonstrated that differences in NT-4 and BDNF action might be probably due to the 
differences in their expression patterns, but also functions. For instance NT-4 has a 
higher potency in promoting survival of sensory neurons and formation of hippocampal 
synapses due to the different activation of TrkB downstream pathways (Fan et al., 
2000). Accordingly, mice carrying a point mutation in the Shc binding site of the TrkB 
receptor lose most of their NT-4 dependent neurons, whereas BDNF-dependent neurons 
remain mostly unaffected (Minichiello et al., 1998). BDNF-/- but not NT-4-/- mice 
showed also altered nociceptive reflexes and reflex plasticity in the spinal cord 
(Heppenstall and Lewin, 2001).  
1.2.3.3. TrkC and NT-3 
TrkC mRNA can be already detected together with its ligand NT-3 in the 
neuroepithelium of E7.5 mouse embryos (Maisonpierre et al., 1990a, Lamballe et al., 
1991, Tessarollo et al., 1993). The expression of the TrkC encoding gene Ntrk3 is 
highly complex. Due to alternative splicing six different isoforms exist in the nervous 
system and in non-neural tissues, of which four are full-length forms and two are 
truncated isoforms lacking a tyrosine kinase domain. In addition to the “normal” full-
length isoform, the three isoforms Ki14, Ki25 and Ki39 contain an insert of 14, 25 or 39 
amino acids respectively in their catalytic domain. The two truncated isoforms T1 and 
T2 differ solely in the length of their cytoplasmic part. Interestingly, all of these 
isoforms are mostly expressed in the same neuronal tissues. However, similar to 
truncated TrkB isoforms, the truncated TrkC isoforms were mostly found in  
non-neuronal tissues and their expression increased during development. All isoforms 
have different biochemical and biological properties such as substrate specificity and 
thus activate different TrkC downstream signalling pathways (Merlio et al., 1992, 
Tsoulfas et al., 1993, Valenzuela et al., 1993, Lamballe et al., 1994, McMahon et al., 
1994, Guiton et al., 1995, Menn et al., 1998, Palko et al., 1999, Funfschilling et al., 
2004). In the embryonic and adult CNS, TrkC and NT-3 are abundant with most 
expression in the hippocampus, in several thalamic nuclei, and in the cerebral cortex 
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and the granular cell layer of the cerebellum and in the spinal cord (Jones and 
Reichardt, 1990, Maisonpierre et al., 1990a, Rosenthal et al., 1990, Tessarollo et al., 
1993). Truncated forms were additionally found in glia cells such as oligodendrocytes 
and astrocytes (Lamballe et al., 1993, Valenzuela et al., 1993, Cohen et al., 1996). In the 
PNS during development TrkC and NT-3 are expressed in neurons derived from neural 
crest and ectodermal placodes such as DRGs, nodose and early TG and support the 
survival and proliferation (Hallbook et al., 1995, Huang et al., 1999) and the formation 
of peripheral and central connections of these neurons (Phillips et al., 1990, Ernfors and 
Persson, 1991). Both TrkC and NT-3 are additionally found in SGCs at early stages, but 
this expression disappears later on (Funfschilling et al., 2004). Further expression was 
detected throughout the enteric nervous system, and mostly truncated isoforms were 
additionally found in the sciatic nerve and in non-neuronal tissues such as spleen, heart, 
connective tissue, muscles, and major blood vessels (Lamballe et al., 1993, Tessarollo et 
al., 1993, Funfschilling et al., 2004). The different functions of truncated and full-length 
isoforms of TrkC receptors were demonstrated by their overexpression in DRGs in 
vitro. Their different effects on axon-outgrowth were revealed, when it was shown that 
the full-length form of TrkC initiates primary process formation, whereas truncated 
TrkC reduced the amount of primary processes but instead enhances branching. 
Recently, the truncated TrkC isoform was also implicated in synaptogenesis (Takahashi 
et al., 2011). 
 Many different mouse models were developed to elucidate the function of TrkC 
and NT-3. For instance NT-3 haploinsufficiency in mice causes movement disorders as 
well as deficient amygdala activity, which is involved in epilepsy, and also 
cardiovascular defects (Ernfors et al., 1994b). This phenotype was obviously more 
severe in NT-3-/- mice, which displayed severe movement defects of the limbs due to 
loss of the majority of peripheral sensory and sympathetic neurons but not motor 
neurons, and most homozygotes died shortly after birth in contrast to heterozygotes 
(Farinas et al., 1996, Wilkinson et al., 1996, Tessarollo et al., 1997). Interestingly, mice 
overexpressing a truncated TrkC receptor showed a similar phenotype to NT-3 deficient 
animals, as they died perinatally, because of severe cardiac defects and PNS 
abnormalities, suggesting a sequestering role of this TrkC isoform (Palko et al., 1999). 
On the other hand the phenotype of TrkC-/- mice lacking the full-length isoform was not 
as severe as the NT-3-/- phenotype. Both show impaired movement, but TrkC-/- mice 
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have no obvious cardiac defects and survive up to 3 weeks (Ernfors et al., 1994b, 
Farinas et al., 1994, Klein et al., 1994). 
 Unlike animals with mutations in other NTs and their corresponding Trk 
receptors, loss of neurons in NT-3-/- mutants exceeds the numbers lost in mutants 
lacking all TrkC receptors (Tessarollo et al., 1997). This indicates that NT-3 is not only 
required for the survival of proprioceptors but that it can also signal through TrkA and 
TrkB receptors. This result was further supported by the fact that TrkA and TrkB 
neurons were also lost in NT-3 null mutants (Liebl et al., 1997) and that NT-3 promoted 
survival of TrkC-/- sensory neurons in vitro (Davies et al., 1995). The importance of 
 NT-3 and TrkC in many other neuronal functions, which are impaired in pathological 
human conditions such as mood disorders, was demonstrated in an interesting mouse 
model that overexpressed full-length TrkC. These mice exhibited a phenotype of an 
anxiety and panic disorder due to increased numbers of catecholaminergic neurons and 
increased hippocampal potentiation, thus providing a good model to study this disease 
(Dierssen et al., 2006). 
1.2.3.4. p75NTR 
The low-affinity neurotrophin receptor p75NTR triggers a diverse repertoire of biological 
functions through protein-protein interactions, because of its ability to act as a 
coreceptor for a diversity of ligands (Teng et al., 2010). For instance it can induce 
apoptosis during development and injury, inhibit axonal growth, modulate synaptic 
plasticity and promote myelination of axons from sensory neurons. It was already 
earlier suggested that in DRG neurons p75NTR is closely related to Trk receptors. 
Interestingly, whereas most TrkA+ or TrkB+ neurons coexpressed p75NTR, half of TrkC+ 
neurons did not (Wright and Snider, 1995). Moreover it is well established that p75NTR 
can regulate Trk function through direct interaction or crosstalk with Trk signalling 
pathways (Reichardt, 2006). For instance p75NTR increases specificity and affinity of 
Trk receptors for their ligands (Lee et al., 1994, Brennan et al., 1999). Further, p75NTR 
can delay destruction of TrkA and TrkB proteins (Makkerh et al., 2005). Its most 
important function in Trk signalling, however, is to facilitate endocytosis and retrograde 
transport of Trk-ligand complexes resulting in enhanced axon growth and cell survival 
and differentiation (Curtis et al., 1995). p75NTR acts especially as a proneurotrophin  
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receptor and promotes apoptosis (Lee et al., 2001). But for now it is still not completely 
understood how p75NTR functions and interactions are brought about. 
1.2.4. Trk and NT signalling pathways in the nervous system 
Binding of NTs to appropriate Trk receptors leads to a rapid activation of downstream 
signalling pathways. In neurons this has a local effect on growth cone motility, neurite 
outgrowth and synapse function. The NT-Trk complex is then internalized via 
endocytosis and ultimately degraded in lysosomes. Alternatively the complex is 
transported in membranous vesicles, the endosomes, in a retrograde manner from distal 
axons to the nucleus, which leads to the expression of genes that promote cell survival, 
proliferation and differentiation (Ginty and Segal, 2002, Zweifel et al., 2005). 
 On the molecular level binding of NTs to Trk receptors leads to their 
homodimerization and activation of their catalytic domains through autotrans-
phosphorylation of ten evolutionary conserved intracellular Tyr residues situated inside 
and outside the catalytic domain. Initially three of these tyrosines (Y670, Y674 and 
Y675 according to human TrkA nomenclature), which lie within the activation loop of 
the kinase domain, are phosphorylated. This event potentiates the tyrosine kinase 
activity leading to the phosphorylation of the remaining seven Tyr residues (Segal et al., 
1996). The phosphorylated tyrosines represent docking sites for a plethora of Src 
homology 2 (SH2) and phosphotyrosine binding (PTB) domain-containing proteins, 
which mediate the major signalling pathways phosphatidylinositol-3-kinase (PI3K)/Akt, 
the phospholipase C-γ (PLCγ)-Ca2+, and the Ras/MAPK pathways (Ullrich and 
Schlessinger, 1990, Kaplan and Miller, 2000). The three phospho-Tyr Y490, Y751 and 
Y785 initiate the mentioned signalling pathways via interactions with adaptor proteins 
and enzymes. Phosphorylated Y490 situated in the juxtamembrane domain interacts 
with adaptor proteins, which consequently activate the Ras/MAPK and PI3K/Akt 
pathways. Phosphorylated Y785 interacts directly with PLCγ-1 and Y751 with PI3K. 
Upon binding to the phosphotyrosines these proteins become also Trk kinase substrates 
and are activated. These mechanisms are, however, still poorly understood. Here I will 
summarize the role of Trk receptors in the major signalling pathways Ras-MAPK, PI3K 
and PLCγ-1 (Figure 1.2). 
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1.2.4.1. Ras-MAPK pathway  
The mitogen activated protein kinase (MAPK) pathways control proliferation and 
differentiation including neurite outgrowth, and prolonged survival of neurons. At least 
five MAPK signalling cascades exist in mammalian cells, which are grouped according 
to their MAPKs including the extracellular signal-related kinases Erk1/2 (also known as 
p44/42), Erk3/4, and Erk5, the c-Jun amino-terminal kinases (JNKs) and the p38 
MAPK. These pathways are sequential phosphorylation cascades of kinases, which are 
initiated by growth factors, mitogens, cytokines, G-Protein-Coupled-Receptors 
(GPCRs) and stress signals ultimately leading to the phosphorylation and activation of 
transcription factors (TFs), which control gene expression (Schlessinger, 2000). 
MAPKs can be activated either transiently or prolonged, which determines the 
biological response. For instance in PC12 cells prolonged activation mediates 
differentiation, whereas transient activation results in proliferation (Qiu and Green, 
1991, Traverse et al., 1992, Yaka et al., 1998). Activated Trk receptors stimulate MAPK 
pathways via at least three phosphorylated tyrosines. The major player in this pathway 
is Y490. For a transient response it recruits the Src homologous and collagen-like (Shc) 
adaptor protein. Upon binding Shc is phosphorylated by Trk and binds to the adaptor 
protein complex growth receptor-bound protein 2 (Grb2)-Son of sevenless (Sos). The 
nucleotide exchange factor Sos catalyses the exchange of GTP to GDP in Ras, which 
leads to the activation of this GTPase. Ras activates the MAPKKK c-Raf (Raf-1). In the 
classical MAPK pathway c-Raf then turns on the MAPKKs MEK1 or MEK2 by 
phosphorylation of a Ser in the activation loop. MEK1/2 phosphorylates the MAPK 
Erk1 or Erk2 on Tyr and Thr residues, which leads to their activation. Activated Erk1/2 
then turns on several TFs such as Elk-1 and Egr-1 leading for instance to axonal growth 
in neurons. Erk1/2 can additionally be directly translocated to the nucleus and thus 
activate the TF cyclic AMP-response element binding (CREB) (Segal and Greenberg, 
1996). CREB initiates for instance cell survival, neurite outgrowth and plasticity in 
neurons (Finkbeiner, 2000). The other MAPK pathways are activated in a similar 
manner and have overlapping but also distinct targets. For instance Erk5 but not Erk1/2 
is involved in retrograde signalling events during Trk trafficking towards the nucleus 
(Watson et al., 2001). The prolonged Erk activation is mediated through the fibroblast 
growth factor receptor substrate 2 (Frs2), which also binds to the phosphorylated Y490 
of Trk receptors. Frs2 is phosphorylated and binds to the adaptor protein and  
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Figure 1.2. Trk receptor signalling pathways.  
Schematic representation of the major intracellular Trk signalling pathways Ras/MAPK, 
PI3K/Akt and PLCγ pathways, which all result in the regulation of gene expression. Upon NT-
binding the Trk receptors dimerize. This initiates transphosphorylation of the tyrosine residues 
and activates the kinase. For simplicity only five of the ten identified tyrosine residues are 
shown. Binding of adaptor proteins and enzymes to the phosphotyrosines results in the 
activation of the signalling pathways. The Ras/MAPK pathway is initiated by Tyr 490 
phosphorylation and leads to neuronal survival, differentiation, proliferation and growth 
including neurite outgrowth. Only the classical Erk1/2 pathway is displayed for simplicity. The 
PI3K/Akt pathway is activated by phosphorylated Tyr 751 or through Ras and Gab-1/2 and 
promotes survival and growth of neurons. The PLCγ-1 pathway is initiated by Tyr 785 
phosphorylation and results in the regulation of Ca2+-dependent synaptic plasticity and is  
cross-linked to the MAPK pathway. 
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proto-oncogene c-Crk (p38), which initiates the interaction of the guanine nucleotide 
exchange factor (GEF) C3G, the small G protein Rap1, and B-Raf and thus initiates the 
Erk cascade (Kao et al., 2001). Additionally, Frs2 provides binding sites for the  
Grb2-Sos complex and thus activates the Ras/MAPK pathway. Another adaptor protein, 
Ankyrin Rich Membrane Spanning (ARMS) protein also interacts with Trk in some 
cells in a similar manner to Frs2 through Crk and B-Raf to activate the MAPK 
pathways (Arevalo et al., 2004) (Figure 1.2).  
1.2.4.2. PI3K/Akt pathway 
The class IA phospholipid kinase (PI3K) pathway is the major regulator of the survival 
of neurons. It can be activated via a Ras-dependent or -independent pathway, which are 
both initiated by the phosphorylation of Y490 in the activated Trk receptor. Ras, which 
is activated as described above for the MAPK pathway, subsequently turns on PI3K. 
This is the major survival pathway in most, but not all neurons. The Ras-independent 
PI3K activation is mediated through Y490-Shc-Grb2 interaction and activation of the 
Grb2-associated binder-1/2 (Gab-1/2), which binds and stimulates PI3K. PI3K also 
binds directly to phosphorylated Y751 in the catalytic kinase domain of Trk receptors 
and is phosphorylated and thus activated by Trk. PI3K then generates  
P3-phosphorylated phosphoinositides, which stimulate the phosphoinositide-dependent 
protein kinase (PDK-1) and subsequently the protein kinase Akt also known as protein 
kinase B (PKB). Akt phosphorylates and inhibits proteins such as Bad, a Bcl2-family 
member of proapoptotic proteins. Additionally Akt regulates the activity of several 
transcription factors such as forkhead, which results in the inhibition of apoptosis or 
activation of NF-κB-promoted neuronal survival. Finally, Akt phosphorylates and 
inactivates the proapoptotic glycogen synthase kinase 3 (GSK-3) thus enhancing cell 
survival (Pap and Cooper, 1998). The PI3K pathway additionally regulates axon growth 
and guidance and neuronal differentiation. For instance the 3-phosphoinositides recruit 
the Rho family of GTPases such as Cdc42 and Rac, which control cell motility, growth 
cone behaviour and the organization of the cytoskeleton and so regulate neurite 
outgrowth and growth cone guidance (Yuan et al., 2003) (Figure 1.2).  
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1.2.4.3. PLCγ  pathway  
The enzyme phospholipase C isoform PLCγ-1 binds directly to phosphorylated Y785 in 
the N-terminus of the Trk receptor and is activated through phosphorylation by Trk 
(Patapoutian and Reichardt, 2001). PLCγ-1 hydrolyzes phosphatidylinositides (PIP2) 
into diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG activates  
DAG-regulated protein kinase C (PKC) isoforms such as PKCδ in neurons, which 
activates the Erk1/2 MAPK pathway and controls for instance NGF-induced neurite 
outgrowth in PC12 cells (Corbit et al., 1999). IP3 promotes the release of Ca2+ ions, 
which activates Ca2+-dependent protein kinase A (PKA) and the synaptic  
Ca2+-calmodulin-regulated protein kinases (CaMPK). An increase in intracellular Ca2+ 
additionally enhances neurotransmitter release and thus implicates the PLCγ-1 in 
synaptic plasticity (Lessmann, 1998). In fact mice with a mutation in the TrkB Y816 
(corresponding to Y785 in human TrkA), the PLCγ-1 binding site, show impaired 
hippocampal long-term potentiation (LTP) similar to TrkB and BDNF null mice 
(Minichiello et al., 2002) and structural abnormality of synapses in vestibular neurons 
(Sciarretta et al., 2010) (Figure 1.2). 
 
The current Trk signalling pathway models mostly include just the major components of 
Trk downstream signalling pathways, which are primarily mediated through the 
phosphorylated Y490, Y751 and Y785 residues and the adaptor proteins Frs-2 and Shc. 
However, Trk signalling is more complex and it is clear that the other seven tyrosines 
also play important roles. In fact many responses are mediated by several tyrosines 
together. For instance the three phosphotyrosines Y643, Y704 and Y760 in rat TrkA in 
addition to Y499 and Y794 (correspond to Y490 and Y785 in human TrkA 
respectively) together mediate NGF-induced neurite outgrowth in PC12 cells (Inagaki et 
al., 1995). Furthermore, two additional adaptor proteins rAPS and SH2-B were 
identified. They are recruited by phosphotyrosines in the activation loop (Y670, Y674 
and Y675) and associate with Grb2 and might thus link to the Ras/MAPK and PI3K 
pathways (Huang and Reichardt, 2003).  
 All of these pathways compete with each other for several proteins and are thus 
also cross-linked. Additionally Trk receptors interact with many other intracellular and 
receptor proteins such as p75NTR and ion channels, which complicates the picture of Trk 
signalling even more (Huang and Reichardt, 2001, Huang and Reichardt, 2003, 
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Reichardt, 2006). The role of Trk receptor function is also not limited to the described 
pathways. Trks can also bind to adapters and enzymes such as c-Abl independently of 
the phosphorylated tyrosine residues and mediate cellular responses such as 
differentiation (Yano et al., 2000). In addition, Trk receptors can be activated  
ligand-independently by interaction with GPCRs, leading to a transactivation of Trk 
receptors similar to other TKR. However, this is a slow and rare event. The two GPCR 
ligands adenosine and pituitary adenylate cyclase-activating polypeptide (PACAP) were 
shown to mediate this transactivation, which selectively results in the activation of the 
PI3K/Akt pathway and thus in cell survival (Lee and Chao, 2001). The cytosolic Src 
family of tyrosine kinases (SFKs) such as FYN, SYK, and ICK etc. can also associate 
with and activate Trk receptors in the absence of NTs. Src phosphorylates the Y490 
residue on Trk receptors and thus promotes neuronal survival and neurite outgrowth 
through activation of the MAPK and/or the PI3K/Akt pathways (Lee and Chao, 2001, 
Encinas et al., 2001). 
 Not all of these pathways are stimulated simultaneously upon Trk activation. 
Which pathway is active depends mainly on the cell type and developmental stage of 
the cell, which influence the presence of specific pathway components and different 
isoforms. But many other control mechanisms exist such as the compartmentalization 
and transport of Trk receptors. As previously mentioned Trk-NT complexes are 
internalised and either degraded or retrogradely transported in endosomes to the nucleus 
or other compartments. These compartments contain specific signalling intermediates 
and thus also determine which pathways are activated. Additionally, it was suggested 
that different types of signalling endosomes exist, which also influence the repertoire of 
Trk signalling (Zweifel et al., 2005). 
 Finally, a regulatory role of several protein tyrosine phosphatases in these 
pathways has also been described. For instance the phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) is a major negative regulator of the PI3 kinase/Akt 
signaling pathway (Cantley and Neel, 1999). Additionally the Src homology 2 domain-
containing protein tyrosine phosphatase 2 (Shp2), another cytosolic PTP, together with 
its substrate signal-regulatory protein (SIRP) was shown to positively regulates  
BDNF-induced PI3K and MAPK pathway activation and thus survival of cortical 
neurons (Takai et al., 2002). Shp2 is also activated through binding to Gab1/2 or Frs2. It 
was suggested to act as an adaptor protein between growth factor receptors and Grb2 
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and so to activate MAPK signalling. Shp2 phosphatase activity in this scenario is also 
essential, but not understood yet (Li et al., 1994). In contrast Shp1 directly associates 
with TrkA in PC12 cells and in sympathetic neurons and dephosphorylates and 
inactivates this growth factor (Marsh et al., 2003). Further, MAPK phosphatases (MKP) 
dephosphorylate MAPK and terminate MAPK signalling (Barr and Knapp, 2006). A 
role of several RPTPs in the regulation of Trk signalling has also been suggested for 
instance as regulators of the SFKs (Bixby, 2001, Johnson and Van Vactor, 2003) or 
directly through Trk dephosphorylation and will be described later in more detail. 
1.2.5. Implication of Trk receptors and NTs in diseases 
Trk receptors and their ligands play essential roles during development and in adult 
organisms. Thus it is not surprising that they are also implicated in the manifestation of 
several human genetic, neurodegenerative, and inflammatory, cardiovascular or 
metabolic diseases. For instance they play a role in diabetes, psychiatric disorders, 
asthma and allergy, and neuropathic pain just to mention a few. Although the molecular 
mechanisms remain mostly unknown, the implication of Trk receptors is supported by 
the correlation of the disease phenotypes with the phenotype of NT and/or Trk deficient 
mouse models.  
 Mutations in the human TrkA gene have been identified in several sensory 
neuropathies such as congenital insensitivity to pain with anhydrosis (CIPA), which is 
characterized by absence of reaction to noxious stimuli, sweating and mental retardation 
and results in self-mutilating behaviour. A cause of CIPA might be the death of  
NGF-dependent neurons during embryogenesis (Indo, 2001). In addition, TrkA function 
is impaired in Leprous, Diabetic and traumatic neuropathies and pain (Anand, 2004). 
TrkA was also linked to neurodegenerative diseases such as Alzheimer’s Disease and 
the psychiatric disorders depression, schizophrenia, autism and eating disorders 
(Ginsberg et al., 2006, Buckley et al., 2007). Aberrant TrkB and BDNF signalling due 
to mutations in their genes have been associated with many neurodegenerative and 
psychiatric disorders in humans, which are often characterized by abnormal synaptic 
plasticity such as sensory impairment, learning and memory deficits, Alzheimer’s, 
Parkinson’s and Huntington’s Disease, eating disorders including obesity, depression, 
bipolar disorders, schizophrenia and obsessive compulsive disorder (OCD) (Sklar et al., 
2002, Alberch et al., 2004, Yeo et al., 2004, Ribases et al., 2005, Buckley et al., 2007, 
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Chen et al., 2008, Pillai, 2008, Dwivedi, 2009, Xiu et al., 2009, Maina et al., 2010). 
Interestingly, a single nucleotide polymorphism (SNP) Val66Met in the BDNF 
prodomain, which results in abnormal BDNF trafficking and distribution, was also 
shown to increase the susceptibility towards several of these disorders (Neves-Pereira et 
al., 2002, Egan et al., 2003, Ribases et al., 2003, Sen et al., 2003). A reduced level of 
TrkC was linked to mood disorders, schizophrenia and neuropathies (Schramm et al., 
1998) and specific loss of NT-3 responsive proprioceptive neurons is also a 
consequence of chemotherapy using cisplatin, diabetes or vitamin B6 (pyridoxine) 
intoxication, resulting in the loss of sense in limb position (Lindsay, 1996).  
 PTKs represent 70% of all known oncogenes and proto-oncogenes as they 
control growth and proliferation. Thus it is not surprising that all three Trk receptors and 
their ligands are also implicated in the formation and progression of several tumours 
and cancers (Nakagawara, 2001). Whereas Trks and NTs are found in neoplastic tissues, 
they are not always expressed in the corresponding normal tissues. Additionally, 
oncogenes with constitutive activation have all been found in non-neuronal tumours, 
whereas proto-oncogenes are also aberrantly expressed in neuronal neoplasms. 
Mutations in the TrkA, TrkB or TrkC genes have been identified in several cancer types 
(Martin-Zanca et al., 1989, Schneider et al., 2001). For example all three Trks are 
associated with two of the most common paediatric neoplasms, the medulloblastoma, a 
malignant tumour of the CNS, and neuroblastoma, a paediatric neuroendocrine tumour, 
which arises from the neural crest-derived sympathetic nervous system and mostly 
originates in the adrenal glands. Trks may play a role in growth control of NBL cells 
and their expression correlates with the outcome. Whereas TrkA and TrkC expression 
correlates with a good prognosis, TrkB and BDNF expression is correlated with a bad 
prognosis (Brodeur, 2003, Schramm et al., 2005). In medulloblastoma TrkC expression 
was correlated with a positive outcome (Segal et al., 1994). 
 Since the 1980’s recombinant NTs were welcomed as “miracle drugs” and 
enthusiastically used in clinical trials for treatment of neurodegenerative diseases such 
as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, Parkinson’s and Huntington’s 
Diseases and peripheral neuropathies. Although animal models were promising, first 
clinical trials by local administration of NTs failed due to lack of effects or severe  
off-site effects as NTs promote a diverse spectrum of mechanisms. Future attempts are 
thus aimed at specific expression of NTs and Trks in target neurons via genetically 
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modified cells or viral transfer. Interference with Trk downstream pathways or 
alternative activation routes of Trks such as transactivation by GPCRs or modulation of 
the p75NTR receptor action are also promising therapeutic goals. Additionally, small 
molecule mimetics of NTs are currently being investigated (Thoenen and Sendtner, 
2002, Price et al., 2007, Skaper, 2008). PTPs, which are recently emerging as regulatory 
molecules of Trk receptors, also become a focus of particular attention. Thus 
understanding the implication of PTPs in these signalling pathways may lead to new 
therapeutic approaches to control aberrant Trk function. 
 
1.3. Protein tyrosine phosphatase (PTP) family  
The counter partners of PTKs are protein tyrosine phosphatases (PTPs). These enzymes 
maintain a determined balance of the phosphorylation state in the cell by removing 
phosphate groups from phosphorylated tyrosine residues in proteins. In the past PTPs 
have been dismissed as passive housekeeping enzymes, which only terminate kinase 
signalling. These assumptions were based on their overall low endogenous expression 
levels, relatively high enzymatic activity and promiscuity and lack of substrate 
specificity in vitro, or lack of knowledge about their regulation. Additionally in the 
beginning the progress in this research field was relatively slow in comparison to the 
analysis of kinases due to several mostly technical limitations such as the poor 
availability of protein tyrosine phosphate substrates for studies. But with the production 
of artificial phosphotyrosine substrates and the development of more advanced technical 
and computational tools, a plethora of studies has been conducted ever since. The  
in vivo function of these enzymes was first analysed in lower organisms such as 
Drosophila melanogaster and Caenorhabditis elegans, and more recently also in 
zebrafish, chick and in mammals. This extensive research led to the understanding that 
PTPs are not just passive actors but that they actively modify RTK signalling either 
negatively or positively (Ostman and Bohmer, 2001). For instance the two receptor-type 
phosphatases RPTPα and CD45 do not inhibit kinase activity as expected but in 
contrary activate it (den Hertog et al., 1993, Mustelin et al., 1989).  
 Nowadays it is known that PTPs play crucial roles in all biological processes 
such as cell survival, growth and differentiation, mitosis, insulin signalling, integrin 
mediated cell-cell or cell-substrate adhesion, the immune system, osteogenesis, 
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angiogenesis, metabolism and many different processes in the developing and adult 
nervous system (Stoker, 2005). It is therefore not surprising that they are also 
implicated in many different diseases such as metabolic, immune, neurological and 
developmental disorders, and some were found to be essential tumour suppressor genes 
such as the popular phosphatase PTEN (Irshad et al., 2004, Ostman et al., 2006, 
Hendriks et al., 2008).  
 To date 106 murine and 107 human PTP genes are known (Alonso et al., 2004). 
And most of these PTPs have homologs and orthologs both in vertebrates and 
invertebrates. PTPs are defined by their active-site signature motive HCX5R, in which 
the cysteine (Cys) residue is crucial for catalysis, and they share a common catalytic 
mechanism and a similar structure (Tonks, 2006). PTPs are classified into four families 
according to the primary structure of their catalytic domains, and are then grouped into 
subfamilies based on their substrate specificities. The class I cysteine-based PTPs 
represent the largest family and constitute of 38 classical PTPs and 60 structurally more 
diverse dual specificity (DSPs) phosphatases. The classical PTPs are further  
sub-categorized into 17 non-transmembrane (NPTPs) and 21 receptor-like PTPs 
(RPTPs) (Figure 1.3). However, this classification is complicated by the fact that due to 
alternative splicing or alternative promoters, several transmembrane and cytoplasmic 
forms can be generated from the same gene. DSPs can dephosphorylate phospho-Tyr, 
phospho-Ser, phospho-Thr residues and non-proteinaceous substrates such as lipids and 
complex carbohydrates and are subdivided according to their substrate specificity into 
seven subfamilies. The Thr- and Tyr-specific MAPK phosphatases (MKPs) include 
eleven PTPs, which are specific for the MAP kinases Erk, Jnk and p38. The group of  
19 atypical DSPs has instead a function unrelated to MAP kinase with DUSP11 even 
dephosphorylating mRNA by interacting with the RNA–ribonucleoprotein complex 1 
(PIR1). Three further groups consist of the three poorly characterized phosphatases of 
regenerating liver (PRLs), the three slingshots (SSHs), which play a role in actin 
dynamics, and the four cell cycle regulating CDC14 phosphatases. The myotubularins 
(MTMs) comprise 16 genes and the PTEN-related phosphatases five genes and both 
groups specifically dephosphorylate the D3-phosphate of inositol phospholipids. The 
single class II cysteine-based PTP is the Tyr-specific low molecular weight phosphatase 
(LMPTP) encoded by Acp1. The class III cysteine-based PTPs are specific for Tyr and 
Thr and comprise the three CDC25 cell cycle regulators. The fourth and last family 
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contains the four Tyr-, or Ser- and Tyr-specific aspartic acid-based haloacid 
dehalogenases (HADs) Eyes absent (EyAs) (Tonks, 2006, Pulido and Hooft van 
Huijsduijnen, 2008, Patterson et al., 2009). 
1.3.1. Receptor‐type protein tyrosine phosphatases (RPTPs) 
The RPTP family is part of the classical PTPs and consists of 21 members grouped into 
eight distinct subfamilies based on the similarity of their ECD. The structure of RPTPs 
consists of an ECD, which potentially allows ligand binding, followed by a TMD and 
an ICD with catalytic activity (Figure 1.3). The ECD is very complex in its structure 
and contains several domains. The FN type III repeats are present in most of the RPTPs 
(PTPR1/6, 2A, 2B, 3 and 5) and possibly promote interaction with integrins 
(Montgomery et al., 1996). The Ig-like domains, present only in the PTPR2A and 2B 
subgroups, have intra-molecular disulfide bonds and have a homophilic binding site that 
is mostly seen in cell-cell adhesion molecules, such as the neural cell adhesion molecule 
(N-CAM) (Frei et al., 1992). Other protein domains present in RPTPs are the 
Mephrin/5A/(PTP)µ (MAM) domain, carbonic anhydrase-like domain (CAH) (PTPR5), 
RDGS-adhesion recognition motif (PTPR8) and the heavily glycosylated domain 
(PTPR4). The PTPR7 subgroup is characterized by the absence of any extracellular 
protein domain (Tonks, 2006). The ECD structures of many RPTPs display 
characteristics of cell-adhesion molecules and their interaction with the extracellular 
matrix and other cells has been shown (Aricescu et al., 2007).  
 The ICDs of all RPTPs show more similarities than their ECDs. Twelve of the 
RPTPs have two tandem PTP domains in their ICD, while the remaining nine RPTPs 
contain a single PTP domain. The PTP domain (D1), which is adjacent to the 
membrane, is catalytically active, whereas the other PTP pseudo-phosphatase domain 
(D2) is catalytically inactive. However, the latter appears to be important for activity, 
specificity, stability and dimerization of the phosphatase (Streuli et al., 1990, Jiang et 
al., 2000, Blanchetot et al., 2002b). An exception to this ICD structure is found in 
RPTPα from the PTPR4 subgroup, with two catalytically active domains and also in the 
two RPTPs IA-2 (PTPRN) and IA-2β (PTPRN2) from the PTPR8 subgroup, which 
contain only the inactive PTP pseudo-phosphatase domain and thus lack catalytic 
activity altogether (Magistrelli et al., 1996, Jiang et al., 1998). Further, RPTPR is the  
Chapter 1 
 
  43 
 
 
 
 
Figure 1.3. The classical PTP family.  
a) 21 receptor-like PTPs (RPTPs) and b) 17 non-transmembrane PTPs (NPTPs) are known in 
mammals, but due to alternative splicing or alternative promoters several transmembrane and 
cytoplasmic forms can be generated from the same gene. The RPTPs are subcategorized into  
8 different subgroups based on their extracellular domain similarities. The names represent 
protein names with gene symbols in brackets (adapted and modified from (Tonks, 2006)). 
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 GENE SYMBOL PROTEIN NAME 
Ntrk1 TrkA 
Ntrk2 TrkB Tr
k 
re
ce
pt
or
s 
Ntrk3 TrkC 
Ptpra RPTPα 
Ptprb VE-PTP 
Ptprc CD45 
Ptprd RPTPδ 
Ptpre RPTPε 
Ptprf LAR 
Ptprg RPTPγ 
Ptprh SAP1 
Ptprj DEP-1 
Ptprk RPTPκ 
Ptprm RPTPµ 
Ptprn IA-2 
Ptprn2 IA2β 
Ptpro PTP-BK 
Ptprq PTPS31 
Ptprr PTPRR 
Ptprs RPTPσ 
Ptprt RPTPρ 
Ptpru RPTPλ 
Ptprv OST-PTP 
 
RP
TP
s 
Ptprz1 RPTPζ 
 
  Table 1.1. Gene and protein names of Trk receptors and RPTPs. 
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only RPTP enzyme that additionally contains in its ICD a membrane proximal  
kinase-interaction motif (KIM), which is normally found in cytoplasmic PTPs and 
mediates interaction with MAP kinases, predominantly Erk1 and Erk2 (Pulido et al., 
1998). Finally, the PTPR2B subgroup contains a cadherin-like motif adjacent to the 
plasma membrane, which is required for catenin binding (Tabernero et al., 2008).  
1.3.2. Regulation of RPTP function  
RPTP function and specificity towards their substrates is highly regulated in vivo at 
different levels. First, differential expression of PTPs in organisms, tissues and cells, 
which is regulated by developmental or cellular processes such as differentiation and 
proliferation, but also for instance by cell density, determines their presence and thus 
function. Additionally, the specific subcellular location of RPTPs such as lipid rafts in 
the plasma membrane determines their interaction partners and function (den Hertog et 
al., 2008). Similar to the previously described Trk kinases, RPTPs also have several 
different isoforms with specific expression patterns and functions due to alternative 
splicing and promoters and also proteolytic cleavage and shedding. This complicates 
even the classification of RPTPs as some of them have intracellular isoforms such as in 
the case of RPTPε (Gil-Henn et al., 2000) and RPTPR (Van Den Maagdenberg et al., 
1999) or secreted extracellular forms such as phosphacan in the case of RPTPζ 
(Garwood et al., 2003). On the molecular level RPTP function is regulated by many 
different mechanisms such as dimerization, ligand binding, and post-translational 
modifications of specific domains like reversible oxidation, glycosylation and also 
phosphorylation. 
 Dimerization is an essential control mechanism of RPTPs and can either activate 
or inhibit RPTP function. Ligand-binding and post-translational modifications affect the 
conformation of the enzyme and thus its dimerization state. Some phosphatases such as 
RPTPα, RPTPδ, RPTPµ, RPTPσ, the leukocyte antigen-related protein (LAR) and 
CD45 (PTPRC) also contain a helix-loop-helix (HLH) wedge-shaped domain between 
the membrane proximal region and the D1 domain, which plays a regulatory role 
(Bilwes et al., 1996). Several studies including crystal structure analysis, biochemical 
studies and yeast two-hybrid screens have suggested an “inhibitory wedge model”, in 
which this domain provides dimerization and inhibition of the phosphatase (Majeti and 
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Weiss, 2001, Blanchetot et al., 2002b, Tonks, 2006). However, in a recent structural 
screen, evidence was provided that such a “wedge”-mediated dimerization is not 
possible for RPTPs other than RPTPα due to conformational hindrance under 
physiological conditions (Barr et al., 2009). Nevertheless, the “wedge” domain plays a 
very important role in the regulation of RPTP function as has been demonstrated by  
Xie et al., who have shown that a LAR wedge Tat peptide inhibits LAR function and 
thus increases proliferation and neurite outgrowth and decreases cell death (Xie et al., 
2006). Whether the “wedge” domain is involved in substrate interaction or has another 
effect on RPTP function remains to be determined. 
 As receptors, RPTPs can either undergo homophilic interactions and build 
adhesion junctions such as in the case of RPTPµ, RPTPκ, RPTPλ and RPTPδ, or 
interact with heterologous ligands. Binding of ligands can cause, prevent or disrupt 
dimerization of the receptors, which subsequently negatively or positively affects their 
function. For instance ligand binding promotes dimerization and inhibits the function of 
RPTPs such as LAR and RPTPζ (Majeti et al., 1998, Jiang et al., 1999, van der Wijk et 
al., 2005) or it disrupts dimerization and activates the phosphatase in case of RPTPα 
(Bilwes et al., 1996, Jiang et al., 2000, Tertoolen et al., 2001a). However, only few such 
ligands have been identified and their function remains mostly uncertain. For instance 
known ligands for RPTPζ are contactin, tenascin and pleiotrophin but only the latter has 
been shown to modulate the activity of this phosphatase (Meng et al., 2000, Perez-
Pinera et al., 2007). Furthermore, DLAR in Drosophila binds to the heparan sulphate 
proteoglycans (HSPG) syndecan and Dallylike and controls the presynaptic 
development of the neuromuscular junction (Fox and Zinn, 2005, Johnson et al., 2006). 
A specific isoform of mammalian LAR, which can be found in non-neuronal cells, was 
also shown to bind the extracellular matrix laminin-nidogen complex (O'Grady et al., 
1998). Moreover, nucleolin and the HSPG agrin and collagen XVIII, and chondroitin 
sulfate proteoglycans (CSPG) such as neurocan and aggrecan, which can be found in 
the nervous system and in skeletal muscles, bind to specific isoforms of RPTPσ 
(Aricescu et al., 2002, Sajnani-Perez et al., 2003, Alete et al., 2006, Shen et al., 2009). 
Interestingly, RPTPσ-dimers can bind their ligands only in a specific conformation  
(Lee et al., 2007). Recently, trans-synaptic adhesion between netrin-G-ligand-3  
(NGL-3) and the three mammalian phosphatases LAR, RPTPσ and RPTPδ, was shown  
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and the regulation of excitatory synapse formation mediated by these complexes was 
demonstrated (Woo et al., 2009, Kwon et al., 2010).  
 Post-translational modifications such as phosphorylation of specific domains 
and reversible oxidation of the catalytic Cys residue by reactive oxygen species (ROS) 
additionally regulate RPTP function (Ostman and Bohmer, 2001). In the case of RPTPα 
reversible oxidation of Cys in the active site of the D2 domains of two RPTPs upon 
treatment with H2O2 causes a conformational change in the D2 domain. This leads to 
the formation of a Cys–Cys disulfide bond between the D2 domains and thus results in 
the stabilisation of the dimers and thus inactivation of RPTPα (Blanchetot et al., 2002a, 
Persson et al., 2004, den Hertog et al., 2005). The phosphorylation of Ser and Tyr 
residues in the RPTPs also controls their function, but the actual mechanisms remain 
unknown. For instance RPTPα is phosphorylated on two Ser residues in its 
juxtamembrane domain, which regulates its activity. It was suggested that the 
phosphorylation of these residues prevents the dimerization and thus inactivation of this 
phosphatase (Tracy et al., 1995, Zheng et al., 2002). Further, RPTPα is phosphorylated 
on a C-terminal Tyr, which creates a binding site for Grb2 and activates downstream 
signalling pathways (den Hertog et al., 1994). Interestingly, RPTPα is dephosphorylated 
by CD45 in T cells, which reveals a cross talk between RPTPs (Maksumova et al., 
2007). These modifications occur mostly in the C-terminus of the ICD and lead 
consequently to conformational changes, which can be transmitted to the ligand-binding 
ECD and the catalytic D1 domain and thus reveal a possibility of a ligand-independent 
“inside-out” signalling mechanism in RPTPs. 
 All these regulatory mechanisms of RPTPs not only complicate the overall 
picture of RPTP function but they also represent potential targets for drugs. Small 
peptides have been developed and already tested as inhibitors or mimetics of the 
catalytic and ligand binding site as well as the wedge domain. But before we proceed 
with the interference with RPTP function more knowledge has to be acquired about 
their function. A first hint towards their possible function is the analysis of their 
expression. 
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1.3.3. RPTP expression and function in the nervous system 
RPTP expression as well as their function is very diverse and also species-specific. 
RPTPs promote ligand-controlled protein tyrosine dephosphorylation of specific protein 
substrates in almost any known signalling pathway in the developing and adult 
organism such as insulin signalling, bone homeostasis, angiogenesis, the immune 
system and the nervous system. RPTPs have also been associated with many human 
diseases due to the alteration of their expression and function under pathological 
conditions (Tonks, 2006). However, the analysis of RPTP function is complicated since 
neither ligands nor substrates are known for most of these phosphatases to date. 
Additionally, in vitro analysis leads to false conclusions due to the promiscuity of 
RPTPs under non-endogenous conditions. Therefore the most reliable analysis of their 
function are loss-of-function studies in animal models such as Drosophila, Xenopus 
laevis, C. elegans, chick, zebrafish and mice. At the current stage mice with RPTP gene 
deletions of all RPTPs with the exception of RPTPλ were generated and provide 
valuable insights into RPTP function (Paul and Lombroso, 2003, Hendriks et al., 2008).  
 The majority of the initially discovered RPTPs from different species were 
found at high levels and often exclusively in the CNS and PNS during axon guidance 
and synapse formation (Sommer et al., 1997, Stoker and Dutta, 1998, Chilton and 
Stoker, 2000). Thus from the beginning the function of RPTPs was extensively studied 
in the nervous system, first in Drosophila and later also in vertebrates. RPTPs were 
shown to play many different roles in the regulation of axon guidance by promoting 
target recognition, as inhibitory guidance cues and in synapse formation in motor 
neurons and within the visual system (Burden-Gulley and Brady-Kalnay, 1999, Wang 
and Bixby, 1999, Sun et al., 2000b, Stepanek et al., 2001, Johnson and Van Vactor, 
2003, Ensslen-Craig and Brady-Kalnay, 2004). RPTPs are also implicated in neural 
tissue histogenesis during development whereby they control the formation of several 
brain areas such as the visual system, cerebellum and hypothalamus and neuromuscular 
development (Ledig et al., 1999b, Sun et al., 2000a, Rashid-Doubell et al., 2002, 
Ensslen-Craig and Brady-Kalnay, 2004). Additionally several knockout mice also show 
neurological and behavioural abnormalities (Hendriks et al., 2008). Together, the 
RPTPs LAR, RPTPσ, RPTPδ, RPTP-BK (an RPTPO form in rodents), RPTPα, RPTPγ, 
RPTPζ, RPTPR, RPTPµ and RPTPκ are all expressed in the nervous system of 
different species, where they play an important role. Strikingly, whereas the expression 
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of some of these RPTPs is similar across species, other RPTPs show completely 
different expression patterns and functions. 
 One of the first cloned RPTPs was LAR, a founding member of the PTPR2A 
subgroup that also includes RPTPδ and RPTPσ. All three mammalian RPTPs are 
expressed in the nervous system and homologues have been found in chick (CRYPα), 
leech (HmLAR1 and 2), Drosophila (DLAR and PTP69D) and C. elegans (CLAR) 
(Van Vactor, 1998), which also play crucial roles in the nervous system. For instance in 
Drosophila DLAR and PTP69D are exclusively expressed in the nervous system, where 
they control axon guidance of motor neurons (Desai et al., 1996, Krueger et al., 1996, 
Sun et al., 2000b) and retinal cells (Garrity et al., 1999, Clandinin et al., 2001, Maurel-
Zaffran et al., 2001). Additionally, DLAR was shown to regulate synapse 
morphogenesis of cultured hippocampal neurons by positively regulating the formation 
of neuromuscular junction (NMJ) synapses (Kaufmann et al., 2002). The expression of 
all three mammalian RPTPs, LAR, RPTPδ and RPTPσ, is very dynamic, partly 
overlapping but mostly distinct during development and persistent into adulthood in 
many neural tissues. Based on the structure of their ECD a role of these RPTPs in cell 
adhesion or cell surface recognition was suggested (Streuli et al., 1989, Harrington et 
al., 2002). However, despite their similar structure and expression patterns these RPTPs 
exhibit different and sometimes contrary functions. 
 LAR, which is encoded by Ptprf, is one of the strongest expressed RPTPs in the 
developing nervous system, but the least specific to neural tissues among the PTPR2A 
members. LAR was indentified during development in the CNS in neurons of the 
cerebellum, cortex, and brain stem. In the PNS it is expressed in neurons in the DRGs 
and the geniculate ganglia. Additionally, LAR was also found in astrocytes and 
pheochromacytoma cells (PC12). LAR expression is mostly restricted to the 
subventricular zone (SVZ) and is rather low in differentiated neuronal cells within the 
CNS but remains high in PNS nuclei (Schaapveld et al., 1998, Van Vactor, 1998). LAR 
is also present in RGCs, where it modulates neuritogenesis and cell survival and its 
expression is elevated during regeneration (Lorber et al., 2004, Lorber et al., 2005). 
LAR was found along neurites and in growth cones and is involved in the proliferation 
and maturation of neurons and regulates axon guidance, growth and regeneration, 
whereby LAR can play both augmenting and inhibiting roles depending on the context 
(Zhang et al., 1998). For instance inhibition of HmLAR2, a leech ortholog of LAR, 
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causes shortened and aberrant neuronal projections, growth cone collapse and 
navigational crossover errors (Gershon et al., 1998, Baker et al., 2000, Baker and 
Macagno, 2000, Baker and Macagno, 2010). An upregulation of LAR in DRGs causes 
enhanced neurite outgrowth (Xie et al., 2001). And an increase of LAR activation 
through peptide mimetics, which bind to the fifth LAR FNIII region in its ectodomain 
and probably prevent homodimerization of LAR and so its inhibition, also resulted in 
increased neurite outgrowth in DRG explants (Yang et al., 2005a, Yang et al., 2005b). 
The absence of LAR in a mixed sensory and motor nerve delayed axonal regeneration 
in vivo following injury (Xie et al., 2001). On the other hand LAR downregulation in 
PC12 cells resulted in an increase in NGF-mediated neurite outgrowth and decreased 
apoptosis (Moshnyakov et al., 1996, Tisi et al., 2000). LAR also regulates excitatory 
synapse formation as LAR downregulation in hippocampal neurons leads to a loss of 
excitatory synapses and dendritic spines (Ip et al., 1993, Marsh et al., 1993, Culmsee et 
al., 2002, Dunah et al., 2005). Interestingly, postsynaptic LAR regulates synapse 
morphogenesis partly through its association with AMPA receptors in cultured 
hippocampal neurons (Dunah et al., 2005), whereas presynaptic LAR regulates synapse 
formation through a trans-synaptic adhesion with NGL-3 regulation (Woo et al., 2009, 
Kwon et al., 2010). LAR-/- mice present a delay in sciatic nerve regeneration and a 
decrease in collateral nerve sprouting after injury (Van der Zee et al., 2000, Xie et al., 
2001) as well as a decrease in innervation of the hippocampus, reduced size of basal 
forebrain cholinergic neurons and impaired spatial learning (Yeo et al., 1997, Van 
Lieshout et al., 2001, Van Der Zee et al., 2003, Kolkman et al., 2004). However, LAR-/- 
mice grow normally and their abnormalities are rather mild. But this could be attributed 
to traces of full-length LAR and a truncated LAR isoform being still present in these 
mouse models (Yeo et al., 1997, Yang et al., 2003). A better LAR-/- mouse model is 
currently not available. 
 RPTPσ is strongly expressed in the PNS, CNS and the endocrine system in 
tissues such as DRGs, the sciatic nerve and cranial nerve ganglia, in the VZ and SVZ of 
the spinal cord and in the developing brain in the cortex, hippocampus, cerebellum, 
brain stem, olfactory bulb, the retinotectal system and the pituitary gland (Yan et al., 
1993, Stoker et al., 1995, Van Vactor, 1998, Elchebly et al., 1999, Wallace et al., 1999, 
Meathrel et al., 2002, Johnson and Van Vactor, 2003). Its expression is strongest during 
embryonic development and was predominantly detected in proliferating and 
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differentiated cells (Sahin et al., 1995, Wang et al., 1995). RPTPσ is expressed in 
neurons but its expression in the VZ and SVZ additionally suggested an expression in 
glia cells. This was supported by detection of a specific shorter RPTPσ isoform in 
cultured primary glia cells and Schwann cells in the adult mouse sciatic nerve (Wang et 
al., 1995, McLean et al., 2002). RPTPσ was the first vertebrate RPTP, whose function 
in axon outgrowth and guidance was demonstrated in the developing chick retina and 
the tectum (Ledig et al., 1999a, Rashid-Doubell et al., 2002). Moreover mammalian 
RPTPσ was recently implicated in glutaminergic pre- and postsynaptic differentiation in 
co-culture experiments with hippocampal neurons (Takahashi et al., 2011). Using 
knockout mice it was also shown that RPTPσ inhibits axon regeneration after peripheral 
nerve injury of sciatic nerve axons and that a loss of RPTPσ enhances the rate of facial 
motor neuron regeneration, which is however accompanied by directional errors 
(Thompson et al., 2001, Thompson et al., 2003). RPTPσ loss also increases axon 
regrowth of RGCs after optic nerve lesion (Sapieha et al., 2005). Interestingly, whereas 
in RGCs and in facial motor neurons RPTPσ gene expression did not change after 
injury (Thompson et al., 2003, Sapieha et al., 2005), in adult DRGs and sciatic nerves 
RPTPσ mRNA increased during regeneration (Haworth et al., 1998, McLean et al., 
2002). This illustrates that RPTPσ gene expression is differently regulated in the CNS 
and PNS, which also differ in their regenerative capacities. Recently, one mechanism 
for the implication of RPTPσ in nerve regeneration was deciphered, when CSPGs, 
which represent a barrier for axon regeneration and are secreted by astroglia at injury 
sites, were identified as ligands for RPTPσ. In culture experiments of RPTPσ-/- DRG 
neurons the inhibitory effect of CSPGs on neurite outgrowth was indeed reduced 
compared to wild type cells. And in an in vivo spinal cord injury model in adult RPTPσ-
/- mice increased neurite outgrowth was observed through the CSPG-rich lesion area 
(Shen et al., 2009). Furthermore, mice lacking RPTPσ show severe growth retardation 
and semi-lethality after birth and the most obvious neurological defects among RPTP 
knockout mice with developmental abnormalities in the pituitary gland, hypothalamus, 
corpus callosum and cerebral cortex. Additionally, RPTPσ-deficient mice suffer from 
hypomyelination of peripheral nerves and defects in proprioception, as well as 
abnormalities in motor coordination and ataxia (Elchebly et al., 1999, Wallace et al., 
1999, Batt et al., 2002, Meathrel et al., 2002). The proprioceptive defects might be 
caused by aberrant RPTPσ expression in DRGs or the cerebellum.  
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 RPTPδ is predominantly expressed in the CNS in the spinal cord, the cortex, 
diencephalon, forebrain and hindbrain and in the retina during early rodent development 
(Van Vactor, 1998, Johnson and Holt, 2000). It is not expressed in the proliferating 
neuroepithelium but instead can be found in differentiated neurons and in connective 
tissues and muscular compartments (Sommer et al., 1997, Schaapveld et al., 1998). 
RPTPδ is a homophilic cell-adhesion molecule (CAM) and promotes neuronal adhesion 
and regulates neurite outgrowth of CNS neurons in chick embryos (Wang and Bixby, 
1999). A soluble ECD of RPTPδ is possibly an attractive guidance cue for retinal and 
forebrain neurons (Sun et al., 2000b), whereas a transmembrane form is a repulsive 
guidance cue in cortical neurons in culture (Tuttle et al., 1999). Interestingly, in contrast 
to rodents and Drosophila, RPTPδ expression was not detected in MNs in chick E4-8 
embryos. RPTPδ knockout mice exhibit growth retardation and neonatal mortality 
caused by insufficient food intake due to motor defects such as abnormal positioning of 
hind limbs and abnormal flexion of limbs. Additionally, they have memory deficits and 
suffer from hypomyelination and hyperpotentiation of hippocampal synapses 
demonstrating that RPTPδ is involved in synapse formation (Uetani et al., 2000). 
 Ptpro encodes a phosphatase of the PTPR3 subgroup, which also contains  
DEP-1, RPTPβ, SAP-1 and PTPS31. In rodents this phosphatase is known as  
RPTP-BK, in humans as PTP-U2, in rabbits as GLEPP-1, in chick as CRYP-2 and in 
Drosophila as PTP10D. Interestingly, the ECD of RPTP-BK is not particularly 
conserved in these species indicating that the physiological function of this domain such 
as ligand binding might be divergent, but probably not their substrate specificity 
(Tomemori et al., 2000). The murine RPTP-BK has five isoforms due to alternative 
splicing; two transmembrane isoforms, of which the smaller one is found in podocytes 
of renal glomeruli and the larger form in the CNS and PNS and three truncated 
isoforms, which lack the ECD and can be found in macrophages, B cells and osteoclasts 
(Tomemori et al., 2000). The mammalian neuronal isoform is expressed in the 
developing brain in postmitotic maturing neuronal cells in the cerebral cortex, olfactory 
bulb and nucleus, thalamus, hippocampus and midbrain, and also motor neurons, the 
midline of the spinal cord and in dorsal root, cranial, and sympathetic ganglia, where it 
is involved in the differentiation and axonogenesis of neurons (Tomemori et al., 2000, 
Beltran et al., 2003). An increase in expression throughout development from E12 on 
and a peak between E16 until P3, the time of highest axonogenesis, was detected  
Chapter 1 
 
  53 
(Van Vactor, 1998). It was also suggested that RPTP-BK exerts its activity in 
undifferentiated progenitor cells in the telencephalon and hindbrain (Sommer et al., 
1997). In chick CRYP-2 is also strongly expressed in the developing brain for instance 
in RGCs and their target the optic tectum during periods of axon outgrowth and 
guidance (Ledig et al., 1999b). CRYP-2 acts as a chemorepulsive guidance cue for RGC 
axons in vitro, induces growth cone collapse and inhibits retinal neurite outgrowth. 
Recently Shintani et al. have elucidated the molecular mechanisms behind these 
observations. They have shown that CRYP-2 regulates the sensitivity of retinal axons to 
ephrins by dephosphorylating Tyr residues in the juxtamembrane region of EphA and B 
receptors, and thus plays a key role in the establishment of retinotectal projections in the 
chick (Shintani et al., 2006). In addition a knockdown of CRYP-2 lead to aberrant axon 
guidance in developing motor neurons (Stepanek et al., 2001). And in Drosophila 
DPTP10D was also shown to control axon guidance of motor neurons (Desai et al., 
1996, Krueger et al., 1996, Sun et al., 2000b). RPTP-BK knockout mice show defects in 
the differentiation but not survival of peptidergic nociceptive and proprioceptive 
neurons in the DRGs, resulting in abnormal projections and behavioural abnormalities 
such as a loss of response to thermal stimuli. Thus it was suggested that RPTP-BK is 
required for differentiation and neurite guidance of sensory neurons and mature sensory 
function (Gonzalez-Brito and Bixby, 2009).  
 Ptprr encodes four different PTPR7-type protein isoforms, the two receptor-type 
isoforms PTPBR7 and the shorter PTP-SL and the two cytosolic isoforms PTPPBSγ-37 
and -47 (Hendriks et al., 1995, Ogata et al., 1995, Chirivi et al., 2004). PTPBR7 is 
expressed in DRGs, and in different brain tissues such as hippocampus and Purkinje 
cells in the cerebellum during early embryonic development. Interestingly, whereas 
PTPBR7 levels decrease postnatally in cerebellar Purkinje cells, PTP-SL transcripts 
arise, which are additionally expressed in most of the other brain tissues (Van Den 
Maagdenberg et al., 1999, Augustine et al., 2000). PTPPBSγ expression is very low in 
the brain, and is instead mostly found in non-neuronal tissues. RPTPR knockout mice 
suffer from impaired motor coordination and balance skills and a mild form of ataxia. 
However, no morphological changes could be observed in the brain of these mice 
compared to their wild type littermates. Since RPTPR interacts and dephosphorylates 
several MAPK, Erk1/2 phosphorylation was significantly elevated in the brain in 
RPTPR-deficient animals (Chirivi et al., 2007). 
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 The expression of RPTPα, a member of the PTPR4 subgroup, is dynamic and 
abundant in the entire developing nervous system and persists into adulthood  
(den Hertog et al., 1996, Ledig et al., 1999b). It is highly expressed in NC derivatives 
such as adrenal gland, and cranial and spinal sensory ganglia, in retina and tectum and 
additionally in radial glia, Bergmann glia and Mueller glia and their extended fibres 
(Van Vactor, 1998, Ledig et al., 1999b). RPTPα was implicated in the differentiation 
and migration of NCCs and neurons (den Hertog et al., 1993, den Hertog et al., 1996, 
Fang et al., 1996). Morpholino studies in Zebrafish embryos revealed its role in retinal 
lamination (van der Sar et al., 2002) and convergence and extension cell movements 
during gastrulation (van Eekelen et al., 2010). RPTPα is expressed in RGCs, where it 
modulates neuritogenesis and cell survival and its expression is elevated after lesion 
(Lorber et al., 2004, Lorber et al., 2005). RPTPα knockout mice do not have an obvious 
phenotype but show some aberrant neurological functions such as impaired neuronal 
migration in the hippocampus (Petrone et al., 2003) and NCAM-mediated neurite 
elongation, affected synaptic plasticity and locomotor activity as well as decreased 
anxiety (Skelton et al., 2003, Bodrikov et al., 2005).  
 RPTPγ is a PTPR5 phosphatase and its expression was documented in the CNS 
and PNS in mice and chick. It was detected in the spinal cord of chick embryos first in 
interneurons and later also in the motor neuron progenitor (pMN) domain (Chilton and 
Stoker, 2000, Gustafson and Mason, 2000, Jessell, 2000). Recently in our lab a role of 
this phosphatase in proliferation, survival and adhesion of progenitor cells was 
demonstrated in gain- and loss-of-function studies in the chick spinal cord. And RPTPγ 
was implicated in the canonical Wnt/β-catenin pathway (Hashemi et al., 2010). 
Surprisingly, in the mouse RPTPγ is not expressed in the early spinal cord but was 
detected predominantly in sensory and pyramidal neurons (Lamprianou et al., 2006). 
RPTPγ immunoreactive protein was also found in neuronal and some glia cells in the 
human brain including Purkinje cells and in Schwann cells of human sensory ganglia 
(Vezzalini et al., 2007). RPTPγ-/- mice are viable and display only moderate behavioural 
changes in comparison to wild type animals such as abnormal motor coordination. Lack 
of RPTPγ expression in proliferating areas of the adult brain also indicated that it is not 
necessary for adult neurogenesis (Lamprianou et al., 2006).  
 RPTPζ (formerly known as RPTPβ), which is also a member of the PTPR5 
subgroup, is predominantly expressed in the CNS and PNS during early and late 
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development in centres of neural proliferation such as the SVZ (Canoll et al., 1996a). Its 
expression was identified in a subset of neurons but predominantly in radial glia cells, 
which give rise to astrocytes and neurons, oligodendrocyte progenitors, and in Schwann 
cells and SGCs surrounding large neurons in rat embryonic and adult DRGs (Canoll et 
al., 1993, Haworth et al., 1998, Shintani et al., 1998, Van Vactor, 1998, Harroch et al., 
2000). The Rptpz1 gene encodes three isoforms. The two transmembrane isoforms are 
found throughout the developing rat brain at earlier developmental stages, and later with 
highest abundance in astroglia (Van Vactor, 1998). The soluble isoform phosphacan is a 
chondroitin sulfate proteoglycan (CSPG), which is released from glia cells. The 
transmembrane isoforms are most abundant during development, whereas phosphacan 
is predominantly expressed during postnatal stages (Canoll et al., 1996a). In vitro assays 
have shown that RPTPζ controls axon outgrowth and cell adhesion (Canoll et al., 1993), 
proliferation and differentiation of radial glia cells and neurogenesis in neural stem cells 
(Lamprianou and Harroch, 2006). Moreover, it is implicated in cell migration, 
synaptogenesis, synaptic function, myelination and neuron–glial interaction (Maeda and 
Noda, 1998, Murai et al., 2002). Phosphacan acts as a ligand for a variety of axonal  
cell-adhesion receptors such as N-CAM and contactin (Milev et al., 1994, Grumet et al., 
1996, Milev et al., 1996, Margolis and Margolis, 1997) and can influence tyrosine 
phosphorylation in cortical neurons (Maeda and Noda, 1996). Despite the many 
different roles RPTPζ plays in the nervous system, knockout mice show only mild 
neuronal defects such as impaired working memory, aberrant motor coordination, and 
reduced responses to moderate but not high nociceptive stimuli (Lafont et al., 2009). 
These mice have also an impaired ability in the recovery from demyelination (Harroch 
et al., 2000, Harroch et al., 2002).  
 RPTPµ is a member of the PTPR2B subgroup and a homophilic CAM, which 
promotes neurite outgrowth. In the chick RPTPµ is expressed in axons and growth 
cones of RGCs and in the tectum (Ledig et al., 1999b, Burden-Gulley et al., 2002), 
where it mediates cell-cell aggregation via trans-homophilic binding and is additionally 
a key regulator of cadherin-dependent neurite outgrowth. Interestingly, RPTPµ appears 
to be both an inhibitory and permissive guidance cue within the visual system at 
specific embryonic developmental stages depending on its concentration and is involved 
in the formation of retinal lamination (Brady-Kalnay et al., 1993, Burden-Gulley and 
Brady-Kalnay, 1999, Ensslen et al., 2003, Ensslen-Craig and Brady-Kalnay, 2004, 
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Major and Brady-Kalnay, 2007, Oblander et al., 2007). Further RPTPµ gene expression 
was found in other CNS areas in non-neural cells, for instance in blood vessels in the 
spinal cord of chick and rat E13.5 embryos (Longo et al., 1993, Van Vactor, 1998, 
Chilton and Stoker, 2000). In mice RPTPµ expression was predominantly found in the  
cardiovascular system but was also detected in Purkinje cells and other neurons in the 
brain. However, RPTPµ mice have no neuronal phenotype (Koop et al., 2003).   
 RPTPκ is similar to RPTPµ a homophilic PTPR2B CAM. Its gene expression 
was documented in the rat CNS in actively developing areas in the hippocampus and 
cerebral cortex, cerebellum, brain stem and spinal cord, and in the adult, in areas 
capable of plasticity such as the cortex, olfactory bulb and the hippocampal formation 
with generally higher expression levels in the developing CNS (Jiang et al., 1993). 
RPTPκ expression suggests an involvement in axon growth and guidance and in fact a 
soluble form of RPTPκ stimulated neurite outgrowth in cultured cerebellar neurons 
(Drosopoulos et al., 1999, Leighton et al., 2001). RPTPκ was also detected in specific 
neurons in murine E14 DRGs (Hantman and Perl, 2005) and in radial processes of 
retinal progenitor cells during murine development. It was suggested to play a role in 
the migration of neurons, possibly mediated through its substrate β-catenin  
(Horvat-Brocker et al., 2008). However, like RPTPµ, RPTPκ-deficient mice do not 
show abnormalities in neural development (Shen et al., 1999).  
 
Since many transgenic animals with RPTP deficiency lack an obvious neurological 
phenotype and appear mostly normal and healthy, a compensatory effect of different 
phosphatases, possibly from the same subgroup, as a safety mechanism was suggested. 
In this respect studies in Drosophila have revealed that RPTPs compensate for each 
other’s loss in motor neurons as only double, triple or quadruple knockouts achieved 
defects (Desai et al., 1997, Sun et al., 2001). However, RPTPs also display antagonistic 
and complementing roles in vivo (Ensslen-Craig and Brady-Kalnay, 2004). For instance 
lack of either LAR or RPTPσ in mice affected the regenerative capacity of their neurons 
in opposite ways. Whereas LAR-deficient animals showed a delay in sciatic nerve 
regeneration and decreased collateral nerve sprouting after injury, RPTPσ-deficient 
animals exhibited enhanced nerve regeneration (Xie et al., 2001, Van Der Zee et al., 
2003). Deficiency in either RPTPδ or RPTPσ in mice results in viable animals with 
mostly neuronal abnormalities. However, an RPTPδ/RPTPσ double knockout in mice 
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resulted in paralysed animals, which could not breathe and died shortly after birth. Since 
these mice showed loss in spinal cord motor neurons and extensive muscle dysgenesis, 
their functional redundancy in motor neuron survival and axon targeting in mammals 
could be demonstrated (Uetani et al., 2006). Nevertheless, a non-redundant function 
between structurally similar RPTPs exists as well and was demonstrated in 
RPTPα/RPTPε double knockout mice (Tiran et al., 2006), which both specifically 
regulate the activity of voltage-gated potassium channels and Src kinase in Schwann 
cells (Tsai et al., 1999, Peretz et al., 2000).  
1.3.4. RPTP substrates and signalling pathways 
RPTPs are implicated in a plethora of physiological processes such as cell-cell and  
cell-matrix adhesions and migration, metabolism, cell survival, growth and death. 
However, we do not only lack knowledge about their ligands but also about their actual 
physiological substrates and thus signalling mechanisms. 
 RPTP function was particularly studied in cell-cell and cell-matrix adhesions 
and migration, which are of immense importance in embryogenesis, angiogenesis, and 
tissue repair and in nerve growth (Larsen et al., 2003). This is due to two main reasons. 
First, it is known that phosphorylation plays a crucial role in these fundamental 
processes and second several RPTPs resemble CAMs and are involved in neural 
outgrowth as described above. It is now appreciated that some RPTPs regulate cell-cell 
and cell-matrix adhesions via association with cadherins and catenins, which are a 
major component of adherens junctions (AJ). For example RPTPµ mediates cell-cell 
adhesion via homophilic trans interactions and binding of its ICD to cadherins and is 
thus implicated in the formation of AJ. Interestingly, RPTPµ has several functions in 
this respect. It dephosphorylates cadherins and catenins, and works as a scaffold for 
additional regulatory proteins. The RPTPs LAR, RPTPκ, RPTPλ, DEP-1, VE-PTP and 
RPTPζ also interact directly with cadherins and/or catenins and dephosphorylate them, 
and so control cell-cell adhesion and some of them also control neurite outgrowth 
(Stoker, 2005, Sallee et al., 2006, Aricescu et al., 2007, Oblander et al., 2007). 
Moreover RPTPs regulate cell-cell and cell-matrix adhesions via interaction with the 
integrin signalling. Integrins are a major component of cell-matrix adhesions as they 
control the formation of so-called focal adhesions (FAs), and thus link the extracellular 
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matrix (ECM) with the actin cytoskeleton of the cell. Integrins are part of a  
multi-molecular complex and are responsible for the activation of FA kinases (FAK) 
and the downstream signalling cascades leading to actin cytoskeleton remodelling, 
which is important for instance at the growth cones during axon guidance and 
extension. The involvement of RPTPs in this process was demonstrated for example for 
LAR. It binds with its D2 domain to α-liprins, which act in this case as scaffold proteins 
and translocate LAR to FAs, where LAR also docks to the Rho/Rac GEF factor TRIO 
and dephosphorylates it (Debant et al., 1996, Serra-Pages et al., 1998, Burridge et al., 
2006). TRIO was demonstrated to control axon guidance in Drosophila (Bateman et al., 
2000) and TRIO is a substrate of FAK and itself activates FAK in a bi-directional 
mechanism (Medley et al., 2003). Interestingly, LAR not only dephosphorylates TRIO 
but also FAK (Cheung et al., 2000) and thus might counteract the formation and 
function of FAs. 
 Furthermore RPTPs can dephosphorylate other receptors such as ion channels. 
As an example RPTPα and RPTPε both regulate the activity of potassium channels 
(Tsai et al., 1999, Peretz et al., 2000), whereas RPTPζ influences the activity of sodium 
channels (Ratcliffe et al., 2000, Salter and Wang, 2000).  
 Many NRTKs and RTKs are also direct physiological substrates of RPTPs and 
can be deactivated or activated upon dephosphorylation (Ostman and Bohmer, 2001). 
For instance RPTPα controls the activity of several members of the cytoplasmic SFKs, 
since RPTPα-knockout mice have reduced Src and Fyn activities in the brain (Ponniah 
et al., 1999, Su et al., 1999). SFKs are implicated in many different signalling pathways 
such as cell migration and adhesion, differentiation, proliferation and mitosis, and so is 
RPTPα. This regulatory mechanism has been well described. RPTPα itself is 
constitutively phosphorylated on its D2 domain, and is thus associated with the  
SH2-containing adaptor protein Grb2. Additional phosphorylation of RPTPα releases 
Grb2 and RPTPα binds and dephosphorylates the autoregulatory Y527 in the  
C-terminus of c-Src leading to its activation (Den Hertog and Hunter, 1996). LAR is 
also known to activate the SFKs LCK and FYN via dephosphorylation of their Y529 
residues (Tsujikawa et al., 2002). Similarly, CD45 dephosphorylates the inhibitory but 
also the stimulatory Tyr of the SKFs Lck in T cells and Lyn in B cells (Li and Dixon, 
2000). CD45 can also bind and directly dephosphorylate the Janus family kinases 
(JAKs) and thus for instance negatively regulate cytokine-induced cell proliferation 
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(Irie-Sasaki et al., 2001). Further, several RTKs were also shown to be substrates of 
RPTPs in vitro. For example RPTPσ can dephosphorylate EGFRs (Suarez Pestana et 
al., 1999). LAR dephosphorylates the HGFR/Met tyrosine kinase (Kulas et al., 1996) 
and Ret (Qiao et al., 2001) and inhibits FGF-induced MAPK activation (Wang et al., 
2000). The insulin receptor can be dephosphorylated by LAR, RPTPα and RPTPε 
(Kulas et al., 1995, Moller et al., 1995). DEP-1 also dephosphorylates HGFR/Met 
(Palka et al., 2003) and additionally controls the function of VEGFRs (Grazia 
Lampugnani et al., 2003) and PDGFRs (Kovalenko et al., 2000). Additionally, DEP-1 
dephosphorylates EGFRs and limits endocytosis of active EGFRs and thus their ability 
to generate intracellular signals (Tarcic et al., 2009). RPTP-BK negatively regulates 
EphRs and so inhibits neurite outgrowth in RGCs (Shintani et al., 2006). Recently 
RPTP-BK phosphorylation on its C-terminus by FYN and its subsequent association 
with FYN and Grb2, a scaffold protein in many growth factor signalling pathways, was 
described. Thus it was suggested that RPTP-BK could also dephosphorylate and 
activate SFKs (Murata et al., 2010). 
 Together, a plethora of different RTKs appear to be physiological substrates of 
RPTPs, and so it is not surprising that some RPTPs can directly bind and 
dephosphorylate Trk receptors as well. 
 
1.4. RPTP and Trk interaction and function - previous findings 
First evidence for an implication of specific RPTPs in Trk signalling arose, when it was 
realized that mRNA expression of some RPTPs and Trks overlaps in specific tissues in 
the nervous system. And both protein types are also localized to neurites and growth 
cones. A role of PTPs in the regulation of neurite outgrowth and specifically in Trk 
signalling was also suggested, when non-specific PTP inhibitors, including vanadate 
and orthovanadate (Rogers et al., 1994, Fujiwara et al., 1997), stimulated neurite 
outgrowth in PC12 cells, a well-characterized model of neural precursor cells, and 
activated Trk signalling and prevented cell death in hippocampal neurons (Gerling et 
al., 2004). 
 LAR was the first RPTP that was suggested to regulate TrkA signalling, as LAR 
mRNA expression increased upon NGF-treatment in PC12 cells, which highly express 
TrkA receptors (Aparicio et al., 1992, Longo et al., 1993). Much evidence has since 
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been provided for a regulation of TrkA and also TrkB by LAR. Interestingly, depending 
on the context, LAR may up- or downregulate NT signalling. Its inhibitory role was 
shown, when an antisense induced downregulation of LAR decreased apoptosis and 
augmented NGF-induced neurite outgrowth in PC12 cells (Moshnyakov et al., 1996, 
Tisi et al., 2000). Further, a specific wedge peptide, which inhibits LAR function, 
caused an augmented NGF-induced activation of TrkA and its downstream pathway 
components Erk and Akt in PC12 cells. Their activation even in the absence of NGF 
lead to the differentiation and survival of PC12 cells and thus suggests a possible effect 
of LAR on the transactivation of Trk receptors (Xie et al., 2006). An augmenting role of 
LAR on TrkB signalling was demonstrated in hippocampal neurons, which 
predominantly express TrkB receptors, lower amounts of TrkC and traces of TrkA 
receptors. This augmenting effect of LAR on Trk signalling was suggested to occur 
indirectly through its interaction with Src and subsequent activation of this kinase, 
which is known to activate Trk receptors (Tsuruda et al., 2004). This hypothesis was 
supported by abolishing the ability of LAR to augment TrkB signalling in hippocampal 
neurons by administration of the Src inhibitor PP2 to the cells (Yang et al., 2006). When 
LAR function was augmented through peptide mimetics an increase in neurite 
outgrowth in DRG explants and hippocampal neurons was observed. On the molecular 
level increased TrkB Y515 phosphorylation and activation of downstream pathway 
components such as Akt, Erk and CREB were detected (Yang et al., 2005a, Yang et al., 
2005b). Additionally LAR co-immunoprecipitates with TrkA and TrkB either via direct 
interaction or in a complex for instance with Src, as Src knockdown prevented  
TrkB-LAR co-immunoprecipitation (Xie et al., 2006, Yang et al., 2006). Finally, LAR-/- 
mice showed impaired neurite outgrowth of CNS (Yeo et al., 1997) and PNS neurons 
(Xie et al., 2001), which express both LAR and Trk receptors, thus supporting an 
augmenting effect of LAR possibly on Trk signalling. Although many insights hint 
towards an implication of LAR in Trk signalling, its function through modulation of 
non-Trk-related mechanisms such as through FAK and EGFR signalling cannot be 
excluded at this point. In fact both of these RTKs are also known to be involved in 
neurite outgrowth and cell proliferation and were shown to interact with LAR (Kulas et 
al., 1996). 
 RPTPσ, another member of the PTPR2A subgroup such as LAR, is expressed in 
overlapping patterns with TrkA, B and C mRNA within the developing nervous system 
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and has been implicated in the regulation of neurite outgrowth; hence an interaction 
with Trks appears to be very likely. In our laboratory Faux et al. investigated the role of 
RPTPσ and demonstrated selective and strong binding to TrkA and C, but only weak 
binding to TrkB in co-IPs. However, a binding to a Trk-complex instead of a direct 
interaction with the receptor cannot be excluded. An indication for this is the ability of 
RPTPσ to dephosphorylate all three Trks despite the differing strengths of their 
interactions. Additionally, the over-expression of RPTPσ in embryonic chick sensory 
neurons resulted in the suppression of NGF-dependent neurite outgrowth but without 
affecting cell survival (Faux et al., 2007). Recently, in a binding assay in COS cells 
RPTPσ, unlike LAR or RPTPδ, was shown to bind a non-catalytic form of TrkC 
through an interaction of their ECDs but not TrkA or TrkB. Additionally a  
trans-synaptic, neurotrophin-independent interaction between axonal RPTPσ and 
dendritic non-catalytic TrkC in co-cultures with hippocampal neurons triggered 
glutaminergic pre- and postsynaptic differentiation (Takahashi et al., 2011). 
Interestingly, RPTPσ-deficient mice suffer from defects in proprioception, thus 
supporting the hypothesis of a possible interaction of RPTPσ with TrkC (Elchebly et al., 
1999, Wallace et al., 1999, Batt et al., 2002, Meathrel et al., 2002). 
 First expression studies of another RPTP, RPTP-BK, during mouse development 
showed specific and almost exclusive gene expression in neurons of the CNS and PNS 
such as in DRGs and TG. Most of these neurons also expressed TrkC, to some extent 
TrkA and fewer neurons also expressed TrkB. Thus a possible role of RPTP-BK in the 
differentiation and axonogenesis of NT-3 and NGF-dependent neurons in the CNS and 
PNS was suggested (Beltran and Bixby, 2003, Chen and Bixby, 2005). In a recent 
overexpression study Hower et al. have shown that an over-expression of RPTP-BK in 
stably TrkC-expressing cell lines decreased NT-3 induced TrkC phosphorylation 
(Hower et al., 2009). Further, RPTP-BK-/- mice show deficits in the development of 
sensory neurons, particularly of peptidergic nociceptors, and abnormalities in neuronal 
guidance of proprioceptors and nociceptors within the spinal cord accompanied by 
behavioural abnormalities such as loss of response to thermal pain (Gonzalez-Brito and 
Bixby, 2009). 
 Recent coexpression studies in HEK293T cells showed that RPTPζ but not 
RPTPγ dephosphorylates Tyr residues in the activation loop of TrkA and that an  
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over-expression of RPTPζ in PC12 cells inhibited NGF-dependent neurite outgrowth 
(Shintani and Noda, 2008). This study contradicts previous findings, where it was 
suggested that RPTPγ and not RPTPζ inhibits NGF-mediated neurite outgrowth in 
PC12 cells (Shintani et al., 2001). It was suggested that whereas RPTPγ probably 
interacts with Trk downstream pathways, RPTPζ directly dephosphorylates Y674 
and/or Y675 in the catalytic domain of TrkA and thus controls its kinase activity 
(Shintani et al., 2001, Shintani and Noda, 2008). The more recent findings are 
consistent with the elevated TrkA-phosphorylation state in RPTPζ-deficient mice 
(Shintani and Noda, 2008) and reduced responses to moderate nociceptive stimuli 
(Lafont et al., 2009). Whereas RPTPγ-deficient mice did not show any abnormalities in 
NGF-induced neurite outgrowth (Lamprianou et al., 2006). An interaction of RPTPζ 
with Trks was suggested early on as RPTPζ is coexpressed mostly with the truncated 
TrkB-isoform in the CNS especially in areas where glia cells reside (Snyder et al., 
1996). 
 Implication of RPTPR in Trk signalling became apparent when RPTPR mRNA 
was twelvefold upregulated in PC12 cells following NGF-treatment (Sharma and 
Lombroso, 1995). Recent studies on RPTP-BR7 and TrkA in an over-expression system 
in COS-1 cells have also demonstrated their binding, as well as dephosphorylation of 
TrkA but not TrkB by RPTPR and possible effects of RPTPR action on TrkA 
maturation (Noordman et al., unpublished data).  
 Taken together, all of these studies provide strong evidence for a possible 
interaction of RPTPs in Trk signalling either directly or in a complex of proteins. 
Thereby they can play either augmenting or inhibitory roles depending on the context. 
But many questions remain unanswered and the actual regulatory mechanisms remain 
mostly in the dark. Shining some light on this interaction will not only expand our 
knowledge about the functional mechanisms of these essential enzymes but also provide 
possible tools to regulate abnormal Trk signalling in diseases. Thus in this PhD project I 
have focused on the analysis of a possible regulation of Trk signalling by RPTPs. 
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1.5. DRGs, a model system to study Trk and RPTP function  
Dorsal root ganglia (DRGs) are a very well established primary neuronal cell system to 
study growth factor signalling pathways. They are especially suitable for the study of 
Trk receptors, which are endogenously expressed and play crucial roles in these ganglia. 
Therefore this cell model system was chosen for the study of RPTPs in Trk signalling. 
 DRGs are spinal ganglia, which contain mainly cell bodies of sensory neurons. 
They are part of the somatic nervous system (SNS), which belongs to the PNS. The 
PNS transmits information from the interior and the environment of the organism to the 
CNS. It contains sensory and motor neurons and consists on the one hand of the 
autonomic nervous system (ANS) including the sympathetic, parasympathetic and 
enteric nervous system, which transmits information from the interior of the body, and 
on the other hand of the mentioned SNS, which conveys information from the external 
environment. The SNS consists of cranial and spinal nerves and ganglia such as TG and 
DRGs, which transmit sensations such as position, touch, pressure, vibration, 
temperature, pain and itching from skin, bones and muscles of the head and face 
directly, and at spinal levels mostly from the limbs through the spinal cord to designated 
areas of the brain.  
 DRGs are situated bilaterally and dorsally along the spinal cord. In most mouse 
strains there are in total 60 DRGs, of which 8 pairs are located at cervical (C1-8),  
13 pairs at thoracic (T1-13), 5 pairs at lumbar (L1-5) and 4 pairs at sacral (S1-4) 
vertebrate levels (Malin et al., 2007). In addition to cell bodies of sensory neurons, 
DRGs contain SGCs (Figure 1.4). The postmitotic bipolar sensory neurons project two 
axonal processes in opposite directions, one towards specific peripheral targets and the 
other towards designated central targets in the spinal cord (Le Douarin and Kalcheim, 
1999). The sensory neurons in DRGs are an extremely heterogeneous population of at 
least 20 different subclasses of neurons. They show variations in sensory modality, the 
content of neurotransmitters, the sites of innervation of central and peripheral targets, 
morphology, growth factor dependencies and neurochemical properties (Scott, 1992). 
The majority of these different classes of neurons express specific Trk receptors. Upon 
peripheral target innervation the ganglia composition changes immensely as the 
majority of neurons undergoes cell death due to limited amounts of NTs at the targets 
(“neurotrophic hypothesis”) (Hamburger and Levi-Montalcini, 1949).  
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 DRGs are derivates of multipotent trunk neural crest cells (NCCs), which 
commit to a sensory fate instructed by BMP and Sox10 from the neural tube, the latter 
being a Wnt/β-catenin pathway mediator. The NCCs migrate, proliferate, and aggregate 
into DRGs, where they differentiate into sensory neurons and SGCs (Le Douarin and 
Kalcheim, 1999). Sensory neurogenesis occurs in three partly overlapping waves 
orchestrated by genetic cascades of specific TFs (Marmigere and Ernfors, 2007). The 
first wave of neurogenesis takes place during the migration of multipotent NCCs at 
around E8.5 and E10 in the mouse. It is initiated in one third of migrating multipotent 
trunk NCCs by the basic helix-loop-helix (bHLH) TF neurogenin 2 (Ngn2). These cells 
express subsequently the forkhead TF Foxs1, terminate migration and express the POU 
homeodomain TF Brn3a, which drives the expression of runt-related transcription factor 
3 (Runx3) (Dykes et al., 2010). Consequently the cells differentiate into large TrkC+ 
neurons (Kramer et al., 2006), which are proprioceptive and allow limb position and 
movement sensations. Down regulation of Runx3 in these cells leads to the generation 
of TrkB+ neurons, which are medium sized cutaneous mechanoreceptive neurons and 
are responsible for touch, pressure and vibration sensations (Huang and Reichardt, 
2003). The expression of TrkC+ and/or TrkB+ neurons shows a peak at E11.5 in lumbar 
sensory neurons of mouse embryos (Phillips and Armanini, 1996, White et al., 1996). 
Neurogenin 1 (Ngn1) drives the second wave of neurogenesis. Multipotent cells within 
the DRGs express Ngn1, Foxs1 and Brn3a, which initiate the expression of Runx3 or 
Runx1 (Dykes et al., 2010) and this drives the production of TrkC+ or TrkA+ neurons, 
respectively. The majority of generated cells in this wave are small TrkA+ nociceptive, 
thermoceptive and pruriceptive neurons responsible for pain, temperature and itching 
sensations, respectively (Liu and Ma, 2010). TrkA expression increases gradually 
between E10 and E13 in DRGs (Lawson and Biscoe, 1979, Phillips and Armanini, 
1996, Farinas, 1999). In the third wave beginning at E10.75 in the mouse boundary cap 
cells (BCC) from the dorsal root entry zone (DREZ) of the spinal cord, which express 
the zinc finger TF Krox20, also known as Egfr2, and proliferate and migrate into the 
DRG. They generate almost exclusively TrkA+ neurons and glia cells. However, the 
genetic cascade controlling this wave remains still unknown (Maro et al., 2004). 
Recently the implication of Islet1 as a pan-sensory TF in these events was described. It 
terminates the expression of neurogenic bHLH TFs Ngn1 and Ngn2 and thus initiates 
the terminal differentiation and specification of TrkA+ and TrkB+ but not TrkC+ neurons 
in DRGs (Sun et al., 2008). An additional subtype of sensory neurons expresses the 
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receptor tyrosine kinase Ret, a co-receptor for the glia cell line derived neurotrophic 
factor (GDNF) family of ligands (Molliver et al., 1997). These neurons are mostly 
mechanoreceptors at embryonic stages and some of them also coexpress TrkB. At 
postnatal stages Ret+ neurons are proprioceptors and to some extent coexpress TrkA. 
The different subtypes of specific Trk+ or Trk- neurons differ further by expression of 
specific ion channels and other receptors, whose expression is partly controlled by Trk 
receptors. The cells generated in the first wave of neurogenesis account finally for 4%, 
in the second wave for 91%, and in the third wave for 5% of the final total neural 
population in DRGs (Marmigere and Ernfors, 2007). However, when Maro et al. 
ablated the BCCs they have detected a much higher decrease in TrkA+ cells than 
estimated and therefore the contribution of neurons from the BCCs could be well 
underestimated and in fact be even as high as 35% (Maro et al., 2004).  
 Some subsets of sensory neurons also coexpress TrkA, TrkB and/or TrkC 
receptors and Ret at early stages or switch expression from one to the other receptor 
(Buchman and Davies, 1993, Liebl et al., 1997, Enokido et al., 1999). First evidence for 
a possible coexpression of Trk receptors in DRG cells was observed in transgenic mice 
with gene deletions of a Trk receptor or NT, as unexpected amounts of surviving cells 
were detected. For example the loss of neurons in double-mutant mice lacking two Trk 
receptors was not additive and therefore indicated a coexpression of these receptors in 
the same cells (Minichiello et al., 1995). A further hint towards coexpression in DRG 
neurons was the observation that Trk receptors were expressed by neurons of many 
different sizes at earlier developmental stages, but that their expression was confined 
mainly to neurons of a specific size at later stages, i.e. TrkA was mostly expressed in 
small neurons, TrkB in medium-sized neurons, and TrkC in large neurons (Mu et al., 
1993, McMahon et al., 1994). Further analysis showed that for instance TrkC and TrkB 
genes are coexpressed at early developmental stages in many regions of the embryo 
such as the pyramidal cell layer of the hippocampus, in the postmitotic mantle of the 
ventral horn of the spinal cord, where motor neurons reside, and in several non-neuronal 
tissues such as mesenchyme and tongue (Tessarollo et al., 1993). TrkA and TrkC 
expression shows remarkable similarities in gene expression patterns during 
development in sympathetic ganglia and DRGs (Ernsberger, 2009). These coexpression 
patterns and switch of Trk expression can be mainly explained by the two major waves 
of neurogenesis in which neurons first express TrkC or TrkB as described above.  
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 Although neurogenesis in DRGs has been extensively studied, our knowledge is 
not complete by far and even less is known about gliogenesis such as of SGCs and 
Schwann cells, which ensheath peripheral nerves. However, these glia cells play crucial 
roles for instance in the control of the neuronal microenvironment and clearing of 
apoptotic cells, and are also involved in chronic pain (Hanani, 2005, Wu et al., 2009, 
Hanani, 2010a, Hanani, 2010b). Interestingly, unlike autonomic SGCs, sensory SGCs 
do not have any synapses (Hanani, 2005). SGCs are mostly generated during the second 
and third waves of neurogenesis and their formation is instructed by Notch signalling 
(Carr and Simpson, 1978, Lawson and Biscoe, 1979, Morrison, 2001, Taylor et al., 
2007). However, details about the genetic cascades, which control these events, remain 
mostly unknown (Wakamatsu, 2004).  
 
 
 
 
Figure 1.4. Schematic presentation of DRGs in mouse embryos and their cell cultures.  
Upper panel: Schematic presentation of DRGs in a mouse embryo, which are situated in  
30 pairs along the spinal cord (SC). Each soma of a neuron is surrounded by several satellite 
glia cells (SGCs). Lower panel: Embryonic DRGs can be cultured in a medium containing 
neurotrophins either as explant cultures (left) or they can be dissociated and cultured (right). 
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DRGs are a good cell model to study neurotrophin signalling 
DRGs offer many advantages as a cell model system. First, DRG composition and 
development have been extensively studied and are well characterized as described 
above. Furthermore the ganglion composition is stereotyped in each mouse and hence 
several DRGs and animals can be pooled and thus supply enough material for many 
different applications. DRGs can be used as whole explant cultures or in a dissociated 
form (Malin et al., 2007) (Figures 1.4 and 1.5). Since DRG sensory neurons are a 
mixture of neurons with different growth factor responsiveness, target tissue 
innervations etc., they allow the analysis of a diverse spectrum of neurons. Additionally 
it is possible to tightly control the extracellular environment, such as by addition of 
specific growth factors, which regulate neuronal phenotype, survival and function in 
vivo. Importantly, these neurons maintain the ability to respond to chemical, thermal 
and mechanical stimuli in culture.  
 
 
 
Figure 1.5. Effects of NTs on neurite outgrowth in chick E7 DRG explant cultures.  
Embryonic chick DRGs were cultured for 48h either in the presence of NGF, BDNF, NT-3, or 
all three NTs (50ng/ml), or without any growth factors. All three neurotrophins caused visible 
neurite outgrowth compared to the untreated control (ctrl). Differences in the amounts, length 
and branching of axons are visible between explant cultures with different neurotrophins 
(unpublished data, Viktoria Tchetchelnitski).  
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1.6. Outline of this thesis  
One of the main goals in the NT field remains to understand the different signalling 
pathways activated by Trk receptors. Recently it has been shown that one component of 
this signalling cascade might be the RPTPs (section 1.4). However, the research of 
phosphatases is technically quite challenging and thus the progress in understanding 
their role in Trk signalling is slow. But with new remarkable technological tools being 
developed we are coming step by step closer to deciphering the role of these important 
enzymes. Understanding how to control Trk activity in diseases can possibly help to 
develop therapeutics in future.  
 Previous studies have suggested a role of RPTPs in regulating Trk signalling and 
therefore the control of important neuronal mechanisms such as differentiation, neurite 
outgrowth and cell survival (section 1.4). However, most of these experiments have 
been performed in over-expression systems and the physiological relevance of the 
interaction of these RPTPs and Trks remains to be demonstrated. Additionally, several 
RPTPs have been implicated and therefore a certain degree of redundancy is possible, 
which was not experimentally assessed yet. Also a certain specificity of RPTPs towards 
certain Trk subtypes was suggested, but remains to be shown in vivo. Furthermore, the 
mechanisms by which RPTPs control Trk receptor phosphorylation remain poorly 
understood. In this study I have addressed these questions. 
 One hint towards a possible interaction of RPTPs and Trks is their temporal and 
spatial coexpression in vivo. Although the expression of RPTPs and Trks has previously 
been described (section 1.2 and 1.3), none of these studies analysed the expression of 
RPTPs and Trks in the same tissue at the same time. Therefore, the first aim of this 
study was to identify which RPTPs are present in murine embryonic DRGs, which also 
highly express Trk receptors (Chapter 3). For this purpose an extensive analysis of the 
gene expression patterns of PTPs with a focus on RPTPs was performed in developing 
murine embryonic DRGs at three time points (E12.5, 13.5 and 14.5) during 
organogenesis. This analysis allowed us to select the highest expressed RPTPs for a 
comparative analysis of their gene expression patterns with Trks (Chapter 4). 
Furthermore, a detailed coexpression analysis of the selected RPTPs and Trks in the 
same sensory neurons was performed. This analysis allowed us to clearly show which  
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RPTPs are coexpressed with Trk receptors at the same time in sensory neurons making 
their interaction with each other likely. 
 In previous studies the mechanisms of the regulation of Trk phosphorylation and 
function were analysed mostly in over-expression systems apart from LAR and TrkB in 
hippocampal neurons (section 1.4). Therefore, the physiological relevance of these 
interactions needs to be assessed. It is a challenging task to investigate the function of 
proteins under physiological conditions and usually knockdown studies are a good 
choice for the analysis. For this purpose transgenic animals are generated or knockdown 
strategies are employed. The latter is a more straightforward approach and was used in 
this study to elucidate the role of RPTPs in Trk signalling. I have therefore established a 
shRNA-mediated knockdown system using lentiviruses (Chapter 5) and analysed the 
effects of the reduction of the three promising candidate RPTPs in Trk signalling, LAR, 
RPTPσ or RPTP-BK, on the direct phosphorylation state of Trk receptors and their 
downstream signalling pathways using immunoblotting, and on the gene expression 
using qPCR (Chapter 6).  
 The (direct) interaction of RPTPs with Trks was previously assessed using  
co-immunoprecipitation, which have shown an interaction of Trks with LAR, RPTPσ or 
RPTP-BK (section 1.4). However, the limitation of this technique is that protein 
interactions are assessed not under physiological conditions. Therefore I have also 
tested an in vivo assay, the Bimolecular Fluorescent Complementation Assay (BiFc), for 
its feasibility to analyse the (direct) interaction of RPTPs with TrkA (Chapter 7). 
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The described protocols are modified versions taken from (Sambrook et al., 1989) or 
instructions from manufacturers if not otherwise stated. General chemicals were 
obtained from BDH, Invitrogen, Sigma or VWR unless otherwise stated. Basic 
techniques were described in this chapter whereas more specific techniques can be 
found in the individual result chapters 
 
2.1. DNA methods 
2.1.1. Growth and maintenance of E.coli 
Escherichia coli (E.coli) were cultured in flasks with sterile LB broth (1% bacto-
tryptone, 0.5% bacto-yeast extract, 1% NaCl, pH 7.0) supplemented with a selective 
antibiotic (ampicilin, carbanecillin or kanamycin) at a concentration of 50 µg/ml in a 
shaker at 250 rpm and 37ºC overnight (< 16 h). Alternatively they were streaked and 
grown on LB agar (1% bacto-tryptone, 0.5% bacto-yeast extract, 1% NaCl, pH 7,  
1.5% agar) plates supplemented with a selective antibiotic at a concentration of  
100 µg/ml at 37ºC overnight. E.coli LB cultures carrying the plasmid of interest were 
preserved with 15% glycerol in a sterile Eppendorf tube at -80°C.  
2.1.2. Transformation of chemically competent E.coli 
An aliquot of 30-50 µl of chemically competent E.coli (DH5α; Invitrogen) were thawed 
on ice and added to 1-10 ng of plasmid DNA and gently mixed. Following incubation 
on wet ice for 30 min the bacteria were heat shocked for 20 sec in a 42°C water bath 
and immediately transferred back on wet ice for 2 min. The transformed bacteria were 
resuspended in 1 ml SOC agar (2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose, pH 7.0) and 
shaken at 250 rpm and 37ºC for 1 h. An aliquot of 100-500 µl was spread on an LB agar 
plate supplemented with a selective antibiotic (100 µg/ml) and grown overnight  
at 37ºC.  
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2.1.3. Plasmid preparations: Mini preps 
The QIAprep® Spin Mini Kit (Qiagen) was used to extract high quality plasmid DNA 
(< 10 kb) from bacterial cultures with an approximate yield of 10 µg. It is based on a 
modified alkaline lysis method of Birnboim and Doly and utilizes binding properties of 
silica-membranes to purify the DNA. Briefly, bacteria are lysed under alkaline 
conditions, neutralized and bound in the presence of high salt (chaotropic agents) and 
appropriate pH to a silica-gel-membrane in a spin column, while impurities (cell debris, 
gDNA, RNA, proteins etc.) are removed. Following several washes with medium salt 
buffers the plasmid DNA is finally eluted from the membrane in low-salt buffer or 
ddH2O. 
  For plasmid preparation transformed E.coli (DH5α; Invitrogen) containing the 
plasmid of interest were cultured in 1-10 ml LB broth supplemented with a selective 
antibiotic for 12-16 h. The bacteria were pelleted by centrifugation for 10 min. All 
centrifugation steps were carried out at 13,000 rpm in a microcentrifuge at room 
temperature. The bacterial pellet was resuspended in 250 µl buffer P1 (50 mM Tris-Cl, 
pH 8.0, 10 mM EDTA) including 100 µg/ml RNAse A, 250 µl buffer P2 (200 mM 
NaOH, 1% w/v SDS) were added and the solution thoroughly mixed by inversion.  
350 µl buffer N3 (25-50% guanidinium chloride, 10-25% acetic acid) were added and 
the mix centrifuged for 10 min. The supernatant was applied onto a QIAprep® spin 
column and centrifuged for 1 min. The flow-through was discarded and the column 
washed with 500 µl PB buffer (25-50% guanidinium chloride, 25-50% propanol) to 
remove endonucleases and endotoxins (depending on bacterial strain optional) and then 
with 750 µl ethanol-containing PE buffer. The column was dried by centrifugation for  
1 min. To elute the plasmid DNA from the column 50 µl of EB buffer (10 mM  
Tris-HCl, pH 8.5), TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) or ddH2O were 
applied onto the column, let stand for 1 min and centrifuged.  
2.1.4. Plasmid preparations: Midi/Maxi preps 
QIAprep® Spin Midi or Maxi Kits (Qiagen) were used to extract larger amounts of high 
quality plasmid DNA from bacterial cultures with approximate yields of up to 100 µg or 
500 µg DNA. It is based on the same modified alkaline lysis method of Birnboim and 
Doly as described for the mini preps (see section 2.1.3) and Anion-Exchange Resin tips 
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with appropriate buffers are used to bind and purify the DNA, which is finally 
concentrated and desalted by isopropanol precipitation. 
 A starter culture of 2-5 ml LB medium supplemented with a selective antibiotic 
containing E.coli (DH5α; Invitrogen) carrying the plasmid of interest was cultured for 
approximately 8 h. 1/1000 of the starter culture were inoculated in 50 ml/100 ml or 
100 ml/500 ml (midi or maxi) LB broth for high or low copy-number plasmids 
respectively and cultured overnight (< 16 h). The bacterial cells were harvested by 
centrifugation at 4600 rpm for 20 min at 4ºC. The pellet was resuspended in 4 ml/10 ml 
buffer P1 (50 mM Tris-Cl, pH 8.0, 10 mM EDTA) including 100 µg/ml RNAse A, 
mixed with 4 ml/10 ml lysis buffer P2 (200 mM NaOH, 1% w/v SDS), inverted 
vigorously and incubated at room temperature for 5 min. It was mixed with 4 ml/10 ml 
chilled neutralization buffer P3 (3 M potassium acetate, pH 5.5) and incubated on ice 
for 15 min/20 min followed by centrifugation at 4600 rpm at 4ºC for 30 min and for 
15 min. The cleared lysate was applied onto QIAGEN tip-100 or -500 equilibrated with 
4 ml/10 ml buffer QBT (50 mM MOPS, pH 7.0, 750 mM NaCl, 15% volume per 
volume (v/v) isopropanol, 0.15% v/v Triton® X-100) and allowed to enter the resin by 
gravity flow. The tip was washed twice with 10 ml/30 ml buffer QC (50 mM MOPS, 
pH 7.0, 1 M NaCl, 15% v/v isopropanol) and the DNA was eluted with 5 ml/15 ml 
buffer QF (50 mM Tris-HCl, pH 8.5, 1.25 M NaCl, 15% v/v isopropanol). To 
precipitate the DNA 0.7 volumes of isopropanol were added and the mix centrifuged at 
12.000 rpm for 30 min at 4ºC. The DNA pellet was washed with 2 ml of 70% ethanol 
and centrifuged at 20.000 rpm for 10 min. The supernatant was discarded; the DNA 
pellet was air-dried for 10 min and resuspended in 100-1000 µl EB buffer (10 mM  
Tris-HCl, pH 8.5), TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) or ddH2O. 
2.1.5. Quantification of nucleic acids 
A NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies) was used to 
determine the amount of DNA or RNA. This method is based on the measurement of 
the absorbance of nucleic acids at 260 nm (A260). Additionally, the ratio of absorbance 
of 260 to 280 nm (A260/A280) between nucleic acids and for instance proteins gives an 
estimation of the purity of the solution, and should ideally lie between 1.8 and 2.0 
(neutral pH). 
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2.1.6. Analytical agarose gel electrophoresis 
DNA or RNA was visualized via agarose gel electrophoresis. To prepare an agarose gel 
of an appropriate concentration (w/v) agarose was boiled in 1x TAE buffer (0.4 M Tris 
acetate, 10 mM EDTA, pH 8.3), chilled to room temperature, ethidium bromide (EtBr; 
0.5 µg/ml) was added and the mixture was poured into a gel cast with a comb to 
polymerize. An aliquot of DNA was mixed 1:5 with a 5x gel loading dye (2.5% 
glycerol or Ficoll 400, 11 mM EDTA, 3.3 mM Tris-HCl, 0.017% SDS, 0.015% 
Bromophenol Blue, pH 8.0; Bioline) to facilitate sample loading and to monitor the 
migration rate of DNA fragments and electrophoresed on the gel next to a 1 kb or  
100 bp DNA-ladder (HyperLadder™ I or V; Bioline) at 50-150 V for 0.5-1 h. A UV 
transilluminator (Uvitec) was used to excite and visualize EtBr, which intercalates into 
double-stranded DNA and fluoresces at 260 nm. 
2.1.7. Restriction enzyme digest 
Restriction enzymes (RE) are endo-deoxyribonucleases that recognize specific DNA 
sequences, and digest double-stranded DNA by cleaving two phosphodiester bonds and 
producing cohesive or blunt ends. This produces a characteristic pattern of DNA 
fragments of different sizes and can be used to create diagnostic plasmid maps or for 
cloning purposes. Each RE requires appropriate conditions such as temperature and 
buffers containing following chemicals at specific concentrations Tris-HCL, NaCl, 
MgCl2, magnesium acetate, potassium acetate, 2-β-mercaptoethanol, 1.4-dithiothreitol 
(DTT), 1.4-dithioerythritol (DTE) at a specific pH. Enzymes used in this project were 
mostly obtained from Promega, New England Biolabs or Gibco BRL.  
 For digestion DNA was mixed with 2 µl of 10x buffer, 2 µl of BSA, and 1 unit 
of enzyme per µg DNA in a final volume of 20 µl of ddH2O. The mixture was quickly 
spun in a table centrifuge and incubated at an appropriate temperature (for most 
enzymes 37°C) for a minimum of 2 h. Enzymes were heat-inactivated if possible or 
removed via phenol-chloroform extraction or another purification method (see below). 
The digest was examined via agarose gel electrophoresis. 
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2.1.8. Polymerase chain reaction (PCR) 
To amplify specific DNA sequences for diagnostic purposes or cloning PCR was 
performed using BIOTAQ™ (Bioline) reagents for most reactions (unless otherwise 
stated). A master mix of a PCR reaction was prepared per primer pair or DNA, if 
several samples were amplified. Each sample contained 1.5-5 mM MgCl2, 1x NH4 PCR 
buffer (160 mM (NH4)2SO4, 670 mM Tris-HCl pH 8.8, 0.1% stabilizer), 200 µM 
dNTPs, 25 nmol primers (Operon), 2.5 units DNA polymerase and 50-100 ng DNA 
templates in a final volume of 25 µl ddH2O. Positive and negative controls were 
included in the experiment. The samples were vortexed, spun and the reaction was run 
in a PCR thermo cycler under conditions summarized in table 2.1. The PCR products 
were analyzed via agarose gel electrophoresis. 
 
 BIOTAQ™ (Bioline)  GoTaq® (Promega) 
STEP TEMPERATURE TIME  TEMPERATURE TIME 
Heated lid 104°C   104°C  
Initial template denaturation  
(and polymerase activation) 94°C 3 min  94°C 5 min 
3-step cycling       
       Denaturation 94°C 0.5-1 min  94°C 0.5-1 min 
       Annealing 50-70°C* 0.5-1 min  50-70°C* 0.5-1 min 
       Extension 72°C 1-4 min**  72°C 1-4 min** 
Number of cycles 29-40   29-40  
Final extension 72°C 10 min  72°C 5 min 
 
Table 2.1. PCR conditions.  
* Annealing temperature was selected 5ºC below the melting temperature (Tm) of the primers;  
** Extension time was set to 1 min/1 kb. 
 
2.1.9. Purification of PCR products and RE digests 
The QIAquick® PCR purification Kit (Qiagen) was used to quickly purify PCR 
reactions and RE digests on column following the manufacturer’s instructions. It is 
based on the same principle as the mini prep (see section 2.1.3) utilizing a  
silica-membrane to bind and purify nucleic acids. All centrifugation steps were carried 
out at 13,000 rpm for 1 min at room temperature.  
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 The DNA solution was mixed with 5 volumes of binding buffer PBI (guanidine 
hydrochloride and isopropanol) and bound on a silica-gel membrane of the spin-column 
by centrifugation. The column was washed with 750 µl of ethanol-containing buffer PE 
and dried in an additional spin. To elute the DNA 30 µl EB buffer (10 mM Tris-HCl, 
pH 8.5) or ddH2O were applied onto the column, incubated for 1 min at room 
temperature and centrifuged. 
2.1.10. Gel extraction of DNA fragments  
Plasmid fragments of specific size derived from digests or PCR reactions were isolated 
via gel extraction using the QIAquick® Gel Extraction Kit (Qiagen) following the 
manufacturer’s instructions. It is based on the same principle as the mini prep (see 
section 2.1.3) utilizing a silica-membrane to bind and purify nucleic acids. All 
centrifugation steps were carried out at 13,000 rpm for 1 min at room temperature. 
 DNA was electrophoretically separated on an agarose gel. The band of correct 
size was cut out from the gel under UV-light using a sterile scalpel. To extract the DNA 
from the agarose gel band it was dissolved in 3 volumes per weight (v/w) of the 
provided buffer QG (containing guanidine isothiocyanate) for approximately 10 min at 
65°C. The DNA was then bound to a silica-gel membrane in a spin-column by 
centrifugation. The column was washed with 750 µl buffer PE and the concentrated 
purified DNA was eluted with EB buffer (10 mM Tris-HCl, pH 8.5) or ddH2O by 
centrifugation after an incubation of 1 min at room temperature. 
2.1.11. Ethanol precipitation of nucleic acids 
To purify and sterilize DNA I used the sodium acetate method. The DNA solution was 
mixed with 1/10 of its volume with 3 M NaOAc (sodium acetate), pH 5.2 and incubated 
for at least 1 h at -20ºC. The salt-DNA mixture was spun at 13,000 rpm for 15 min at  
4°C. The pellet was washed twice with 1 ml 70% ethanol to remove the salts. The pellet 
was air dried and resuspended in an appropriate volume of sterile Tris-EDTA (TE) 
buffer or ddH2O and stored at -20°C. 
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2.1.12. Phenol‐chloroform extraction 
In order to purify DNA from other organic substances such as lipids and proteins for 
instance after a RE digest phenol-chloroform extraction was performed. It is based on 
the properties of phenol to dissolve lipids and proteins, whereas DNA solubilises in an 
aqueous solution and so can be separated. 
 The DNA solution was mixed with an equal volume of phenol:chloroform: 
isoamylalcohol-solution pH 7.0 (25:24:1; Sigma) in a fume hood. The mixture was 
centrifuged at 13,000 rpm for 3 min at room temperature. The upper aqueous layer 
containing the DNA was transferred into a new tube and the lower phase was discarded. 
This step was repeated twice and subsequently ethanol precipitation (as described 
above) was performed. 
2.1.13. Alkaline phosphatase treatment 
In order to prevent re-circularisation of the plasmid after linearization with RE it was 
treated with Shrimp Alkaline phosphatase (AP). This enzyme removes the phosphate 
groups from the 5’-end and thus prevents plasmid re-circulation. 4 µl AP buffer, 1 µl 
AP (1 unit/ 1 µg DNA, Roche) and 5 µl ddH2O were added to the purified digest (30 µl) 
and incubated for 1 h at 37ºC. The AP was irreversibly deactivated by incubation for 
15 min at 65°C. 
2.1.14. Plasmid ligation 
100-200 ng linearized and AP-treated plasmid backbone were mixed with insert DNA 
in a molar ratio of 1:1, 1:2 or 1:3 (estimated by agarose gel electrophoresis), 2 µl (2U) 
T4 DNA ligase (Roche) and 4 µl ligation buffer (660 mM Tris-HCl, pH 7.8, 50 mM 
MgCl2, 10mM DTT and 10 mM ATP; Roche) in a total volume of 20 µl. The mixture 
was incubated overnight at 15°C. An aliquot of the ligation mixture was used for the 
transformation of competent E. coli.  
2.1.15. Blue‐white screen of recombinant bacterial colonies 
The blue-white screen allows the detection of successful ligations transformed into 
bacteria through the colour of the bacterial colony. It is based on the principle that the 
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β-galactosidase (β-gal) enzyme encoded by the LacZ gene can be split into two  
non-functional peptides the α and Ω subunits. Most E.coli strains used in the lab encode 
only the Ω subunits and the vectors used in this screen contain the α subunit with an 
internal multiple cloning site (MCS), into which the insert is ligated. The colourless 
modified galactose sugar X-gal, which is metabolized into the characteristic insoluble 
blue product 5-bromo-4 chloroindole, is used as an indicator. Additionally isopropyl  
β-D-1-thiogalactopyranoside (IPTG), an inducer of the transcription of the Ω subunit 
from the Lac operon in the bacterial chromosome, is used as an enhancer. When the 
ligated vector contains an insert in the MCS, the α subunit is not correctly expressed, no  
functional β-gal enzyme can be assembled, X-gal is not metabolized and hence the 
bacterial colonies remain white. If the vector is empty the colonies turn blue.  
 E.coli were transformed with the ligation mixture and grown on LB agar plates 
coated with 2 mg X-gal and 100 µM of IPTG overnight at 37ºC, and the colour 
development was examined on the following day. 
2.1.16. Micropreps 
Micropreps were used for rapid screening of a large number of bacterial colonies for the 
presence of recombinant plasmids containing inserts (protocol modified after 
(Sambrook et al., 1989)). In principle bacterial colonies are lysed in an alkaline solution 
and directly electrophoresed on a denaturing agarose gel. 
 Bacterial colonies were picked from the agar plate and incubated in 3 ml LB 
medium containing a selective antibiotic overnight at 37ºC in a shaker at 250 rpm.  
10 µl of the bacterial culture were mixed with 5 µl of protoplaster buffer (30 mM  
Tris-Cl pH 8.0, 5 mM Na2EDTA, 50 mM NaCl, 20% sucrose, 50 µg/µl RNAse A and 
50 µg/µl lysozyme), vortexed and incubated for 10 min at room temperature. 5 µl of 
lysis solution (1x TAE buffer, 2% SDS, 5% sucrose, bromophenol blue) were loaded 
into each slot of a 1% agarose gel containing 0.05% SDS and the bacterial lysate was 
added. As a control (preferably a bacterial colony containing) an empty uncut non-
recombinant plasmid was used. The gel was initially electrophoresed for 15 min at 40 V 
and then for approximately 90 min at 100 V and examined under a UV transilluminator. 
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2.1.17. Sequencing 
DNA sequencing was delegated to the Scientific Support Service at the Wolfson 
Institute for Biomedical Research at UCL. Samples were prepared with a concentration 
of 0.1 µg/1 µl of template plasmid DNA per sequencing reaction in a total volume of  
10 µl ddH2O. Standard primers were provided by the Sequencing Service (summarized 
in Table 2.2). Custom primers were provided at a concentration of 5 pmoles/ 1 µl. 
 The sequencing results were analysed using the 4 Peaks software 1.5 
(Mek&Tosj), DNASTAR Lasergene 7.2.1 software and the BLAST search against 
whole mouse genome option on NCBI/BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
 
Table 2.2. Standard sequencing primers.  
Primers were provided by the Scientific Support Service at the Wolfson Institute for Biomedical 
Research at UCL. 
 
2.1.18. Genomic DNA extraction 
Cultured cells were rinsed three times with PBS and PK lysis buffer (10 mM Tris pH 8, 
10 mM NaCl, 10 mM EDTA pH 8, 1% SDS) was added. After incubation for 5 min on 
wet ice the cells were scraped off the plate using a cell scraper and the cell suspension 
was transferred into an Eppendorf tube. Proteinase K was added at a final concentration 
of 0.5 mg/ml and the digests were incubated overnight at 55ºC until the solution was 
clear. The gDNA was then extracted using the phenol:chloroform procedure (as 
described in section 2.1.12). 
STANDARD PRIMERS SEQUENCE (5’   3’) TM (ºC) 
T3 AAT TAA CCC TCA CTA AAG GG 56.23 
T7 GTA ATA CGA CTC ACT ATA GGG C 56.02 
Sp6 ATT TAG GTG ACA CTA TAG 42.58 
M13-40 GTT TTC CCA GTC ACG AC 56.14 
M13 Reverse GGA AAC AGC TAT GAC CAT G 58.01 
Universal T7 TAA TAC GAC TCA CTA TAG GG 50.83 
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2.2. RNA methods 
2.2.1. Isolation of RNA from tissue and cell samples 
2.2.1.1. Isolation of RNA with the RNeasy® Plus Mini Kit (Qiagen) 
The RNeasy® Plus Mini Kit (Qiagen) was used to extract RNA and proteins in parallel 
from animal tissues and cells following manufacturer’s instructions. In principle, 
guanidine isothiocyanate (GITC)-containing lysis buffer and ethanol are added to the 
sample to create conditions that promote selective binding of RNA to the RNeasy® 
silica-gel membrane, contaminants are efficiently washed away, and high quality RNA 
is eluted in water. In parallel proteins may be recovered using acetone precipitation. All 
steps were carried out quickly at room temperature under RNAse-free conditions unless 
otherwise stated. All centrifugation steps were performed at 13,000 rpm in a  
micro-centrifuge at room temperature (20-25ºC). 
 For sample preparation DRGs were collected, washed with phosphate-buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, 
pH 7.4) and either snap frozen on dry ice and stored at -80ºC or directly used for RNA 
extraction. Cultured cells were washed with PBS and directly lysed on the plate with 
350 µl RLT buffer (contains GITC and 10 µl/1 ml 14.3 M β-mercaptoethanol (β-ME)) 
collected in Eppendorf tubes and stored at -20ºC or used directly for RNA extraction. 
The lysed tissue or cell samples were homogenized by passing the lysate at least 
10 times through a 20-gauge needle fitted onto an RNAse-free syringe. The sample 
lysate was spun for 3 min and the cleared lysate was transferred to a gDNA Eliminator 
spin column and centrifuged for 30 sec. The flow-through was mixed with 1 volume of 
70% ethanol and applied to a silica-gel-membrane containing RNeasy® spin column and 
centrifuged for 15 sec. The flow-through was kept for protein extraction (see below). 
The spin column was first washed with 1 volume of buffer RW1 (containing GITC and 
ethanol) and then with 500 µl buffer RPE by centrifugation for 15 sec each. To dry the 
silica-gel membrane it was spun for 2 min. RNA was eluted 2 times by centrifugation 
for 15 sec with 15 µl RNAse-free ddH2O. One µl of RNAse inhibitor (RNAsin, 
Promega) was added and the riboprobe was stored at -20ºC. 
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Acetone precipitation of protein from buffer RLT lysates  
Four volumes of ice-cold acetone were added to the flow-through of the RNeasy spin 
column, incubated for 30 min on ice and centrifuged for 10 min at 4ºC. The pellet was 
air-dried and resuspended in SDS-PAGE loading buffer, heated for 10 min at 100ºC and 
stored at -20ºC. 
2.2.1.2. Isolation of RNA with the RNeasy® Lipid Tissue Kit (Qiagen) 
At Merck Serono in Geneva the RNeasy® Lipid Tissue Kit (Qiagen) was used to extract 
RNA from murine embryonic DRGs. All centrifugation steps were performed at 
8000 x g at room temperature unless stated otherwise. Briefly, the DRG samples were 
unfrozen on wet ice and 1 ml QIAzol Lysis Reagent was added immediately. The tissue 
was disrupted with the Precellys®24 homogenizer and the samples were incubated for 
5 min at room temperature. 200 µl chloroform were added and the samples were 
vigorously shaken for 15 sec before another incubation at room temperature for 2-3 min 
followed by a centrifugation at 12.000 x g for 15 min at 4ºC. The upper, aqueous phase 
was transferred to a new tube, 1 volume of 70% ethanol was added and the sample was 
mixed. The solution was applied onto a spin column, centrifuged for 15 sec and the 
flow through discarded. In order to avoid genomic DNA contamination a DNAse I 
digest was performed using an RNAse-free DNAse Set (Qiagen). 350 µl supplied buffer 
RW1 were added to the spin column, which was centrifuged for 15 sec. 10 µl DNAse I 
stock solution were mixed with 70 µl buffer RDD and directly added onto the spin 
column membrane and incubated for 15 min at room temperature. The column was 
washed sequentially with 350 µl buffer RW1 and 500 µl buffer RPE and the membrane 
was dried by centrifugation for 1 min. For RNA elution 30 µl of RNAse-free water were 
added onto the column and centrifuged for 15 sec. The elution was repeated with the 
eluted 30 µl to concentrate the RNA. mRNA purity (260/280 ratio) and concentration 
were measured using the NanoDrop. The RNA was stored at –80ºC for further use. 
2.2.2. Test of RNA integrity 
The integrity of ribosomal RNA (rRNA) was measured using the RNA 6000 Nano 
LabChip® Kit (Agilent) on an Agilent 2100 BioAnalyzer® (Agilent Biotechnologies) as 
an indicator for total RNA integrity in the samples. To prepare the multi-well chip 65 µl 
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of filtered gel matrix and 1 µl of dye were mixed and centrifuged at 13,000 x g for  
10 min. Nine µl of this matrix-dye solution were added to each well of the chip and 
pressed through with a 1 ml-piston for 30 sec. Then 5 µl of Nano Marker were added in 
all wells of the chip. Finally 2 µl of the RNA samples were heated for 2 min at 70°C 
and added to the wells as well as 1 µl of the ladder. The chip was then vortexed for  
1 min at 2400 rpm and placed into the BioAnalyzer to start the analysis. The integrity of 
the RNA is indicated by the RIN values of the rRNA (18S and 28S rRNA) and the 
electropherogram, which should reveal two distinctive peaks or bands of the rRNA. 
Only RIN values between 4-10 are acceptable.  
2.2.3. Reverse transcription (RT) of mRNA into cDNA 
2.2.3.1. RT using the QuantiTect® RT Kit (Qiagen) 
The QuantiTect® RT Kit (Qiagen) was used to transcribe mRNA into cDNA following 
manufacturer’s instructions. It utilizes a transcriptase mix of Omniscript™ and 
Sensiscript™ Reverse Transcriptases and an optimized blend of oligo-dT and random 
primers, which allows highly efficient cDNA transcription from all regions of RNA 
transcripts and even 5’ regions. All reactions were assembled on ice. To eliminate 
residual genomic DNA in the RNA sample, 1 µg of RNA and 2 µl of the 7x gDNA 
wipe-out buffer were mixed in a total volume of 14 µl RNAse-free ddH2O, incubated 
for 2 min at 42ºC and then cooled on ice. For the reverse transcription reaction the 
entire genomic elimination reaction was mixed with 1 µl transcriptase, 4 µl 5x RT 
buffer and 1 µl RT primer mix and incubated for 20 min at 42ºC in a PCR cycler. The 
transcriptase was inactivated by heating at 95ºC for 3 min. The total cDNA 
concentration was adjusted to 10 ng/µl with RNAse-free ddH2O and stored at -20ºC. 
2.2.3.2. RT using the iScript™ cDNA Synthesis Kit (BioRad) 
At Merck Serono, Geneva, the mRNA was reverse transcribed into cDNA using 
the iScript™cDNA Synthesis Kit (BioRad). iScript™ is a modified MMLV-derived 
reverse transcriptase. Briefly, 1x reaction mix containing RNAse inhibitor and a blend 
of oligo (dT) and random hexamer primers, 2 µl reverse transcriptase and 1 µg mRNA 
were mixed in a total volume of 30 µl ddH2O. The mix was incubated for 5 min at 
25ºC, 30 min at 42ºC, and 5 min at 85ºC in a PCR thermo cycler. The reaction was  
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adjusted with RNAse-free ddH2O to a concentration of 1 µg/100 µl total cDNA and 
stored at -20ºC.  
2.2.4. Quantitative RT real‐time PCR (qPCR) with SYBR Green 
For gene expression analysis the QuantiFast® SYBR Green PCR Kit (Qiagen) was used. 
It contains a master mix of HotStarTaq Plus DNA Polymerase, SYBR Green I, ROX as 
a passive reference dye, dNTPs and an optimized QIAGEN PCR buffer system, which 
provides stringent primer annealing conditions and hence increased PCR specificity. It 
also contains Q-Bond, which increases the affinity of Taq DNA polymerases for short 
single-stranded DNA and reduces the time required for primer annealing. 
 A master mix was prepared per primer pair and combined with the cDNA on a 
96-well-plate at room temperature. Each reaction contained 6.25 µl 2x SYBR Green 
PCR Master mix, 1.25 µl 10x QuantiTect® Primer Assay mix, 1.5 µl (~15 ng) template 
cDNA and 3.5 µl ddH2O in a total volume of 12.5 µl.  
 All primers were obtained as QuantiTect® Primer Assays (Qiagen) unless 
otherwise stated. A proprietary algorithm was used to design these primers, which only 
amplify RNA sequences (overlap a splice site). The primers were all bioinformatically 
validated and also randomly tested in qRT-PCR experiments. They were only selected, 
when the criteria of high sensitivity, efficiency and specificity such as a single peak in 
the melting curve analysis and no primer dimers in the no-template control (NTC) etc. 
were met. 
 The qPCR was run in duplicates in the 7500 Fast Real-Time PCR System 
(Applied Biosystems) under following PCR conditions: stage 1 (initial activation step): 
95ºC for 5 min, stage 2: 40 cycles (10 sec at 95ºC (denaturation) and 30 sec at 60ºC 
(annealing and extension)), stage 3 (dissociation curves): 15 sec at 95ºC, 15 sec at  
60ºC, 15 sec at 95ºC with a heated lid at 105ºC. Data acquisition was performed during 
the combined annealing and extension step. PCR products were examined by agarose 
gel electrophoresis.  
 For data analysis the 7500 software SDS v 2.0.1 (Applied Biosystems) was used 
to adjust the baseline measured between cycles 3 and 15 and to set the threshold to 
ΔRn 0.1. Dissociation curves of each reaction were examined for a single product peak 
and no primer dimer formation otherwise data were omitted from the analysis. In 
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ambiguous cases products were examined for specificity of the reaction (single product 
band) via gel electrophoresis. In ideal cases no amplification was observed in the  
non-targeting control (NTC) samples containing ddH2O instead of template DNA or in 
some cases the shift in the CT value or in the melting curve between experimental and 
control sample was sufficient to distinguish between specific and non-specific signals. 
CT values were then extracted and analysed with Microsoft® Excel®. Data were 
normalized to an endogenous reference gene (ΔCT) and compared to an untreated or 
mock treated control sample (ΔΔCT) (Livak and Schmittgen, 2001). The results were 
displayed as percentage of expression relative to the control sample. Statistical analysis 
was performed using Prism 4 (GraphPad Software) as described in section 2.7. 
 
2.3. Protein methods 
2.3.1. Cell lysis  
Cultured cells (5-10 x 106) were washed twice with ice-cold PBS. Depending on the cell 
amount they were either collected via trypsinization or directly scraped from the plate in 
PBS and collected in a 15 ml falcon tube. The cell suspension was centrifuged for 4 min 
at 1500 rpm and the supernatant was aspirated. The cell pellet was dissolved in 1-2 ml 
of lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl2, 1% Triton x-100, 200 µl 50x serine 
and cysteine proteinase inhibitor cocktail (Complete EDTA-free tablets; Roche), 2 mM 
of the PTP inhibitor Sodium Orthovanadate (BioLabs) and incubated on ice for 30 min. 
The lysate was centrifuged at 13,000 rpm for 30 min at 4ºC and the supernatant was 
saved and frozen at -20ºC. 
2.3.2. Protein quantification  
To measure the protein amount in lysates the Bradford assay (Bio-Rad) was used. It is a 
colorimetric method based on the Coomassie dye, which binds through ionic 
interactions and non-covalent bonds to non-polar amino acids in the polypeptides. Upon 
binding of Coomassie dye to proteins in an acidic medium its absorption maximum 
shifts from 465 to 595 nm causing a colour change from brown to blue. Relative protein 
concentrations are estimated by comparison of the absorbance of the sample to the 
absorbance obtained from a series of standard protein dilutions (Bradford, 1976). 
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 A protein standard consisting of 5 serial dilutions of bovine serum albumin 
(BSA) ranging from 1.5 to 0.1 mg/ml in lysis buffer including a blank (no protein) was 
prepared. Experimental protein samples were diluted 1:2 or 1:5 in lysis buffer. 10 µl of 
sample or standard were mixed with 200 µl of Bradford reagent (Coomassie® Brilliant 
Blue G-250, methanol, phosphoric acid) in a well of a 96-well-plate in duplicates. 
During incubation at 37ºC for 10 min the reagent changed colour from brown to blue. 
The absorbance was read at 595 nm on a micro-plate-reader (Dynex Revelation 4.21, 
Dynex Technology). For data analysis all measurements were corrected for blank and a 
plot of standard vs. concentration prepared. The slope was used to estimate the protein 
concentration of the unknown samples. 
2.3.3. Western blotting/ Immunoblotting 
In principle the denaturing one dimensional (1-D) polyacrylamide gel electrophoresis 
(PAGE) separates proteins according to their molecular weight. The proteins are 
subsequently electrophoretically eluted from the gel onto a membrane and the proteins 
of interest are detected with specific antibodies in an immuno assay. A denaturing Tris-
Glycine system and a semi-dry blotting system from Bio-Rad Laboratories were used. 
2.3.3.1. Sample preparation 
Protein lysates were mixed in a 1:1 ratio with 2x Laemmli buffer (4% sodium-dodecyl-
sulphate (SDS), 20% glycerol, 10% β-ME, 0.004% bromophenol blue, 0.125 M  
Tris-HCl, pH 6.8; Sigma), heated at 100ºC for 5 min to denature the proteins and stored 
on ice to be loaded on the gel.  
2.3.3.2. SDS-polyacrylamide gel electrophoresis (PAGE) 
Eight and 10% polyacrylamide gels consisting of a stacking and a resolving gel were 
used. To prepare the separating gel 3.3 ml of 30% acrylamide/bis-acrylamide (29:1) 
solution (Bio-Rad) were mixed with 2.5 ml gel buffer (1.5 M Tris-HCL, pH of 8.8),  
4.1 ml ddH2O, 100 µl 10%-SDS and finally 50 µl 10%-amonium persulfate (APS, 
Sigma) and 5 µl TEMED (N,N,N',N'-Tetrame-thylethylene-diamine, Sigma). The mix 
was poured into a vertical gel mould, covered with isobutanol and left to polymerize for 
30 min. When set, the isobutanol was poured off and the mould was washed with 
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ddH2O. A 1% stacking gel consisting of 650 µl 30% acrylamide/bis-acrylamide solution 
(Bio-Rad), 1.25 ml gel buffer (0.5 M Tris-HCL, pH of 8.8), 3 ml ddH2O, 50 µl 10% 
SDS, 25 µl 10% APS and 2.5 µl TEMED was poured onto the resolving gel, a multi-
well-comb was inserted and the gel left to polymerize for 20 min. 15 µl protein ladder 
(Precision Plus Protein™, BioRad) and protein samples were then loaded onto the gel. It 
was placed into a running chamber filled with running buffer (25 mM Tris-base,  
192 mM glycine, 10% SDS, ddH2O) and electrophoresed first at 70 V until the samples 
reached the resolving gel and then at 100-200 V for 1-1 ½ h. 
2.3.3.3. Transfer of proteins onto PVDF membranes  
After electrophoreses the gel was equilibrated for 15-30 min in transfer buffer (39 mM 
glycine, 48 mM Tris-Base, 0.13 mM SDS, ddH2O, 20% methanol). Meanwhile the 
polyvinylidene difluoride (PVDF) membrane (Immobilon Transfer Membrane; 
Millipore) was activated in methanol for 1 min, washed in ddH2O for 2 min and 
equilibrated in transfer buffer for 10 min. 2 Whatman filter papers were soaked in 
transfer buffer and a transfer sandwich was assembled by placing the gel onto the 
membrane between the two Whatman filter papers. The transfer occurred at 22 V for  
1 h towards the positive electrode in a semi-dry electroblotting apparatus (TransBlot SD 
Semi Dry transfer cell, Bio-Rad). 
2.3.3.4. Immunoblotting 
Following the transfer the membrane was incubated in methanol for 10 sec and dried for 
15 min at room temperature to enhance the adsorption of the proteins to the PVDF 
polymer. The membrane was again wet in methanol for 5 min and incubated in blocking 
solution (5% Milk Powder (Waitrose or Tesco), TBST buffer (50 mM Tris, 150 mM 
NaCl, 0.2% Tween® 20, Sigma) for 1h with gentle agitation on a shaker at room 
temperature to block non-specific binding sites. The membrane was washed 2 times 
5 min in TBST and incubated for 1 h at room temperature or overnight on a roller at  
4ºC in 5%-milk-TBST solution containing monoclonal primary antibodies or in  
5%-BSA fraction V-TBST solution containing polyclonal primary antibodies  
(Table 2.3). 
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2.3.3.5. Detection of antibodies 
The membrane was washed 3 times each 10 min in TBST and incubated in 5%-milk-
TBST solution containing the secondary IgG horseradish peroxidase (HRP) conjugated 
antibody (Table 2.4) with gentle agitation for 1-2 h at room temperature. The membrane 
was washed once again and the antibodies were detected with ECL Plus Western 
Blotting Detection System (Amersham Biosciences), an Enhanced Chemiluminescence 
(ECL) method. In principle chemiluminescence is the emission of light resulting from 
the release of energy from a substance in an excited state caused by a chemical reaction. 
The chemical reaction is an HRP/Hydrogen Peroxide catalyzed oxidation of luminol, a 
cyclic Diacylhydrazides, in alkaline conditions, resulting in light emission in the 
presence of chemical enhancers such as phenols. The membrane was incubated for 
5 min with ECL reagent and wrapped in saran foil followed by exposure of a light 
sensitive autoradiography film (Chemiluminescence BioMax Light Film, KODAK) 
placed into an x-ray film cassette in the dark. The films were developed in the Compact 
X4 Automatic X-ray Film Processor (Xograph Healthcare Ltd). 
2.3.3.6. Stripping membranes for reprobing 
In order to apply a further primary antibody on the same blot, the membrane was 
stripped after detection. For this the membrane was wet in methanol for 10 sec and 
incubated in stripping buffer (100 mM β-ME, 2% SDS, 62.5 mM Tris-HCl pH 6.7) with 
occasional agitation for 30-45 min at 50-60ºC. It was washed 4 times each 5 min with 
TBST and used for further immunoblotting as described above beginning with the 
blocking step. 
2.3.3.7. Quantitative densitometry analysis  
Quantitative western blotting analysis was performed on technical replicates of blots 
from two or three independent experiments. Briefly, developed films were scanned with 
the GS-800 Calibrated Densitometer (Bio-Rad) using Quantity One® Software (version 
4.6.3, Bio-Rad). For analysis of protein signals the Volume Rectangle Tool of the 
Quantity One® Software with equal space areas were used to quantify signal intensity of 
specific protein bands. The volume values, reduced by global background, are the sum 
of the intensities of the pixels inside the volume boundary multiplied by the area of a 
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single pixel (in mm2). The data were exported to Microsoft® Excel® and protein 
expression was normalized to the expression of the HKG β-tubulin or to the total 
unphosphorylated protein. Ratios of normalized volumes were calculated in respect to 
the mock treated or wild type control (= 1) and standard errors (SE) were determined. 
2.3.4. Coomassie Brilliant Blue staining of PAGE gels 
Polypeptides separated by SDS-PAGE gels can be stained with Coomassie Brilliant 
Blue R250, a dye that binds through ionic interactions and non-covalent bonds to non-
polar amino acids and thus visualizes the polypeptides. This procedure was used to 
analyse gels for complete electrophoretic transfer onto membranes and also to estimate 
total protein amounts in the samples. 
 After electrophoreses the SDS-PAGE gel was submerged in a Coomassie-
staining and fixation solution (0.25% Coomassie Brilliant Blue R250 (Invitrogen),  
40% methanol, 10% acetic acid) with gentle agitation for 30 min at room temperature. 
To remove background it was incubated in coomassie-destaining solution  
(40% methanol, 10% acetic acid) with gentle agitation and frequent changes of solution 
for up to 24 h. The destained gel was scanned with the GS-800 Calibrated Densitometer  
(Bio-Rad) and stored in ddH2O. 
2.3.5. Primary and secondary antibodies 
Primary and secondary antibodies were commercially obtained or kindly provided by 
collaborators as listed in tables 2.3 and 2.4. Primary Trk and pTrk antibodies were 
tested in WB experiments for their specificity (Appendix, Figures 1 and 2). 
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PRIMARY 
ANTIBODY SPECIES 
SUPPLIER 
(Cat. No.) 
EPITOPE and 
REFERENCES 
DILUTION   
IHC/ WB 
TrkA  Rabbit, polyclonal 
Upstate            
(# 06-574) 
ECD of TrkA protein 
(Clary et al., 1994, Kramer et al., 
2006) 
1:500/ 1:5000 
TrkB  Goat, polyclonal R&D (AF1494) 
ECD of TrkB protein (Komori et 
al., 2008) 1:75/ 1:3000 
TrkC   Goat, polyclonal R&D (AF1404) 
ECD of TrkC protein (Nakamura et 
al., 2008, Zhang et al., 2010) 1:75/ 1:3000 
panTrk (C-14) Rabbit, polyclonal SC (sc-139) 
ICD of all Trk proteins (Lo et al., 
2005, Nikoletopoulou et al., 2010) 1:125/ 1:1000 
pTrkA (Y496) (E-6) Mouse, monoclonal SC (sc-8058) 
Phosphorylated Y496 of all TrkA 
proteins (Jullien et al., 2003) 1:1000 (WB) 
pTrkA (Y674/Y675)/ 
TrkB (Y706/Y707)  
Rabbit, 
monoclonal CS
 (# 4621) 
Phosphorylated Y674/675 of TrkA 
and Y706/707 of TrkB and TrkC 
(Lo et al., 2005) 
1:1000 (WB) 
pTrkA (Y490)  Rabbit, polyclonal CS (# 9141) 
Phosphorylated Y490 of all Trk 
proteins (Lo et al., 2005, Yang et 
al., 2006) 
1:1000 (WB) 
pTrkA (Y794)  
(= pTrk*) 
Rabbit, 
polyclonal 
M. Chao/ 
S.Harroch 
Phosphorylated Y794 of all Trk 
proteins, (Rajagopal et al., 2004) 1:1000 (WB) 
pTrkB (Y816) 
(= pTrk**) 
Rabbit, 
polyclonal 
M. Chao/ 
S.Harroch 
Phosphorylated Y816 of all Trk 
proteins, (Arevalo et al., 2006). 1:1000 (WB) 
pAkt (S473) (D9E) 
XP™ 
Rabbit, 
monoclonal CS (# 4060) 
Phosphorylated S473 of Akt protein 
(Lo et al., 2005, Mandai et al., 
2009) 
1:2000 (WB) 
p44/42 MAPK Rabbit, polyclonal CS (# 9102) 
Total p44/42 MAP kinase 
(Erk1/Erk2) protein (Lo et al., 2005, 
Mandai et al., 2009) 
1:1000 (WB) 
p44/42 MAPK 
(T202/Y204) (E10) 
Mouse, 
monoclonal CS (# 4060) 
p44/42 MAPK (Erk1/Erk2) when 
dually phosphorylated at T202 and 
Y204/T815 and Y187 (Lo et al., 
2005, Mandai et al., 2009) 
1:2000 (WB) 
Stat3 (124H6) Mouse, monoclonal CS (# 9139) 
Total Stat3 protein (Zhang et al., 
2007b, Miranda et al., 2010) 1:1000 (WB) 
pStat3 (Y705) 
(M6C6) 
Mouse, 
monoclonal CS (# 4113) 
Phosphorylated Y705 of Stat3 
protein (Zhang et al., 2007b, 
Miranda et al., 2010) 
1:2000 (WB) 
TU-20 (Tuj1) Mouse, monoclonal CI (MAB1637) 
C-terminus of β III tubulin in 
neuronal processes (Vaegter et al., 
2011) 
1:150 (IHC) 
β  tubulin (H-235) Rabbit, polyclonal SC (sc-9104) 
Amino acids 210-444 of β tubulin 
protein (Sacco et al., 2009) 1:5000 (WB) 
 
Table 2.3. Primary antibodies used for ICC, IHC and WB.  
CI stands for Chemicon® International, R&D for R&D Systems, SC for Santa Cruz 
Biotechnology, INC., CS for Cell Signaling Technology®, SA for Sigma-Aldrich®.  
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SECONDARY 
ANTIBODY SPECIES 
SUPPLIER           
(Cat. No.) EPITOPE 
DILUTION    
IHC/ WB 
anti-mouse/goat/rabbit 
Immunoglobulins/ 
Biotinylated 
Goat/rabbit, 
polyclonal 
Dako Cytomation 
Denmark A/S 
Mouse/rabbit or goat 
immunoglobulins of all 
classes 
1:200/ 
1:10000 
anti-mouse/ goat/rabbit 
Immunoglobulins/HRP 
Goat/rabbit, 
polyclonal 
Dako Cytomation 
Denmark A/S 
Mouse/rabbit or goat 
immunoglobulins of all 
classes 
1:200/ 
1:10000 
anti-goat Alexa Fluor® 
488  
Donkey, 
polyclonal 
Invitrogen®           
(A-11055) 
goat immunoglobulins 
of all classes 1:100 (IHC) 
FluoroLink™Cy™3 
labelled streptavidin  
Amersham Biosciences 
(PA43001) Biotinylated antibodies 1:400 (IHC) 
 
Table 2.4. Secondary antibodies and dyes used for ICC, IHC and WB. 
 
2.4. Histology and cytology methods 
2.4.1. Collection of mouse embryos 
Wild type CD-1 mice were maintained and matings set up by the Western Laboratory at 
the Institute of Child Health. Detection of vaginal plugs was considered 0.5 days of 
gestation (E0.5). The mice and embryos were sacrificed at midday of E12.5, E13.5 and 
E14.5. Uteri were dissected and the embryos were immediately placed into Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma). Extra-embryonic tissue was removed and 
the embryos were either washed in PBS and fixed (section 2.4.2) or used for DRG 
dissections (section 2.5.3). 
2.4.2. Sample tissue preparation and cryosectioning 
For sample preparation the mouse embryos (E12.5-14.5) were fixed in 4%-paraform-
aldehyde (PFA)-PBS solution overnight at 4ºC and cryoprotected by equilibration in an 
RNAse-free 20%-sucrose-PBS solution for 4-5 hours at room temperature. The 
embryos were embedded either in Cryo-M-bed O.C.T. embedding compound (Bright 
Instrument Co.), a formulation of water-soluble glycerols and resins, or in gelatine.  
 For embedding in O.C.T. embryos were briefly washed in PBS after 
cryoprotection and submerged in O.C.T. in a polystyrene beaker (cryomold), which was 
cooled in a pentane - dry ice-bath until fully frozen, which was indicated by its opaque 
colour, and stored at –80ºC.  
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 For embedding in gelatin embryos were incubated in sucrose–gelatine solution 
(15% sucrose, 7.5% gelatine (from bovine skin, type B; Sigma), diethyl-pyrocarbonate 
(DEPC)-treated PBS) for 1 hour at 37ºC. They were placed into a fresh sucrose-gelatine 
solution in a petri dish and cooled until set. The embryos were cut out into appropriate 
blocks, placed onto thin cork pieces with a drop of O.C.T., immersed in isopentane  
pre-cooled to -80ºC (with liquid nitrogen) for 1 min and stored at -80ºC.  
 For sectioning the embryos were equilibrated to -20ºC and sectioned (11 µm) 
with a cryostat (Leica CM 1900 UV). Sections were thaw-mounted onto charged 
SuperFrost® Plus microscope slides (VWR) and stored at -20ºC. 
2.4.3. In situ hybridization 
In situ hybridization (ISH) is a technique used to visualize the location of DNA or RNA 
in cells. Probes, which are reverse complimentary or “anti-sense” to the nucleic acid 
sequence of interest, are labelled with chemical groups, which can be recognized by 
specific antibodies linked to reporter enzymes. The probes are hybridized under 
stringent conditions to the specimen and excess probes are removed with several 
washes. Antibodies linked to reporter enzymes recognize the label on the probes and 
can be detected by addition of substrates of the reporter enzymes such as chromophores 
or fluorophores.  
 The used protocol in this study is a modified version of published protocols 
(Alonso et al., 2004, Schaeren-Wiemers and Gerfin-Moser, 1993, Wilkinson and Nieto, 
1993, Pringle et al., 1996). All materials were RNAse-free, solutions were prepared 
with RNAse-free chemicals and DEPC-treated reagents, which were all obtained from 
Roche unless otherwise stated. 
2.4.3.1. Generation of template DNA  
A transcription plasmid containing the cDNA of the gene to be analyzed was linearized 
with appropriate RE in order to obtain RNA probes (sense and anti-sense) of defined 
length. 10-20 µg of template DNA were digested in a total volume of 100 µl for 1-2 h at 
37ºC and an aliquot was examined on an agarose gel. The digested template DNA was 
cleaned using the QIAquick® PCR purification Kit (Qiagen).  
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2.4.3.2. In vitro transcription of in situ riboprobes 
The RNA-probe was transcribed using a specific phage RNA-polymerase, which 
anneals to and transcribes from promoters such as T3, T7 or SP6. For chromogenic ISH 
probes were labelled with digoxigenin (DIG) and for fluorescent ISH one of the probes 
was also labelled with fluorescein isothiocyanate (FITC). 
 The in vitro transcription reaction containing 2.5 µl of linearized template DNA 
(approx. 1 µg), 2 µl of 10x transcription buffer, 6 µl of 100 mM DTT, 2 µl of 10x DIG 
or FITC RNA labelling mix (10 mM each of dATP, dCTP, dGTP, 6.5 mM dUTP, 
3.5 mM DIG-11-UTP or 3.5 mM FITC-12-UTP), 1 µl (20 U) RNAse Inhibitor 
(Bioline), 2 µl (20 U) of the appropriate RNA polymerase (SP6, T3 or T7) and ddH2O 
in a final volume of 20 µl was set up at room temperature. The mixture was gently 
mixed and incubated for 2 h at 37ºC. An aliquot was examined by agarose gel 
electrophoresis using DEPC-treated gel-loading dye (50% glycerol, 1 mM EDTA 
pH 8.0, 0.25% bromphenol blue, 0.25% xylene cyanol FF). 
 The probe was cleaned from unincorporated nucleotides, which might increase 
background, by size exclusion chromatography using a resin-containing spin column 
(CHROMA SPIN™-1000 DEPC-H2O Columns, BD Biosciences). The spin column was 
prepared by re-suspending the resin by inverting and drying via centrifugation in a  
15 ml-falcon tube at 700 g for 5 min at 4°C. 40 µl DEPC-treated H2O were added to 
20 µl of the transcription reaction and the mix was loaded in the centre of the column, 
spun at 700 g for 5 min at 4°C and eluted into a centrifuge tube. 40 µl of 100 mM DTT 
and 1 µl RNase inhibitor were added to the probe, which was stored at -20°C. An 
aliquot was examined by agarose gel electrophoresis using a formaldehyde-loading dye. 
2.4.3.3. Single chromogenic and fluorescent ISH  
Single chromogenic and fluorescent ISH was performed on O.C.T. or gelatine sections. 
Frozen slides with O.C.T. sections were dried at room temperature, whereas slides with 
gelatine sections were washed in DEPC-treated PBS at 37ºC for 30 min before 
hybridization.  
 RNA probes were diluted 1:100 in pre-warmed (65ºC) hybridization buffer 
(1x "salts" (0.2 M NaCl, 5 mM EDTA, 10 mM Tris-HCl pH 7.5, 5 mM NaH2PO4.2H2O, 
5 mM Na2HPO4), 50% deionized formamide, 0.1 mg/ml yeast tRNA, 10% dextran 
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sulphate, 1x Denhardt's solution (1% Ficoll 400, 1% Polyvinylpyrrolidone (PVP), 1% 
BSA). Slides were incubated with 300 µl of this solution covered with a coverslip and 
incubated in a sealed humidified chamber filled with wash buffer (1x sodium citrate 
chloride (SSC) buffer (0.3 M sodium citrate, 3 M NaCl), 50% formamide, 0.1%  
Tween-20) at 65ºC overnight. After hybridisation the coverslips were removed and the 
slides were washed twice for 5 min at room temperature in MABT (100 mM maleic 
acid, 150 mM NaCl, 0.1% Tween-20, pH 7.5), followed by 2 stringency washes for  
30 min at 65ºC in wash buffer in order to remove non-specifically bound probes. After a 
second round of washes in MABT the slides were incubated in blocking solution  
(2% blocking reagent (Roche), 10% heat inactivated sheep serum, MABT) in a 
humidified chamber for 1 h at room temperature.  
 For chromogenic detection of the probe alkaline phosphatase (AP)-conjugated-
anti-DIG/FITC Fab fragments (Roche) were diluted 1:1500 or for fluorescent detection 
horseradish peroxidase (HRP)-conjugated anti-DIG/FITC Fab fragments (Roche) at a 
dilution of 1:500 in blocking solution were used. 500 µl of the antibody-solution were 
added per slide and incubated in a humidified chamber filled with water overnight at  
4ºC. The excess antibodies were washed off with MABT for chromogenic detection or 
PBS-T (PBS with 0.1% Triton x 100) for fluorescent detection 3 times each for 10 min. 
 For chromogenic detection the slides were washed for 2 min at room 
temperature in developing buffer (100 mM Tris pH 9.8, 100 mM NaCl, 50 mM MgCl2) 
and incubated with 500 µl per slide of developing buffer containing 5% 
polyvenylalcohol (PVA) and the AP substrates 0.12 mM NBT (Nitro-Blue Tetrazolium 
Chloride) and 0.11 mM BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine 
Salt). The purple colour was developed for at least 1 h to overnight. Reactions were 
stopped using tap water. 
 For fluorescent detection the Tyramide Signal Amplification (TSA) plus 
fluorescent system kit (PerkinElmer Life Sciences) was used. Briefly, HRP-conjugated 
antibodies against DIG or FITC-labelled probes are used to catalyze the deposition of a 
fluorophore-labelled tyramide amplification reagent, FITC or Tetramethylrhodamine, 
onto tissues. The fluorophore-labelled tyramide dissolved in dimethyl sulphoxide 
(DMSO, Sigma) was mixed 1:150 with amplification buffer (100 mM borate buffer 
pH 8.0 (borax and boric acid), 0.004% H2O2) prior to detection. 200 µl of this reagent 
mix were added per slide covered with a coverslip and incubated in the dark for 10 min 
Chapter 2 
 
  94 
at room temperature. After a wash in PBS-T for 10 min the slides were examined under 
a fluorescent microscope. 
 The stained slides were finally washed with ddH2O and dried. Chromogenically 
stained slides were mounted in VectaMount™ medium (Vector Laboratories), allowed to 
dry and stored at room temperature. Fluorescent slides were mounted in Vectashield® 
medium (Vector Laboratories) containing 4',6-diamidino-2-phenylindole (DAPI), a 
fluorescent stain that binds strongly to DNA and hence stains cell nuclei. The coverslip 
was sealed with nail polish and the slides were stored in the dark at cold temperatures. 
2.4.3.4. Double fluorescent ISH on O.C.T. sections  
In principal double fluorescent in situ hybridization (DFISH) was performed in the 
same way as single ISH, but instead of one probe two differently labelled (DIG and 
FITC) probes were hybridized to the specimen in the same step. After the first colour 
reaction the reporter enzyme was deactivated by incubation for 30 min in 3%  
H2O2-PBS solution before proceeding with the second colour reaction starting with the 
blocking step. 
2.4.3. Fluorescent ICC and IHC/ Immunofluorescence 
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are techniques used to 
detect antigens on cells or in tissue sections respectively using specific antibodies. 
Fluorescent ICC and IHC are also referred to as immunofluorescence (IF). Primary and 
secondary antibodies and fluorophores used in the present study are summarized in 
tables 2.3 and 2.4.  
 For ICC the cells were fixed onto coverslips or directly on the plate with 4% 
PFA–PBS for 15 min, washed twice with PBS and stored in PBS containing 0.2% 
sodium azide at 4ºC. For IHC tissue sections were obtained and prepared as described in 
section 2.4.2. To prevent non-specific binding, the samples (cells or sections) were pre-
blocked with 1% BSA/PBS/0.05% Triton X-100 for 15 min at room temperature. The 
primary antibody was diluted in 3% BSA/PBS/0.05% Triton and added to the section or 
coverslip. After incubation in a humidified chamber for 30-60 min, depending on the 
antibody, the slides or coverslips were washed 3 times each for 5 min with 0.1% 
BSA/PBS/0.05% Triton. The secondary biotin-conjugated antibody was diluted in 3% 
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BSA/PBS/0.25% Triton and added for 1h, followed by washes as above. The 
streptavidine-conjugated fluorophore was diluted in 3% BSA/PBS/0.25% Triton and 
incubated in the dark for 1 h at room temperature followed by washes as above. For 
double immunostaining the section or coverslip was blocked once again and the same 
procedure was carried out with a second primary antibody of an other species than the 
first primary antibody as described above. Slides or coverslips were mounted with 
Vectashield® medium containing DAPI. Pictures were taken and processed as described 
in section 2.6. 
 
2.5. Cell culture methods 
2.5.1. Maintenance of adherent cell lines 
In this project two different cell lines were used, HEK 293T cells and 3T3 cells. HEK 
293T cells are human embryonic kidney cells, which were transformed with an 
adenovirus. This particular variant contains the SV40 Large T-antigen, which allows the 
replication of plasmids containing the SV40 origin of replication (Graham et al., 1977). 
The 3T3 cell line is a standard fibroblast cell line originally obtained by Todaro and 
Green from Swiss mouse embryo tissue, that spontaneously immortalized during 
cultivation (Todaro and Green, 1963). 
2.5.1.1. Culture of adherent cell lines 
HEK 293T and NIH 3T3 cells were cultured in growth medium containing DMEM,  
10% heat-inactivated fetal bovine serum (FBS; Sigma) and 1% penicillin (100 U/ml) 
and streptamycin (100 µg/ml) mixture (Sigma) in a tissue culture incubator in the 
presence of 5% CO2 at 37ºC. Cells were fed 2 to 3 times a week. 
 For subculturing of the adherent cells they were washed with pre-warmed PBS, 
harvested with a trypsin-EDTA solution (0.05% trypsin and 0.5 mM EDTA; Sigma) and 
pelleted at 1000 rpm for 4 min. The cell pellet was resuspended in an appropriate 
amount of growth medium containing serum, which inhibits trypsin. 10 µl of cell 
suspension were mixed 1:1 with 0.4% trypan blue (Sigma), which stains dead cells, 
incubated for 5-10 min at room temperature, and cells were counted using a 
haemocytometer (Neubauer improved, Superior Marienfeld Laboratory Glassware). An 
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appropriate amount of cells was plated on dishes or in flasks in growth medium and 
incubated in a 5% CO2-incubator at 37ºC. 
2.5.1.2. Freezing and thawing of cell lines 
Cell lines can be frozen and preserved indefinitely in liquid nitrogen (N2, -196ºC). A 
cryoprotective agent such as glycerol or dimethyl sulfoxide (DMSO, Sigma) has to be 
used as it lowers the freezing point and hence prevents crystal formation inside the cells 
and hence lethal rupture of the cells. Storage of cells below -130ºC further retards 
crystal formation. 
 The cells were harvested and resuspended at a concentration of 106-107 cells/ml 
in ice-cold freezing medium containing 90% FBS and 10% DMSO. 1 ml aliquots were 
transferred into cryo vials on ice and placed in the “Mr. Frosty” (Nalgene® labware), a 
Cryo Freezing Container, which contains isopropanol and decreases its temperature at a 
rate of 1º/min, and stored at -80ºC overnight. Finally the cells were transferred into 
liquid nitrogen.  
 To thaw frozen cells, vials were recovered from liquid nitrogen and transferred 
into a water bath at 37ºC for 1 min. The cells were seeded on dishes with pre-warmed 
growth medium and cultured overnight. Dead floating cells were removed during 
washes with PBS and cells were grown for one week to recover before their use in 
experiments.  
2.5.1.3. Transient transfection with calcium phosphate  
Cells were cultured until they reached a confluence of 70-80% and before transfection  
the medium was replaced with fresh growth medium. Per transfection of a 10 cm2 
dish/12-well-plate 10/1-2 µg of sterile high quality DNA in 450/90µl ddH2O were 
mixed with 50/10 µl of 2.5 M CaCl2. 500/100 µl of 2x HeBS (280 mM NaCl, 50 mM 
HEPES, 1.5 mM Na2HPO4, pH 7.05 adjusted with 5 M NaOH) were preloaded in a 
sterile 15 ml conical tube and the DNA/CaCl2 mixture was added drop-wise, whilst 
bubbling air up with an automatic pipette pump. The DNA/CaCl2/2x HeBS solution was 
incubated for 20 min at room temperature and then pipetted drop-wise onto the cells. 
After an incubation time of 6-16 h the cells were washed with PBS and fresh complete 
medium was added. 48 h after transfection the cells were examined for transgene 
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expression as described in section 2.6, if a GFP-expressing vector was used, and/or else 
harvested for western blotting analysis. 
2.5.2. Primary murine embryonic DRG cultures 
2.5.2.1. Dissociation of murine embryonic DRGs with papain, collagenase  
   and dispase 
The protocol used for dissociation of murine DRG cells in the current study was a 
modified version of the protocol published by Malin et al. (Malin et al., 2007). 
 CD-1 wild type mouse embryos (E12.5 - 14.5) were harvested as described in 
2.4.1. and kept in DMEM (Sigma) at room temperature. Dissection was carried out in 
DMEM under sterile conditions (i.e. sterile tools, EtOH-desinfected surfaces etc.). 
DRGs were dissected from the intervertebral foramen along the spinal cord of the 
embryos, collected in a centrifuge tube and spun down at 1000 rpm for 2 min. Under 
laminar flow the medium was replaced with 750 µl Hank’s balanced salts (HBSS) 
medium (Invitrogen) and 750 µl papain dissociation solution (40 U/ml papain 
(Worthington), 2 µl/ml saturated NaHCO3, 0.7 mg/ml L-Cysteine (Sigma), 0.2 mg/ml 
DNaseI (Sigma), HBSS) and the cells were incubated for 10 min at 37ºC. The tubes 
were spun for 2 min at 1000 rpm, the medium was replaced with 1.5 ml dispase and 
collagenase II (CLS2) dissociation medium (6 mg CLS2 (Sigma), 7 mg dispase type II 
(Sigma), HBSS) and the cells were incubated for 10 min at 37ºC. The tubes were spun 
for 2 min at 1000 rpm and the medium was replaced with 1 ml fresh complete DRG 
medium (fresh DMEM, 1% Pen/Strep, 10% FCS, 50 ng/ml murine NGF (Promega),  
25 ng/ml human recombinant BDNF (Insights Biotechnology Ltd.) and 25 ng/ml human 
recombinant NT-3 (Sigma)). The DRGs were mechanically dissociated by trituration 
with a 23- and 21-gauge needle attached to a sterile 1 ml-syringe sequentially. The cells 
were pre-plated on a petri dish (bacterial) and incubated for 1 h in a tissue culture 
incubator. During this time the fibroblasts and glia cells attached to the petri dish, 
whereas the neurons floated in the medium. The neurons containing cell suspension was 
collected and cells were counted using a haemocytometer. An appropriate amount of 
cells was seeded in fresh complete DRG medium on coated plates with poly-L-lysine 
and fibronectin (as described in section 2.5.4). One day after plating, mitotic inhibitors 
(50 mM Floxuridine (FdUrd; Calbiochem®) and 150 mM Uridine (Sigma) in ddH2O) 
Chapter 2 
 
  98 
were added to the cells to eliminate non-neural cells such as glia cells and fibroblasts. 
Pictures and estimations of the composition of the cell cultures are displayed in the 
appendix (Appendix, Figure 5). 
2.5.2.2. Dissociation of embryonic chick DRG cells with trypsin 
Fertilized eggs from brown Leghorn chickens (Henry Stewart & Co. Ltd.) were kept in 
an incubator at 38.5ºC. At a specific developmental stage eggs were opened, embryos 
removed and rinsed in PBS. DRGs were dissected from the embryos in DMEM, 
aspirated into an Eppendorf tube and incubated in DMEM containing 0.1% trypsin 
(Sigma) and 0.2 mg/ml DNAseI (Sigma) for 30 minutes at 37ºC. The tube was 
centrifuged at 4000 rpm for 2 minutes, the supernatant was aspirated and 1 ml of pre-
warmed fresh complete DRG medium (fresh DMEM, 1% Pen/Strep, 10% FCS, 
50 ng/ml murine NGF (Promega), 25 ng/ml human recombinant BDNF (Insights 
Biotechnology Ltd.) and 25 ng/ml human recombinant NT-3 (Sigma)) was added. The 
DRGs were sequentially gently triturated with a 23-gauge and 21-gauge needle 
connected to a 1 ml-syringe. The cell suspension was pre-plated on a petri dish 
(bacterial) for 1-1.5 hours in a tissue culture incubator. The neurons containing cell 
suspension was collected and cells were counted using a haemocytometer. An 
appropriate amount of cells was seeded in fresh complete DRG medium on plates or 
coverslips coated with poly-L-lysine and fibronectin (as described in section 2.5.4). 
2.5.2.3. Embryonic chick and mouse DRG explants 
Murine or chick DRGs were dissected out as described above. The DRGs were crushed 
with forceps and a couple of DRGs was placed on a pre-coated culture dish or plate in a 
drop of medium for 30 min in the tissue culture incubator to allow attachment. The 
wells were then filled with complete DRG medium (DMEM, 1% Pen/Strep, 10% FCS, 
50 ng/ml murine NGF (Promega), human recombinant BDNF (Insights Biotechnology 
Ltd.) and human recombinant NT-3 (Sigma)) and cultured in a tissue culture incubator. 
2.5.3. Preparation of coverslips 
Coverslips (Agar Scientific) were rinsed for 30 min in concentrated nitric acid on a 
shaker at room temperature. They were first rinsed for 30 min with distilled water and  
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then with absolute methanol for another 30 min. Coverslips were finally air dried and 
baked in a conventional oven for 4 h (or overnight) at 150ºC. 
2.5.4. Coating of plates and coverslips with PLL and FN for DRG cultures 
Unlike most cell lines primary cells only attach and grow on specific substrates and not 
on untreated culture dishes. Therefore plastic ware and coverslips were coated with 
reagents such as poly-L or D-lysine (PLL, PDL), fibronectin (FN), laminin (LN) etc. 
Poly-lysine (PLL and PDL) enhances electrostatic interactions by increasing the number 
of positively charged sites available for cell binding. And fibronectin, an adhesive 
glycoprotein, which is found both as cell surface protein and in plasma, contains active 
domains for collagen binding, cell adhesion, heparin binding and neurite outgrowth. 
 For DRG cultures plates and activated coverslips (section 2.5.3) were coated 
first with PLL and subsequently with FN. The whole procedure was carried out under 
sterile conditions in a laminar flow tissue culture hood. PLL (Sigma) was diluted at a 
final concentration of 0.02 mg/ml in sterile ddH2O and added onto the culture ware or 
coverslip and incubated for at least 30 min at room temperature. The PLL-solution was 
removed and the culture ware or coverslip was washed with PBS and dried for at least 
30 min at room temperature. FN (Sigma) was diluted at a final concentration of 
0.02 mg/ml in PBS and added to the culture ware or coverslip and incubated for at least 
30 min at room temperature. The FN solution was removed; the culture ware or 
coverslips were dried at room temperature and used for cell culture immediately or 
stored for up to 4 weeks at 4ºC. 
 
2.6. Photography of cells and tissue sections 
Pictures of cultured cells were taken with the Zeiss Axiovert-135 and the Hamamatsu 
ORCA-ER digital camera using Openlab 5.5.1 or Volocity 5.3.1 software (both 
Improvision). Pictures of the in situ hybridized and/or immuno-stained sections were 
taken with the Zeiss Axiophot and Leica DC 500 camera and with the Zeiss Imager.Z1 
ApoTome using the AxioVision40 V 4.8.0.0 software. Images were processed using 
Adobe Photoshop and Illustrator CS4. 
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2.7. Statistical analysis 
Statistical analysis was performed with Prism 4 (GraphPad Software). One-way 
analysis of variance (ANOVA) with the Tukey’s Multiple Comparison post-test was 
used to analyse data for significant changes. Data were categorized according to their  
p values as non-significant (ns) with p > 0.05, significant (∗) with 0.01 < p < 0.05, very 
significant (∗∗) with 0.001 < p < 0.01 and extremely significant (∗∗∗) with p < 0.001. 
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3.1. Introduction 
Several RPTPs play important roles in neurons by controlling for instance their 
differentiation, neurite outgrowth and synapse formation and plasticity similar to Trk 
receptors (sections 1.2 and 1.3). Some of these RPTPs were therefore previously 
analysed for their role in regulating Trk signalling. However, most of these studies were 
undertaken in over-expression experiments (section 1.4), while the physiological 
relevance of the RPTP and Trk interaction has yet to be shown.  
 First valuable hints towards a possible biological function of proteins are 
provided by their expression patterns. Similarities in temporal and spatial expression 
patterns of several proteins might also be indicative of a possible interaction of these 
proteins with each other. Therefore a detailed analysis of the gene expression patterns of 
RPTPs and Trks was performed in this study on DRGs from wild type mouse embryos, 
which is a widely accepted cell model to study Trk signalling (reviewed in 1.5.). The 
aim of this chapter was to select candidate RPTP genes based on their relatively high 
temporal gene expression levels for further in-depth analysis of their spatial expression 
patterns in comparison to Trk expression and the coexpression of these enzymes in the 
same sensory neurons (chapter 4). 
 The expression of all three Trk genes was previously analysed in different 
species during development in a variety of tissues including DRGs (described in section 
1.2.3). Also he expression of several RPTP genes has been previously studied during 
development, implicating some of these RPTPs in the development and function of 
neurons. In particular, the genes Ptpra (encoding RPTPα), Ptprf (LAR), Ptprg 
(RPTPγ), Ptpro (RPTP-BK), Ptprr (RPTPR), Ptprs (RPTPσ), Ptprz1 (RPTPζ), Ptprn 
(IA2) and Ptprk (RPTPκ) were found to be expressed in DRGs at different 
developmental stages in mice and other species (described in section 1.3.3). Due to 
some similarities to the expression of Trk enzymes specific RPTPs were suggested to be 
implicated in Trk signalling. However, so far no gene expression study has been 
performed for Trks and most RPTPs in parallel in the same tissue and at the same time 
points, which has the advantage of a direct and accurate comparison of the gene 
expression patterns with each other. Therefore, we have analysed almost the entire PTP 
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family and assessed whether RPTPs are among the highest expressed PTPs in DRGs, 
which also naturally and highly express Trk receptors.  
 This study was carried out on DRGs from murine embryos at the developmental 
stages E12.5, 13.5 and 14.5 (Theiler stages 20, 21 and 22 respectively). Such a  
three-time-point analysis allowed us to create a characteristic expression profile of each 
analysed gene throughout development and to compare it to other genes, and in 
particular to Trks. These specific developmental stages cover the time window, when 
sensory neurogenesis in DRGs is almost complete but the neurites did not yet innervate 
their targets. Once the targets are reached at around E15.5 in hind limb innervating 
DRGs (White et al., 1996), target-mediated apoptosis occurs and this is accompanied by 
changes in many signalling mechanisms and in ganglia composition (Hamburger and 
Levi-Montalcini, 1949, Carr and Simpson, 1978). Most mouse strains have 60 DRGs 
grouped into cervical, thoracic, lumbar and sacral DRG pairs according to their position 
relative to the spinal cord. In this study the analysis was mainly performed on 
cervical/thoracic and lumbar DRGs from fore and hind limb regions, since  
limb-innervating ganglia are much larger and contain more cells compared to other 
ganglia due to lower cell death (Hamburger and Levi-Montalcini, 1949).  
 Most of the previous studies were carried out using in situ hybridization (ISH) 
and in some cases RT-PCR. In our study gene expression was analysed using three 
different techniques. First, recently designed qPCR arrays, which allow the analysis of 
the entire PTP family in parallel, were used on whole DRG tissue and additionally an 
exon microarray was tested. Usually both techniques are used to compare samples under 
different conditions with each other such as treated or untreated with chemicals. 
However, in this study I have unconventionally used them to create a gene expression 
profile similar to at least one reported study (Lakics et al., 2010). Both techniques 
provided us convincingly with the same outcome. Furthermore, I have confirmed these 
results for selected highly expressed RPTP genes using chromogenic ISH on mouse 
embryo sections, which additionally provided spatial information of the expression of 
these genes in DRGs. This analysis was then further expanded in order to assess the 
coexpression of selected RPTPs and Trks in the same neurons in Chapter 4, which 
further supports the hypothesis of a possible interaction of RPTPs with Trk receptors. 
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3.2. Experimental procedures 
3.2.1. qPCR arrays ‐ semi‐automated high‐throughput qPCR analysis 
Semi-automated qPCR arrays developed by the laboratory of Dr. Rob Hooft van 
Huijsduijnen at Merck-Serono Pharmaceuticals AG in Geneva, Switzerland, were used 
with the assistance of Dr. Monique van den Eijnden to screen samples from murine 
embryonic DRGs (E12.5, 13.5 and 14.5) for PTP and Trk gene expression.  
 QPCR arrays are 384-well-plates, robotically pre-filled with primers for 
92 PTPs and four different housekeeping genes (HKG): Psmb2 (proteasome  
subunit beta type2), Hprt1 (hypoxanthine-guanine phosphoribosyltransferase 1), Ubc 
(ubiquitin C) and Gps1 (G protein pathway suppressor 1). Additionally, a screen with 
PTP primers for Dusp27 (FMDSP) and Ptpru (PTPλ) and primers for Ntrk1 (TrkA), 
Ntrk2 (TrkB) and Ntrk3 (TrkC) and four HKGs was performed using manually pre-
filled 384-well-plates. Primers were obtained as QuantiTect® Primer Assays (Qiagen) 
(Table 3.1 and Appendix, Table 1) and tested for primer dimer formation and specificity 
by Dr. M. van den Eijnden. The primers for Dusp9 (MKP4), Dusp13a (MDSP), 
Dusp13b (TMDP), Dusp21 (LMW DSP21), Tpte (TPIP), Dusp24 (STYXL1), the four 
Asp-based HADs and Mtmr14 (MTMR14) and Mtmr15 (MTMR15) were excluded 
from the final analysis, as these genes were either not expressed in our samples 
(provided undetermined CT values) or (good) primers were unavailable. Details of the 
general techniques were described in section 2.2.  
3.2.1.1. Sample preparation  
DRGs from limb regions of E12.5 (44, 65, 65 DRGs from 8 embryos of the same litter), 
13.5 (55, 65, 65 DRGs from 8 embryos of the same litter) and 14.5 (65, 65, 65 DRGs 
from 11 embryos of the same litter) mouse embryos were dissected, snap frozen and 
shipped on dry ice to Merck-Serono, Geneva, Switzerland. There Monique and I 
extracted RNA from all samples in parallel using the RNeasy® Lipid Tissue Kit 
(Qiagen). RNA purity (260/280 ratio) and concentration were measured using the 
NanoDrop ND-1000 Spectrophotometer and the integrity of the mRNA was tested with 
the Agilent Bioanalyzer using the RNA 6000 Nano LabChip Kit according to 
manufacturer’s instructions. The RIN values of all RNA samples were high quality with 
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values above 8.6. mRNA was reverse transcribed into cDNA using the iScript™cDNA 
Synthesis Kit (BioRad) for all samples in the same reaction to minimise variability.  
A qPCR test with primers spanning intron regions of Gapdh and Actb was carried out to 
control for gDNA contamination, which was neglectable in the samples. 
3.2.1.2. qPCR reactions 
Each qPCR reaction contained 1.25 ng of cDNA, 2.5 µl primer pair and 5 µl of 
2x QuantiTect® SYBR Green PCR Master mix (Qiagen) including HotStart Taq DNA 
polymerase, QuantiTect® SYBR Green PCR buffer (Tris·HCl, KCl, (NH4)2SO4, 5 mM 
MgCl2, pH 8.7), dNTP mix, SYBR Green I, ROX passive reference dye and RNase-free 
H2O. The experiments were performed in technical duplicates with three biological 
replicates for each embryonic stage. The 384-well-plates containing qPCR reactions  
were run in a LightCycler (ABI 7900HT Fast Real-Time PCR System) under the  
following PCR conditions: stage 1: 95ºC for 5 min, stage 2: 40x (10 sec at 95ºC,  
30 sec at 60ºC), stage 3 (dissociation curves): 15 sec at 95ºC, 15 sec at 60ºC, 15 sec at  
95ºC with a heated lid at 105ºC. 
3.2.1.3. Data analysis  
CT values were extracted with the Fast 7900 SDS 2.2.2 software (Applied Biosystems) 
after adjustment of the baseline between cycles 3 and 15 and the threshold at ΔRn 0.1, 
and analysed using a Microsoft® Excel® analysis. Dissociation curves of each reaction 
were examined and only data with a single product peak and no primer dimer formation 
were used for analysis. Amplification plots of each reaction were analysed and omitted, 
if they were not parallel to the HKGs (~ similar PCR amplification efficiency). For 
relative global gene expression analysis, 2-ΔCT values were calculated with ΔCT  
representing the expression of the gene of interest (GOI) normalized to the mean of  
three HKGs (Psmb2, Hrpt1 and Gps1, see below). The results were displayed as 
percentage of expression compared to the set of HKGs (% 2-ΔCT). For instance, a value 
of 100% means that the expression of the HKGs equals the expression of the GOI  
(ΔCT = 0). 300% gene expression means that the expression of the GOI is 3x higher 
than the expression of the HKGs and 5% means that the expression of the GOI is  
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GENE 
NAME  
AMPLICON 
SIZE (bp) 
COVERED 
EXONS  
DETECTED 
TRANSCRIPTS  OLIGO ID 
Ptpra 87 3/4 1 and 2 QT00141610 
Ptprb 106 16/17 1 QT00197981 
Ptprc 96 7/8/9 1 and 2 QT00139405 
Ptprd 125 4/5/6 2 but not 1 QT01167180  
Ptpre 99 17/18 1 QT00101941 
Ptprf 115  33 1 PPM05105E 
Ptprg 73 9/10 1 QT00160832  
Ptprh 104 9/10/11 1 QT01059415  
Ptprj 111 5/6 1 and 2 QT00169785 
Ptprk 147 30/31 1 QT01063615 
Ptprm 81 17/18 1 QT00167545 
Ptprn 79 4/5 1 QT01748971 
Ptprn2 139 9/10 1 QT01057868 
Ptpro 119 15/16/17 1 and 2, not 3 and 4 QT00134540 
Ptprq 123 8/9 1 QT01077237 
Ptprr 105 2/3 1, not 3, 4 or 5 QT00173530 
Ptprs 107 7/8 1 QT00150416 
Ptprt 71 14/15 1 QT01063594 
Ptpru 71 14/15 2 but not 1 QT00101430 
Ptprv 110 19/20/21  1 QT01070930 
RP
TP
S 
Ptprz1 125 9/10/11 1 QT01057854  
Ntrk1 137 2/3/4 1 QT01046143 
Ntrk2 67 6/7 1 and 2 QT00132111 
NT
RK
S 
Ntrk3 135 8/9/10 1 and 2 QT00146153 
Psmb2 67 4/5 1 QT00113701 
Hprt1 168 3/4/5 1 QT00166768 
Ubc 75 / 1 QT00245189 
Gps1 79 3/4 1 and 2 QT00120113 
Gapdh 144 2/3 1 QT01658692 
HK
G S
 
Actb 149 1/2 1 QT01136772 
 
Table 3.1. Primers used in the qPCR arrays.  
All primers to detect RPTP, Trk and HKG gene expression were obtained as QuantiTect primer 
assays from Qiagen. The information of the detected transcript variants is based on the 
information from EntrezGene/NCBI with 1 meaning only one transcript variant exists. (For a 
full list of primers see Appendix, Table 1.) 
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1/20 of the expression of the HKGs. For comparison and evaluation of global gene 
expression, the mean of all three stages was calculated. Statistical analysis was 
performed with Prism 4 (GraphPad Software) as described in section 2.7. 
3.2.1.4. Expression stability analyses of HKGs  
3.2.1.4.1. Comparison of CT values 
To assess the variation in gene expression of the four HKGs (Psmb2, Hrpt1, Ubc and 
Gps1) during development, 2-CT values were calculated for each embryonic stage and 
compared with each other and with Gapdh and Actb (Schmittgen and Livak, 2008). 
3.2.1.4.2. GeNorm software 
GeNorm V 3.5, a publicly available Microsoft® Excel® Visual Basic Application 
(Vandesompele et al., 2002), was used to determine the most stabile reference genes in 
the analysed samples among a set of candidate genes using data from the qPCR 
analysis. It is based on the principle that the expression ratio between two ideal 
reference genes is identical in all analysed samples. It calculates the standard deviation 
of the logarithmically transformed expression ratios between analysed genes and 
calculates the gene expression stability measure M as the average pairwise variation V 
for that gene with all other tested reference genes and provides a ranking based on M. 
The lower the M value, the higher the gene stability. For the calculations of M CT values 
of the HKGs were transformed into quantities by using a comparative ΔCT method. For 
each gene the lowest CT value (highest relative quantity) was subtracted from its  
CT value and this ΔCT value was converted to a relative abundance value (EΔCT) due to 
the exponential nature of PCR with E representing the amplification efficiency (2 for 
100%). The CT value with the highest relative quantity was set to 1. These raw (not  
normalized) reference gene quantities were the input data for geNorm analysis 
(Vandesompele et al., 2007). 
3.2.1.4.3. NormFinder software 
NormFinder, a publicly available Microsoft® Excel® Visual Basic Application 
(Andersen et al., 2004), is used to identify the optimal reference gene among a set of 
candidate genes using data from any quantitative analysis such as qPCR and 
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microarrays. It estimates the overall expression variation of the reference genes and the 
variation between sample subgroups. The calculated stability value is a direct measure 
for the estimated expression variation. The input data are the same as used for geNorm 
(see above). The log transformation and extended analysis options were used. 
Intergroup variances were plotted for all candidate genes with the average of the 
intragroup variances as error bars. The higher the stability of the candidate gene, the 
closer the intergroup variance to zero and the smaller the error bars.  
3.2.2. Microarray analysis 
Microarray analysis is a fast high throughput technique for global gene expression 
analysis and other applications. The basic concept is to hybridize labelled cDNA 
samples onto chips containing many thousands or millions of different oligonucleotide 
sequences corresponding to specific genes and detect their binding. The pilot 
microarray experiment in this study was performed by the Institute of Child Health 
Microarray Facility (UCL Genomics, http://www.genomics.ucl.ac.uk/platforms/ 
affymetrix.htm) using a GeneChip® Mouse Exon 1.0 ST array (Affymetrix). The high-
density mouse chip contains 1.2 million probe sets, which target approximately one 
million exons. A probe set consists of four probes, which are categorized into “core 
probes”, “extended probes” or “full probes” according to the underlying mRNA 
evidence. “Core probes” detect fully annotated exons for instance from RefSeq and are 
regarded as the most confident. “Extended probes” target exons with partial mRNA 
evidence such as ESTs. And “full probes” target exons, which are only supported by 
computational predictions. The detected exons are grouped into transcript clusters 
(genes) (Affymetrix, 2005).  
3.2.2.1. Sample preparation  
60 DRGs from fore and hind limb regions were dissected from E12.5 mouse embryos 
and snap frozen on dry ice and stored at -80°C. RNA was extracted using the 
RNAeasy® Mini Kit (Qiagen) following manufacturer’s instructions (see chapter 2.2.1). 
RNA was quantified with the NanoDrop® ND-1000 Spectrophotometer (NanoDrop 
Technologies) and its quality was verified with the Agilent 2100 BioAnalyzer® (Agilent 
Technologies). Samples were labelled for hybridisation to the array according to the 
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GeneChip® Whole Transcript (WT) Sense Target Labelling Assay. Briefly, cDNA was 
synthesized with random hexamers incorporating a T7 promoter sequence using the 
GeneChip® WT cDNA Synthesis and Amplification Kit (Affymetrix). The 
recommended rRNA reduction step to minimize possible non-specific hybridisation on 
the array was omitted since not enough RNA was available. The generated double 
stranded cDNA was used to generate cRNA with random priming from the  
T7 promoters, which was then used to generate single stranded cDNA in the sense 
direction for hybridisation to the array. After fragmenting and end labelling of the 
cDNA with the GeneChip® Terminal Labelling Kit (Affymetrix), the cDNA fragments 
were hybridized to the GeneChip® Mouse Exon 1.0 ST array (Affymetrix) at 45°C for 
16 h, followed by washing and staining on the automated Fluidics station 450 
(Affymetrix) using the Hybridization Wash and Stain Kit (Affymetrix). The chip was 
finally scanned on the GeneChip® Scanner 3000.  
3.2.2.2. Data analysis  
The Affymetrix® GeneChip® Command Console® 3.1.1 and Expression Console™ V 
1.0 software products were used to perform qualitative and quantitative analysis for 
each probe set by subtracting the background and annotation of the probe sets to obtain 
gene-level and exon-level signal estimates. Additionally the Detection Above 
Background (DABG)-P-values were calculated by comparing the probe signals with the 
signals of the background probes with the same GC-content and using the Wilcoxon’s 
Signed Rank Test. Further analysis was performed with Microsoft® Excel® using 
additional information retrieved from the web-based Affymetrix® NetAffx™ Analysis 
Centre. The analysis was restricted to RPTPs, Trks and the two HKGs Psmb2 and  
Ubc. First, data from probe sets of the Expression Console™ “exon report” were 
selected with DABG-P-values < 0.01 and unique hybridization to a single target  
(cross-hybridisation = 1) and for most analyzed genes only data from “core probes” 
were used. For Ptprh, Ptprq, Ptprz1 and Ntrk1 no “core probes” were available and 
therefore data from the “extended probes” were used. To estimate overall gene 
expression from the selected data the signal intensity values (log2) of all selected probe 
sets for a transcript cluster (= gene) were displayed in “box plots” to visualize overall 
abundance, whereby the signal intensity values represent a quantitative measure of the 
relative abundance of a transcript or exon. For calculations of the medians and quantiles 
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all intensity values were used except outliers with log2 < 5. These data were compared 
to the results from the “gene report”, in which the expression of transcript clusters based 
on the expression profile of “core probes” was calculated by the Expression Console® 
software. The cut-off for reliable exon and transcript detection was set to the signal 
intensity value of log2 7 based on previous experiences of the Bloomsbury Centre for 
Bioinformatics, UCL (http://www.bcb.lon.ac.uk/). The NetAffx™ analysis centre was 
used to retrieve additional information about the transcript clusters and probe sets 
(http://www.affymetrix.com/analysis/index.affx). 
3.2.3. Chromogenic in situ hybridisation 
Chromogenic in situ hybridisation (ISH) was performed on transverse O.C.T. 
cryosections of wild type CD-1 mouse embryos at the developmental stages E12.5, 13.5 
and 14.5 and on E13.5 sagittal gelatine mouse embryo sections as described in 2.4.2. 
Hybridisation of all available sense probes did not provide any specific signal 
(Appendix, Figure 1) compared to corresponding antisense probes. 
3.2.3.1. In situ riboprobes 
Antisense and sense probes were generated by in vitro transcription from DNA 
templates using T3-, T7- or Sp6 RNA polymerases as described in 2.4.2.2. DNA 
templates such as transcription plasmids or cDNAs were obtained from collaborators 
from within PTPNET or elsewhere, or from the I.M.A.G.E. Consortium (LLNL) cDNA 
Clones (Lennon et al., 1996) (Geneservice, Cambridge, UK). If necessary they were 
modified by cloning. All plasmids were verified by restriction enzyme digests and 
sequencing.  
 The riboprobe for Ptpra was a gift of Prof. Jeroen den Hertog and was 
previously described (den Hertog et al., 1992, den Hertog et al., 1993). A fragment 
bp 342-1799 of NM_008980 was subcloned between the BamHI restriction sites of 
pT7/T3α-19 (Gibco BRL). The antisense RNA probe was transcribed with 
T3 polymerase from the plasmid linearized with HindIII, and the sense probe with 
T7 polymerase from the plasmid linearized with Asp718. Both sense and antisense 
riboprobes were approx. 1.4kb in size and covered the entire ECD and TM and almost 
the entire D1 domain. The antisense probe matches bp 342-1799 of transcript 1 
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(NM_008980) and bp 342-1089 and bp 1090-1691 of transcript 2 (NM_001163688). 
Transcript 2 lacks 100 bp corresponding to an alternate in-frame exon in the 5' coding 
region, to which the probe aligns. Still since this part is flanked by around 600 bp on 
each side, this transcript is likely to be detected by the antisense probe. 
 The riboprobe for Ptprd was a gift of Dr. Wiljan Hendriks and was previously 
described (Mizuno et al., 1993, Schaapveld et al., 1998). The cDNA fragment matches 
bp 2544-3956 of transcript 1 (NM_001014288) and bp 3226-4638 of transcript 2 
(NM_011211), which covers most of the ICD. The 1.7 kb antisense probe was  
transcribed with T7 RNA polymerase from the plasmid linearized with NotI. The sense 
probe was transcribed with T3 polymerase from the plasmid linearized with XhoI.  
 Ptprf riboprobe was a gift of Dr. Wiljan Hendriks (Schaapveld et al., 1995). The 
antisense probe was transcribed with T3 polymerase from the plasmid linearized with 
NotI and the sense probe with T7 polymerase from the plasmid linearized with HindIII. 
Both probes cover bp 4712-6881 of NM_011213, which includes the whole D2 and a 
part of the D1 domain and the 3' UTR.  
 The riboprobe for Ptprg was a gift of Dr. Sheilla Harroch (Lamprianou et al., 
2006). It was transcribed by T3 polymerase from the plasmid linearized with KpnI and 
is coding for the N-terminus of the carbonic anhydrase domain of RPTPγ (amino acids 
1-832) and hence recognizes all isoforms. It corresponds to bp 460-1291 of 
NM_008981. 
 A cDNA encoding RPTPJ was PCR amplified with the primers: forward  
5’-GGTCTAGACAGATCCAGGGAATCTCCAA-3’ and reverse 5’-GGTCTAGAATT 
CCTCTGCAAACCCACAG-3’) from total cDNA isolated from DRGs of E13.5 CD-1 
mouse embryos. Both primers contained an XbaI site (TCTAGA) for cloning into 
pT7T3α-18 (Gibco BRL). The antisense RNA probe was transcribed using Sp6 RNA 
polymerase from the plasmid linearized with NcoI and the sense probe by 
T7 polymerase from the plasmid linearized with HindII. Both probes were 
approximately 1.3 kb in size. The antisense probe corresponds to bp 1889-3182  
of transcript variant 1 (NM_08982) and bp 1655-2948 of transcript variant 2 
(NM_001135657) spanning the entire ECD, TM domain and part of the ICD until D1. 
 Ptprk cDNA was a gift of Prof. Jan Sap (Jiang et al., 1993). To obtain a smaller 
riboprobe the plasmid was digested with HindIII and religated, thus deleting the entire 
      Chapter 3 
 
  112 
ICD and TM domains and part of the ECD. The remaining fragment of 2 kb 
corresponds to bp 262-2040 of NM_008983. The 1.9 kb antisense probe was generated 
from the T3 promoter of the plasmid linearized with XhoI. The 1.8 kb sense probe was 
transcribed with T7 RNA polymerase from the plasmid linearized with HindIII. 
 The riboprobe for Ptprm was a gift of Dr. Claire Faux (Faux et al., 2010). Both 
sense and antisense probes were 1.6 kb in size and detect bp 471-1448 in the ECD of 
NM_008984. The antisense RNA probe was generated from the T3 promoter and the  
sense probe from the T7 promoter of the plasmid linearized with SalI or NotI 
respectively.  
 The Ptpro cDNA was a gift of Dr. Takahiko Shimizu (Tomemori et al., 2000). A 
fragment covering bp 522-2409 in the ECD of NM_011216 and also transcript variant 2 
(NM_001164401) was subcloned into pT7T3α-19 (Gibco BRL) between XbaI and 
HindIII. The antisense probe was transcribed with T3 polymerase from the linearized 
plasmid with HindIII and the sense probe with T7 polymerase from the plasmid 
linearized with XbaI. Both probes are 1.7 kb in size. The antisense probe detected both 
known transcript variants 1 and 2, but not 3 and 4. The latter lack the ECD and are 
known as PTPφ or PTPROt and are not expressed in neurons (Tomemori et al., 2000). 
 The cDNA for Ptprr was a gift of Dr. Wiljan Hendriks and Irene Chisini and 
was previously described (Van Den Maagdenberg et al., 1999). A fragment 
corresponding to bp 301-1580 of transcript variant 1 (NM_011217) covering the ECD, 
TM domain and part of the ICD until D1 was subcloned between the BamHI and EcoRI 
sites of pT7T3α-19 (Gibco BRL). The 1.9 kb antisense RNA probe was transcribed 
with T3 RNA polymerase from the plasmid linearized with XhoI. The 1.8 kb sense 
probe was transcribed with T7 polymerase from the plasmid linearized with HindIII. 
The antisense riboprobe corresponds to bp 301-1580 of transcript variant 1 
(NM_011217), bp 369-931 of variant 3 (NM_001161838), bp 60-622 of variant 4 
(NM_001161839) and bp 252-814 of variant 5 (NM_001161840).  
 Ptprs cDNA was a gift of Dr. Masato Ogata (Osaka University Medical School, 
Japan) and was previously described (Ogata et al., 1994). A fragment corresponding to 
bp 400-2142 (only ECD) of NM_011218 was subcloned between HindIII and BamHI of 
pT7T3α-19 (Gibco BRL). The 1.2 kb antisense riboprobe was transcribed with 
T7 polymerase from the plasmid linearized with XbaI and corresponds to bp 977-1142 
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of NM_011218. The 0.8 kb sense probe was transcribed with T3 polymerase from the 
plasmid linearized with BglII.  
 The transcription plasmids containing mPtprz1-CAH-pBS-KS2 and  
mPtprz1-385mD2-pTOPOII containing fragments of Ptprz1 cDNA were gifts of  
Dr. Sheilla Harroch and were previously described (Harroch et al., 2002). The 500 bp 
antisense riboprobe Ptprz1-CAH was transcribed with Sp6 polymerase of the plasmid 
linearized with EcoRI and detected all known isoforms of Ptprz1. The 1 kb antisense 
riboprobe Ptprz1-385mD2 was transcribed with T7 polymerase from the corresponding 
plasmid linearized with BamHI, and detected only the transmembrane isoform. 
 Ntrk1 cDNA was obtained from the I.M.A.G.E. Consortium as clone  
ID: 5256438, which contains a 960 bp fragment from lung tissue of the mouse in 
pT7T3D-PacI between EcoRI and NotI. It corresponds to bp 1321-2280 of 
NM_001033124. The 900bp antisense riboprobe was transcribed with T3 polymerase 
from the linearized plasmid with XhoI. The 900bp sense probe was generated with T7 
polymerase from the plasmid linearized with NotI. 
 Ntrk2 cDNA was obtained from the I.M.A.G.E. Consortium as clone  
ID: 5707891. It contains a cDNA fragment corresponding to bp 869-2424 of transcript 
variant 2 NM_008745 with an additional poly-A tail in pYX-Asc between EcoRI and 
NotI. The 1.6kb antisense riboprobe was transcribed with T3 polymerase from the 
plasmid linearized with HindIII. It corresponds to bp 793-1920 of transcript variant 1 
(NM_001025074) and bp 869-2422 of transcript variant 2 (NM_008745) covering most 
of the ECD and the TM domain. The 1.5 kb sense probe was transcribed with 
T7 polymerase from the plasmid linearized with BglII. 
 Ntrk3 cDNA was obtained from the I.M.A.G.E. Consortium as clone  
ID: 40110345. A cDNA fragment corresponding to bp 16-1898 of transcript variant 2 
(NM_182809) was subcloned between the XbaI and HindIII sites of pT7T3α-19 (Gibco 
BRL). The 1.2kb antisense riboprobe was transcribed with T3 polymerase from the 
plasmid linearized with HindII. It is complementary to bp 707-1878 of transcript variant 
2 (NM_182809) and bp 707-1640 of transcript variant 1 (NM_008746) covering most 
of the ECD, The TM and part of the ICD in transcript 1 until the kinase domain and in 
transcript 2 the entire protein encoding region. The 1.9 kb sense probe was transcribed 
with T7 polymerase from the linearized plasmid with BamHI. 
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3.3. Results 
3.3.1. QPCR arrays for PTP and Trk gene expression analysis  
QPCR is a very sensitive quantitative gene expression analysis technique, but it is 
mostly used to analyse the expression of just a few genes at a time. Recently,  
high-throughput qPCR arrays have been developed, which allow the analysis of 
hundreds of genes in parallel in one sample and additionally save reagents, template 
cDNA amounts, and experimental time. This is most suitable for the analysis of gene 
families with 100-400 members and is more accurate and sensitive than microarray 
analysis. For instance Schmittgen et al. (Schmittgen et al., 2008) have profiled the 
expression of microRNA using 384-well-plate qPCR arrays. And in a similar approach 
Lakics et al. have recently compared the expression of cyclic nucleotide-specific 
phospho-diesterases mRNA across 24 different tissues (Lakics et al., 2010). 
Additionally commercial qPCR arrays from different companies became available 
recently, such as the RT2 Profiler PCR Array from SABiosciences, Qiagen, 
(http://www.sabiosciences.com/PCRArray Plate.php). For this study I had the 
opportunity to use a semi-automated high-throughput qPCR array tailor-made for the 
analysis of almost the entire murine PTP gene family. This was made available to us by 
the laboratory of Dr. Rob van Huijsduijnen at Merck-Serono Geneva, Switzerland, a 
member of PTPNET. I used this array to profile the gene expression of PTPs in parallel 
with Trk receptors in murine embryonic DRGs across the developmental stages E12.5, 
13.5 and 14.5. 
3.3.1.1. Selection of HKGs  
The PTP qPCR array can be used to analyse gene expression of 94 of the 106 known 
PTP genes in murine tissues. A relative quantification (ΔCT) method is utilized for data 
analysis similar to the one described by Lakics et al. (Lakics et al., 2010), which 
requires reference genes as an endogenous control to normalize differences in template 
cDNA amounts in the samples due to possible variations in mRNA quantity and quality, 
efficiency of cDNA synthesis, pipetting errors etc. The choice of reference genes is 
crucial for optimal relative expression results in order to identify real gene-specific 
differences and is a challenging task especially for samples from developing organisms. 
A good reference gene is constitutively expressed in the samples and does not change 
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under the experimental conditions. As there is no universal reference gene, each 
candidate gene has to be tested in the experimental set-up for suitability. 
 The PTP qPCR array contains four different HKGs Psmb2, Hprt1, Ubc and 
Gps1, which were selected due to their stable expression in several neuronal mouse 
tissues (personal communication with Dr. M. van den Eijnden). Psmb2 encodes the 
proteasome subunit beta type 2, which is involved in the cleavage of proteins and is 
highly expressed in eukaryotic cells. Hprt1 encodes the hypoxanthine-guanine 
phosphoribosyl transferase 1, an essential enzyme for purine recycling. The protein 
product of Ubc is ubiquitin C, a small regulatory protein, which binds to proteins and 
directs them towards recycling or other functions. Gps1 encodes the G-protein pathway 
suppressor 1, which suppresses the expression of G-protein and mitogen-activated genes 
in mammalian cells. All four are frequently used as reference genes in relative 
quantification analyses of different tissue types.  
 To identify the most suitable reference genes for this study among these four 
HKGs, I have analysed the robustness of their expression in the murine embryonic DRG 
tissue. Additionally I have compared these data with the expression of two of the most 
frequently used reference genes in qPCR experiments, Gapdh (glyceraldehyde- 
3-phosphate dehydrogenase) and Actb (β-actin). First, I examined the variations in gene 
expression between samples of different embryonic stages using 2-CT values from all 
qPCR experiments (Schmittgen and Livak, 2008) (Figure 3.1A). Psmb2 expression 
values varied least among all HKGs at the three developmental stages, followed by 
Hprt1 and Gps1, whereas Ubc showed least stable expression during development due 
to increased expression at E14.5. Therefore it was not surprising that the mean of the 
expression values of Psmb2, Hprt1 and Gps1 was more stable compared to the mean of 
all four HKGs. In comparison Actb showed a very strong decrease in expression at 
E14.5 and Gapdh showed a peak at E13.5 and high variation between samples of the 
same stage. Although both genes were previously seen as universal reference genes, 
their regulation was subsequently proven in many different experiments (Schmittgen 
and Zakrajsek, 2000). Overall the mean of the expression values of Psmb2, Hprt1 and 
Gps1 was more stable than the expression of any individual gene. 
 In addition, I have used two publicly available Microsoft® Excel® Visual Basic 
applications geNorm V 3.5 (Vandesompele et al., 2002) and NormFinder (Andersen et 
al., 2004) to assess the expression stability of the reference genes. Both methods are 
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widely recognized and used to determine gene expression stability among a set of 
reference genes, which is reflected in hundreds of citations of both methods. GeNorm is 
based on the principle that the expression ratio between two ideal reference genes is 
identical in all analysed samples. This program identified Actb as the least robust gene 
(Figure 3.1B) in agreement with the described analysis of individual data points (see 
above). However, Ubc, which showed highest variation in CT values between samples 
across different embryonic stages (Figure 3.1A), together with Hprt1 were chosen by 
this program to be the most stable among the four HKGs in contrast to the individual 
data point analysis. This is due to the nature of the algorithm, which identifies similarity 
in expression among genes. Thus geNorm falsely identifies co-regulated genes as best 
reference genes, and does not reflect variation between different subgroups 
(developmental stages) (Jung et al., 2007). The second application NormFinder is a 
model based estimation method, which uses analysis of variance on all log-transformed 
values simultaneously to calculate gene stability values for the most stable gene or the 
best combination of two genes. In contrast to geNorm this program estimates not only 
the variation among candidates but also the variation between sample subgroups 
(embryonic stages in this case) and was reported to be more robust towards co-regulated 
genes. Due to the nature of its algorithm it was possible to additionally include two 
averages of HKGs into the calculations, all four genes Psmb2, Hprt1, Ubc and Gps1 
together and an average lacking Ubc. Unlike the first tested application NormFinder has 
confirmed the analysis of the differences in CT values during development for the tested 
HKGs. It has ranked the genes according to their robustness in gene expression with 
Actb as the least stable gene and the average of the HKGs Psmb2, Hprt1 and Gps1 
as most stable (Figure 3.1C). The intergroup variance, which reflects the log differences 
between embryonic stages (Figure 3.1D), agreed with the analysis of the CT values for 
each gene as described above. Additionally the intragroup variance displayed in the 
graph as error bars highlighted for instance in case of Gapdh the big differences among 
samples from the same embryonic stage, which makes this gene a less good candidate 
reference gene. Overall the average of the HKGs Psmb2, Hprt1 and Gps1 was evaluated 
as the most robust among tested candidates. Similar to Psmb2 this set of HKGs shows a 
small stability value and also small intergroup variance, but additionally a slightly 
smaller intragroup variance than Psmb2.  
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Figure 3.1. Assessment of the stability of HKG expression during DRG development.  
A) Mean expression is represented as 2-CT ∗ 107 for each HKG (Psmb2, Hprt1, Ubc, Gps1, Actb 
and Gapdh) and two averages (Psmb2, Hprt1, Ubc and Gps1) or (Psmb2, Hprt1, Gps1) across 
three developmental stages. Error bars represent standard deviations (SD). B) Average gene 
expression stability values (M) of remaining reference genes during stepwise exclusion of the 
least stable gene were calculated with geNorm software. C) Average expression stability values 
of reference genes were obtained with NormFinder software. D) Intergroup variance displayed 
as log differences between groups (embryonic stages) were calculated with NormFinder 
software. Error bars represent averages of intragroup variances. 
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 Taken together, the individual data point and NormFinder analyses agree with 
each other on the set of HKGs Psmb2, Hprt1 and Gps1 as the most suitable reference 
genes for the qPCR analysis among the six tested genes. GeNorm has proven to be an 
unsuitable tool for our purposes due to the nature of its algorithm as it suggests 
regulated genes with similar expression as best reference genes. As it was pointed out in 
many studies and reviews, it is preferable and of more advantage to use several 
reference genes. And thus finally a set of the three HKGs Psmb2, Hprt1 and Gps1 was 
used for normalization of the qPCR data generated with the qPCR array. 
3.3.1.2. Trk gene expression in murine embryonic DRGs 
Using the described qPCR array we could show that all three Trk genes were highly 
expressed in murine embryonic DRGs at the three analyzed developmental stages with a 
dynamic expression pattern (Figure 3.2). It has to be noted that all given expression 
values refer to the expression of the HKGs (see 3.2. for more details). Ntrk1 gene 
encoding TrkA was as expected the most abundant of all three Trk genes with a mean 
expression of 183% relative to the set of HKGs, followed by Ntrk3 encoding TrkC with 
79% and finally Ntrk2 encoding TrkB with 24%. The expression levels of Ntrk2 and 
Ntrk3 decreased significantly during development, whereas the expression of Ntrk1 
showed a peak in expression at E13.5 but without statistical significance (Figure 3.2A). 
It is important to keep in mind that these described gene expression dynamics refer to 
samples containing whole DRGs with many different subpopulations of sensory 
neurons and also SGCs. Possible residual axons encircled by Schwann cells and some 
fibroblasts surrounding the DRGs and endothelial cells might be present in the samples 
as well. Therefore an observed decrease or increase in gene expression can reflect a 
change in gene expression in the subpopulation of cells per se or a change in the 
proportion of cells in the DRGs expressing this particular gene. Thus the observed 
decrease in TrkB and TrkC gene expression in this study can be interpreted in several 
ways. First, as described by the “three wave-theory of neurogenesis in DRGs” (see 
Introduction section 1.3) the proportion of TrkB+ and TrkC+ neurons in DRGs at the 
analysed stages decreased due to higher expansion of other neuronal subpopulations 
such as TrkA+ neurons and glia cells. Into the bargain, there is evidence of early  
pre-target-mediated cell death of neuronal populations, which results in a decrease in 
cell numbers of TrkB and TrkC neurons but not TrkA neurons at this time-point (White 
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et al., 1996). In the case of TrkC a termination of its expression in specific cells, which 
switch to TrkB and/or Ret expression at around E14.5 in mouse embryos (Marmigere 
and Ernfors, 2007), is also responsible for the observed decrease in gene expression.  
 Overall these results are in strong agreement with numerous IHC and ISH 
studies, which analysed Trk expression in rodent embryonic and postnatal DRGs, 
although the numbers in these reports vary between studies due to different techniques 
(White et al., 1996, Molliver and Snider, 1997, Farinas et al., 1998, Ernsberger, 2009). 
Previously it was reported that TrkC expression begins at around E10 in thoracolumbar 
DRGs in mouse embryos and that the proportion of TrkC+ cells at E11 increases to  
70% of all cells. At E11.5 the majority of lumbar DRG cells are TrkC+ and their 
proportion drops to less than 10% at E13 (Phillips and Armanini, 1996, White et al., 
1996, Farinas et al., 1998). The generation of TrkB+ neurons was first observed at 
E10.5. At E11 these neurons account for 40% of all L1 sensory neurons with a peak of 
expression at E11.5 (Phillips and Armanini, 1996, White et al., 1996). Their proportion 
drops to around 8% at E13 and remains constant into adulthood (Farinas et al., 1998).  
 The changes in Ntrk1 expression in this analysis were a bit trickier to interpret, 
as they were not statistically significant due to a high variation in expression in different 
biological samples at E13.5 (Figure 3.2B). A technical cause such as an inhibitory effect 
on reverse transcription or on PCR amplification efficiency in this particular sample 
cannot be ruled out but is unlikely, for all samples were processed simultaneously using 
the same reagents. A biological explanation concerning differences in developmental 
stages of the mouse embryos used for the analysis is also unlikely since a pool of 
embryos from one litter was used for all three samples per stage. Thus the reason for 
this observation remains unknown. Nevertheless, in two out of three samples the 
expression of Ntrk1 at E13.5 was well above the expression levels at the other stages, 
thus pointing to a possible peak in mRNA expression of TrkA at this stage. Previous 
IHC and ISH studies have shown that the amount of TrkA+ neurons increases constantly 
during development until it reaches a peak of expression at early postnatal stages in 
mice. It was reported that TrkA+ cells could be detected as early as E10.5 in mouse 
DRGs. At E11 20% of L1 DRG cells were TrkA+ and at E11.5 50% of the cells were 
positive for TrkA mRNA (White et al., 1996). At E13 and E15 80% of cells are TrkA+ 
and in neonatal mice TrkA mRNA expression was detected in around 80-90% of cells. 
Their proportion drops to 60% at P7 and 40% in adult mice (Molliver and Snider, 1997, 
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Farinas et al., 1998, Ernsberger, 2009). In this study we observed a possible peak in 
Ntrk1 expression at E13.5 and a decrease in expression at E14.5, back to the E12.5 
levels. This is in contrast to previous studies. The discrepancies between the present 
results and previous findings might stem from the nature of the used techniques. 
Whereas this study accurately quantifies mRNA present in total DRGs, previous studies 
are merely based on cell counts and not intensity of the staining. Therefore a peak in 
expression might be caused by higher amounts of mRNA in individual neurons at 
E13.5, which would have not been picked up by cell counts alone. The possible drop 
back at E14.5 would be likely due to a down regulation of mRNA expression in 
individual cells and increased proliferation of non-neuronal cells such as SGCs in 
DRGs. In fact in birthdates studies Lawson et al., have demonstrated that the generation 
of non-neuronal cells in the mouse DRGs begins at around E10-11 and that it shows a 
peak in proliferation at around E13 (Lawson and Biscoe, 1979).  
 Our results for TrkB and TrkC strongly agree with documented Trk gene 
expression in rodent embryonic DRGs and confirm the validity of the qPCR array. 
Especially the differences in expression levels not only between developmental stages, 
but also between the genes agree with previously reported studies. The differences 
between the present data and reported findings for TrkA might be due to the differences 
in the nature of the used techniques as described above. Nevertheless, as reported, the 
gene expression levels of TrkA were well above both TrkB and TrkC genes at all three 
developmental stages as expected. This unique Trk expression profile was further used 
for a comparison to RPTP gene expression as an indication of possible coexpression 
and hence potential interaction of the encoded proteins (chapter 4). 
3.3.1.3. PTP gene expression in murine embryonic DRGs 
The qPCR arrays were used to create a quantitative gene expression profile of 96 of 106 
known PTPs (Alonso et al., 2004) in E12.5, 13.5 and 14.5 murine DRGs. We have 
analysed the gene expression of all known classical PTPs comprising 21 RPTPs and  
17 NPTPs (Figure 3.4) and 52 of the 60 known DSPs. The latter group consists of the 
class I Cys-based DSPs comprising MKPs the atypical DSPs, PRLs, SSHs, CDC14s, 
PTENs and MTMs (Figures 3.3A and B), the class III Cys-based CDC25 subfamily and 
the single class II Cys-based LMPTP Acp1 (Figure 3.3C). The expression levels of 
different RPTP genes cannot be strictly speaking compared with each other directly due  
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Figure 3.2. qPCR analysis of Trk gene expression during DRG development.  
Expression of Ntrk1, Ntrk2 and Ntrk3 encoding TrkA, B and C respectively was measured in 
murine embryonic DRGs at the developmental stages E12.5, 13.5 and 14.5 using qPCR arrays. 
Results of the relative quantification analysis are displayed as 2-ΔCT % gene expression relative 
to the HKG set. A) Average Trk gene expression in E12.5 (blue), 13.5 (red) and 14.5 (green) 
murine DRGs. SD and statistical analysis (ANOVA) included in the graph with p > 0.05  
non-significant (ns), 0.01 < p < 0.05 significant (∗), 0.001 < p < 0.01 very significant (∗∗) and  
p < 0.001 extremely significant (∗∗∗). B) Trk gene expression in individual DRG samples. The 
approximate amounts of used DRGs in the samples are included behind the sample names in 
brackets. 
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to possible differences in the efficiencies of the PCR reactions. However, our results 
from the previously described Trk expression analysis have demonstrated that the 
different levels in Trk gene expression in fact mostly agree with previous findings and 
thus allow at least a careful inter-gene analysis. Therefore to create a broad expression 
profile of the PTPs in DRGs I have divided the different expression levels into five 
categories: “extremely high” gene expression relative to the HKGs for values above  
60%, “very high” levels for values between 30 and 60%, “high” levels for values 
between 15 to 30%, “moderate” levels for values between 5 and 15%. Values below the 
set threshold of 5% were seen as too low to be of much interest for this study, since any 
in situ analysis would likely be impractical. The actual means of gene expression were 
included in brackets for reference. 
 In general the gene expression of all PTPs appeared to be very dynamic with 
decreasing, increasing or stable expression levels across development. Each PTP 
subfamily contained members that showed expression levels above the set threshold of 
5% gene expression relative to the HKGs.  
 Overall seven PTPs showed “extremely high” gene expression above 60%, 
which represents only 7% of all analysed PTPs. These highly expressed PTPs 
comprised the two RPTP genes Ptprf (355% mean relative gene expression) and Ptprs 
(156%), which were the most prevalent genes identified in DRGs across all analyzed 
developmental stages, the two PRL phosphatases Ptp4a2 (122%) and Ptp4a1 (75%), a 
further RPTP Ptprr (94%), and Pten (75%) and Dusp11 (65%). 
 Approximately 9% of all PTPs were expressed at “very high” levels (30 and  
60%), 26% at “high” levels (15 to 30%), 29% of PTPs at “moderate” levels (for 5 to 
15%) and the highest proportion of 30% were expressed below the set threshold of  
5%. However, since the relative comparative ΔCT method was used for analysis, low 
percentage does not necessarily represent low gene expression per se but a large 
difference between the CT value of the PTP gene and the CT value of the set of HKGs. 
This means, if a strongly expressed HKG is chosen, the percentage of expression will be 
consequently smaller. Additionally, all these data were retrieved from whole DRGs and 
as described above it is possible that some of the PTPs are expressed for instance at 
high levels in a small proportion of cells, but show overall low or moderate expression 
in the whole DRGs. This latter issue was addressed using ISH (section 3.3.3 below). 
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  3.3.1.3.1. DSP gene expression 
In the present analysis most members of the PRL, MTM, PTEN subfamilies and Acp1 
showed the highest expression levels among all analyzed DSPs, followed by several 
members of the MKPs and atypical DSPs and at last the SSHs, CDC14s and CDC25s 
with the lowest, but still moderate expression levels. Members of specific DSP 
subfamilies show similar substrate specificities and functions, but differ in their 
expression patterns (for more details on PTP categorization see section 1.3). They will 
be described as whole subfamilies, whereas RPTP gene expression, the focus of this 
thesis, will be described in more detail.  
 Two of the three members of the PRL subfamily were among the highest 
expressed PTP genes in DRGs. Ptp4a1 (122%) and Ptp4a2 (78%) were both expressed 
at extremely high levels with a significant decrease in expression at the analysed stages. 
In contrast to this the third member Ptp4a3 was expressed at moderate levels (13%) 
with no significant changes in gene expression. These phosphatases are expressed in a 
variety of tissues and exhibit diverse functions and therefore a role in normal tissue 
homeostasis has been suggested (Dumaual et al., 2006). 
 MTMs, PTENs and Acp1 are all involved in many homeostatic and metabolic 
signalling pathways, such as cell growth and survival, development and differentiation, 
cell migration and motility and metabolism. Thus their presence in DRGs was not 
unexpected. 
 Most members of the MTM subfamily were expressed at high levels in murine 
embryonic DRGs. Of the thirteen analysed MTMs four showed very high expression 
levels (Mtmr2, Mtmr4, Mtmr9 and Sbf2) and three high expression levels (Mtmr6, 
Mtmr7 and Sbf1). Three MTMs (Mtmr1, Mtmr3 and Mtmr12) were expressed at 
moderately high levels and the remaining three MTMs (Mtm1, Mtmr10 and Mtmr11) 
were expressed below the threshold at all embryonic stages. All MTMs showed a 
significant decrease or no changes in gene expression. MTMs comprise both 
catalytically inactive and active phosphatases, which are known to dephosphorylate 
phosphoinositides that are implicated in proliferation, differentiation and transport 
(Laporte et al., 2003). 
 Acp1 was expressed at very high levels (56%) and was among the highest 
expressed PTPs in DRGs at the analyzed stages. It also showed a significant decrease in 
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gene expression (Figure 3.3C). The low molecular weight phosphatase Acp1 is 
ubiquitously expressed in a variety of tissues and is known to regulate many TKRs such 
as PDGFR and EphR and is involved among other processes in growth inhibition 
(Kikawa et al., 2002, Raugei et al., 2002). 
 Among the four members of the PTEN subfamily the two phosphatases Pten  
(75%) and Tns1 (23%) were expressed at extremely high and high levels respectively. 
Pten expression did not change significantly during development. Whereas uniquely 
among all analysed PTPs (RPTPs not included) Tns1 expression doubled at each 
developmental stage, which might indicate an expression in non-neural cells and will be 
discussed later. The remaining two phosphatases from this subfamily Tenc1 and Tns3 
(both 6%) were expressed at moderate levels and showed a decrease in expression 
during development. The PTEN family members are all tumour suppressors that 
modulate signalling pathways such as the PI3 kinase pathway and inhibit cell 
proliferation, growth, migration and survival (Leslie and Downes, 2004). 
 The MKPs and the atypical DSPs apart from Dusp11 displayed slightly lower 
gene expression levels than the previously mentioned subfamilies, with the majority of 
the members showing a decrease or no change in gene expression. Both subfamilies are 
involved in a wide range of important cellular processes such as gene expression, 
differentiation, proliferation and cell survival, which are among others controlled by Trk 
signalling. Thus their expression in DRGs was also not surprising.  
 Among the ten analysed members of the MKP subfamily Dusp1 showed highest 
expression (35%), four MKPs showed high expression levels (Dusp4, Dusp6, Dusp7 
and Dusp8), two MKPs (Dusp10 and Dusp16) were expressed at moderate levels and 
only three MKPs were expressed below the threshold (Dusp2, Dusp5 and Styxl1). Most 
MKPs showed a significant decrease or no changes in gene expression except Dusp10, 
which showed a significant peak in expression at E13.5. MKPs regulate MAP kinases. 
 Among the 15 atypical DSPs, four phosphatases were expressed below the 
threshold and the remaining PTPs were expressed at moderate to high levels with the 
exception of Dusp11, which showed very high expression levels (65%). Most members 
of this subfamily showed a decrease in gene expression or no significant changes, 
except Dusp26 and Styx with a significant peak at E13.5 and Dusp15 and Dusp23 with a  
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significant increase in gene expression. The atypical DSPs have a broad substrate 
specificity ranging from proteins to mRNA; the latter is a substrate of Dusp11.  
 The SSHs, CDC14s and CDC25s, showed the lowest gene expression profile 
compared to other DSP subfamilies. The three SSHs were expressed at moderately high 
levels. Ssh1 and Ssh2 showed a significant decrease in expression whereas Ssh3 
expression increased. The four members of the CDC14 subfamily were all expressed at 
low levels with half of them even below the threshold. And all four showed significant 
decrease in gene expression. Two of the three PTPs from the class III Cys-based 
CDC25 subfamily (Cdc25a, Cdc25b and Cdc25c) showed a mean expression level 
above the threshold (Figure 3.3C) and a very significant decrease in gene expression 
across the analysed stages. These phosphatases are involved among other processes in 
actin dynamics and cell cycle regulation, and their expression profile possibly indicates 
that the proportion of proliferating cells in the DRGs decreases across development. 
 To sum up, several of the DSP genes show high expression levels with an 
interesting pattern in murine embryonic DRGs. Most DSPs are implicated in crucial 
signalling pathways and thus not surprisingly in human diseases, especially in 
cancerogenesis and neurological disorders (Pulido and Hooft van Huijsduijnen, 2008, 
Patterson et al., 2009). It would be interesting in future to analyse, whether their 
expression is specific to this tissue or rather ubiquitous and what roles they might play 
and whether some of them are also implicated directly and specifically in Trk 
signalling.  
  3.3.1.3.2. NPTP and RPTP gene expression  
The classical Tyr-specific PTPs NPTPs and RPTPs play important roles in many 
different signalling pathways and their expression and function has been extensively 
studies in a variety of tissues among others in DRGs. In this study the gene expression 
levels of the 17 known murine NPTPs were relatively high for the majority of 
phosphatases and at similar levels as of the MKPs (Figure 3.4A). Among all NPTP 
genes Ptpn12 was the most abundant (34%). The seven NPTPs Ptpn1, Ptpn2, Ptpn3, 
Ptpn9, Ptpn11, Ptpn13 and Ptpn23 were expressed at high levels and Ptpn4 and Ptpn5 
at moderate levels. The seven remaining NPTPs were expressed below the threshold of  
5% with Ptpn6, Ptpn7, Ptpn18, Ptpn20 and Ptpn22 even below 1%. Overall the 
majority of NPTPs showed a decrease in gene expression during development with the 
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Figure 3.3. QPCR analysis of PTP gene expression during DRG development I.  
PTP gene expression was measured in murine embryonic DRGs at the developmental stages 
E12.5 (blue), 13.5 (red) and 14.5 (green). Displayed are relative gene expression levels of A) 
MKPs and atypical DSPs, B) PRLs, SSHs, CDC14s, PTENs and MTMs and C) CDC25s and 
the LM PTP. Gene expression levels were calculated as 2-ΔCT % relative to the HKG set. SD and 
statistical analysis (ANOVA) were included in the graphs and categorized as following:  
p > 0.05 non-significant (ns), 0.01 < p < 0.05 significant (∗), 0.001 < p < 0.01 very significant 
(∗∗) and p < 0.001 extremely significant (∗∗∗). 
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exception of Ptpn5, Ptpn20 and Ptpn22, which revealed a significant increase. NPTPs 
are involved in many important signalling mechanisms, for instance they modulate 
growth factor signalling pathways in the immune system, metabolism and the nervous 
system. They control cell adhesion and motility, and are implicated in the onset of many 
diseases such as cancer, diabetes and neurodegenerative disorders. NPTPs, which were 
at least moderately expressed in DRGs in the present study, were all implicated in 
signalling pathways in the nervous system. The highest expressed NPTP in DRGs  
PTP-PEST (Ptpn12) is a ubiquitously expressed regulator of integrin signalling, which 
is especially highly expressed during development and is implicated in vascularisation 
and neurogenesis (Sirois et al., 2006). Another highly expressed PTP SHP-2 (Ptpn11) is 
a known oncogene, which is implicated in several types of leukaemia and in 
neuroblastoma and developmental disorders (Ostman et al., 2006). Most importantly for 
my analysis SHP-2 has also been identified as a mediator of TrkA and TrkB signalling 
in vitro (Yamada et al., 1999, Chen et al., 2002). NPTPs, which were expressed at the 
lowest or almost undetectable levels, were implicated in many signalling pathways 
other than the nervous system, such as in haematopoiesis and the immune system, apart 
from SHP-1 (Ptpn6), which was identified in the CNS especially in glia cells but not in 
the PNS (Horvat et al., 2001). Altogether, some of the NPTPs are likely to be 
specifically involved in Trk signalling and could be analysed in future. 
 The analysis of the expression of all 21 known RPTP genes, the focus of this 
thesis, revealed that Ptprf, Ptprs and Ptprr were the most abundant PTPs in DRGs as 
mentioned above (Figure 3.4B). Ptpra was expressed at very high levels (40%) 
followed by Ptpro (28%), Ptprz1 (22%), Ptprn (20%), Ptprd (18%) and Ptprg (16%) 
with high expression levels. Ptprn2, Ptprj, Ptprk and Ptprm showed moderate to low 
expression levels. The remaining eight RPTPs Ptprb, Ptprc, Ptpre, Ptprh, Ptprq, Ptprt, 
Ptpru and Ptprv showed expression levels at all developmental stages below the cut-off 
of 5%. Overall the thirteen RPTPs Ptprf, Ptprs, Ptprr, Ptpra, Ptpro, Ptprz1, Ptprn, 
Ptprd, Ptprg, Ptprn2, Ptprk, Ptprj and Ptprm were detected above the threshold in 
DRGs during development. Then again it is important as previously stated to keep in 
mind that we have analysed the expression in whole DRGs and that the expression of 
some RPTPs in specific cell populations within the DRGs might be different. For 
instance an RPTP gene with low expression levels in our screen might be in fact  
strongly expressed in a small specific subpopulation of cells within the DRGs, but its  
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Figure 3.4. QPCR analysis of gene expression during DRG development II.  
A) NPTP and B) RPTP gene expression in murine embryonic DRGs was measured at the 
developmental stages E12.5 (blue), 13.5 (red) and 14.5 (green). Results of the relative 
quantification analysis are displayed as mean 2-ΔCT % gene expression relative to the HKG set. 
SD and statistical analysis (ANOVA) were included in the graphs and categorized as following: 
p > 0.05 non significant (ns), 0.01 < p < 0.05 significant (∗), 0.001 < p < 0.01 very significant 
(∗∗) and p < 0.001 extremely significant (∗∗∗). 
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expression was diluted out in the analysis of whole DRGs. The analysis of the 
expression profiles of the RPTPs across the analyzed developmental stages revealed 
three different patterns. Ptpra, Ptprb, Ptprc, Ptprd, Ptprk, Ptprm and Ptpru 
demonstrated a significant decrease, whereas Ptpre, Ptprt, Ptprv and especially Ptprz1 
showed a significant increase in expression during development similar to the 
previously mentioned DSP gene Tns1. The remaining nine RPTP genes Ptprf, Ptprs, 
Ptprg, Ptprh, Ptprj, Ptprn, Ptprn2, Ptpro and Ptprq did not reveal any significant 
changes in expression across analysed developmental stages (Figure 3.4B). These 
patterns will be compared to Trk gene expression patterns in the following chapter 
(Chapter 4). 
 The eleven candidate RPTP genes, the strongly expressed genes Ptprf, Ptprs, 
Ptprr, Ptpra, Ptpro, Ptprz1, Ptprd, Ptprg and the marginal candidate genes Ptprk, Ptprj 
and Ptprm, were further analysed using ISH (section 3.3.3). Ptprn and Ptprn2, despite 
being positive in the qPCR analysis, were omitted from the final candidate gene set. 
This will be discussed later in this chapter together with the function and reported 
expression of the candidate RPTP genes.  
3.3.2. RPTP and Trk gene expression analysis – a pilot exon microarray 
           study 
Another very popular high-throughput technique to study gene expression is microarray 
analysis. It allows the analysis of thousands or even millions of genes in parallel in one 
sample. However, it is widely known that microarray chips also suffer from high batch-
to-batch variability and poor sensitivity and specificity depending on the hybridization 
efficiency of the probes. Thus such experiments always require further validation of the 
results for instance using qPCR. Several different chip types have been developed such 
as the commonly used 3’ microarrays and the recently developed exon microarrays. The 
latter was tested in the present study. An exon microarray provides in addition to a 
global gene expression analysis, also information about differently spliced isoforms, 
and due to its design it compensates for some of the mentioned drawbacks. Each probe 
set consists on average of four different probes, which cover a specific region of an 
exon, and around four different probe sets cover different parts of the exon. 
Additionally probes are selected across the entire length of the transcript (for more 
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details see section 3.2). For these reasons the exon array represents a robust gene-level 
analysis and is not biased towards the 3’ end unlike traditional 3’ microarrays.  
 In a pilot microarray experiment to analyse PTP gene expression in DRGs I have 
tested the GeneChip® Mouse Exon 1.0 ST array (Affymetrix). However, due to several 
limitations of this experiment such as that several genes of interest were only covered 
by probes with low confidence (“extended probes”), as well as time intensive and 
challenging data analysis and high costs, this experiment was not extended to a multi- 
chip study. Instead, the semi-automated qPCR arrays, specifically set up for PTP gene 
expression analysis, became available and were then used (section 3.3.1). Nevertheless, 
the pilot microarray analysis was performed on an E12.5 murine DRG sample before 
the qPCR arrays could be used. Thus I have analysed the data obtained from this single 
exon microarray for several RPTP and the three Trk genes and have finally compared 
them to the data obtained from the qPCR screen for a partial validation of the results. 
 To select data I have used a stringent cut-off value of signal intensity log2 7 for 
an overall detected expression according to the experience of the Bloomsbury Centre 
for Bioinformatics, UCL (personal communication). In our analysis this was further 
justified by the expression of the two HKGs Psmb2 and Ubc, which were both 
expressed above this threshold, and additionally the expression of Ptprc below the 
threshold (Figure 3.5). Ptprc (CD45) is expressed in haematopoietic cell types 
(Alexander, 2000) and no expression was reported in DRG cells to date.  
 Two approaches were used for data analysis. In addition to a manual analysis of 
selected probe sets (Figure 3.5A), I have also used the “global analysis option” of the 
Expression Console® software (Affymetrix) to retrieve information about global gene 
expression (Figure 3.5B). In general both methods agreed in their outcome, but differed 
in the levels of signal intensity for some of the genes. This was due to the rather 
stringent selection of the probe sets in the manual analysis and the removal of 
considered outliers. The analysis of the different probe sets additionally provided an 
overview of the different intensities of specific probe sets, which cover specific exons. 
However, since only one chip was used, an analysis of the different splice forms was 
not possible.  
 Overall, all three Trk genes were expressed at very high levels in murine E12.5 
DRGs (Figure 3.5). The majority of all probe sets was expressed not only above the set 
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threshold but also mostly above the signal intensity of log28. Ntrk1 was detected only 
by low confidence “extended probes” on this chip and therefore its expression was 
evaluated with more caution. The analysis of RPTP gene expression revealed 13 RPTPs 
with values above the set threshold based on the median of the signal intensity of their 
probe sets (Figure 3.5) and among these Ptprf and Ptprs were expressed at the highest 
levels. All of their probe sets were expressed highly above the threshold with signal 
intensities of log2 9 - log210 for Ptprs and log2 10 - log211 for Ptprf. Ptprg and Ptprr 
showed very high expression levels with the majority of probe sets with signal 
intensities of log2 8 - log29.5. Ptpra, Ptprd, Ptprn and Ptpro were expressed at relatively 
high levels with the majority of signal intensities between approximately log2 7.5 and 
log2 9.  
 The RPTP genes Ptprj, Ptprk, Ptprm, Ptprn2 and Ptprz1 were expressed only 
moderately with most signal intensities between log2 7 and log2 8. The remaining eight 
RPTP genes Ptprb, Ptprc, Ptpre, Ptprh, Ptprq, Ptprt, Ptpru and Ptprv were expressed 
below the set threshold, with Ptprc, Ptprh and Ptprq with lowest values. Ptprh, Ptprq 
and Ptprz1 were detected only by low confidence “extended probes”.  
 In summary the results from the microarray analysis agree remarkably well with 
the results obtained from the qPCR analysis at E12.5 (Table 3.2) and thus validate each 
other. Both analyses revealed expression of the same RPTP genes Ptpra, Ptprd, Ptprf, 
Ptprg, Ptprj, Ptprk, Ptprm, Ptprn, Ptprn2, Ptpro, Ptprr, Ptprs and Ptprz1 in murine 
embryonic DRGs during organogenesis. Differences in expression levels between qPCR 
and the microarray studies are likely to be caused by alterations in primer efficiencies in 
the qPCR analysis and the hybridisation strengths to the probes on the chip. Another 
likely factor could be the detection of different transcripts on the chip and by the 
primers used for qPCR. However, this point cannot be further addressed, as no 
information on the detection of different transcripts was available from a single exon 
microarray. Finally, the agreement between the data sets suggests that indeed the  
inter-gene comparison in the qPCR is to some extent justified. 
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Figure 3.5. Microarray analysis of RPTP, Trk and housekeeping gene expression in E12.5 
DRGs.  
The expression of RPTP, Trk and housekeeping genes (HKGs) was analysed in E12.5 DRGs 
from CD-1 mouse embryos using a GeneChip® Mouse Exon 1.0 ST array (Affymetrix). A) The 
box plot represents the distribution of signal intensities (log2) of detected and stringently 
selected probe sets (exons) for each transcript cluster (gene) as calculated manually. B) Medians 
of signal intensities (log2) of transcript clusters as calculated by the Expression Console® 
software (Affymetrix) are displayed. The differences in several signal intensity values are due to 
the more stringent selection of probe sets in the manual analysis and the removal of considered 
outliers. A value of log2 7 signal intensity was used as a cut-off point to discriminate, whether 
genes were present or absent in the sample (see text for more explanations). 
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GENE 
SYMBOL 
PROTEIN 
NAME 
SIGNAL 
INTENSITY 
(GENES) 
SIGNAL 
INTENSITY 
(EXONS) 
MICROARRAY 
RESULTS 
QPCR 
RESULTS COMPARISON 
Ntrk1 TrkA [9.3] [9.6] [+++] ++++ ++++ 
Ntrk2 TrkB 9.0 9.2 +++ ++ ++(+) 
Ntrk3 TrkC 8.7 9.3 +++ ++++ +++(+) 
Ptpra RPTPα  8.1 8.6 ++ +++ ++(+) 
Ptprb VE-PTP 6.7 6.7 – – – 
Ptprc CD45 3.6 6.4 – – – 
Ptprd RPTPδ  8.4 8.6 ++ ++ + + 
Ptpre RPTPε  5.8 6.0 – – – 
Ptprf LAR 10.7 10.6 ++++ ++++ ++++ 
Ptprg RPTPγ  8.8 9.1 +++ + ++ 
Ptprh SAP1 [3.6] [5.8] [–] – – 
Ptprj DEP-1 7.6 7.9 + + + 
Ptprk RPTPκ  7.3 7.4 + + + 
Ptprm RPTPµ  7.3 7.6 + + + 
Ptprn IA-2 8.5 8.5 ++ ++ ++ 
Ptprn2 IA2β  7.5 7.7 + + + 
Ptpro PTP-BK 7.8 8.0 ++ ++ ++ 
Ptprq PTPS31 [4.5] [6.0] [–] – – 
Ptprr PTPRR 9.1 9.2 +++ ++++ +++(+) 
Ptprs RPTPσ  10.2 10.3 ++++ ++++ ++++ 
Ptprt RPTPρ  5.8 6.0 – – – 
Ptpru RPTPλ  6.1 6.5 – – – 
Ptprv OST-
PTP 
5.0 6.7 – – – 
Ptprz1 RPTPζ  [6.9] [7.5] [+] + + 
 
Table 3.2. Comparison of microarray and qPCR results in E12.5 murine DRGs.  
Displayed are log2 signal intensity (si) values of probe sets (exons) as calculated manually and 
of transcript clusters (genes) as calculated by Expression Console® software (Affymetrix). 
These results were compared to the qPCR analysis of RPTP and Trk gene expression in murine 
E12.5 DRGs. The genes Ntrk1, Ptprh, Ptprq, Ptprz1 were covered only by low confidence 
“extended probes” on the microarray chip and were therefore considered with caution (in square 
brackets “[ ]”). Keys for evaluation of qPCR expression levels (x) and log2 signal intensity (si) 
in microarrays: 
        ++++ (extremely high)                       x > 50%                si > log210 
          +++ (very high)      0% > x >  30%  log210 > si > log29  
            ++ (high)    30% > x >  15%   log29 > si > log28  
              + (moderate)     15% > x >    5%    log28 > si > log27  
              – (low)        5% > x     log27 > si 
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3.3.3. ISH analysis of Trk and RPTP gene expression  
ISH is a powerful technique to visualize mRNA expression on the cellular level and so 
provides information about the location of mRNA transcripts. In this study I have used 
chromogenic ISH to confirm the results obtained from the quantitative analysis in 
addition to the analysis of the location of gene expression in the DRGs. Negative sense 
ISH controls were performed for all analysed Trk and RPTP genes with the exception of 
Ptprg and Ptprz1 due to unknown transcription plasmids. Pictures are provided in the 
appendix (Appendix, Figure 3). The results from this analysis were also compared and 
complemented with entries from the recently developed database GenePaint 
(http://www.genepaint.org) (Visel et al., 2004), which contains a public collection of 
pictures of ISH sagittal sections from E14.5 C57BL/6 mouse embryos of almost all 
PTPs (Appendix, Figure 4). 
3.3.3.1. RPTP genes, which were expressed in DRGs 
The ISH analysis showed extremely high to very high expression of the three Trk genes 
in the DRGs at all analysed developmental stages in agreement with the quantitative 
analysis (Figure 3.6C). Ntrk1 was expressed in the majority but not all cells in the 
DRGs at all analyzed stages. Ntrk2 and Ntrk3 expression was restricted to a specific 
subpopulation of DRG cells scattered within the DRGs with more Ntrk3+ than Ntrk2+ 
cells present. The proportion of both Ntrk3+ and Ntrk2+ cells appears to decrease during 
development. However, no cell counts were performed at this point. These results are in 
strong agreement with previously reported findings (see section 3.3.1). 
 High expression in DRGs, as estimated by quantitative analysis, of the candidate 
RPTP genes Ptpra, Ptprd, Ptprf, Ptprg, Ptpro, Ptprr and Ptprs was also confirmed by 
ISH (Figure 3.6A). The sense riboprobes did not provide any specific staining 
(Appendix, Figure 3). 
  Ptprf was expressed in most cells in the DRGs without apparent changes in 
their amount between E12.5 and E14.5. Previously Ptprf expression was documented in 
embryonic and adult murine DRGs (Schaapveld et al., 1998) specifically in neurons but 
not in any non-neural cells (Longo et al., 1993, Zhang et al., 1998).  
 Ptprs was expressed rather ubiquitously in almost all tissues but with most 
hybridised riboprobes in specific cells within DRGs. Ptprs expression was previously 
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found in proliferating and differentiated neurons in DRGs in embryonic and adult 
rodents (Yan et al., 1993, Wang et al., 1995, Haworth et al., 1998, Schaapveld et al., 
1998, Van Vactor, 1998).  
 Ptprd expression was also detected in DRGs at all three embryonic stages. The 
results retrieved from the GenePaint database also demonstrate that Ptprd is expressed 
in E14.5 DRGs in the mouse (Appendix, Figure 4). Surprisingly, in contrast to these 
findings Shaapveld et al. reported no expression of Ptprd in murine E14.5 DRGs using 
the same riboprobe (Schaapveld et al., 1998). In our analysis Ptprd staining was also 
very weak to almost undetectable on some sections. To analyse whether this might be 
due to the location within the DRG or whether there is a difference between different 
DRGs depending on their position in the embryo (cervical or thoracic) ISH was 
performed on sagittal sections (see chapter 4 Figure 4.4). However, no differences were 
detected between DRGs. Potentially this might be due to a more rapid degradation of 
Ptprd mRNA in comparison to other RPTPs for unknown reasons. Therefore particular 
care is needed when using the Ptprd probe in these studies.  
 Ptpro was strongly expressed in the quantitative analysis, and ISH analysis 
showed very high expression of Ptpro in large and medium sized cells in the DRGs 
(Figure 3.6A). The neuronal Ptpro isoform has been previously detected in a specific  
subset of neurons in dorsal root, cranial and sympathetic ganglia and in specific brain 
areas (Haworth et al., 1998, Beltran et al., 2003).  
 Ptpra was ubiquitously expressed in the mouse embryos with stronger 
expression in DRGs. The quantitative analysis showed a decrease in the expression 
levels at E14.5 compared to E13.5, but no obvious changes were seen on the in situ 
hybridized sections (Figure 3.6A). Ptpra expression was found in DRG neurons at all 
three developmental stages and in adult rodents with a peak in expression at E13.5 (den 
Hertog et al., 1996, Haworth et al., 1998, Van Vactor, 1998).  
 Ptprg was moderately expressed in the quantitative analysis with no significant 
changes during development. Its expression in DRGs was also detected with ISH, but 
the staining was not very strong, and possibly restricted to specific cells within the 
DRGs (Figure 3.6A). Previously this phosphatase was detected in neurons in the murine 
embryonic CNS such as pyramidal neurons and in DRGs at E14.5 and E17.5 
(Lamprianou et al., 2006).  
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Figure 3.6. qPCR and ISH analyses on murine embryonic DRGs.  
To confirm the qPCR analysis ISH was performed on transverse cryosections through limb 
regions of mouse embryos at the developmental stages E12.5, E13.5 and E14.5. Displayed are 
the results from the qPCR (graphs) and ISH analyses (DRGs) of A) eight candidate RPTP genes 
(Ptpra, Ptprd, Ptprf, Ptprg, Ptpro, Ptprr, Ptprs and Ptprz1), B) threshold candidate RPTP genes 
(Ptprj, Ptprk and Ptprm) and C) Trk genes (Ntrk1, Ntrk2 and Ntrk3). The sense probes did not 
provide any specific staining (Appendix, Figure 3). 
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 Ptprz1 was expressed at moderate levels in the qPCR screen and its expression 
patterns showed an interesting increase during development (Figure 3.6A). ISH staining 
of Ptprz1 was not particularly strong and was developed for several days in comparison 
to few hours for most other riboprobes. However, Ptprz1 expression in DRGs could be 
confirmed. The used riboprobe detected the long transmembrane isoform specifically, 
but similar results were obtained with a riboprobe that hybridized to all three known 
isoforms (data not shown). In agreement with the presented results, some staining could 
also be detected in DRGs on the E14.5 sagittal embryo section retrieved from 
GenePaint (Appendix, Figure 4), but the staining was very faint especially in 
comparison to the staining in the VZs in the brain. The expression of this phosphatase in 
DRGs was previously mostly attributed to SGCs (Haworth et al., 1998).  
 The candidate gene Ptprr was strongly and specifically expressed in DRGs in 
the quantitative analysis and also with ISH. Its expression is significantly 
downregulated at E14.5 in the qPCR analysis. ISH staining however, does not show an 
obvious decrease in expression. Only PTPBR7, the longest transmembrane isoform of 
RPTPR, was previously detected in DRGs during development at the analyzed stages 
and in adult mice (Van Den Maagdenberg et al., 1999).  
 The expression of the marginal candidate genes Ptprj, Ptprk and Ptprm was 
very low to almost undetectable in DRGs, in agreement with the qPCR analysis  
(Figure 3.6B). However, ISH is not a very sensitive technique and therefore undetected 
genes might still be expressed in DRGs at very low levels. To increase the signal levels 
the probes were left to develop for several days, but this increased the background 
rather than the actual signal. The riboprobes were additionally tested on brain sections 
and appeared to hybridize correctly and at significant levels (data not shown). These 
results also agree with data retrieved from GenePaint (Appendix, Figure 4). In more 
detail, Ptprj was expressed at levels above Ptprm, the lowest expressed gene among all 
candidate RPTPs in the quantitative analysis. However, in the ISH analysis almost no 
signal could be located within the DRGs for both Ptprj and Ptprm. Ptprk was expressed 
at slightly stronger levels than Ptprj and showed a significant decrease in expression in 
the quantitative analysis. However, ISH with a riboprobe detecting all isoforms was 
very weak at E12.5 with slightly increasing levels during development (Figure 3.6B). 
Whereas RPTPκ was previously detected in small to medium sized neurons in murine  
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DRGs at E14 (Jiang et al., 1993, Hantman and Perl, 2005), Ptprm and Ptprj expression 
in DRGs was not reported to our knowledge. 
3.3.3.2. RPTP genes, which were not expressed in DRGs 
The genes Ptprb, Ptprc, Ptpre, Ptprh, Ptprq, Ptprt, Ptpru and Ptprv were expressed 
below the set threshold in the qPCR screen and were therefore excluded from further 
ISH analysis in this study. Nevertheless, in order to confirm their low or absent 
expression in DRGs, which will support our results, I have used ISH data retrieved from 
the GenePaint database (Appendix, Figure 4) and previous publications. 
 On in situ hybridized sections form the GenePaint database Ptprb staining was 
absent from cells in the DRGs, but it was very strong in specific blood vessels. Indeed 
previous findings have associated the encoded vascular endothelial tyrosine phosphatase 
(VE-PTP) as its name suggests with the remodelling of blood vessels and angiogenesis 
(Baumer et al., 2006). Ptprc expression was absent in DRGs and only detectable in the 
thymus. As mentioned earlier the expression of the encoded CD45 protein was 
previously detected on all nucleated haematopoietic cells and was shown to play an 
important role for instance in the activation of T-cells (Alexander, 2000, Hermiston et 
al., 2003). Ptpre expression was detected in the murine NS but not in DRGs. It is 
expressed in the neural tube of mouse embryos at E12 and later stages and in specific 
brain areas such as the granular cells of the cerebellum at E14.5. It was suggested to 
play a role in the differentiation and maturation of these cells (Mukouyama et al., 1997). 
RPTPε is also involved in osteoclast formation and function (Granot-Attas et al., 2007), 
negative regulation of insulin receptors (Nakagawa et al., 2005) and in the myelination 
by Schwann cells through regulation of potassium channels (Peretz et al., 2000). Ptpru 
was not expressed in murine DRGs at E14.5 but it was previously found in various 
regions of the brain and within the motor columns of the spinal cord in E15.5 rat 
embryos (Van Vactor, 1998). Ptprv was not detected in DRGs of E14.5 mouse embryos 
(Appendix, Figure 4). The encoded OST-PTP phosphatase was not associated with the 
nervous system but instead is involved in bone remodelling and is a tumour suppressor 
and a direct target of p53 (Doumont et al., 2005). Ptprt was strongly expressed in the 
CNS apart from some stained cells in the DRGs (Appendix, Figure 4). Previous studies 
have shown however, that RPTPρ is exclusively expressed in the CNS, where it is 
involved in the regulation of synapse function (Lim et al., 2009). Ptprq encodes 
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PTPS31, which is specific for inositol phospholipids. It is expressed and exerts its 
function in the kidney glomeruli and the inner ear (Goodyear et al., 2003). It was among 
the lowest expressed genes in the developing DRGs in the qPCR screen. However, no 
data were available on any public ISH database to validate these results. Nevertheless, 
no expression has ever been reported in DRGs. 
 In summary, the results obtained in the quantitative gene expression analysis 
could be confirmed using ISH, and these data were also largely in agreement with 
previous reports. The strong candidate genes Ptpra, Ptprd, Ptprf, Ptprg, Ptpro, Ptprr 
and Ptprs were highly expressed in DRGs either in almost the entire DRG or in a subset 
of cells. Surprisingly, weak expression of Ptprz1 transcripts was detected in DRGs 
using ISH, whereas moderately high expression was seen in the quantitative analysis. 
The marginal genes Ptprj, Ptprk and Ptprm were also almost undetectable in the ISH 
study in agreement with their low expression in the quantitative analysis.  
 
3.4. Discussion 
The aim of this chapter was to identify candidate RPTPs based on their gene expression 
levels in developing DRGs, which are likely to interact with Trk receptors and might so 
play a role in neuronal functions such as differentiation, survival and neurite outgrowth. 
 It is always preferable to analyse the expression of proteins instead of genes as a 
gene expression analysis merely reports the amount of mRNA present in the tissue. But 
it does not provide any information of whether the mRNA is in fact translated into 
active proteins, with correct folding, localization and post-translational modification or 
proteolytic cleavage. However, an analysis on the protein levels is limited by the 
availability of specific antibodies. At the moment when this study was conducted no 
suitable antibodies against RPTP epitopes were available to us and the lack of such 
antibodies still hinders the field as a whole. Under such circumstances the alternative 
analysis of gene expression was a valuable starting point to select candidate RPTP 
genes. A gene expression approach has also the great advantage that a plethora of high-
tech and high-throughput techniques exists, which allows the analysis of many genes in 
parallel.  
 In the present study three different types of gene expression techniques were 
used. The high-throughput techniques qPCR arrays and microarrays are very valuable 
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tools for rapidly analysing a large group of genes, from small amounts of samples. But 
they also come with caveats and these limitations have to be taken into consideration for 
the interpretation of the results. As with all such general screening methods, not all of 
the parameters can be exactly determined, but instead plausible assumptions are made. 
For instance in the qPCR array the PCR amplification efficiency and the efficiencies of 
the primers, which have to be similar for target and control genes (HKGs), were not all 
previously experimentally examined. However, all used primers were commercially 
obtained as validated assays from Qiagen and Dr. Vasu Akepati (Weismann Institute, 
Israel) has validated a selection of primers and confirmed their approximately 100% 
efficiency (personal communication). Additionally the amplification curves of all 
primers were monitored and appeared to be approximately parallel implying similar 
qPCR amplification efficiencies. Similar limitations apply to classic microarrays since 
each individual probe has a different hybridisation affinity. In exon arrays this problem 
is partly compensated for by the design of the array as described earlier and thus 
provides a robust gene-level analysis. Since only one single microarray was run, no 
conclusions about technical and biological repeatability and their statistical robustness 
could be made. Both the qPCR and the microarrays were used in this study to create a 
gene expression profile and not for a comparison of individual gene expression under 
different conditions as is normally done. Although this is a rather unconventional way 
of data analysis, our data sets from the qPCR and the microarray analyses agreed with 
each other on the evaluation of RPTP and Trk gene expression and thus support and 
validate each other. Additionally the expression of all relevant candidate genes was 
confirmed using ISH. The advantage of this unconventional analysis method is that it 
allows an estimation of the gene expression levels in the samples, whereas the 
conventional analysis only provides information about the changes of gene expression  
under experimental conditions. Thus our analysis was more suitable to us for the 
selection of highly expressed genes for further study. 
 Another important point, which needs to be considered for the interpretation of 
the results, is that gene expression analysis on a mixed population of cells such as in the 
DRGs used in this analysis lacks information about the location of the mRNA in 
specific cell types. Although several different techniques are available to separate cells 
such as fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting 
(MACS), most of these techniques require dissociation of DRG cells, which is known to 
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have a fundamental impact on gene expression and represents rather a regeneration than 
an in vivo system (see chapter 6 for more details). Performing gene expression analysis 
directly on fresh frozen DRG tissue provides information closer to the in vivo state and 
thus was preferred to the aforementioned selection of specific cell subtypes. Moreover, 
the main interest of this expression analysis was to select candidate genes for further  
in-depth coexpression analysis with Trks (chapter 4), which also provided greater 
spatial information. Therefore the techniques used were well suited for this purpose.  
 
The present study represents the only comprehensive such gene expression analysis of 
the PTP family and especially of RPTPs in developing sensory ganglia in the mouse at 
the developmental stages E12.5 to E14.5. Based on the qPCR array and exon 
microarray analyses I have selected eleven RPTP genes encoding RPTPα, RPTPδ, 
LAR, RPTPγ, RPTP-BK, RPTPR, RPTPσ, RPTPζ and the marginal candidates DEP-1, 
RPTPκ and RPTPµ as possible candidate genes and confirmed their expression in 
DRGs via ISH. The genes of the first eight RPTPs apart from RPTPζ were strongly 
expressed in both analyses, whereas the expression of DEP-1, RPTPκ and RPTPµ genes 
was detected in our quantitative analyses, but was almost undetectable in DRGs with 
the less sensitive ISH method. Expression of all these RPTPs was previously described 
in different parts of the nervous system of several species during development and in 
adult organisms. Their function was also implicated in neuronal events such as axon 
guidance, neurite outgrowth, or neuronal tissue histogenesis during development 
(section 1.3.3). Therefore their presence in our candidate list was not surprising. All of 
the candidate RPTPs apart from DEP-1, RPTPµ and also RPTPδ were also previously 
detected in DRGs (section 1.3.3). A reason for the presence of the latter three RPTPs in 
our candidate gene panel might be due to the more sensitive qPCR technique we have 
used compared to previous studies, which were mostly performed with ISH. However, 
whereas the expression of DEP-1 and RPTPµ was indeed very low in the ISH study, 
RPTPδ expression was clearly detectable in DRGs and its expression was also 
documented in the GenePaint databank. RPTPδ plays in fact a role in the nervous 
system as knockout mice show neuronal abnormalities such as memory deficits, 
hypomyelination and hyperpotentiation of hippocampal synapses, posture and motor 
defects (Uetani et al., 1997, Uetani et al., 2000). However, until now RPTPδ was 
implicated in neuronal adhesion and neurite outgrowth only in CNS neurons (Tuttle et 
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al., 1999, Wang and Bixby, 1999, Chilton and Stoker, 2000, Sun et al., 2000b). An 
expression of DEP-1 and RPTPµ in DRGs can be attributed to both non-neural cells and 
to neurons. DEP-1 belongs to the same PTPR3 subgroup as RPTP-BK, but in contrast to 
the latter it is usually expressed in hematopoietic lineages, endothelial cells, fibroblasts, 
and different epithelial and smooth muscle cells. It regulates cell-contact mediated 
growth, as it is directly related to cell-density (Ostman et al., 1994). It plays additionally 
an important role in vascularisation (Borges et al., 1996, Autschbach et al., 1999, 
Schraven, 2000, Jandt et al., 2003) and was shown to dephosphorylate VEGFRs, 
PDGFRs and EGFRs (Kovalenko et al., 2000, Grazia Lampugnani et al., 2003, Tarcic et 
al., 2009). Therefore its expression in DRGs might be attributed for instance to the 
presence of developing blood vessels, which express these kinases. On the other hand 
recently DEP-1 was also detected in retinal progenitor cells and postmitotic neurons in 
the mouse retina and a possible role in the regulation of proliferation and differentiation 
of these cells was suggested (Horvat-Brocker et al., 2008). A similar role of DEP-1 in 
progenitor cells within the DRGs is hence also possible. Like RPTPκ, RPTPµ is a 
member of the CAM-like PTPR2B subgroup, which is known to mediate neurite 
outgrowth and growth cone repulsion. Gene expression of RPTPµ was previously 
detected in different neurons in the murine CNS, but it was also found to be localized to 
non-neural cells for instance in blood vessels (Fuchs et al., 1998, Van Vactor, 1998, 
Chilton and Stoker, 2000). In this respect RPTPµ and RPTPκ were both identified in 
RGCs (Ledig et al., 1999b, Burden-Gulley et al., 2002, Horvat-Brocker et al., 2008), but 
only RPTPκ gene expression was also found in specific neurons in murine E14 DRGs 
(Hantman and Perl, 2005). Further RPTPµ was shown to regulate N-cadherin-dependent 
neurite outgrowth in chick (Burden-Gulley and Brady-Kalnay, 1999, Ensslen et al., 
2003, Major and Brady-Kalnay, 2007). Therefore RPTPµ might possibly play a similar 
role either in non-neuronal or neuronal cells in developing murine DRGs. The 
expression analysis of RPTPζ provided us with some interesting results. In our qPCR 
analysis we observed an increase in RPTPζ gene expression throughout development 
possibly indicating expression in proliferative cells such as SGCs (Lawson and Biscoe, 
1979). Indeed its expression was previously identified in SGCs surrounding large 
neurons in rat E14 DRGs and other glia cells in the CNS and PNS (Canoll et al., 1993, 
Shintani et al., 1998, Van Vactor, 1998, Harroch et al., 2000). Nevertheless, RPTPζ 
expression was previously also documented in a subset of neurons (Harroch et al., 
      Chapter 3 
 
  144 
2000). I have detected only weak staining in DRGs using an ISH probe against all three 
isoforms in the current study, in contrast to its high expression in the qPCR analysis. 
Strangely, whereas in one ISH study strong expression of RPTPζ in murine E14 DRGs 
was reported (Canoll et al., 1996b), another group reported negligible levels of RPTPζ 
expression in rat E14 (corresponding to E12.5 in mouse) DRGs (Haworth et al., 1998). 
In the latter study small, scattered RPTPζ-labelled cells were also detected at E18 in rat 
DRGs and throughout the spinal cord, which is consistent with labelling in non-neural 
cells.  
 We have excluded the two catalytically inactive RPTPs IA2 and IA2β, encoded 
by Ptprn and Ptprn2 respectively (Jiang et al., 1998), from further analysis although 
both RPTPs were strongly and specifically expressed in DRGs (Appendix, Figure 24). 
However, these phosphatases were previously only linked to insulin receptors and 
knockout mice of both phosphatases show no obvious phenotype apart from a glucose 
intolerance and impaired insulin secretion (Saeki et al., 2002, Kubosaki et al., 2004). 
The expression of these phosphatases in sensory neurons might be therefore linked to 
insulin receptors, since insulin-receptor-like receptors (IRR) are expressed in Trk+ 
neurons (Reinhardt et al., 1994).  
 Together, our gene expression analysis has confirmed and expanded the 
knowledge of the expression patterns of Trk genes in murine embryonic DRGs at the 
developmental stages E12.5 – E14.5. This comprehensive analysis has further shown 
that specific RPTP genes are among the highest expressed PTPs in developing murine 
DRGs, which strengthens the case of their possible implication with Trks in neurons as 
previously suggested. Based on the gene expression levels in DRGs and on previous 
reports we have finally selected eleven candidate RPTP genes encoding RPTPα, 
RPTPδ, LAR, RPTPγ, RPTP-BK, RPTPR, RPTPσ, RPTPζ and the marginal candidates 
DEP-1, RPTPκ and RPTPµ for further in-depth analysis of their spatial expression 
(chapter 4). All of these RPTPs were previously implicated in functions of the nervous 
system and some of them were also suggested and shown to play a role in Trk 
signalling. In our further analysis we concentrated in particular on the coexpression of 
these RPTPs with Trk receptors in the same neurons in DRG (chapter 4) as their 
coexpression would further support a possible role of RPTPs in Trk signalling in 
neurons and so a function in crucial neuronal processes. 
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4.1. Introduction 
The quantitative analysis described in the previous chapter provided first insights into 
the expression levels of RPTP genes in comparison to almost the entire PTP family and 
the Trk receptors in murine embryonic DRGs during organogenesis (E12.5-14.5). The 
chromogenic ISH study confirmed these results and provided further valuable 
information about the location of gene expression in the tissue. Altogether eleven 
candidate RPTP genes, the strongly expressed genes Ptprf (encoding LAR), Ptprs 
(RPTPσ), Ptprr (RPTPR), Ptpra (RPTPα), Ptpro (RPTP-BK), Ptprz1 (RPTPζ), Ptprd 
(RPTPδ), Ptprg (RPTPγ) and the marginal candidates Ptprk (RPTPκ), Ptprj (DEP-1) 
and Ptprm (RPTPµ) were selected mainly based on their expression levels to further 
investigate their possible implication in Trk signalling.  
 A role for the RPTPs LAR, RPTPσ, RPTPR, RPTPα, RPTP-BK, RPTPζ and 
RPTPγ (see section 1.4) has been previously suggested in molecular studies mainly 
using over-expression approaches. Only for LAR these experiments were carried out in 
primary embryonic hippocampal neurons. Also, a coexpression analysis of RPTPs with 
Trk receptors, which would support a physiological interaction, was previously only 
performed for RPTP-BK in murine E16 DRGs and TG (Beltran et al., 2003). Together 
these studies have shown that several RPTPs seem to interact at least with one of the 
Trk receptors. Therefore the questions arise, whether these Trks are substrates of all of 
these RPTPs under physiological conditions, suggesting a possible redundancy among 
RPTPs, and whether RPTPs have a preference towards a specific Trk receptor under 
physiological conditions (see section 1.4). 
 The first aim of the experiments in this chapter was hence to compare the 
temporal and spatial expression patterns of these candidate RPTP genes with the 
expression of Trk genes in murine embryonic DRGs at E12.5, E13.5 and E14.5. For this 
purpose I have extended the previously described qPCR analysis (chapter 3) to a 
comparative analysis of the expression profiles of candidate RPTP genes with Trk genes 
during development. Further ISH analysis was used to compare the specific spatial 
expression patterns of Trk and selected RPTP genes not only in DRGs but also in the 
surrounding tissues.  
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 The second goal was to perform a detailed coexpression analysis of the strongest 
expressed candidate RPTP genes and Trk genes in the dorsal root sensory neurons of 
E13.5 mouse embryos using a combination of fluorescent ISH and immuno-
fluorescence. As described above a close coexpression of particular RPTPs and Trk 
members would potentially implicate the encoded enzymes in each other’s signalling 
pathways in sensory neurons during development. In contrast, a lack of close 
coexpression would suggest that specific RPTPs and Trks are not in tight co-regulatory 
partnerships or developmentally co-regulated. 
 
4.2. Experimental procedures 
4.2.1. qPCR analysis 
The qPCR protocols were described in detail in the previous chapter. For data analysis 
in this chapter the ΔΔCT-method was used. For the relative comparative gene expression 
analysis between different embryonic stages, 2-ΔΔCT values were calculated with ΔΔCT 
representing the difference between normalized ΔCT values to HKGs of two embryonic 
stages. Hereby each sample from a certain developmental stage was compared to all 
three samples from the other developmental stage and a SD was calculated. Data were  
displayed as fold changes (2-ΔΔCT). Statistical analysis was performed with Prism 4 
(GraphPad Software) as described in section 2.7. 
4.2.2. Chromogenic and double fluorescent ISH and immunofluorescence 
ISH and immunofluorescence (IF) were performed on transverse cryosections of E13.5 
wild type (CD-1) mouse embryos as described in 2.4. The used antibodies were 
described in tables 2.3. and 2.4. The details of the used riboprobes were summarized in 
section 3.2.1. 
 Following ISH and IF cells were counterstained with DAPI to visualize the 
nuclei and allow counting of total cell numbers. It has to be noted that some of the big 
neurons (TrkB and TrkC), although positive for Trk staining, did not show nuclei 
staining, as the section was not going through the nucleus. Additionally, staining 
detected in red blood cells was an artefact caused by endogenous peroxidase activity.  
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 Pictures were taken and processed as described in section 2.6. Manual cell 
counting was performed on pictures, whereby only neurons, identified by their big 
round nuclei, were counted (Figures 1.4 and 4.1). A range of around 200-1400 neurons 
on 5 to 15 different pictures of randomly selected DRG regions from several embryos 
were counted per RPTP and Trk combination. The percentage of cells unambiguously 
positive for RPTP and/or Trk receptors was determined and SDs were calculated. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Cell counting.   
Examples of coexpressing neurons (indicated by arrows) and non-coexpressing neurons 
(indicated by arrowheads) in the DFISH and IF and FISH expression study. 
 
 
4.3. Results 
4.3.1. Comparison of RPTP and Trk gene expression patterns using  
     qPCR arrays 
qPCR arrays were used to compare the expression patterns of RPTP and Trk genes. The 
analysis revealed that, whereas the expression patterns of some RPTP genes were 
similar to Trk gene expression, others showed a completely different temporal pattern 
(Figure 4.2). In this respect the expression pattern of Ptprr resembled mostly the 
expression of Ntrk1, while Ptpra and Ptprd expression and to some extent Ptprg 
expression were mostly similar to the expression of Ntrk1 and Ntrk2 together. Ptprf and 
Ptpro expression did not change significantly at any embryonic stage unlike any of the  
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Figure 4.2. Comparison of the gene expression patterns of candidate RPTPs with Trks.  
Displayed are fold changes between expression levels at different embryonic stages of  
A) candidate RPTP genes, B) individual Trk genes (red) and their combinations (grey), 
(comparative expression at two chosen stages: E13.5:E12.5; E14.5:E13.5; E14.5:E12.5). Results 
are displayed as bars representing mean 2-ΔΔCT values with SD. Statistical analysis (ANOVA) 
was included with p > 0.05 non-significant (ns), 0.01 < p < 0.05 significant (∗), 0.001 < p < 0.01 
very significant (∗∗) and p < 0.001 extremely significant (∗∗∗). Values below the x-axis stand 
for a decrease and values above the x-axis for an increase in gene expression across 
development. 
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individual Trk genes or a combination of these and might indicate an expression in a 
subpopulation of cells. Ptprs expression patterns could be similar to the expression 
pattern of Ntrk1, a combination of Ntrk1 and Ntrk3 or all three Trk genes combined. 
Ptprj, Ptprk and Ptprm expression patterns were similar to each other and appeared to 
have similarity to Ntrk2 expression alone or in combination with Ntrk3. Ptprz1 
expression pattern was unique among the candidate RPTP genes, as it revealed an 
increase during development unlike any Trk gene. A similar pattern was already 
observed for Tns1, a dual-specificity phosphatase from the PTEN subfamily, although 
its increase in expression during development was much higher than the increase of 
Ptprz1 (chapter 3). These observations might indicate an expression in highly 
proliferative non-neural cells of both phosphatases as suggested in the previous chapter. 
 The data in Figure 4.2 collectively suggest that most RPTP genes are not 
straightforwardly co-regulated with specific Trk genes, either in level or temporal 
pattern.  
4.3.2. Comparison of RPTP and Trk spatial gene expression patterns  
     using ISH 
A comparison of the spatial expression patterns of RPTPs in DRGs and surrounding 
embryonic tissues with those of Trks was carried out. All three Trk genes and the 
analysed RPTPs showed unique expression patterns especially in DRGs and the spinal 
cord. Among the Trk genes Ntrk1 as well as Ntrk3 were expressed exclusively in DRGs, 
whereas Ntrk2 was also found in the ependymal layer of the VZ around the central canal 
in the spinal cord (Figure 4.3). The expression around this region decreased throughout 
development. It is the area where solely the truncated isoform of TrkB was previously 
detected (Armanini et al., 1995, Kumanogoh et al., 2008). Additionally, in the present 
study Ntrk1+, Ntrk2+ or Ntrk3+ neurons were found in the DRGs without any restriction 
to specific areas at the analysed developmental stages. This is in agreement with 
previous studies in rodent DRGs. In contrast, avian DRGs display a specific segregation 
pattern of neuronal subtypes. For instance Rifkin et al. have shown that specific trk+ 
neurons are spatially segregated in DRGs of chick embryos after E6 (corresponding to 
approximately E13.75 in mouse embryos). They found that trkA+ neurons were located  
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in the dorsal medial 2/3 of the DRG, whereas trkB and trkC were mostly expressed in 
neurons in the ventral lateral regions (Rifkin et al., 2000).  
 All analysed candidate RPTP genes showed unique expression patterns in DRGs 
and surrounding tissues (Figure 4.4). Several of these genes were exclusively expressed 
in DRGs either in a scattered fashion similar to Trk gene expression or in almost the 
entire DRG. Some of the RPTPs showed high apparent similarity to Trk gene 
expression, whereas the results for other RPTPs were more ambiguous.  
 Ptprf was highly expressed in the majority of the cells within the DRGs and thus 
appears to be similar to the expression of all three Trk genes. It was also detected in the 
VZ around the spinal canal at E12.5 similar to Ntrk2 expression. However, Ptprf 
staining differed from the latter in intensity and shape, as unlike Ntrk2 it did not appear 
in the ependymal layer. The expression in the spinal cord almost disappeared entirely at 
later stages.  
 Ptprs expression was rather ubiquitous but stronger staining could be detected in 
DRGs and the VZ at E12.5. The staining in this area decreased at E13.5 and 
disappeared at E14.5. At E13.5 and E14.5 some expression in the ventral lateral part of 
the grey matter, where motor neurons reside, was also observed. Ptprs expression in the 
spinal cord resembled Ptprf and thus Ntrk2 expression. But it appeared to spare the 
region adjacent to the spinal canal unlike Ntrk2. Ptprs expression in the DRGs therefore 
resembled the expression of all three Trk genes.  
 Ptprd was expressed in DRGs. In addition stronger expression was detected in 
the motor neuron pool in the spinal cord similar to Ptprs expression. Especially at E12.5 
and partly at E13.5 staining could also be seen in the intermediodorsal and ventricular 
population of cells. These findings are in agreement with previous studies in mice and 
rats (Sommer et al., 1997, Van Vactor, 1998). Ptprd expression is thus different from 
any Ntrk expression in the spinal cord, but in the DRGs its expression might resemble 
the expression of all three Trks genes.  
 Ptpro expression was detected in specific cells within the DRGs at all analysed 
stages. It was also detected in the ventral lateral part of the grey matter in the motor 
neuron region similar to Ptprs expression. From E13.5 onwards intense staining of 
Ptpro was also detected in the roof plate, which extends from the central canal to the 
dorsal margin of the spinal cord, where radial glia fibres are situated. Its expression 
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Figure 4.3. ISH analysis of Trk gene expression on transverse mouse embryo sections.  
Riboprobes targeting all identified transcripts of Ntrk1, Ntrk2 and Ntrk3, encoding TrkA, TrkB 
and TrkC respectively, were hybridised to transverse sections through the limb regions of 
mouse embryos at the developmental stages E12.5, 13.5 and 14.5. Ntrk1+ cells were found most 
DRG cells. Ntrk2 and Ntrk3 were expressed in a subset of DRG cells. Ntrk2 was additionally 
expressed in the VZ around the central canal in the spinal cord but this expression decreased 
during development. The sense probes did not provide any specific staining (Appendix,  
Figure 3). 
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pattern resembled mostly Ntrk2 and Ntrk3 expression, as it was detected in an obviously 
higher proportion of cells than either Ntrk2 or Ntrk3 alone. However, no cell counts 
were performed at this stage. Similar to previous reports the staining intensity with the 
Ptpro riboprobe ranged from faint to very strong in cells within the DRGs (Haworth et 
al., 1998).  
 Ptpra expression was rather ubiquitous but slightly stronger in DRGs, especially 
at later stages. Staining was also found in the motor neuron region. The corresponding 
sense probe showed no signal (Appendix, Figure 3). This expression pattern is in  
agreement with previous reports (den Hertog et al., 1996, Haworth et al., 1998). Ptpra 
expression in DRGs was similar to the expression of all Trk genes.  
 Ptprr was specifically expressed in the majority of cells within the DRGs and no 
staining could be seen either in the spinal cord or in surrounding tissues. This 
expression pattern was most similar to the expression of Ntrk1.  
 Ptprg expression was detected in DRGs, but the staining was not very strong. 
However, Ptprg appears to be expressed in specific cells within the DRGs. 
Additionally, some ubiquitous but very faint staining was detected in the surrounding 
nervous tissues. Its expression pattern was similar to the pattern of Ptpra and Ptprs 
expression and hence resembled the expression of all three Trks. Some expression was 
also visible in the motor neuron domain at E13.5 and E14.5. 
 Ptprz1 was expressed at very low levels in DRGs unlike any Trk receptor. 
Expression of this phosphatase was previously reported in SGCs in embryonic and adult 
rat DRGs (Haworth et al., 1998). Similar to the expression of the truncated TrkB 
isoform, Ptprz1 expression was visible in the ventral ependymal layer at E12.5 but this 
expression decreased at later developmental stages. In fact, a coexpression of the 
truncated TrkB isoform and Ptprz1, mostly in non-neural cells, was reported (Snyder et 
al., 1996). 
 The expression of the threshold candidates Ptprj, Ptprk and Ptprm was lower 
than the expression of any other candidate RPTP gene, despite the NBT/BCIP 
developing time of several days. However, the staining with each probe was stronger 
than staining with the sense riboprobe (Appendix, Figure 3). The lowest gene 
expression was seen for Ptprj at all three developmental stages in DRGs and the 
surrounding tissues. Only some specific staining was detected in the ventral ependymal  
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Figure 4.4A. ISH analysis of Trk and RPTP gene expression on transverse E12.5 mouse 
embryo sections (continued).  
 
 
Chapter 4 
 
  155 
 
 
 
 
 
Figure 4.4B. ISH analysis of Trk and RPTP gene expression on transverse E13.5 mouse 
embryo sections (continued).  
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Figure 4.4. ISH analysis of Trk and RPTP gene expression on transverse E12.5, E13.5 and 
E14.5 mouse embryo sections.  
ISH was performed on transverse cryosections through the limb region of A) E12.5, B) E13.5 
and C) E14.5 mouse embryos with riboprobes detecting all isoforms of Trk genes and the major 
isoforms of candidate RPTP genes as stated in the experimental procedures section 3.2.3. The 
sense probes provided no specific staining (Appendix, Figure 3). 
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layer of the spinal cord at E12.5, similar to Ptprz1. Ptprk and Ptprm expression was also 
rather weak but slightly stronger in the DRGs than in the spinal cord at all three 
analysed stages. No obvious similarities to Trk expression could be detected for these 
three genes. 
 The comparison of the gene expression patterns of RPTPs with those of Trks 
using qPCR arrays and ISH shows that both techniques produced datasets, which 
broadly agree with each other. The differences stem probably from the complementary 
nature of the techniques, with the low sensitivity of ISH and the lack of spatial  
information of the qPCR analysis. All in all, most of the RPTP genes appear to have 
similar expression patterns to more than one Trk receptor gene (Ptpra, Ptprd, Ptprf, 
Ptprg, Ptprr, Ptprs) and some have even more similarity to a specific subpopulation of 
neurons (Ptprf and Ptpro) or even non-neural cells such as SGCs (Ptprz1). The 
expression pattern obtained with the qPCR arrays for the marginal candidate RPTP 
genes (Ptprj, Ptprk and Ptprm) appears to be similar to Ntrk2 and/or Ntrk3, but the ISH 
analysis did not reveal any strong staining in the DRGs and thus no similarities to Trk 
expression. 
4.3.2.1. No rostrocaudal gradient of Trk and RPTP gene expression was  
   detected in E13.5 DRGs 
The generation of mouse lumbar DRG cells begins at around E9, shows a peak at E12.5 
and is complete by E14-14.5. In agreement with a known rostrocaudal gradient in 
development of sensory ganglia and spinal cord it was described that the generation of 
cervical DRG neurons is 12-24 h ahead of the lumbar DRGs (Lawson and Biscoe, 
1979). Since the expression of specific Trk receptors is timed as well (reviewed in 
1.1.3), an expected rostrocaudal gradient should be observed. In previous ISH studies, 
however, no apparent rostrocaudal gradient was reported (Klein et al., 1990b, Tessarollo 
et al., 1993). In contrast to this in studies using specific Trk antibodies a rostrocaudal 
gradient was shown in E10 mouse embryos (Farinas et al., 1998). The authors 
concluded that this discrepancy might suggest a translational control mechanism. 
 In order to analyse whether any significant differences and possible similarities 
are visible in the expression patterns of Trk and candidate RPTP genes in murine E13.5 
DRGs across the spinal cord, I performed ISH on sagittal embryo sections. This is of 
particular importance for the comparison of gene expression patterns and also the  
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Figure 4.5. ISH of Trk and RPTP candidate genes on sagittal E13.5 mouse embryo 
sections.  
Sagittal murine embryo sections of the cervico-thoracic and thoracic regions were in situ 
hybridised with probes against Trk genes (upper row) and eleven RPTP genes. The expression 
of some RPTP genes was restricted only to specific cells within the DRGs, whereas the 
expression of other genes was rather ubiquitous. No obvious changes in gene expression were 
detectable between the most caudal and rostral DRGs. No specific staining was detected with 
the sense probes (Appendix, Figure 3). 
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coexpression analysis since sections from slightly different spinal regions were used 
and this might alter the results. In contrast to aforementioned findings, this expression 
analysis (Figure 4.5) and additionally the ISH analysis of almost all RPTPs on E14.5 
C57BL/6 mouse embryo sections retrieved from the GenePaint database (Appendix, 
Figure 4) did not reveal any obvious rostrocaudal gradient in expression of either Trk or 
RPTP genes at the analysed stages.  
4.3.3. Coexpression analysis of Trks and RPTPs in murine E13.5 DRGs 
For an accurate coexpression study of RPTPs and Trks it was important first to establish 
how many cells express Trk receptors in E13.5 mouse DRGs and whether a significant 
number of these neurons coexpresses at least two of these enzymes. Both questions 
were previously addressed in several IHC and ISH studies on different species of wild 
type and transgenic animals and most of these reports agree on the relative proportion of 
Trk expressing cells. They have also confirmed coexpression of at least two Trk 
receptors in DRGs, TG and other tissues in rodents and other species and have shown a 
decrease in coexpression during development. Nevertheless, these studies are 
conflicting on the degree of coexpression mostly due to technical differences. Therefore 
it was important to analyse Trk coexpression in our system before their coexpression 
with RPTP genes could be assessed. 
 In the present study I have used different combinations of FISH and IF  
(Figure 4.6 and Appendix, Table 2) for an expression and coexpression analysis of Trks 
and RPTPs in murine E13.5 DRG neurons. All Trk antibodies recognized an epitope in 
the ECD and thus detected all known isoforms of the specific Trk receptors (specificity 
test see Appendix, Figure 1). The riboprobes against Trk genes detected all known 
transcript variants (previously described in chapter 3). 
4.3.3.1. Expression of Trk receptors  
In this study TrkA+ neurons represented the majority of cells in E13.5 murine DRGs 
with 75 +/- 12% (IF) or 60 +/- 10% (FISH). TrkB+ neurons accounted for  
6.5 +/-1.5% (IF) or 4.5 +/- 1.9% (FISH) and the proportion of TrkC+ neurons was 
around 8.4 +/- 3.3% (IF) or 9.6 +/- 4% (FISH). The amounts of neurons detected with 
either IF or FISH in the present study differed slightly from each other. This might be  
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Figure 4.6. Expression of Trk receptors in murine E13.5 DRG neurons.  
Immunofluorescence (IF) (A, C, E) and fluorescent ISH (FISH) (B, D, F) were performed on 
transverse cryosections through E13.5 mouse embryos. TrkA, TrkB and TrkC antibodies 
detected the ECD of the corresponding Trk receptor and the riboprobes detected all known Trk 
transcripts. Cell nuclei were counterstained with DAPI (blue). G and H) Percentage of Trk or 
Ntrk positive neurons. Trk+ and DAPI+ neurons were counted on pictures and the mean 
percentage and SD of unambiguously stained neurons was determined (Appendix, Table 2). 
Pictures were taken on the Zeiss Axiophot with a 20x objective and the Zeiss Imager.Z1 
ApoTome with a 63x objective.  
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caused by technical difficulties since cell counting especially using FISH, was 
sometimes challenging when no cell borders were detectable. Thus due to some 
ambiguous cases the cell numbers could have been slightly under- or overestimated. 
Nevertheless, the proportions of the different Trk expressing subtypes of neurons in the 
DRGs were approximately the same using both techniques and agree well with prior 
findings where IHC demonstrated in E13 murine DRGs that almost 80% of neurons 
were TrkA+, 8% were TrkB+ and around 10% were TrkC+ (Phillips and Armanini, 1996, 
White et al., 1996, Farinas et al., 1998, Ernsberger, 2009). 
4.3.3.2. Coexpression of Trk receptors 
In the present study the coexpression analysis revealed that at least two Trk receptors 
were coexpressed in E13.5 DRG neurons but that this proportion was small (less than 
5%) in reference to the total population of Trk+ DRG neurons (Figure 4.7F and 
Appendix, Table 3). Cell counts showed that around 0.9 +/- 0.7% (DFISH) and  
1.3 +/- 0.9% (IF and FISH) of all DRG neurons were TrkA+ and TrkB+, 2.0 +/- 1% 
(DFISH) and 2 +/- 1.5% (IF and FISH) were TrkA+ and TrkC+ and 1.4 +/- 0.1% 
(DFISH) were TrkB+ and TrkC+. Since labelling with all three Trk receptors was 
technically not possible, it cannot be excluded that some neurons also coexpress all 
three Trk receptors. In reference to the individual Trk+ subpopulations (Figure 4.7G and 
Appendix, Table 3) no more than approximately 3% of the total TrkA+ neurons 
coexpressed another Trk receptor. In contrast to this, a much higher proportion of both 
TrkC+ and TrkB+ neurons coexpressed another Trk receptor. Interestingly, among TrkB+ 
or TrkC+ neurons more cells coexpressed TrkA than TrkC or TrkB respectively and 
both TrkA+/TrkB+ and TrkA+/TrkC+ proportions were similar (almost 1/3). I have also 
observed that almost twice as many TrkB+ neurons coexpressed TrkC than vice versa. 
 Coexpression of Trk receptors in DRGs and other tissues was previously 
reported in several IHC and ISH studies and observed in transgenic mice (summarized 
in 1.3.). These results are mostly in agreement with the present findings. For instance 
Kramer et al. have shown that at E11.5 75% of murine lumbar DRG cells coexpressed 
TrkB and TrkC receptors. This amount dropped to 40% at E12 and 10% at E12.5 and at 
E14.5 no coexpression was detected in lumbar DRGs (Kramer et al., 2006). This is well 
in agreement with the current study as only around 1.4% of all neurons coexpressed 
TrkB and TrkC. Similar findings were made in TG (Funfschilling et al., 2004). TrkA 
Chapter 4 
 
  162 
and TrkC coexpression was prior reported in E11.5 mouse DRGs, but was almost 
absent from E12.5 onwards in murine DRGs (Kramer et al., 2006, Sun et al., 2008) and 
TG (Huang et al., 1999). In the present study the prevalence of TrkA+ and TrkC+ 
neurons at E13.5 was around 2-3% and is thus well in agreement with these reports. 
TrkA and TrkB coexpression was previously detected in E10.5 until E12 mouse TG 
(Dykes et al., 2010), but was not analysed in murine DRGs yet to our knowledge. It is 
possible, however, that this is also the case in DRGs. Considering the delay in 
development of DRGs in comparison to TG this agrees with our findings of 1% total 
TrkA+ and TrkB+ neurons. 
 In summary, coexpression of Trk receptors in E13.5 murine DRG neurons is low  
(< 5%), but cannot be neglected as it accounts for a high percentage of the specific 
TrkB+ and TrkC+ subpopulations. We found that whereas coexpression among TrkA+ 
neurons is rare, one third of TrkB+ neurons coexpressed either TrkA or TrkC at E13.5. 
Among TrkC+ neurons less than one third coexpressed TrkA and the TrkB+/TrkC+ 
population was almost half as big as the TrkC+/TrkB+ population, but still 14% and thus 
not negligible. Together, among all Trk+ subpopulations, more TrkB+ neurons 
coexpressed another Trk receptor than either TrkA+ or TrkC+ neurons. However, it is 
not known whether among these neurons some also coexpress the third Trk receptor and 
thus the amount of coexpressing neurons might be lower. In fact Moshnyakov et al. 
have performed RT-PCR on individual E12 and E16 rat TG neurons and have shown 
that several of these cells express all three Trk receptors (Moshnyakov et al., 1996). 
However, this study was not quantitative and no prevalence of these triple-expressing 
neurons was determined. 
 The total amount of all detected Trk+ neurons accounts for around 87 +/- 6%, if 
coexpression is taken into account. Thus these results demonstrate that most of the cells 
in E13.5 DRGs are Trk+. The remaining Trk- neurons could for instance represent non-
neuronal cells or possibly Ret+ neurons or other neural subtypes. Finally, this detailed 
Trk expression study validates the technical approach of using DFISH and IF especially 
for a coexpression analysis as the results mostly agree with previous findings. In 
addition these data also expand previous knowledge on Trk coexpression in murine 
embryonic DRG neurons. 
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Figure 4.7. Coexpression of Trk receptors in murine E13.5 DRG neurons.  
Double fluorescent ISH (DFISH) and immunofluorescence (IF) were performed sequentially on 
transverse cryosections through the limb region of E13.5 mouse embryos for coexpression 
analysis. The TrkA antibody detected the ECD and the riboprobes detected all known 
transcripts. Nuclei were counterstained with DAPI (blue). A and C) IF (TrkA, red) and 
fluorescent ISH (TrkB or TrkC, green), B, D, E) DFISH. Pictures were taken on the Zeiss 
Imager.Z1 ApoTome with a 63x objective. Scale bar = 20 µm. Arrowheads indicate non-
coexpressing neurons, whereas coexpressing neurons are shown in the insets. Percentages of F) 
Trk coexpressing neurons in reference to all detected DRG neurons and G) of Trk coexpressing 
neurons among TrkA+, TrkB+ or TrkC+ neurons. SDs were included in the graph. The lighter 
columns represent DFISH staining and the darker columns IF and FISH. Scale bar = 2 µm. 
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4.3.3.3. Coexpression of RPTPs and Trks 
Having characterised Trk expression, I then analysed the detailed coexpression of all 
three Trk receptors with the seven strongest expressed candidate RPTP genes: Ptpra, 
Ptprd, Ptprf, Ptprg, Ptpro, Ptprr and Ptprs. The marginal candidates Ptprj, Ptprk and 
Ptprm and also Ptprz1 were not included in this study due to their low expression levels 
in DRGs and the detection limits of ISH. FISH and IF are both powerful techniques to 
obtain spatial information of the expression of Trks and RPTPs simultaneously in the 
same cell. RPTPs were detected by FISH, and TrkA was detected with an antibody 
against the ECD thus recognizing all known TrkA isoforms. IF with the TrkA antibody 
had the advantage of visualizing the cell membrane and thereby facilitating the 
localization of cells. The antibodies against TrkB and TrkC epitopes could not be used 
because they were unfortunately destroyed during ISH, and thus DFISH was performed 
instead. 
 Among the analysed phosphatases Ptpra, Ptprd, Ptprg and Ptprs were found in 
over 90%, whereas Ptprf, Ptprr and Ptpro were expressed in around 82%, 70% and  
12% of sensory neurons respectively (Figure 4.11A and Appendix, Table 4). All seven  
phosphatases were coexpressed with all three Trk receptors, but in different 
characteristic patterns (Figure 4.8 - 4.11 and Appendix, Table 5).  
 The phosphatases Ptpra, Ptprd, Ptprg and Ptprs were found in around  
90% or more of TrkA+ neurons and Ptprf in around 82%. These phosphatase genes 
were also expressed in 100% of TrkB+ or TrkC+ neurons (Figure 4.11C). The total 
proportion of Trk+ neurons coexpressing these phosphatases (Figure 4.11B) broadly 
agreed with the distribution of these neuronal subtypes in the DRGs (section 4.3.4.1). 
As previously described TrkA was expressed in around 75% (IF), TrkB in 5% (FISH) 
and TrkC in 10% (FISH) of cells in E13.5 DRGs. A high SD indicated that not all 
TrkB+ neurons appeared to coexpress Ptprd on all sections, which might however be 
due to the previously mentioned issues with the Ptprd riboprobe (Figure 4.11C). 
Additionally, although all Ntrk3+ neurons coexpressed Ptprg, the proportion of these 
cells in comparison to the total amount of DRG cells was less than half as big compared 
to the total amount of TrkC+ neurons in DRGs (Figure 4.11B). However, this was 
simply caused by the fact that sections with less TrkC+ neurons than usual were picked 
for cell counting. 
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 Ptprr expression was also observed in all TrkB+ and almost all TrkC+ neurons, 
but only around 80% of TrkA+ neurons coexpressed this phosphatase (Figure 4.11C). 
The other way round 90% of all Ptprr+ neurons were also TrkA+ and around 6% and 
15% coexpressed TrkB or TrkC respectively (Figure 4.11C). The number of Ptprr+ cells 
coexpressing TrkA was higher than the actual proportion of these cells in DRGs, 
because not all cells in DRGs express Ptprr and these calculations refer to the total 
amount of cells expressing this phosphatase (Figure 4.11D, Appendix, Table 5).  
 The coexpression of Ptpro with Trks differed significantly from any of the other 
analysed phosphatases. It was expressed in only around 5% of TrkA+ neurons, but  
78% of TrkC+ and almost all TrkB+ neurons. TrkB+/Ptpro+ neurons were the most 
prevalent with 56% occurrence; followed closely by TrkC+/Ptpro+ neurons with 49% 
and only 28% of Ptpro+ neurons coexpressed TrkA. Since these numbers do not add up 
to 100% this indicates that Ptpro+ is expressed in neurons that coexpress at least two 
Trk receptors. So do all of these neurons coexpress TrkB? This assumption suggests 
itself, as all TrkB neurons coexpress Ptpro (Ptpro+/TrkB+). However comparing these 
numbers with the results from the Trk coexpression analysis (section 4.3.4) it appears 
that this is not the case. Only 14% of all TrkC+ neurons were TrkB+ (TrkB+/TrkC+) in 
comparison to 78% of Ptpro+/TrkC+ neurons. And in the case of TrkA 5% of the 
neurons were Ptpro+/TrkA+, but less than 2% of TrkA+ neurons coexpressed TrkB 
(TrkB+/TrkA+). Additionally, all TrkB+ neurons were Ptpro+ but only around 50% of 
TrkB+ neurons coexpress another Trk receptor. And the Trk coexpression study showed 
less than 5% total Trk coexpression, whereas 11% of all DRG cells expressed Ptpro. 
Together these findings indicate that Ptpro expression is not directly linked to TrkB 
coexpression patterns in E13.5 DRGs. Surprisingly, one correlation seems to add up 
however, which is that around 5 (+/- 3.2)% of TrkA+ neurons coexpress either TrkB or 
TrkC 5 (+/- 3.2)%, almost the total amount of Ptpro+/TrkA+ neurons (5.3 +/- 2.4%). It 
has to be noted that my analysis was restricted to high expression intensities, but Ptpro 
expression was also found in a subset of neurons with very low staining intensity 
similar to previous reports in rat E14 and E18 DRGs (Haworth et al., 1998). 
 To sum up, first none of the analysed RPTPs was coexpressed with only one 
particular Trk receptor. Second, only few Trk+ DRG neurons did not coexpress one of 
the six RPTP genes (excluding Ptpro). This was the case for a minority of TrkA+ 
neurons, which did not coexpress Ptprf, Ptprs, Ptprg or Ptprr. And third, neurons  
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Figure 4.8. Expression of RPTP genes and TrkA in murine E13.5 DRG neurons.  
Fluorescent ISH and IF were performed sequentially with riboprobes detecting RPTP genes 
(green) and TrkA antibody (red) on transverse cryosections of E13.5 mouse embryos. Nuclei 
were counterstained with DAPI (blue). Arrowheads indicate non-coexpressing neurons, whereas 
coexpressing neurons are indicated with full arrows. Neurons were identified by the presence of 
big round nuclei. Pictures were taken on the Zeiss Imager.Z1 ApoTome with a 63x objective. 
Scale bar = 2 µm. 
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Figure 4.9. Expression of RPTP genes and Ntrk2 in murine E13.5 DRG neurons.  
Double fluorescent ISH was performed with riboprobes detecting RPTP genes (green) and 
Ntrk2 (red) on transverse cryosections of E13.5 mouse embryos. Nuclei were counterstained 
with DAPI (blue). Arrows indicate coexpressing neurons (with big round nuclei). Pictures were 
taken on the Zeiss Imager.Z1 ApoTome with a 63x objective. Scale bar = 2 µm. 
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Figure 4.10. Expression of RPTP genes and Ntrk3 in murine E13.5 DRG neurons.  
Double fluorescent ISH was performed with riboprobes detecting RPTP genes (green) and 
Ntrk3 (red) on transverse cryosections of E13.5 mouse embryos. Nuclei were counterstained 
with DAPI (blue). Arrows indicate coexpressing neurons (with big round nuclei). Pictures were 
taken on the Zeiss Imager.Z1 ApoTome with a 63x objective. Scale bar = 2 µm. 
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Figure 4.11. RPTP and Trk coexpressing cells in murine E13.5 DRG neurons.  
Double fluorescent IHC and IF were performed on transverse cryosections of murine E13.5 
embryos. TrkA was detected with an antibody against the ECD. Ntrk2, Ntrk3 and Rptps were 
visualized with riboprobes. The cells were counterstained with DAPI. Trk+ and/or Rptp+ and 
DAPI+ neurons were counted on pictures. Neurons were identified by the presence of big round 
nuclei. A) Total proportion of Rptp+ neurons. B) Total proportion of Trk+ & Rptp+ neurons. C) 
Proportion of Trk+ neurons, which coexpress an RPTP gene (Rptp+/Trk+). D) Proportion of 
Rptp+ neurons, which coexpress a Trk receptor (Trk+/Rptp+). Data are additionally presented in 
the Appendix, Table 5. 
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expressing a specific Trk receptor coexpressed numerous RPTP genes. Ptpro was the 
only RPTP, which stood out in this analysis concerning its expression and coexpression 
patterns.  
4.4. Discussion 
Previous studies have shown a molecular interaction of particular RPTPs with Trk 
receptors mostly in over-expression systems (section 1.4). In order to assess the 
physiological relevance of these proposed interactions I have analysed and compared 
the expression profiles of selected highly expressed RPTPs with Trk receptors in murine 
embryonic DRGs followed by an extensive coexpression analysis of Trks with seven of 
the strongest expressed RPTPs in the same sensory neurons, which is a prerequisite for 
their possible interaction. Here I will briefly discuss the findings of particular RPTPs 
and compare these to previous reports. 
 
Among the analysed phosphatase genes Ptprf, Ptprs and Ptprr were strongly and 
specifically but also rather ubiquitously expressed in DRG neurons. An interaction with 
specific Trk receptors was previously attributed to all three RPTPs (section 1.4).  
 Ptprf is a very good candidate gene to be implicated in Trk signalling due to its 
specific and very strong expression in DRG neurons at the analysed embryonic stages, 
similar to Trk expression. Ptprf was expressed in almost all Trk+ neurons apart from a 
minor proportion of small TrkA+ neurons. It was reported that LAR could indeed 
possibly regulate TrkA and TrkB receptors for instance in PC12 cells and in embryonic 
hippocampal neurons, respectively, either directly or through the activation of Src (Tisi 
et al., 2000, Tsujikawa et al., 2002, Yang et al., 2003, Yang et al., 2005a). A clear 
coexpression of the LAR gene with all Trk receptors indicates the additional possibility 
of TrkC regulation. 
 Ptprs expression was rather ubiquitous in all tissues but stronger expression was 
detected in DRGs. It has been described before that many tissues express the long 
isoform of RPTPσ whereas the shorter isoform is highly enriched in neurons (Stoker, 
1994). We detected both isoforms in this study. Ptprs was expressed in all Trk+ neurons, 
with the exception of a small population of TrkA+ neurons. In previous over-expression 
studies in HEK293T cells in our lab RPTPσ could be co-immunoprecipitated with TrkA 
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and TrkC, but not TrkB, though it was able to dephosphorylate all three Trk receptors. 
Additionally, over-expression of RPTPσ in embryonic chick sensory neurons resulted in 
the suppression of NGF-dependent neurite outgrowth but without affecting cell survival 
(Faux et al., 2007). The absent binding to TrkB but its dephosphorylation by RPTPσ 
might indicate an indirect regulation of TrkB. Thus, Ptprs expression in all Trk+ cells 
supports the realistic hypothesis of its possible interaction with all three Trk receptors.  
 Ptprr expression is almost exclusive to sensory neurons during murine 
development and was detected in the majority of DRG neurons in our study. The qPCR 
analysis revealed a similar expression profile specifically to TrkA, but in the ISH 
analysis a likely expression in almost all Trk+ neurons was more apparent. Indeed, in 
my coexpression analysis Ptprr was expressed in all TrkB+ or TrkC+ neurons, but only 
around 80 (+/- 8)% of TrkA+ neurons also hybridized Ptprr. On the one hand our 
findings suggest a potential interaction between RPTPR with all Trk receptor types. A 
current unpublished study showed that RPTPR indeed binds and dephosphorylates 
TrkA and even possibly controls its maturation. However, it has apparently no effect on 
TrkB (Noordman, Y. et al., unpublished data). But like in many of these interaction 
studies the experiments were performed in an over-expression system (COS cells) and 
have to be confirmed in vivo. On the other hand the absence of Ptprr in a small, yet 
uncharacterised population of TrkA+ neurons questions the previous assumptions of an 
interaction of this phosphatase particularly with TrkA receptors. Therefore one might 
speculate that its expression in TrkA, B and C neurons might be there for other reasons 
than Trk signalling. 
 The phosphatase genes Ptpra, Ptprd and Ptprg were also rather ubiquitously 
expressed in DRGs, similar to the previously described RPTPs, but at much lower 
levels. All three were also coexpressed with Trks. And although none of these RPTPs 
was previously directly linked to Trk signalling, they are all implicated in neuronal 
functions and might play Trk-dependent or -independent roles in DRGs.  
 Ptpra was ubiquitously expressed in many tissues of the mouse embryos but 
with stronger staining in DRGs similar to Ptprs expression. RPTPα is implicated in the 
differentiation and migration of NCCs and neurons (den Hertog et al., 1993, den Hertog 
et al., 1996, Fang et al., 1996) and it was previously detected within neurons in DRGs 
(Haworth et al., 1998). The qPCR analysis revealed a similarity in the expression of 
Ptpra and all three Trk genes, in agreement with their coexpression, thus suggesting a 
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possible interaction with all Trk receptors. However, previous experiments in HEK293T 
cells in our lab have shown that RPTPα neither binds nor dephosphorylates TrkA 
directly (Faux et al., 2007). But RPTPα may still play an indirect role in TrkA 
regulation, for instance through Src, which is indeed known to be activated by RPTPα 
and to transactivate Trks (Zheng et al., 1992, den Hertog et al., 1993, Fang et al., 1994, 
Zheng et al., 2000, Johnson and Van Vactor, 2003). An effect on TrkA might have not 
been detected in previous experiments for instance due to low expression of Src in the 
used cell line. However, RPTPα might also be expressed in Trk+ neurons for reasons 
unrelated to Trk regulation. 
 Ptprd expression showed similarity to the expression of Ntrk1 and Ntrk2 in the 
qPCR screen, but it was coexpressed with all Trk receptors by in situ. No interaction 
between RPTPδ and any Trk protein was previously reported nor was its expression 
actually detected in DRGs in contrast to our study. However, RPTPδ plays a role in the 
nervous system as knockout mice show neuronal abnormalities (Uetani et al., 1997, 
Uetani et al., 2000). In chick embryos RPTPδ was predominantly found in differentiated 
neurons in the CNS, where it promotes neuronal adhesion and regulates neurite 
outgrowth as an attractive and repulsive guidance cue and might be involved in synapse 
formation (Sommer et al., 1997, Schaapveld et al., 1998, Van Vactor, 1998, Wang and 
Bixby, 1999, Johnson and Holt, 2000). RPTPδ could also full-fill Trk-dependent or 
independent functions in DRGs.  
 Ptprg was also ubiquitously expressed in DRGs and surrounding tissues, and the 
qPCR array analysis revealed a possible similarity to TrkA and TrkB expression. The 
coexpression analysis additionally confirmed its expression in all Trk+ neurons. But in 
similarity to Ptprf, Ptprs and Ptprr, not all TrkA+ neurons expressed this phosphatase. 
Interestingly, RPTPγ-deficient mice did not show any abnormalities in NGF-induced 
neurite outgrowth (Lamprianou et al., 2006). In addition, contradictory findings have 
previously shown that RPTPγ and not RPTPζ inhibits TrkA-mediated neurite outgrowth 
in PC12 cells, but more recently the opposite has been reported. The authors of both 
papers postulated, that whereas RPTPγ interacts with Trk downstream pathways, 
RPTPζ directly dephosphorylates Y674 and/or Y675 in the catalytic domain of TrkA 
and thus controls its kinase activity (Shintani et al., 2001, Shintani and Noda, 2008). 
Therefore, RPTPγ might also play Trk-dependent or -independent functions in DRGs. 
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 The increasing expression of Ptprz1 in the qPCR analysis indicated a possible 
expression in glia cells. Further, strong expression was detected in the ependymal layer 
lining the spinal canal at earlier developmental stages and this tissue contains indeed 
mostly glia cells. The staining in DRGs was very faint but might be located around 
neurons. RPTPζ expression was previously identified predominantly in glia cells such 
as Schwann cells and SGCs in embryonic and adult rat DRGs but also in a subset of 
neurons (Canoll et al., 1993, Haworth et al., 1998, Shintani et al., 1998, Van Vactor, 
1998, Harroch et al., 2000). Its expression also partly correlated with the truncated TrkB 
isoform in non-neuronal cells (Snyder et al., 1996). In previous coexpression studies in 
HEK293T cells RPTPζ dephosphorylated TrkA and an over-expression of RPTPζ in 
PC12 cells inhibited NGF-induced neurite outgrowth (Shintani and Noda, 2008). These 
findings are consistent with the elevated TrkA-phosphorylation state in RPTPζ-deficient 
mice, which also display aberrant motor coordination, and reduced responses to 
moderate nociceptive stimuli (Lafont et al., 2009). In addition these mice have also an 
impaired ability in the recovery from demyelination (Harroch et al., 2000, Harroch et 
al., 2002). The expression of Ptprz1 in DRGs was unfortunately too low for a 
coexpression analysis with Trk receptors. Together with previous studies our findings 
support a role of RPTPζ possibly in glia cells, which might be Trk-dependent  
or -independent. 
 Ptpro expression was the most unique and interesting among all analysed RPTP 
genes. The qPCR analysis indicated no similarity to any specific Trk gene expression, 
but suggested a possible expression in a subtype of neurons. The ISH analysis showed 
that Ptpro was expressed in particular cells within the DRG, but this amount of cells 
appeared to be bigger than TrkB+ or TrkC+ neurons alone, thus suggesting an 
expression in these two cell types together. The coexpression analysis revealed that 
approximately 56% of Ptpro+ neurons coexpressed TrkB (100% of TrkB+ neurons), 
 49% coexpressed TrkC (78% of TrkC+ neurons) and 28% coexpressed TrkA  
(5% of TrkA+ neurons). These results confirm the previous assumption that a specific 
subpopulation of Trk+ neurons expresses this phosphatase. Our findings partly agree 
with a previous expression study by Beltran et al. on murine cervical and cranial ganglia 
at E16. In their analysis, twice as many Ptpro+ neurons were detected in E16 DRGs, in 
agreement with the increase of RPTP-BK expression during development. Of these,  
50% coexpressed TrkC (80% of all TrkC+ neurons) and only 15% coexpressed TrkB 
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(19% of all TrkB+ neurons). TrkA and Ptpro coexpression was also abundant especially 
in TG but was not quantified (Beltran et al., 2003). Interestingly, a comparison between 
these two studies showed a possible dynamic change in the coexpression of Ptpro with 
TrkA and TrkB receptors but no changes in the proportion of TrkC and Ptpro 
expressing neurons across development between E13.5 and E16.  
 So, which neurons express Ptpro? First, Ptpro could be expressed in neurons 
that coexpress more than one Trk receptor. If this were true, its expression would be 
very high at earlier stages and disappear completely at later stages like TrkA/TrkB/TrkC 
coexpression. However, instead an increase in Ptpro expression throughout 
development from E12 onwards and a peak between E16 until P3 was detected (Van 
Vactor, 1998). In addition, as described above, the cell amounts of Trk-coexpressing 
cells do not add up to confirm an expression of Ptpro in Trk-coexpressing neurons only, 
as the amount of Ptpro+ neurons is considerably higher than the amount of  
Trk-coexpressing neurons. Though interestingly the amount of TrkB/TrkA and 
TrkC/TrkA-coexpressing neurons together was similar to the total amount of 
Ptpro/TrkA-coexpressing neurons (both around 5%) (Figure 1.12). Additionally, my 
analysis was restricted to neurons with the highest expression intensities to avoid 
ambiguous results, but Ptpro expression was in fact also found in a subset of neurons 
with very low staining intensity similar to reported findings (Haworth et al., 1998). This 
might complicate matter, but also possibly explains the lack of an obvious correlation 
with Trk-expression.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Schematic representation of Ptpro/Trk coexpression in murine E13.5 DRGs.  
Displayed are a fraction of TrkA+ neurons (blue) and the entire TrkB+ (red) and TrkC+ (green) 
neuronal populations. The dotted line represents the population of Ptpro+ neurons. The 
coexpression analysis revealed that all TrkB+ neurons, around 80% of TrkC+ neurons and 
around 5% of TrkA+ neurons coexpress Ptpro. 
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 A coexpression and possible interaction of RPTP-BK with Trk receptors is also 
supported by the fact that RPTP-BK-/- mice show nociceptive (TrkA) and 
proprioceptive (TrkC) defects (Gonzalez-Brito and Bixby, 2009). Interestingly, the 
phenotype of RPTP-BK-/- mice appears to be similar to the phenotype of mice deficient 
in the TFs Runx1 and Runx3, which control the differentiation of TrkA and TrkC 
sensory neurons by initiating TrkA and TrkC expression and partly suppressing TrkB 
expression (Gonzalez-Brito and Bixby, 2009). So, Ptpro expression might be in fact 
linked to Trk expression on the level of transcriptional control.  
 Additionally, RPTP-BK homologs in Drosophila and chick are able to control 
axon guidance in CNS neurons (Desai et al., 1996, Krueger et al., 1996, Ledig et al., 
1999b, Sun et al., 2000b, Stepanek et al., 2001). And RPTP-BK-/- mice also showed 
neurite guidance defects of proprioceptive and nociceptive neurons (Gonzalez-Brito and 
Bixby, 2009), similar to the phenotype observed in Runx3-/- mice (Arber et al., 2000, 
Inoue et al., 2002). These findings together with our coexpression data point to a yet 
unknown connection between RPTP-BK and Trk expression and function. In this 
context, RPTP-BK might control the differentiation of Trk+ neurons possibly on the 
transcriptional level. It will be of particular interest to analyse the function of this RPTP 
in context with Trk expression and function in more detail. 
 The marginal candidate genes Ptprj, Ptprk and Ptprm were expressed at the 
lowest levels in the qPCR analysis and almost no expression was detected using ISH. 
The comparative qPCR analysis revealed that these genes might be expressed in the 
smallest subpopulation of DRG neurons like TrkB and/or TrkC, but this similarity 
might also be brought about merely by their low expression. However, due to the 
sensitivity threshold of ISH no coexpression analysis was performed. We conclude that 
these phosphatases might be indeed expressed in DRG cells, either in neurons or more 
likely in non-neuronal cells (see also discussion chapter 3). Based on their low  
expression and lack of similarity to Trk-expression an implication in Trk signalling is 
unlikely.  
 
Taken together the qPCR and ISH expression analyses performed on embryonic DRGs 
at three developmental stages (E12.5 - E14.5) displayed how dynamic the expression of 
Trks and RPTPs is during development. These expression profiles were used to identify 
similarities between Trk and RPTP expression and revealed a unique expression pattern 
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for all eleven analysed phosphatases. Most of the strongly expressed genes 
demonstrated a certain degree of similarity to the expression of Trk receptors. However, 
none of these phosphatases showed similarity in gene expression to one particular Trk 
receptor but instead to at least two but mostly all three Trks. The coexpression analysis 
of selected RPTP genes with Trk receptors in E13.5 DRG neurons supported these 
results as the majority of Trk+ neurons expressed more than one RPTP gene and vice 
versa. The fact that with all of the RPTPs detailed here, there is a small percentage of 
TrkA-expressing neurons that do not express them, indicates that there can be no hard 
link between the regulation of TrkA signalling and any specific RPTP. Presumably if 
RPTPs are to be seen as key regulators of TrkA as previously suggested, then in any 
particular neuron TrkA has many RPTPs to choose from. This in turn should imply a 
high potential for functional redundancy in RPTP action and in turn confirm, indirectly, 
the likely promiscuity in RPTP target specificity. This also agrees with the molecular 
studies of some RPTPs and Trks to date.  
 Among the RPTPs studied here, RPTP-BK showed the most interesting 
coexpression patterns with Trks. Along with the highly expressed RPTPs LAR and 
RPTPσ, RPTP-BK function and their possible implication in Trk signalling, which 
governs crucial neuronal processes such as neurite outgrowth and cell survival, as was 
previously suggested mostly in over-expression systems, was further studied in 
knockdown experiments in dissociated primary murine embryonic DRG cells  
(chapter 6). 
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5.1. Introduction 
The function of some RPTPs in Trk signalling was previously analysed but mostly in 
over-expression assays (section 1.4). The aim of these experiments was therefore to 
establish an assay for the analysis of the physiological function of specific RPTPs in 
Trk signalling in primary murine embryonic sensory neurons.  
 In general the physiological function of proteins can be analysed by reducing or 
even eliminating them from a particular system such as a cell or a whole organism and 
examining the effects thereafter. For this purpose either knockout animals are generated 
or knockdown techniques such as RNA interference (RNAi) tools are used. A 
transgenic animal allows analysis of the protein function in its endogenous environment 
and even behavioural studies can be carried out. However, it is not always the best 
solution as it is expensive and time-consuming to generate a transgenic animal and in 
many cases these animals have either no particular phenotype or die prenatally, which 
complicates the analysis. RNAi represents a very powerful tool to analyse the function 
of a protein in a rather simple and straightforward manner and was therefore used in this 
study.  
 RNA interference (RNAi) is a naturally occurring highly conserved mechanism 
in certain organisms and cell types, which is thought to be part of a natural defence 
system against exogenous viral agents, or is involved in transposon-silencing or gene 
regulation. During this posttranscriptional gene silencing mechanism, double-stranded 
RNA (dsRNA) causes degradation of the homologous mRNA and thus prevents its 
translation into a protein. Gene silencing was long known to exist only in plants, until 
Fire and Mello identified dsRNA as the initiators of the RNAi pathway also in 
Caenorhabditis elegans (Fire et al., 1998). Later on its existence in eukaryotic cells 
such as in mammals was also proven. The RNAi pathway is known to consist of five 
steps. First the dsRNA is cleaved into short 21-25 nucleotide small interfering RNAs 
(siRNAs) by the ribonuclease Dicer. In the second step the siRNAs assemble with 
several proteins into the RNA-inducing silencing complex (RISC). In the next step the 
ATP-generated unwinding of the siRNA activates RISC, which then binds to the 
homologous mRNA transcript by base pairing interactions and cleaves it. The mRNA 
pieces are no longer protected by the poly-A-tail and the cap-structure and are thus 
degraded by exonucleases (Dykxhoorn et al., 2003).  
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 Scientists have exploited this gene silencing mechanism to study gene function. 
In simple organisms such as C. elegans and Drosophila, RNAi can be induced by long 
dsRNA. In complex mammalian organisms however, dsRNA longer than 30 bp 
activates a non-specific, interferon-mediated response, which shuts down any 
translation and initiates apoptosis. To overcome this problem, siRNA, which mimic the 
first step of the endogenous RNAi pathway, are used in mammalian cells. These siRNA 
molecules can be chemically synthesised, transcribed in vitro or generated by digestion 
of long dsRNA by RNAse III or Dicer, and are then introduced into the cells. However, 
this achieves only transient effects and once the siRNA pool is depleted the mRNA is 
no longer destroyed. To overcome this problem, plasmids were developed that 
intracellularly express siRNA in the form of small hairpin RNA (shRNA). The shRNA 
is encoded by sense and antisense RNA strands which are separated by a short loop. 
After transcription it folds into an shRNA and is cleaved by Dicer into siRNA, which 
initiates the RNAi response (Mittal, 2004, Sandy et al., 2005).  
 However, the introduction of the si/shRNA molecules into the cells of choice 
remains one of the main hurdles for a successful knockdown experiment. This has 
proven to be especially challenging for postmitotic primary cells such as primary 
sensory neurons, which were used in this study. Therefore in this chapter I have 
explored possibilities to introduce shRNA molecules targeting candidate RPTP genes 
into primary sensory neurons with highest efficiency, which is essential to achieve a 
proper knockdown of these genes.  
 Many different gene delivery techniques are being developed to introduce 
foreign nucleic acids into the cells of choice. These are on the one hand non-viral 
chemical or mechanical transfection techniques such as liposome-based methods or 
electroporation and on the other hand transduction with viral particles. Both techniques 
have advantages and disadvantages. Non-viral techniques are less costly and easy to 
use, but are not efficient in all cell types and can also be cytotoxic. Viral techniques are 
very efficient in postmitotic cells, but depending on the virus type could also cause 
advert effects such as an immunological response, or disruption of genes in the case of 
integrating viruses. They are also more time-consuming and costly. 
 In this chapter I have analysed both non-viral and viral gene delivery methods 
for their efficiency to introduce DNA plasmids into murine embryonic sensory neurons. 
Whereas different non-viral methods proved to be inefficient, the lentiviral approach 
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was very successful. Subsequently, I have set-up a lentivirus-mediated gene knockdown 
assay and have analysed the effects of lentiviral transduction on gene expression and 
morphology of the sensory neurons. The final RPTP knockdown experiments and the 
analysis of the effects on NT signalling pathways will be described in Chapter 6. 
 
5.2. Experimental procedures 
Protocols for cell culture techniques, DNA preparation and the preparation and 
maintenance of murine DRG cultures were described in the General Materials and 
Methods section (chapter 2). 
5.2.1. Transient transfection techniques 
5.2.1.1. Calcium phosphate transfection 
Dissociated murine embryonic DRG cells were seeded at a confluence of 50-60% in a 
precoated (PLL and FN) 6-well-plate. Before transfection the medium was replaced 
with fresh growth medium. The transfection mixture was prepared as following: per 
transfection 2 µg of sterile high quality DNA in 90 µl ddH2O were mixed with 10 µl of 
2.5 M CaCl2. One hundred µl of 2x HeBS (280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4, pH 7.05 adjusted with 5 M NaOH) were preloaded in a sterile Eppendorf 
tube and the DNA/CaCl2 mixture was added drop-wise to the 2x HeBS whilst bubbling 
air up through the mixture. The DNA/CaCl2/2x HeBS solution was incubated for 
20 min at room temperature in order to allow crystal formation and then added  
drop-wise to the cells. After an incubation time of 6 to 16 h the cells were washed with 
PBS and fresh complete medium was added. 48 h after transfection the cells were 
examined for transgene expression and pictures were taken and processed as described 
in section 2.7.  
5.2.1.2. Transfection with Lipofectamine™ and PLUS™ reagent  
Dissociated murine embryonic DRG cells were seeded at a confluence of 70-80% in a 
precoated 12-well-plate. Before transfection the medium was replaced with fresh 
growth medium. For transfection of one well, 1 µg of sterile high quality plasmid DNA 
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was mixed with 200 µl Opti-MEM® I Reduced medium without serum (GIBCO).  
One µl of PLUS™ reagent (Invitrogen) was added to the diluted DNA and gently mixed. 
The mixture was incubated for 5-15 min at room temperature and 2.5 µl of 
Lipofectamine™ LTX reagent (Invitrogen) were gently added to the DNA/Plus reagent 
mixture and incubated for 30 min at room temperature to allow formation of complexes. 
One hundred µl of DNA/PLUS™-reagent/ Lipofectamine™ LTX complexes were added 
to each well. For optimisation of the transfection efficiency varying ratios of DNA to 
PLUS reagent (DNA (µg): PLUS reagent (µl): 1:0.5, 1:1, 1:2) and amounts of these 
complexes (1x, 2x and 3x) were tested. After incubation of the cells with the complexes 
for 6 h fresh medium was added. 48 h after transfection the cells were examined for 
transgene expression as described above.  
5.2.1.3. Transfection with Lipofectamine™ and ME27 peptide 
Dissociated murine embryonic DRG cells were seeded at a confluence of 70-80% in a 
precoated 6-well-plate. Per transfection reaction 1 µl lipofectamine was diluted in 60 µl 
OptiMEM and 40 µl (4 µg) of peptide ME27 and 1 µg of plasmid DNA diluted in 
100 µl ddH2O were added. After the growth medium was replaced with 1 ml fresh 
medium per well the lipid/protein/DNA solution was added. After incubation for 4-6 h 
the medium was replaced. 24-48 h after transfection, the cells were examined for 
transgene expression as described above.  
5.2.2. Test of lentiviral pseudotypes 
All viral preparations for this experiment were kindly provided by Dr. Natalie Ward. 
The eGFP-lentiviruses (pLNT/SFFV-eGFP-WPRE) were pseudotyped with envelop 
proteins from Vesicular Stomatitis Virus (VSVg), Baculovirus gp64 (gp64), Ebola Zaire 
(EboZ), Ross River Virus (RRV), Murine Leukaemia Virus – Amphotropic (MLV-A), 
Murine Leukaemia Virus – Ecotropic (MLV-E) and Hanta virus.  
 Dissociated DRGs from E13.5 CD-1 mouse embryos were seeded at a density of 
30% (40.000 cells per well) in two 12-well-plates coated with PLL and FN and 
transduced as above at three different MOIs (25, 50 and 100) with the seven differently 
pseudotyped eGFP-expressing lentiviruses. The MOIs were determined by 
measurement of the mass of HIV-1 p24 antigen in the lentiviral vector preparation using 
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the Beckman Coulter HIV‐1 p24 antigen assay according to the manufacturer’s 
instructions (physical titration). Three wells were left untransduced. The cells were 
cultured in NGF-containing (50 ng/ml) complete medium for 96 h before fixation with 
4% PFA (section 2.4.3). The cells were daily examined for eGFP-expression with the 
Zeiss Axiovert-135 and approximately ten pictures were taken per virus type as above. 
Exposure BF: 100 msec, GFP: 1 sec, Gain: 0, Digital gain: 1x. 
 To calculate transduction efficiency, fluorescent and total amount of neurons 
(120 to 290 neurons were counted per lentiviral type) was determined by manual cell 
counting on pictures using Openlab software and the percentage of transduced cells was 
calculated. 
5.2.3. Production of HIV‐1‐derived replication deficient lentiviruses 
5.2.3.1. Plasmids for virus production (2nd generation) 
The packaging GAG-POL plasmid pCMVΔR8.74 was a gift of Dr. Natalie Ward in 
Prof. Adrian Thrasher’s laboratory (Molecular Immunology Unit, ICH; originally 
obtained from Prof. Luigi Naldini, Istituto Scientifico H, San Raffaele, Italy).  
 The envelope plasmid pCEE encoding the envelope glycoproteins for murine 
leukaemia virus ecotropic (MLV-E) was a gift of Dr. Natalie Ward (originally obtained 
from Prof. Michael Green, University of Massachusetts). 
 For the virus production and titration studies the previously described vector 
plasmid pLNT/SFFV-eGFP-WPRE was used (Demaison et al., 2002). It is a variant of 
the pHR second-generation HIV-1-based vector containing a self-inactivating 3’ LTR, a 
central polypurine tract (cppt), the spleen focus-forming virus U3 promoter (SFFV), an 
enhanced green fluorescent protein reporter gene (eGFP), and the woodchuck hepatitis 
virus posttranscriptional regulatory element (WPRE). 
 For knockdown experiments, I used the MISSION TRC lentiviral expression 
vector pLKO.1 containing shRNA directed against murine RPTP genes (Sigma, 
described in Figure 5.4 (Moffat et al., 2006)), which was kindly provided by Dr. Jörg 
Mueller and Prof. Frank Böhmer (PTPNET member, University of Jena, Germany). 
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5.2.3.2. Preparation of MLV-E pseudotyped lentiviruses  
For virus production, 12 x 106 HEK293T cells were seeded in T175 cm2 flasks the day 
before transfection (~ 80% confluence) as described in section 2.5.1. Per flask a DNA 
solution consisting of 19.2 µg vector construct, 28.8 µg envelope plasmid pCEE and 
28.8 µg packaging plasmid pCMVΔR8.74 was prepared in a total volume of 1080 µl 
sterile ddH2O. 120 µl CaCl2 were mixed with the DNA solution and immediately added 
drop by drop to 1200 µl 2x HBS solution whilst bubbling it with an automated pipette. 
The mixture was allowed to form crystals for 20 min at room temperature. Meanwhile 
the medium was changed on the cells to 8 ml medium containing DMEM, 1% P/S 
antibiotics, 10% FBS, 20 mM HEPES buffer and 25 µM chloroquine to enhance virus 
production. Cells were overlaid with the transfection mix and incubated at 37ºC,  
5% CO2 for 6 h. After the incubation time the medium was changed to 15 ml normal 
growth medium. The cell supernatant was harvested after 48 and 72 h and concentrated 
as described below.  
5.2.3.3. Concentration of MLV-E pseudotyped lentiviruses 
5.2.3.3.1. Centrifugation method 
Virus containing supernatants from three transfected T175 cm2 flasks collected at 48 h 
and 72 h were pooled and cell debris was removed by filtering through a 0.22 µm filter 
(Millipore) (supernatant was stored at 4ºC for 24 h). 45 ml of this supernatant were spun 
in a 50 ml Falcon tube at 4000 rpm for 20 h at 4ºC in a centrifuge with a swing-rotor. 
Virus pellets were carefully resuspended in 120 µl OptiMEM (GIBCO) and incubated 
on ice for 20 min. The virus pellets were pooled and aliquots stored at -80ºC. 
5.2.3.3.2. Filter Devices  
Virus-containing supernatant from two transfected T175 cm2 flasks collected at 48 h 
were passed through 0.22 µm filters (Millipore). 15 ml filtered supernatant were loaded 
into each Amicon Ultra-15 Centrifugal Filter Device (Millipore) and spun at 2500 rpm 
for 45 min at 4ºC. This step was repeated with an additional 15 ml supernatant using the 
same filter. The flow-through was discarded and the virus containing filtrate was stored 
at -80ºC. 
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5.2.3.4. Transduction of target cells with MLV-E pseudotyped lentiviruses  
Target cells of interest (3T3 cells or murine dissociated DRGs) were seeded at a desired 
density one day before transduction. The culture medium was renewed shortly before 
infecting the cells with the lentiviruses. 24 h after transduction the culture medium was 
renewed and the cells were cultured for 48-72 h. The cells were daily examined for 
GFP-expression and morphological changes and pictures were taken and processed as 
described in section 2.7. 
5.2.3.5. Titration of MLV-E pseudotyped lentiviruses – expression titre 
Multiplicity of infection (MOI) is used as a parameter for the prediction of gene transfer 
events or viral infectivity in a population of target cells. MOI represents the ratio of 
input infectious units (titred on the target cell line) to the number of cells available for 
transduction (MOI = TU/amount of target cells). Hereby “infectious units” (IU), also 
referred to as transduction units (TU), represent the smallest amount of virus capable of 
infecting a cell. The ”titre” of the original virus stock is defined as the number of 
infectious units per unit volume of the virus preparation. In theory the relationship 
between virus titre, its dilution, volume of viral stock used, and the proportion of 
infected cells, should be linear. However, in reality the transduction of cells to estimate 
viable virus titres is non-linear and depends on many different factors such as number of 
target cells, inoculum volume, time of transduction etc. Thus all calculations are rather 
estimates than exact values (Zhang et al., 2004). 
 To estimate the titre (TU/ml) of eGFP-lentiviral vectors, target cells of interest 
(NIH 3T3 cells or DRG cells) were seeded into a multi-well-plate at a confluence of  
50-60% one day before transduction. A one-fold dilution series of lentiviruses from  
60, 30, 10 µl down to 10-6 µl in 100 µl aliquots of OptiMEM (GIBCO) was prepared 
and the target cells were immediately transduced with each dilution per well (100 µl) in 
a constant final volume. 72 h after transduction the cells were examined under a 
fluorescent microscope and five pictures were taken per well as described above. The 
amount of fluorescent neurons and total number of neurons were determined by manual 
cell counts on pictures with 5-50% positive cells as values below 5% are close to 
background and above 50% have an increased chance for multiple infections per cell. 
The area of the plate and the proliferation rate of NIH 3T3 cells (doublings time of  
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approximately 24 h) were taken into consideration. The average of the titres from all 
dilutions represented the final estimated titre of the virus preparation. 
5.2.4. Initial test of the effects of MLV‐E lentivirus infection on gene  
    expression in primary sensory neurons 
To assess the effect of MLV-E pseudotyped lentivirus transduction, non-targeting 
shRNA (Sigma or Qiagen) and two different concentration techniques 
(ultracentrifugation (centri) or filtration with Amicon Ultra-15 Centrifugal Filter 
Devices (filtered)) on the gene expression of dissociated DRG cultures from E13.5  
CD-1 mouse embryos, the cells were infected with different MLV-E control lentiviruses 
and gene expression of Trks and several RPTPs was assessed with qPCR. 
 DRG cells were seeded at a density of 50% (250.000 cells per well)  
in 12-well-plates coated with PLL and FN and transduced with the following  
MLV-E pseudotyped control viruses: centri or filtered eGFP lentiviruses  
(pLNT/SFFV-eGFP-WPRE) and centri or filtered control lentiviruses containing non-
targeting shRNA from Sigma or Qiagen in pLKO.1 puro. The cells were infected in 
duplicates with half of the whole virus production in a total volume of 450 µl per well. 
The cells were cultured in NGF- and BDNF-containing (50 ng/ml) complete medium 
for 72 h, daily examined and pictures were taken as described above. 
 QPCR analysis was performed to assess the effect of viral infection on gene 
expression in DRGs. RNA was extracted from the transduced cells after 72 h, reverse 
transcribed and qPCR was performed on 15ng cDNA of each sample on 96-well plates 
with primers against all three Trk genes and the RPTP genes Ptpra, Ptprf, Ptpro, Ptprr 
and Ptprs. Psmb2 was used as a HKG for comparative data analysis. The experiments 
were performed in duplicates. Detailed protocols can be found in Chapter 2.2. 
 
NOTE: To eliminate any viral residues all disposable equipment and cells, which came 
in contact with the virus particles, were treated with Virkon disinfectant (Anachem) for 
at least 24 h before appropriate disposal. 
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5.3. Results 
5.3.1. Non‐viral DNA delivery techniques 
Different non-viral transfection techniques have been developed to introduce DNA into 
eukaryotic cells by either chemical reagents such as calcium phosphate (CaPO4) and 
liposomes or physical methods such as microinjection and electroporation. They are 
mostly technically easy to use, not expensive, cause little or no cytotoxicity and 
unrestricted amounts of DNA can be used. Transfection is a transient event and the 
integration of foreign DNA into the chromosome of the target cell or stable episomal 
maintenance occurs at very low frequency. Therefore reporter gene systems such as 
drug resistance or fluorescent reporters for instance the green fluorescent protein (GFP) 
and its derivatives are used, which allow us not only to monitor the transfection 
efficiency but also to select for successfully (stably) transfected cells. Non-viral 
techniques are the method of choice to introduce nucleic acids quickly and efficiently 
into many different cell types. However, the transfection efficiency is the main limiting 
factor and it is known that some cell types such as primary neurons are difficult to 
transfect.  
5.3.1.1. Non-viral DNA delivery techniques were unsuccessful in  
  introducing plasmids into murine embryonic DRGs 
Three different non-viral gene delivery methods available in our laboratory were tested 
for their efficiency to introduce an eGFP-expressing plasmid into primary sensory 
neurons from dissociated murine embryonic DRGs (Figure 5.1). The routinely used 
CaPO4 transfection is based on the formation of a precipitate containing CaPO4 and 
DNA. The precipitate adheres to the cell surface and is internalized via endocytosis or 
phagocytosis by the cell. This method was very efficient for plasmid delivery into cell 
lines such as HEK293Ts (see chapter 7), but no transfection of neurons was observed 
using this technique (Figure 5.1A).  
 Further, liposome-mediated transfection techniques were tested, which are very 
sensitive and non-toxic to primary cells. In principle lipids are mixed with DNA and 
build complexes, which are taken into the cells via endocytosis or membrane fusion. 
The lipids disrupt the endosome and the DNA is released into the cytoplasm and thus 
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escapes endosomal degradation. In this study I have used Lipofectamine™ Reagent 
(Invitrogen), which is a 3:1 liposome formulation of the polycationic lipid DOSPA and 
the neutral lipid DOPE. Lipofectamine alone did not transfect primary sensory neurons 
(data not shown). Current research investigates possibilities to enhance lipid-mediated 
transfection into cell types, which are non-permissive to many non-viral transfection 
methods such as primary neurons, for instance by addition of reagents or proteins. In 
this study I have tested two such methods.  
 First, a lipofection-based formulation containing the integrin-targeting peptide 
ME27 kindly provided by Dr. S. Hart (Molecular Immunology Unit, ICH) was tested. 
The peptide ME27 consists of an integrin targeting cyclic RGD domain and a sixteen 
lysine domain for DNA binding, separated by a four-amino-acid-linker sequence, which 
is cleavable by endosomal enzymes (Hart et al., 1998). Endosomal cleavage promotes 
disengagement from the integrin receptor and its release into the cytoplasm. A similar 
lipid-peptide formulation was previously used for transfection of neuroblastoma cells 
very efficiently (Grosse et al., 2010). The transfection rate for sensory neurons in this 
study however, was very low. Only non-neural cells were fluorescent green with the 
exception of one or two neurons (Figure 5.1B).  
 I have then assessed the transfection efficiency of lipofectamine™ LTX with 
PLUS™ reagent (Invitrogen). Different DNA:PLUS reagent ratios and varies amounts 
of the mixture to transfect dissociated murine DRG cultures were tested. The efficiency 
of transfection of the whole DRG cell population was highest at a ratio of 1:1 and 
increased with the amount of the liposome-DNA-PLUS reagent mixture added onto the 
cells. But almost exclusively non-neural cells were transfected using this method 
(Figure 5.1C).  
 The mechanical non-viral delivery method nucleofection, a type of 
electroporation, was previously tested by Dr. Claire Faux (Stoker’s group). However, 
this had also a low transfection rate and caused a high amount of cell death (Faux et al., 
2007). Thus it was not appropriate for our study especially since the cells would be very 
stressed, causing an alteration of their signalling pathways.  
 In summary, none of the non-viral techniques tested in this study have proven to 
be efficient enough to transfect primary sensory neurons. Therefore the viral gene 
delivery system was assessed.  
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Figure 5.1. Non-viral gene delivery techniques.  
Three different non-viral gene delivery techniques were tested for their transfection efficiency 
of murine embryonic sensory neurons. A) CaPO4 transfection, B) transfection with 
lipofectamine (Invitrogen) and peptide ME27 C) transfection with lipofectamine LTX with 
PLUS reagent (Invitrogen). All three techniques were inefficient to introduce an eGFP-plasmid 
into murine embryonic DRG cells. Pictures were taken with the Zeiss Axiovert-135 fluorescent 
microscope in bright field (BF) or FITC channel for GFP detection. Scale bar = 10 µm. 
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5.3.2. Viral gene delivery techniques – Transduction with HIV‐1‐derived  
     replication‐deficient lentiviruses  
Viral techniques have proven to be very efficient in transducing cells, which are hardly 
or not at all permissive or too sensitive for transfection, such as primary neurons. Many 
different well-characterized viruses i.e. adenoviruses, adeno-associated-viruses (AAV) 
and retroviruses have been genetically modified, and are commonly used as gene 
delivery vehicles for instance in gene therapy. They are either non-integrating or 
integrating and can infect non-dividing cells or are dependent on the mitotic cycle of the 
host cell. Whereas integration is desirable as it provides stable gene delivery, it is also 
rather random and can lead to insertional mutagenesis and subsequent cell damage. The 
immune response is another major problem especially for gene therapy.  
 One of the most popular viruses used as a gene delivery vehicle is the retrovirus 
and it was also the virus of choice for the first successful experiments to introduce 
dsRNA into primary almost non-transfectable cells and to induce RNAi (Barton and 
Medzhitov, 2002). Retroviruses are naturally occurring pathogens, which infect host 
cells in order to use their cellular machinery for the production of new progeny. For 
their life cycle they require proteins, which are encoded by the viral RNA. This RNA is 
replicated into DNA and integrated into the host chromosomes after infection. Thus 
proteins for the viral infection and production such as the reverse transcriptase/integrase 
POL, GAG for viral structural proteins and ENV for the viral envelope glycoproteins 
are produced and new viral particles assembled. The latter determines the tropism or 
host specificity of the virus by interaction with receptors on the surface of the host cells. 
Scientists have exploited these very efficient mechanisms of cell entry for stable gene 
delivery but developed replication-deficient virus particles for safety reasons (see 
below). Moreover as the encoded sequence such as a transgene or an shRNA construct 
integrates into the genome of the target cells, it allows a long-term transgene expression 
or knockdown and they are not silenced during development. Nevertheless, one major 
caveat of retroviruses is that they can only integrate their viral genome during the 
mitotic phase and thus differentiated or non-cycling cells such as neurons are resistant 
to these viruses.  
 Lentiviruses such as the human immunodeficiency virus type 1 (HIV-1) are a 
type of retrovirus and thus encompass all the beneficial characteristics of retroviruses, 
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but can additionally integrate into the genome at both mitotic and post-mitotic stages. 
Therefore lentiviruses have been the tool of choice for the generation of replication-
deficient viral transfer tools (Somia and Verma, 2000, Quinonez and Sutton, 2002, Sinn 
et al., 2005). 
5.3.2.1. Efficiency screening of pseudotyped HIV-1-based replication 
  deficient lentiviruses on murine embryonic DRG cultures 
Pseudotyping is a naturally occurring event. It has been observed long ago that when a 
retrovirus and a Vesicular Stomatitis Virus (VSV) infect the same host cell, progeny 
virions contain the genome of one virus encapsidated by the envelope of the other virus 
and are called pseudotypes (Zavada, 1972). In the lab lentiviral vectors can be produced 
with virtually any kind of tropism and this has been exploited to generate species- and 
tissue-specific viral vehicles (Cronin et al., 2005). 
 In order to find the most efficient lentivirus with the right tropism for murine 
embryonic sensory neurons, we have tested seven differently pseudotyped  
eGFP-expressing lentiviruses. We used glycoproteins from VSV (VSVg), Baculovirus 
gp64 (gp64), Ebola Zaire (EboZ), Ross River Virus (RRV), Murine Leukaemia Virus – 
Amphotropic (MLV-A), Murine Leukaemia Virus – Ecotropic (MLV-E) and Hanta 
virus. All viruses used in this experiment were produced and kindly provided by  
Dr. Natalie Ward. We infected dissociated murine embryonic DRG cells with the listed 
viruses at three different multiplicities of infection (MOI) 25, 50 and 100 and examined 
the transduced cells daily (Figure 5.2).  
 The first fluorescent cells were detected after 48 h in wells infected with MLV-E 
and VSVg pseudotyped lentiviruses at all MOIs. Both viruses infected different cell 
types in the culture including neurons. The intensity of the transduced cells however, 
was higher for MLV-E pseudotyped than VSVg pseudotyped lentiviruses. Very faint 
green non-neural cells were also detected in wells pseudotyped with glycoproteins from 
RRV and Hanta virus. After 72 h transduced cells were seen in all wells with the 
exception of cells transduced with MLV-A pseudotyped viruses. At lowest MOIs some 
glia cells but no neurons were transduced by RRV, Hanta, EboZ and gp64 pseudotyped 
viruses. Many green cells, mostly neurons, were detected in wells transduced with 
VSVg and MLV-E pseudotyped viruses at all MOIs, but the latter virus generated 
stronger fluorescent signals. 96 h post transduction no changes were detected in 
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Figure 5.2. Screen of seven different pseudotypes of HIV-1 derived lentiviruses on murine 
E13.5 DRG neurons.  
Primary dissociated murine embryonic DRG cultures were infected with HIV1-derived 
replication deficient eGFP-lentiviruses (pLNT/SFFV-eGFP-WPRE) pseudotyped with seven 
different envelope proteins from A) Murine Leukaemia Virus – Ecotropic (MLV-E), 
B) Vesicular Stomatitis Virus (VSVg), C) Murine Leukaemia Virus – Amphotropic (MLV-A), 
D) Ross River Virus (RRV), E) Ebola Zaire Virus (EboZ), F) Baculovirus gp64 (gp64) and 
G) Hanta virus (kindly provided by Dr. Natalie Ward, IMU). Three different MOIs (25, 50 and 
100) per virus were tested. Scale bar = 10 µm. H) Transduction efficiency. 165-330 neurons 
were counted on pictures using Openlab software and efficiencies were calculated (Appendix, 
Table 5). 
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comparison to 72 h apart from the cells infected with the Hanta pseudotyped virus, 
which showed brighter intensity. 
 Among all seven differently pseudotyped lentiviruses tested in the present 
experiment the virus pseudotyped with MLV-E proved to be the most efficient at 
transducing sensory neurons with 95% transduction efficiency at an MOI of 50. No 
improvement could be seen at an MOI of 100. This was closely followed by the 
lentivirus pseudotyped with VSVg, which infected the primary neurons with an 
efficiency of 80% at an MOI of 100. All other viruses transduced preferably non-neural 
cells. Unexpectedly the MLV-A pseudotyped lentivirus did not transfect any cells at all. 
Since this experiment was performed just once, it cannot be excluded that something 
might have been wrong with this batch of MLV-A virus solution. Other batches of this 
virus, however, were tested on other cell types and successfully infected different cell 
types (personal communication with Dr. Natalie Ward). Cell death was not 
experimentally evaluated, but observations did not show any remarkable increase in cell 
death compared to untransduced controls.  
 Lentiviruses pseudotyped with glycoproteins from the ecotropic 
gammaretrovirus MLV (MLV-E) belonging to the Moloney strain have proven to be the 
most efficient to transduce almost all of the murine embryonic DRG neurons at an MOI 
of 50. MLV-E encodes Pr80env, a glycosylated envelope precursor, which is 
proteolytically cleaved into the extraviral surface subunit (SU) gp70, which mediates 
viral binding, and the transmembrane (TM) subunit p15E, which mediates viral fusion. 
The final envelope complex is a trimer of heterodimers of both subunits (Pinter and 
Fleissner, 1979). The murine receptor on the host cells is the cationic amino acid 
transporter (CAT1), which can only be found on murine and rat cells (Kim et al., 1991). 
As expected MLV-E pseudotyped lentiviruses did not infect human HEK293T cells but 
did infect murine NIH 3T3 cells (data not shown). 
 Glycoproteins from the rhabdovirus VSV are today used the most to pseudotype 
lentiviral vectors due to their broad tropism. VSVg interacts with a ubiquitous cellular 
“receptor” of most eukaryotic cells. Additionally VSVg pseudotyped virus particles are 
very stable and can be therefore concentrated to a high titre by ultracentrifugation. 
However, VSVg is highly cytotoxic on the packaging cell line and may stimulate the 
host antiviral immune response. Since it can also infect human cells, it harbours a great 
risk for the scientist and many precautions have to be taken when work with this virus 
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type is carried out. In this respect MLV-E pseudotypes are more convenient for daily  
work (Schambach et al., 2006) on top of being more efficient for the transduction of 
primary sensory neurons. Therefore they were the pseudotype of choice in this study. 
5.3.2.2. Production of MLV-E pseudotyped lentiviruses  
For the production of HIV-1 derived replication-deficient lentiviruses usually a 
 “third-generation” split plasmid system is used. Producer cells such as HEK293Ts are 
transfected simultaneously with three recombinant plasmids, which separately encode 
only essential genes for virus assembly and infection. One plasmid encodes the proteins 
GAG and POL for packaging and production of new viral particles and the second 
encodes envelope glycoproteins of the virus such as MLV-E. The third plasmid is the 
modified HIV-1 backbone vector, which harbours the gene or sequence of interest such 
as an shRNA construct to be transferred into the target cell. The producer cells then 
generate new replication-deficient viral particles, which are harvested, concentrated, 
titred and finally used to infect the target cells (Kutner et al., 2009). Each of these steps 
has to be optimized for the target cells of choice and thoroughly tested. 
 A sufficiently high titre for an efficient infection of the target cells is crucial for 
any experiment and for this purpose the produced viruses are further concentrated. Two 
different techniques for the concentration of MLV-E pseudotyped lentiviral particles 
were tested, the concentration via ultracentrifugation (centri) and concentration using 
Amicon Ultra-15 Centrifugal Filter Devices (Millipore) (filtered). The functional virus 
titres of the differently concentrated eGFP-HIV1-derived lentivirus preparations were 
determined by infection of NIH 3T3 cells and dissociated DRG cells. Although usually 
Fluorescent-activated cell sorting (FACS) methods are used for this purpose, due to the 
heterogeneity of the DRG cultures we have instead performed cell counts on pictures to 
determine the transduction efficiency specifically for neurons. Transduction of NIH 3T3 
cells was performed as an estimation of the actual virus titre, whereas transduction of 
DRG cultures with the same virus preparation was used to assess specifically the 
transduction of neurons.  
 All in all the filtered viruses appeared to be twice as infectious as lentiviruses 
concentrated via ultracentrifugation on both NIH 3T3 and DRG cells (Table 5.2). One 
of the reasons for this result might be the damage of sensitive MLV-E glycoproteins by 
long ultracentrifugation. The differences in the titre values obtained on the different 
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cells are not unusual and in our study additionally explained by the fact that only 
transduced neurons were counted in the DRG cultures neglecting transduced non-neural 
cells (Zhang et al., 2004). Nevertheless, these numbers were only used as crude 
estimates and sufficient for the knockdown experiments (chapter 6). 
 
 
Table 5.1. Test of two different concentration techniques for MLV-E pseudotyped  
eGFP-HIV1-derived lentiviral particles.  
Murine embryonic DRG cultures and NIH 3T3 cells were infected with MLV-E pseudotyped 
HIV1-derived replication deficient eGFP-lentiviruses (pLNT/SFFV-eGFP-WPRE) from two 
virus preparations, which differed in the concentration technique used, either ultracentrifugation 
or filtration using Amicon Ultra-15 Centrifugal Filter Devices, to prepare them. * In the case of the 
DRGs these values refer only to transduced neurons. 
 
5.3.3. Lentivirus‐mediated knockdown of RPTPs using shRNA constructs 
5.3.3.1. The MISSION  TRC shRNA lentiviral vector pLKO.1 puro (Sigma) 
For the knockdown of specific RPTPs the commercially available MISSION TRC 
(The RNAi Consortium) lentiviral expression vector pLKO.1 puro from Sigma 
containing shRNA sequences directed against murine RPTP genes were used. This 
HIV-1 derived lentiviral vector contains several important features for the assembly of 
replication incompetent viral particles, integration into the genome of the target cell, 
transcription of the shRNA transcript, and resistance genes for selection in bacterial and 
in transduced cells. Specifics are described in Figure 5.3. The shRNA sequence contains 
21 “sense” bases, which are identical to the GOI, a loop containing an XhoI restriction 
site and 21 “antisense” bases, which are complementary to the “sense” bases, followed 
by a poly T-termination sequence for the RNA Polymerase III. These shRNA constructs  
 
CONCENTRATION TECHNIQUE TITRE (TU/ml) 
NIH 3T3 cells  
   ultracentrifugation 3.3*106 
   Amicon Ultra-15 Centrifugal Filters  7.7*106 
Murine embryonic DRG cells*  
   ultracentrifugation 2.1*106 
   Amicon Ultra-15 Centrifugal Filters 5.9*106 
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are designed using a proprietary algorithm (Ref.1, Ref.2) and most of them were also 
validated experimentally. Here I will briefly describe this system and several test 
experiments, which are crucial for a successful knockdown study. 
 
 
Figure 5.3. MISSION™  TRC lentiviral expression vector pLKO.1. 
The HIV-1 derived replication incompetent lentiviral vector (Sigma) comprises a 5’ long 
terminal repeat (RSV/5’LTR), an RNA packaging sequence Ψ, a Rev response element (RRE), 
the shRNA sequence under the transcriptional control of the U6 promoter (U6), a central 
polypurine tract (cppt), a puromycin resistance gene (puroR) under the control of the human 
phosphoglycerate kinase promoter (hPGK), a 3’ self-inactivating long terminal repeat 
(SIN/3’LTR) and f1 origin of replication (f1 ori), the ampicillin resistance gene (ampR) and 
pUC origin of replication (pUC ori) (Moffat et al., 2006). 
 
5.3.3.2. MISSION  TRC shRNA-containing lentiviral vectors are stable and  
   not immunogenic 
For virus preparation, large amounts of vector DNA are needed. To test the stability of 
the pLKO.1 puro plasmids and assess whether any recombination occurred during 
plasmid preparation diagnostic restriction enzyme digests with HindIII were performed. 
No evidence of recombination was observed (data not shown). 
 One major concern when using RNAi constructs in mammalian cells is the 
induction of a non-specific defence mechanism (as mentioned above), which results in 
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an interferon response of the host cell leading to the complete shutdown of protein 
synthesis. However, TRC researchers at the Broad Institute, who have developed the 
shRNA containing vectors used in this study, have shown that these shRNA constructs 
did not induced any interferon response in the tested adenocarcinoma human alveolar 
basal epithelial cells (Moffat et al., 2006, Ref.3). 
5.3.3.3. Effects of the transduction with MLV-E pseudotyped lentiviral  
   particles on gene expression in primary sensory neurons 
To assess whether the infection of dissociated murine E13.5 DRG cells with lentiviruses 
has any effects on their morphology and gene expression, which could potentially affect 
the interpretation of the results after the knockdown of RPTPs, I have performed an 
initial test experiment.  
 The sensory neurons were infected with different types of MLV-E pseudotyped 
lentiviruses that either contained eGFP in pLNT/SFFV-eGFP-WPRE or a non-targeting 
shRNA from Sigma or Qiagen in the pLKO.1 puro backbone vector or the cells were 
treated only with media, either Opti-MEM® or filtered HEK 293T supernatant 
consisting of highly concentrated DMEM medium supplemented with FBS and 
antibiotics, which were used as a carriers for the differently concentrated viruses. The 
cells were infected with half of the whole virus production per well in the same volume 
at an approximate MOI of 3 - 8 for the eGFP-encoding viruses (section 5.3.2.2). The 
MOI of the lentiviruses containing shRNA sequences could not be determined due to 
the lack of appropriate reporter genes in the constructs and titration tools. However, to 
some extent it can be assumed to be in the range of the MOI of the eGFP-lentiviruses, 
although differences in the backbone vectors might affect virus production and 
expression of the GOI slightly. The shRNAi-containing lentiviruses were successfully 
produced and were functional as gene knockdown was observed and the integration 
PCR assay was positive (chapter 6). In the initial test experiment the effects of the 
transduction with these lentiviruses on gene expression, specifically of all three Trk 
genes and the RPTP genes Ptpra, Ptprf, Ptpro, Ptprr and Ptprs, were assessed using 
qPCR analysis. Additionally cell morphologies were also examined. 
 First, the effect of the virus-containing media (filtered HEK 293T supernatant 
and Opti-MEM®) on the sensory neurons was assessed and compared to untreated cells 
(Figure 5.3A). Overall, gene expression was not much affected by these media. Further, 
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the effects of the differently concentrated viruses normalized to the medium of the virus 
preparation were compared with each other and all showed an effect on gene expression 
but with a varying degree (Figure 5.4B). In the case of the filtered lentiviruses, mostly  
eGFP-expressing viruses (eGFP filtered) and non-targeting Sigma control lentiviruses 
(ctrl S filtered) affected gene expression. The filtered eGFP-lentivirus boosted gene 
expression only of the three RPTPs Ptpra, Ptpro and Ptprr but did not alter Trk gene 
expression. Cells treated with the filtered non-targeting Sigma control lentiviruses 
showed increased expression of Ntrk1, Ptpra and to a higher degree of Ptpro and Ptprs, 
but slightly suppressed expression of Ntrk2. The control lentivirus containing a  
non-targeting shRNA from Qiagen also boosted the expression of Ptpro but to a lesser 
degree than the non-targeting Sigma control lentivirus. All centrifuged lentiviruses had 
a stronger effect on gene expression in sensory neurons than the described filtered 
lentiviruses and suppressed gene expression in some cases even to less than half of their 
expression in the Opti-MEM® control. The strongest effects were observed in cells 
transduced with eGFP-lentiviruses and non-targeting Sigma control viruses, which 
strongly suppressed gene expression of all Trks and RPTPs apart from Ptprf. The 
lentiviruses containing non-targeting shRNA from Qiagen also suppressed gene 
expression of all Trks and Ptprf, Ptprr and Ptpra but to a slightly smaller degree than 
the described non-targeting Sigma control virus; or boosted it instead of suppressing it 
for Ptprs and Ptpro.  
 Overall the lentiviruses concentrated via ultracentrifugation had a strong 
suppressing effect on gene expression, whereas the filtered viruses showed a smaller 
suppressing and sometimes even boosting effect on gene expression. However, no 
obvious morphological changes were observed in the cell cultures infected with either 
virus type (Figure 5.5). Additionally the non-targeting Sigma shRNA appears to have a 
stronger effect on gene expression than the non-targeting Qiagen shRNA. These results 
agree with observations made by Prof. F. Böhmer and Dr. J. Mueller (personal 
communication). It has to be noted that also the non-targeting Qiagen shRNA caused up 
to 20-30% changes in gene expression. However, this experiment was performed only 
once and at least two more repeats would be necessary for a reliable estimation. Finally, 
it was decided that the filtered MLV-E-pseudotyped lentiviruses and the non-targeting 
Qiagen shRNA were to be used in the knockdown study (chapter 6).  
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Figure 5.4. Effects of lentiviral infection of dissociated E13.5 DRGs on gene expression. 
Primary dissociated murine DRG cultures were infected with MLV-E pseudotyped HIV1-
derived replication deficient eGFP-lentiviruses (pLNT/SFFV-eGFP-WPRE) and control (ctrl) 
lentiviruses containing non-targeting shRNA from Sigma (S) or Qiagen (Q). Two different 
concentration techniques, ultracentrifugation (centri) and filtration (filtered), were tested and 
lentiviral infection was compared to cells incubated with Opti-MEM® (OPTI) or HEK293T 
supernatant (sup) depending on the concentration technique. A) Average gene expression in 
infected and control cells (ΔCT) normalised to Psmb2. B) Changes in gene expression (ΔΔCT) 
upon infection with different viruses. Corresponding pictures of the cell cultures are displayed 
in Figure 5.5. 
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Figure 5.6. Effects of lentiviral infection of dissociated E13.5 DRGs on cell morphology.  
Displayed are pictures of primary dissociated murine DRG cultures with different treatments 
corresponding to the qPCR results displayed in Figure 5.4. Cells were infected with MLV-E 
pseudotyped HIV1-derived replication deficient eGFP-lentiviruses (GFP) and control (ctrl) 
lentiviruses containing non-targeting shRNA from Sigma (ctrl S) or Qiagen (ctrl Q) that were 
concentrated either by ultracentrifugation (centri) or filtration (filtered) or cells were treated 
with Opti-MEM® (OPTI centri) or HEK293T supernatant (sup filtered). Scale bar = 10 µm. 
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5.4. Discussion 
The results in these experiments have demonstrated that a lentivirus-mediated shRNA 
knockdown assay can be used in order to study the physiological function of RPTPs in 
Trk signalling in dissociated primary murine embryonic sensory neurons. 
 Primary sensory neuron cultures are a very suitable cell model system to analyse 
Trk signalling. However, these cells are difficult to manipulate in terms of the 
introduction of foreign DNA. As efficient introduction of shRNA constructs into the 
cells is the main requirement for a successful RNAi effect, different techniques were 
tested here to introduce DNA such as eGFP and shRNA constructs into primary sensory 
neurons. Whereas different transfection methods resulted in very low efficiency, the 
lentiviral approach was more promising. In a pseudotype screen we could show that 
MLV-E pseudotyped lentiviral particles transduced DRG cells with more than 90% 
efficiency. They are additionally safe to use as they only infect murine cells. Many 
different commercial lentivirus-based RNAi systems are nowadays available and we 
have tested the MISSION™ TRC lentiviral expression vector pLKO.1 from Sigma 
containing shRNA sequences targeting GOIs such as RPTPs.  
 In an initial test experiment the infection of DRG cells with non-targeting 
shRNA-containing lentiviral particles revealed no major changes in the morphology or 
gene expression of these cells after transduction with lentiviral particles concentrated 
via filtration at an MOI between 3 and 8. This number is noticeably much lower than 
the MOI used in the pseudotype screen, but cells infected with eGFP-lentiviruses were 
still sufficiently fluorescent. Also MOIs do not represent an exact value and depend on 
the methods used for their determination. In this study the MOI of viruses used in the 
pseudotype screen is based on a physical titre, which only calculates the amount of viral 
particles but not their infectivity. In contrast the MOI calculated for the test experiments 
is based on a functional titre and thus reflects the actual infectious nature of the virus. In 
the end it is solely important for our experiments that the viruses are successfully 
produced and infect neurons, which was shown to be the case. In fact a low MOI is 
preferable for our knockdown study as an overexpression of shRNA could overwhelm 
the RNAi machinery and produce aberrant results (Huppi et al., 2005).  
 Together, the lentiviral approach to introduce DNA into sensory neurons was 
successful and very efficient. Additionally, since lentiviruses are integrating, the shRNA 
Chapter 5 
 
  207 
constructs will be constantly produced and thus provide a stable and long-term 
knockdown. Therefore the lentiviral approach was finally used to knockdown RPTP 
genes in sensory neurons in order to assess their function in Trk signalling (chapter 6).  
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6.1. Introduction 
NT signalling controls vital functions of neurons such as survival or death, and 
proliferation and differentiation and thus it has been extensively studied since the 
discovery of NTs and Trk receptors (section 1.2). However, the regulation of the 
signalling cascades is still poorly understood and many questions remain unanswered. 
In recent years work has been carried out to analyse the implication of phosphatases 
including RPTPs in Trk signalling, but the vast majority of these studies was performed 
in artificial over-expression systems and their physiological relevance needs to be 
demonstrated (section 1.4).  
 In this study I have aimed for the challenging analysis of the physiological 
effects of specific RPTPs on Trk signalling in their endogenous environment, the 
sensory neurons from embryonic DRGs. In particular I was interested in the functional 
analysis of the three RPTPs, which were previously implicated in Trk signalling; the 
two strongest expressed RPTPs in DRGs, LAR and RPTPσ, and also RPTP-BK, which 
has a unique and very interesting coexpression pattern with Trks in DRGs (chapter 4). 
For this purpose I have employed the lentiviral-mediated RNAi approach (described in 
chapter 5) to knockdown these RPTPs and analyse the effects on Trk signalling on the 
protein and mRNA level.  
 One of the major advantages of the analysis of endogenous proteins in primary 
cells is the natural environment of these proteins. Unlike in artificial over-expression 
systems, all cell signalling components are present and thus results will not be altered 
for instance by missing adaptor proteins or the presence of different protein isoforms. 
Additionally, over-expression of proteins might cause adverse effects on cell signalling, 
and so this might be avoided by studying endogenous proteins in primary cell cultures. 
Thus the latter represents a valid approach to analyse the actual physiological function 
of the proteins of interest. It is important to take into account that sensory neurons from 
dissociated DRG cultures as used in the current study show many characteristics of 
regenerating sensory neurons in vivo, due to axotomy of their processes during culture 
preparation. But as many developmental processes are in fact recapitulated during 
regeneration, deciphering the active signalling pathways during this event can also lead 
to the understanding of neural development.  
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Trk signalling pathways and the involvement of RPTPs in those were thoroughly 
described in sections 1.2.3. and 1.4. Here, I will briefly recapitulate the major aspects 
relevant for the current study. 
 Trk signalling is initiated upon NT-binding, which leads to receptor 
dimerization, autophosphorylation of ten tyrosine residues and activation of the kinase 
activity. The Tyr autophosphorylation has two main purposes. On the one hand the 
phosphorylation of the three Tyr residues Y670, Y674 and Y765 (human TrkA) in the 
kinase domain potentiates kinase activity and the phosphorylation of the other residues. 
On the other hand phosphorylated Tyr residues represent docking or recognition sites 
for other signalling proteins (Schlessinger and Ullrich, 1992, Kaplan and Stephens, 
1994). The best-analysed Tyr residues outside the catalytic domain are Y490, Y751 and 
Y785 mostly due to the availability of antibodies against these epitopes. Phosphorylated 
Y490 is required for Shc or Frs2 association and activation of the Ras-MAPK pathways 
leading to proliferation, differentiation, cell growth and neurite outgrowth. Phospho-
Y785 binds directly to PLCγ-1, which leads for instance either to PKCδ-mediated 
MAPK pathway activation or Ca2+-mediated regulation of synaptic plasticity through 
enhanced neurotransmitter release. The phosphorylation at Y751 is required for PI3K 
association and activation of the Akt signalling cascade, which inhibits apoptosis and 
activates prosurvival factors. All these pathways are interlinked and can activate each 
other under certain circumstances. As it has become apparent in recent years, an 
important component of the regulation of Trk signalling seems to occur through the 
tyrosine phosphatases. 
 In this study I have primarily analysed the phosphorylation of Trk Y785, due  
to the availability of good antibodies. This is a docking site for PLCγ-1, and upon  
binding PLCγ-1 is phosphorylated and can initiate neurite outgrowth via the  
PLCγ-1/PKCδ/MAPK pathway (Corbit et al., 1999). It can also enhance 
neurotransmitter release via the PLCγ-1/Ca2+/CaMPK and PLCγ-1/Ca2+/PKA pathways 
and is thus implicated in synaptic plasticity (Lessmann, 1998). The pTrk Y785/PLCγ-1 
signalling additionally controls expression and activity of many proteins such as ion 
channels (Toledo-Aral et al., 1995, Klein et al., 2005). Mice with a specific mutation in 
the TrkB Y816 show impaired hippocampal LTP in the CNS (Minichiello et al., 2002) 
and also structural abnormality of synapses and impaired fibre guidance in vestibular 
neurons in the PNS (Sciarretta et al., 2010). I have additionally looked at the MAPK 
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Erk1/2 pathway and the Akt pathway, which both control neurite outgrowth and cell 
survival. These three pathways are mainly initiated through pY490 and pY751 in Trk 
signalling. However, Trk signalling pathways are cross-linked with many other 
pathways and remain poorly understood. 
 One of the best-analysed RPTPs implicated in this signalling pathway is LAR. 
Both augmenting and inhibitory roles for LAR on Trk-mediated and Trk–independent 
neurite outgrowth, cell survival and synapse morphogenesis depending on the context 
were discovered. For instance a knockdown study in hippocampal neurons presented an 
augmenting role of LAR on TrkB Y515 initiated signalling and a positive effect of LAR 
on the MAPK and Akt pathways. LAR knockdown resulted in a decrease in protein 
expression after 3 days, leading to a decrease in TrkB Y515 phosphorylation upon 
BDNF-treatment and a decrease in phosphorylation of the analysed downstream 
pathway components Shc, Erk and Akt and of the TF CREB. Additionally a 
deactivation of Src and a decrease in the BDNF-induced neurotrophic activity were 
observed. These data suggested an activation of Src by LAR, which then phosphorylates 
TrkB Y515 (Yang et al., 2006). In DRG explant cultures LAR activation showed also 
an augmenting effect on neurite outgrowth (Yang et al., 2005a). In PC12 cells LAR 
plays an inhibitory role on TrkA, as LAR downregulation resulted in an increase in 
NGF-mediated neurite outgrowth and decreased apoptosis (Moshnyakov et al., 1996, 
Tisi et al., 2000). In support of these findings inhibition of LAR in PC12 cells through a 
specific wedge peptide also resulted in an augmented NGF-induced phosphorylation of 
Tyr 490 of TrkA and its downstream pathway components Erk and Akt and enhanced 
neurite outgrowth (Xie et al., 2006). The effect of LAR on the phosphorylation state of 
Trk-Y785 was previously not directly assessed in any study. But in one report 
augmented LAR function in hippocampal TrkB+ neurons lead to an increase in PLCγ 
phosphorylation. In the same study Erk phosphorylation was only slightly elevated 
(Yang et al., 2005a). Nevertheless, in this study these effects could also possibly be 
attributed to an effect of LAR on other growth factor receptors, which signal through 
the PLCγ-pathway. LAR could also have either a positive or a negative effect on Trk 
phosphorylation in sensory neurons. Therefore I have aimed to analyse the direct effect 
of LAR on Trk Y785 phosphorylation in DRG cells in my knockdown experiments.  
 RPTPσ is another RPTP, which was implicated in Trk signalling. RPTPσ is 
strongly expressed in the entire nervous system and RPTPσ-/- mice display the most 
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obvious neurological defects among all RPTP knockout mice (Elchebly et al., 1999, 
Wallace et al., 1999, Batt et al., 2002, Meathrel et al., 2002). Therefore the implication 
of this phosphatase especially in neurite outgrowth was previously analysed in several 
studies also in context with Trk signalling. Faux et al. have shown that RPTPσ can 
dephosphorylate all three Trks in an over-expression system in HEK293T cells and that 
an over-expression of RPTPσ in embryonic chick sensory neurons from dissociated 
DRGs resulted in the suppression of NGF-dependent neurite outgrowth without 
affecting their survival (Faux et al., 2007). These results support previous findings in 
adult retinal cells in RPTPσ-/- mice, in which increased neurite outgrowth was observed 
after a lesion. These mice displayed a constitutive elevation of the MAPKs Erk1/2 and 
Akt kinases, but PLCγ activation was not observed. An implication of RPTPσ in these 
downstream signalling pathways was suggested and possibly linked to Trk and EGFR 
signalling (Sapieha et al., 2005). However, in contrast to LAR the affected Trk Tyr 
residues were not identified yet and the physiological relevance of its interaction with 
Trk receptors also remains to be shown. Therefore its function in Trk signalling was 
also assessed in my knockdown study. 
 RPTP-BK appears to have a specific function in DRGs possibly mediated 
through Trk receptors. The importance of RPTP-BK in sensory neurons is most 
apparent in RPTP-BK-/- mice, which clearly display nociceptive and proprioceptive 
abnormalities such as the loss of the response to thermal pain (Gonzalez-Brito and 
Bixby, 2009). An interaction of RPTP-BK with TrkC was also previously studied and it 
was shown that both enzymes could interact with each other, whereby RPTP-BK also 
dephosphorylates TrkC (Hower et al., 2009). However, these experiments were 
performed in an over-expression system and the physiological relevance of this 
interaction remains to be assessed and the dephosphorylated TrkC tyrosines identified. 
Especially in regard to our findings in chapter 4, which have shown that RPTP-BK is 
expressed not only in TrkC+, but also TrkA+ and TrkB+ RPTP-BK could play a role in 
the signalling pathways of all three Trk receptors. 
 The main focus in this study was to assess whether Trk receptors could be direct 
substrates of the RPTPs LAR, RPTPσ and RPTP-BK by analysing the phosphorylation 
state of Trk receptors, in particular of Tyr 785, following RPTP knockdown. To 
complement this analysis the function of two downstream signalling pathways, the 
Erk1/2-MAPK and to some extent the PI3K/Akt pathway, was studied.  
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6.2. Experimental procedures 
6.2.1. Generation of lentiviruses and transduction of sensory neurons 
The generation of MLV-E pseudotyped lentiviruses and transduction of sensory neurons 
was thoroughly described in chapter 5. 
6.2.2. ShRNA and control plasmids 
In this study MISSION TRC shRNA lentiviral vectors pLKO.1-puro (Sigma) 
targeting the murine RPTP genes Ptprf, Ptpro and Ptprs encoding LAR, RPTP-BK and 
PTPRσ respectively were used (Figure 6.1). A set of 4-5 sequence-verified shRNA 
constructs was provided per gene with a guaranteed knockdown efficiency of at least  
70% (Sigma). As a non-targeting control (ctrl) I have used the pLKO.1-puro vector 
containing a non-targeting shRNA sequence from Qiagen kindly provided to us by  
Dr. Jörg Mueller (University of Jena, Germany). 
 
  
CONSTRUCT TRC No. TARGETED SEQUENCE (5’3’) 
 SH 1 TRCN0000029944 GCCTCGAATTACGTGGATGAA 
 SH 2 TRCN0000029945 GCCGTATGTGAAATGGATGAT 
 SH 3 TRCN0000029946 CCACCAGTGTTACTCTGACAT 
 SH 4 TRCN0000029947 GCCCTTCAAGATCCTGTACAA 
LA
R 
 SH 5 TRCN0000029948 CGCTTTGAGGTAATTGAGTTT 
 SH 1 TRCN0000029984 CCAGAGTTGATTCAACAGTTT 
 SH 2 TRCN0000029985 CGATTCTTACATCAAGGATAT 
 SH 3 TRCN0000029986 GCGCTCATACCGAATGTCAAT 
 SH 4 TRCN0000029987 CCATTCACAGAAGAACCCATT RP
TP
-B
K 
 SH 5 TRCN0000029988 CCTACAACAGAAGTCCCACAT 
 SH 1 TRCN0000029994 CCTTCCTCATTCCCTTCTGAT 
 SH 2 TRCN0000029995 CCAGCTTTATCGACGGCTATA 
 SH 3 TRCN0000029996 CGAAATCACAATTCATGCAAA 
 SH 4 TRCN0000029997 GCAGAACTACTTCATTGTGAT P
TP
Rσ
 
 SH 5 TRCN0000029998 CCACGGCCATATTGGTAAGTT 
  Ctrl Q non-targeting shRNA from Qiagen in pLKO.1 puro 
 
Table 6.1. MISSION  pLKO.1-puro lentiviral expression vectors.  
The pLKO.1-puro constructs (Sigma) contain shRNA sequences directed against the murine 
RPTP genes Ptprf, Ptprs, Ptpro and a non-targeting control shRNA from Qiagen. SH = small 
hairpin, ctrl = control. 
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6.2.3. Lentivirus‐mediated knockdown of RPTP genes  
The day before transduction, DRGs were dissected from E13.5 CD-1 mouse embryos 
and dissociated and cultured as described in section 2.5.3. Approximately 250,000 cells 
were seeded per well of a PLL and FN pre-coated 12-well-plate. One day after plating 
the cells were infected with shRNA-containing lentiviruses, whereby one entire 
production of filtered lentivirus was equally distributed onto three wells in a final 
volume of 1 ml complete DRG medium. After 24 h the cells were washed gently with 
PBS and cultured for 72 or 96 h. The cells were examined for morphological changes 
each day starting 24 h after plating and pictures were taken as described in section 2.6. 
Finally the cells were harvested for mRNA and protein extraction (section 2.2.11) and  
gDNA isolation (section 2.1.18). Experiments were performed first without and then 
with mitotic inhibitors. 
6.2.4. Integration PCR  
To test whether the lentiviruses integrated into the genome of the target cells as a proof 
of presence of lentiviruses, PCR was performed on extracted gDNA from infected cells.  
 Each PCR reaction contained 5 µl 25 mM MgCl2, 5 µl 5x GoTaq® Flexi Buffer, 
200 µM dNTPs (Bioline), 10 µM integration primers, 1 unit GoTaq® Hot Start 
Polymerase (Promega) and 200 ng gDNA or 50 ng plasmid DNA template in a final 
volume of 25 µl ddH2O. The reaction was run in a PCR thermo cycler under following 
conditions with a heated lid at 104ºC: polymerase activation: 94ºC for 5 min,  
3-step-cycling: 40x (30 sec at 94ºC (denaturation), 30 sec at 50ºC (annealing), 45 sec at 
72ºC (extension)), final extension: 5 min at 72ºC. The forward primer anneals to U6 and 
the reverse primer to cppt in the pLKO.1-puro vector (Table 6.2) producing a PCR 
product of 309 bp.  
 
Table 6.2. Integration primers. 
 
INTEGRATION PRIMER SEQUENCE (5’   3’) TM (ºC) 
Forward (iF) – cppt TAC AAA ATA CGT GAC GTA GAA A 52.8 
Reverse (iR) – U6 TTT GTT TTT GTA ATT CTT TA 43 
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6.2.5. Assessment of the knockdown effects  
6.2.5.1. QPCR 
RNA was extracted from transduced cells, reverse transcribed and qPCR was performed 
on 15 ng cDNA of each sample in duplicates on 96-well plates as described in 
section 2.2. 
6.2.5.2. WB analysis 
Protein samples were obtained from infected DRG cultures during mRNA-extraction by 
acetone precipitation (section 2.2.1.1). Samples were removed from the freezer and 
warmed to 65ºC. For estimation of protein amounts different Bradford assays were 
tested. However, this approach was technically not feasible for the DRG samples due to 
unknown reasons. Therefore, instead, aliquots of the samples were electrophoresed on 
PAGE gels and commassie stained (section 2.3.4) followed by densitometry analysis to 
broadly estimate protein concentration. Western blotting and quantitative densitometry 
analysis were performed as described in section 2.3. Antibody details are described in 
Tables 2.3 and 2.4. The Trk antibodies specifically detect only the corresponding TrkA, 
TrkB or TrkC receptor (Appendix, Figure 1). The two antibodies pTrkA Y794 (rat) and 
pTrkB Y816, referred to as pTrk* and pTrk** respectively, detected endogenous levels 
of Trk receptors phosphorylated at the Y785 (human TrkA). The pTrk** antibody 
cross-reacted with the corresponding phosphorylated Tyr residues of all Trk receptors in 
contrast to previous reports. The pTrk* antibody also recognized phosphorylated TrkC 
and possibly also phosphorylated TrkB (see also explanations in the text in section 
6.3.1)(Appendix, Figure 2). For data analysis the protein expression was normalized to 
the HKG β-tubulin or to the expression of the total unphosphorylated protein.  
In the case of phospho-Trk expression, data for each of the two pTrk antibodies  
(pTrk* = pTrkA Y785 and pTrk** = pTrkB Y816) were normalized to the expression of 
panTrk, which detects the ICD of all Trk receptors and thus the full-length isoforms. 
Results were expressed as ratios of normalized volume with respect to the mock treated 
or wild type control (= 1) with standard errors (see Materials and Methods section 
2.3.3.7 for more details). 
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6.3. Results 
6.3.1. Design of knockdown experiments  
All knockdown experiments were performed with independent lentiviral preparations on 
freshly prepared dissociated DRG cultures. Four to five different shRNA lentiviral 
constructs were used per gene to knockdown Ptprf (LAR), Ptprs (RPTPσ) or Ptpro  
(RPTP-BK) mRNA. The non-targeting shRNA from Qiagen in the pLKO.1 vector was 
used as a control (and reference) in all experiments (Table 6.1). All shRNA sequences 
have different knockdown efficiencies depending on the cell type and additionally some 
shRNA constructs might cause “off-target” effects. In recent studies some researchers 
have used a pool of different shRNA constructs. However, a possible off-target effect 
might be mixed with target-specific effects in such experiments thus altering the results 
of the RNAi phenotype (Moffat et al., 2006). For these reasons different shRNA 
constructs to knockdown RPTP gene expression in our study were used in independent 
experiments.  
 Lentiviruses carrying shRNA were prepared, and dissociated murine E13.5 DRG 
cells were infected at an MOI of around 3-8 as described in chapter 5. As these viruses 
do not contain any suitable marker to assess or track infection, in order to confirm 
successful transduction, I have performed PCR with primers annealing to the integrating 
part of the shRNA pLKO.1 construct (cppt and U6, Table 6.2) on gDNA extracted from 
selected infected cells. PCR on all of these samples from infected cells and the positive 
controls (lentiviral backbone vectors) yielded a characteristic band of 309 bp, and as 
expected untreated DRGs and cells infected with eGFP viruses remained negative (data 
not shown). 
 In general the cells were cultured for 3 days after transduction in medium 
containing NGF, BDNF and NT-3, apart from one Ptpro knockdown experiment, which 
was extended to 4 days. The two first Ptprf and Ptprs experiments were also performed 
without NT-3 due to its unavailability. As my amendments and improvements of the 
DRG culturing system and the knockdown experiments caught up at this point, one of 
each of the knockdown experiments was performed with the mitotic inhibitors FdUrd 
and Uridine. These inhibitors reduced the amount of proliferating cells such as glia cells 
and fibroblasts in the culture from 80% to 60% after 3 days and even to 40% after  
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4 days and improved the read-out of the RNAi phenotype in neurons (Appendix,  
Figure 5).  
 The knockdown efficiency of the small hairpins (from now on referred to as SH) 
was assessed on the mRNA level with qPCR using primers from the qPCR screen 
(chapter 3). Data were normalized to Psmb2 only, instead of three HKGs like in the 
qPCR arrays, due to a restricted amount of mRNA from the samples available. 
Nevertheless, since analysis on only one embryonic stage was performed, a relatively 
stable gene like Psmb2 was fully sufficient for this purpose. As some proteins might 
have a long half-life, it is best to confirm the knockdown also on the protein level. 
However, this was not possible due to the lack of specific antibodies against RPTPs.  
 The effects of the RPTP knockdowns were analysed via WB with antibodies 
against specific phosphorylation sites of Trk receptors and components of several 
downstream signalling pathways such as Erk1/2, Akt1/2 and Stat3. Although I believe 
this was broadly successful, it was a very challenging task given that little material from 
primary cells was available, the protein levels were difficult to quantify (see material 
and methods section 6.2) and only low endogenous levels of Trk receptors were present. 
  As a control for Trk expression I have used TrkA, TrkB and TrkC specific 
antibodies, which recognized the ECD of the corresponding Trk receptors thus detecting 
all Trk protein isoforms, and a panTrk antibody, which recognizes the ICD of all Trk 
receptors thus detecting only the full-length isoforms (Appendix, Figure 1). In the case 
of TrkA, several protein sizes exist: the 80 kDa core protein, which is immediately 
glycosylated to an immature 110 kDa protein (gp 110) and a fully mature 140 kDa 
glycoprotein (gp140), as well as a shed membrane-bound ICD of 41 kDa and a soluble 
ECD (Martin-Zanca et al., 1989). In the case of TrkB and TrkC the full-length mature 
145 kDa glycoproteins (gp145) and different non-catalytic glycosylated 95 kDa (gp95) 
isoforms are the most predominant (Klein et al., 1989, Lamballe et al., 1991, 
Middlemas et al., 1991). I have concentrated my analysis on the full-length 140 and  
145 kDa proteins.  
 Further, I have tested several phospho-Trk antibodies. However, despite 
enormous efforts to find appropriate conditions for these antibodies, in order to improve 
the background to signal ratios, only two antibodies provided reasonable results. The 
commercially available antibodies recognizing phosphorylated Y490 or Y674/Y675 
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(from different companies) worked only on over-expressed Trk receptors, but not well 
on phosphorylated endogenous Trk receptors in lysates from primary sensory neurons. 
In contrast to this the two antibodies pTrkA Y794 (rat) and pTrkB Y816, referred to as 
pTrk* and pTrk** respectively, both detected endogenous levels of Trk receptors 
phosphorylated at the Y785 (human TrkA). These antibodies were kindly provided by 
Dr. Sheilla Harroch (PTPNET member, Institute Pasteur Paris, France) and were 
originally generated by Dr. M. Chao’s lab (Rajagopal et al., 2004, Arevalo et al., 2006). 
The pTrk** antibody cross-reacted with the corresponding phosphorylated Tyr residues 
of all Trk receptors in contrast to previous reports (Appendix, Figure 2). The pTrk* 
antibody also recognized phosphorylated TrkC but not phosphorylated TrkB in 
agreement with published results (Rajagopal et al., 2004). However, the TrkB control 
sample in my test did not produce a strong band with the pTrkB (pTrk**) antibody as 
well, thus possibly indicating poor TrkB phosphorylation levels in this sample. 
Therefore it cannot be completely excluded that the pTrk* antibody in fact also  
cross-reacts with TrkB. Both antibodies were used to assess directly the 
phosphorylation state of the Trk receptors following RPTP knockdown.  
 The effects on the Trk downstream signalling pathways were examined with 
antibodies against phospho-Akt, -Erk1/2 and -Stat3. The kinase Akt is a major executer 
of the PI3K pathway, mainly initiated by phosphorylated Y751 and also Y490 in the 
Trk receptors. It controls cell survival by inhibiting apoptosis through phosphorylation 
and inactivation of Bad, forkhead TFs, c-Raf and caspase-9 etc. Akt is activated by 
phospholipid binding and phosphorylation of T308 within the activation loop and S473 
in the C-terminus. Our antibody detected the latter. Erk1 (p44) and Erk2 (p42) are 
mediators of the classical MAPK pathway, which is initiated in Trk signalling mainly 
through phosphorylated Y490 residues. Additionally the MAPK pathway is also 
initiated through phosphorylated Y785, which activates the PLCγ-1 pathway. Erk1/2 
activation leads to cell proliferation, differentiation and survival. Furthermore the 
available phospho-Stat3 Y705 antibody was used. The signal transducer and 
transcription activator 3 (Stat3) is a TF and is activated by phosphorylation of its Y705 
and its S727 depending on the cell type, which induces dimerization, nuclear 
translocation and DNA binding. Stat3 is involved in cell proliferation and regulates the 
expression of anti-apoptotic genes (Darnell, 1997). In addition to its nuclear function as 
a TF Stat3 also regulates cell migration (Gao and Bromberg, 2006). Initially discovered 
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as a cytokine signal transducer, Stat3 was recently also identified as a signal transducer 
of TrkA signalling (Ng et al., 2006). In PC12 cells TrkA leads to Stat3 phosphorylation 
at S727 but not Y705, and the activation of several TrkA downstream pathways such as 
cell proliferation and neural differentiation. More recently, it was also shown that Trk 
oncogenes mediate phosphorylation of Stat3 additionally at T705, which is targeted by 
our antibody. This phosphorylation is partially mediated through the MAPK pathway 
and is possibly due to the high expression levels of Trk (Miranda et al., 2010). In our 
experiments we should not detect the T705 phosphorylation under normal conditions. 
All WB experiments were performed with several technical replicates and the 
expression levels were densitometrically estimated.  
 Together the different knockdown experiments were carried out with several 
SHs per gene and at least twice, but under different culturing conditions, and the effects 
of the knockdowns were assessed on the mRNA and protein levels. Repeats of the 
experiments were attempted, but unfortunately due to a unit-wide contamination of the 
tissue culture facility for several months, all these experiments were lost. Nevertheless, 
since several different SHs for each gene were used in each experiment, a comparison 
between these provided us with several effective replicates and thus valuable results. 
6.3.2. Ptprf knockdown in murine embryonic sensory neurons 
Two independent knockdown experiments targeting Ptprf were performed. In both 
experiments the cells were cultured for 3 days after transduction, but in the first 
experiment no mitotic inhibitors and no NT-3 were used. The first experiment was also 
conducted with three shRNA-containing lentiviruses (SH1, SH3 and SH5), whereas the 
second one was carried out with all five available different shRNA-containing 
lentiviruses. Overall, all SH constructs caused a knockdown of Ptprf mRNA in both 
experiments. SH1 caused a knockdown of 63 and 46%, SH2 of 55%, SH3 of 28 and  
63%, SH4 of 53% and SH5 of 63 and 69% (Figures 6.1D and 6.2D). 
 In the first experiment the analysis of the expression of all Ntrk genes and the 
corresponding proteins revealed a decrease in Ntrk2 and Ntrk3 gene expression and 
TrkA, B and C protein expression in the knockdown samples SH1 and SH3. The 
expression in the SH5 sample remained mostly unchanged (Figure 6.1A-C). The 
expression of Ptprs, another member of the PTPR2A group like Ptprf, did not change 
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significantly upon knockdown in any sample. This indicates that no compensation for a 
deficiency in LAR took place by this phosphatase at this time point. The 
phosphorylation of Trk Y785 (pTrk** antibody) appeared to be elevated in all 
knockdown samples compared to the mock-treated control. This was accompanied by a 
slightly increasing trend in Erk1/2 phosphorylation. The phosphorylation of Stat3 was 
decreased in the samples SH1 and SH3 and of Akt in sample SH1. The cell 
morphologies in all samples were comparable to each other (Figure 6.1E). The unstable 
Trk gene and protein expression mostly complicated the interpretation of the results in 
samples SH1 and SH3 but not of SH5, which showed rather stable Trk expression. In 
this sample the 63% Ptprf knockdown resulted in a twofold increase in Trk pY785 
phosphorylation but with no major changes in Erk1/2 or Akt phosphorylation. 
 In the second experiment the expression of the Ntrk genes fluctuated again 
across the samples (Figure 6.2A). However, for most of the samples these changes were 
within the previously observed range of up to 30% (chapter 5). The elevated amount of 
Trk proteins mostly correlated with their gene expression. Once again in sample SH5 
Trk protein expression was least varying and although the gene expression levels were 
decreased, they were still within the usual fluctuation range. Ptprs expression was 
especially increased in samples SH2 and SH3, but rather stable in the remaining 
samples. Both pTrk Y785 antibodies (pTrkA Y794 = pTrk* and pTrkB Y816 = pTrk**) 
worked on these samples and the results agreed on an overall increase in Trk Y785 
phosphorylation in samples SH4 and SH5. Whereas SH1 showed an elevation and SH3 
a decrease in phosphorylation with the pTrk* antibody, no changes were visible with 
the pTrk** antibody (Figure 6.2B-C). The phosphorylation of Erk1/2 was either 
decreased or mostly unchanged, especially in sample SH5. Akt phosphorylation was 
possibly decreased in samples SH1 and SH4, but unchanged in all other samples with a 
similarity in this pattern to Erk1 phosphorylation. Stat3 phosphorylation was decreased 
in all knockdown samples, with highest values for SH5. Too little protein was present in 
sample SH2 for accurate densitometry analysis of Trk expression and phosphorylation. 
The morphology of the cells in all samples was similar (Figure 6.2E), but in comparison 
to the first experiment more neurons and less glia cells were present. Together, in this 
experiment the knockdown of Ptprf caused an overall increase in the phosphorylation 
state of Trk Y785 and possibly no effect or a downregulation of Erk1/2 phosphorylation  
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Figure 6.1. Effects of Ptprf knockdown in murine E13.5 sensory neurons. Experiment 1.  
This experiment was carried out with three shRNA (SH1, 3 and 5) lentiviruses targeting Ptprf 
and a non-targeting control (ctrl) lentivirus, but without mitotic inhibitors and NT-3 for 3 days. 
The effects on gene expression and protein phosphorylation were analysed. A) qPCR analysis of 
gene expression of Ntrk1-3, Ptprf and Ptprs. Results were normalized to Psmb2 as a HKG and 
the difference in ΔCT values between cells infected with shRNA targeting Ptprs and the non-
targeting control (ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT  %). 
The error bars represent SDs between samples from separate wells, which were infected with 
the same virus. B) Representative WB and C) densitometry analysis. Results were compared to 
protein expression in cells infected with the ctrl virus. In the case of phospho-antibodies, 
expression was normalized to the protein amount (with the exception of pAkt, as the Akt 
antibody was not available). Several technical repeats were performed. And when data were 
available for the antibody from more than one western blot, standard errors were calculated and 
included in the graphs. pTrk** = pTrkB Y816 antibody detecting phosphorylated TrkA,  
TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. E) Cell morphologies.  
Scale bar = 10 µm. 
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Figure 6.2. Effects of Ptprf knockdown in murine E13.5 sensory neurons. Experiment 2.  
This experiment was carried out with five shRNA (SH1-5) lentiviruses targeting Ptprf and a 
non-targeting control (ctrl) lentivirus and with mitotic inhibitors for 3 days. The effects on gene 
expression and protein phosphorylation were analysed. A) qPCR analysis of gene expression of 
Ntrk1-3, Ptprf and Ptprs. Results were normalized to Psmb2 as a HKG and the difference in 
ΔCT values between cells infected with shRNA targeting Ptprs and the non-targeting control 
(ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT %). The error bars 
represent SDs between samples from separate wells, which were infected with the same virus. 
B) Representative WB and C) Results were compared to protein expression in cells infected 
with the ctrl virus. In the case of phospho-antibodies, expression was normalized to the protein 
amount (with the exception of pAkt, as the Akt antibody was not available). Several technical 
repeats were performed. And when data were available for the antibody from more than one 
western blot, standard errors were calculated and included in the graphs. pTrk* = pTrkA Y794 
antibody detecting phosphorylated TrkA and TrkC Y785 sites, pTrk** = pTrkB Y816 antibody 
detecting phosphorylated TrkA, TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. 
E) Cell morphologies. Scale bar = 10 µm. 
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in most knockdown samples. Akt phosphorylation was slightly affected. Ntrk 
expression was unstable and Stat3 phosphorylation was decreased. Once again in 
sample SH5 Trk expression was the most stable among the analyzed samples and the  
phosphorylation state of Trk Y785 in this sample was upregulated, but Erk1/2 and Akt 
phosphorylation remained not significantly changed, and Stat3 was the least decreased.  
 The results from these two Ptprf knockdown experiments were difficult to 
interpret due to unstable Trk expression. But overall the downregulation of LAR 
possibly resulted in an upregulation of Trk Y785 phosphorylation. The MAPK and Akt 
signalling pathways were possibly unaffected in the first experiment but slightly 
downregulated in the second. 
6.3.3. Ptprs knockdown in murine embryonic sensory neurons 
Two knockdown experiments, each with four different shRNA lentiviruses targeting 
Ptprs mRNA and a non-targeting control virus, were performed. Similar to the  
Ptprf knockdown experiments the cells were cultured for 3 days after transduction 
either with or without mitotic inhibitors. The first experiment also lacked NT-3 in the 
culture medium. 
 The knockdown efficiencies of the four shRNA were comparable in both 
experiments apart from SH3 (Figures 6.3.D and 6.4D). Two of the shRNA constructs 
(SH1 and SH2) knocked down Ptprs mRNA expression in both experiments, but with 
higher knockdown efficiency in the second experiment (> 78%) compared to the first 
one (> 43%). The SH4 did not result in any knockdown in both experiments, whereas 
SH3 reduced mRNA expression by > 60% in the second experiment, but had an effect 
only in one out of two samples (same virus, two different wells) in the first experiment. 
Integration PCR was performed on gDNA from cells of the first experiment and showed 
that viruses were integrated in the cell chromosomes. Thus the complete lack of 
knockdown by SH4 was not caused by an absence of the virus. Also, the constructs 
appeared not to have recombined during large-scale propagation when analysed by RE 
digests (data not shown), which could lead otherwise to their inactivation. Interestingly, 
when tested in HEPA cells by researchers from the Broad Institute (Sigma), only SH4 
caused a 65% decrease in mRNA expression of Ptprs (Sigma) and no knockdown was 
reported for any of the other hairpin sequences. This might be explained by the fact that 
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different hairpins can target different transcript variants or transcript regions containing 
single nucleotide polymorphisms (SNPs) and thus cause a particular shRNA to work in 
one cell type but not as effectively or at all in another, if this protein isoform is missing.  
 In the first experiment the analysis of gene expression of all Ntrk genes 
demonstrated that in both samples with a successful Ptprs knockdown (SH1 and SH2) 
the expression of these genes was downregulated. Especially in sample SH2 these 
changes were higher than the frequently observed fluctuation ratio of up to 30%  
(Figure 6.3A) and correlated with decreased protein levels (Figures 6.3B and C). The 
strongest decrease in expression in this sample was observed for TrkB. The gene 
expression levels in sample SH1 were also decreased (Figure 6.3A), but the expression 
on the protein level was upregulated (Figures 6.3B and C). Interestingly, Ptprf 
expression was also downregulated in the samples with a successful knockdown. The 
phosphorylation of Trk Y785 in samples SH1 and SH2 was upregulated in comparison 
to the control sample. Increased phosphorylation of Trk Y785 was also detected for 
SH3, but not SH4, which showed no knockdown of Ptprs at all. The phosphorylation 
state of the downstream pathway components Erk1/2, Stat3 and Akt appeared to be 
mostly unaltered in the successful knockdown samples. No obvious differences in cell 
morphologies were detected upon knockdown of Ptprs (Figure 6.3E). These results 
show a possible up regulation of Trk Y785 phosphorylation upon Ptprs knockdown, 
which was however not accompanied by any changes in the analysed downstream 
pathway components.  
 In the second experiment Ntrk1-3 and Ptprf expression fluctuated again  
(Figure 6.4A). Among the samples with a Ptprs knockdown these changes were, 
however, within the ratio of 30% for the samples SH1 and SH2. But in the sample SH3 
Ntrk2 expression was highly upregulated, whereas Ptprf expression was downregulated 
by over 30%. In sample SH4, which showed a high upregulation of Ptprs expression 
instead of a knockdown, Ntrk1 expression was also highly upregulated. Interestingly no 
such increase in gene expression was detected for the other Ntrk genes or Ptprf in this 
sample, thus showing no obvious possible systematic error during data collection. On 
the protein level the expression of all Trks was upregulated in all knockdown samples, 
but panTrk expression, which detects the full-length isoforms, was rather 
downregulated or unchanged (Figure 6.4B and C). The phosphorylation state of Trk 
Y785 was upregulated in all knockdown samples, except for sample SH4, which did not  
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Figure 6.3. Effects of Ptprs knockdown in murine E13.5 sensory neurons. Experiment 1.  
The experiment was carried out with four shRNA (SH1-4) lentiviruses targeting Ptprs and a 
non-targeting control (ctrl) lentivirus without mitotic inhibitors and NT-3 for 3 days. The effects 
on gene expression and protein phosphorylation were analysed. A) qPCR analysis of gene 
expression of Ntrk1-3, Ptprf and Ptprs. Results were normalized to Psmb2 as a HKG and the 
difference in ΔCT values between cells infected with shRNA targeting Ptprs and the non-
targeting control (ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT %). 
The error bars represent SDs between samples from separate wells, which were infected with 
the same virus. B) Representative WB and C) densitometry analysis. Results were compared to 
protein expression in cells infected with the ctrl virus. In the case of phospho-antibodies, 
expression was normalized to the protein amount (with the exception of pAkt, as the Akt 
antibody was not available). Several technical repeats were performed. And when data were 
available for the antibody from more than one western blot, standard errors were calculated and 
included in the graphs. pTrk** = pTrkB Y816 antibody detecting phosphorylated TrkA,  
TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. E) Cell morphologies.  
Scale bar = 10 µm. 
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Figure 6.4. Effects of Ptprs knockdown in murine E13.5 sensory neurons. Experiment 2.  
The experiment was carried out with four shRNA (SH1-4) lentiviruses targeting Ptprs and a 
non-targeting control (ctrl) lentiviruses and with mitotic inhibitors for 3 days. The effects on 
gene expression and protein phosphorylation were analysed. A) qPCR analysis of gene 
expression of Ntrk1-3, Ptprf and Ptprs. Results were normalized to Psmb2 as a HKG and the 
difference in ΔCT values between cells infected with shRNA targeting Ptprs and the non-
targeting control (ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT %). 
The error bars represent SDs between samples from separate wells, which were infected with 
the same virus. B) Representative WB and C) densitometry analysis. Results were compared to 
protein expression in cells infected with the ctrl virus. In the case of phospho-antibodies, 
expression was normalized to the protein amount (with the exception of pAkt, as the Akt 
antibody was not available). Several technical repeats were performed. And when data were 
available for the antibody from more than one western blot, standard errors were calculated and 
included in the graphs. pTrk** = pTrkB Y816 antibody detecting phosphorylated TrkA,  
TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. E) Cell morphologies.  
Scale bar =10 µm. 
 
 
 
 
 
 
 
Chapter 6 
 
  230 
 
 
 
 
Chapter 6 
 
  231 
knock down. In contrast to the previous experiment Erk1/2 phosphorylation was slightly 
reduced in all SH-treated samples with a smaller effect in the sample SH4. The 
phosphorylation of Stat3 and possibly Akt was not significantly affected. The  
morphology of the cells appeared also unaltered in all samples with more neurons and 
less glia cells present in this experiment compared to the previous one (Figure 6.4E).  
 Together the results from both Ptprs knockdown studies showed an increase in 
the phosphorylation of Trk Y785 and no changes in Stat3 or Akt phosphorylation upon 
Ptprs knockdown. Whereas this increase in Trk phosphorylation was not accompanied 
by any changes in pErk1/2 in the first experiment, we observed a significant decrease of 
these MAPK downstream pathway components in the second experiment. This 
downregulation is however marginal when compared to sample SH4 with no 
knockdown. These differences might be explainable by different culturing conditions 
and thus the composition of the cell cultures. The majority of cells in the first 
experiment were glia cells and due to mitotic inhibitors less glia cells and more neurons 
were present in the second experiment.  
6.3.4. Ptpro knockdown in murine embryonic sensory neurons 
Two independent knockdown experiments, each with five different shRNA lentiviruses 
targeting Ptpro mRNA and a mock virus, were performed. The first experiment was 
carried out for 3 days without mitotic inhibitors, whereas in the second experiment the 
cells were cultured for 4 days with mitotic inhibitors. Independent of the differences in 
the composition of the cell cultures, knockdown efficiency of Ptpro in both experiments 
ranged between 82 and 96%, with SH5 and SH1 being most successful in both 
experiments (Figures 6.5 and 6.6).  
 In the first experiment a striking downregulation of Ntrk1 expression by over  
80% in all samples apart from SH1, in which it was downregulated by approximately 
20%, was observed. The corresponding TrkA protein expression was in contrast to this 
elevated in all samples, especially in sample SH5. Ntrk2 expression was upregulated in 
the samples SH1 and SH2 but downregulated in samples SH4 and SH5. Ntrk3 
expression was upregulated in samples SH1 and SH3 and downregulated in samples 
SH4 and SH5. Both TrkB and TrkC expression levels were upregulated especially in 
samples SH1 and SH2. Ptprr expression was also assessed as it was suggested to 
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interact with TrkA, whose expression might be influenced by Ptpro downregulation. 
And in fact Ptprr expression was decreased in all knockdown samples similar to TrkA 
expression. Trk Y785 phosphorylation was slightly upregulated in sample SH2 but 
downregulated in the remaining samples. Erk1/2 phosphorylation was only marginally 
affected. Stat3 phosphorylation was downregulated in samples SH1 and slightly in SH3 
but unchanged in the remaining samples. Akt phosphorylation was highly upregulated 
in sample SH1, and also to some extent in samples SH4 and SH5, whereas it remained 
unchanged in samples SH2 and SH3. Together, the samples SH1 and SH5 revealed in 
comparison to the other three samples a strange pattern in gene and/or protein 
expression. No apparent changes in cell morphologies were visible (Figure 6.5E).  
 In the second experiment (Figure 6.6) Ntrk1 expression was repeatedly strongly 
decreased, whereas TrkA expression remained unchanged. Ntrk2 and Ntrk3 expression 
was also strongly downregulated in the samples SH1, SH3 and SH5 but to a lesser 
extent in samples SH2 and SH4. TrkB was mostly unchanged, whereas TrkC levels 
were decreased apart from sample SH5. Ptprr expression was downregulated in most 
samples apart from sample SH5. Overall a decrease in the expression of all genes was 
observed in sample SH1 with no corresponding changes in protein expression. This 
might be caused by a systematic error such as an inhibitory effect on the qPCR. This 
particular hairpin already altered gene and protein expression in comparison to other 
samples in the first experiment, thus suggesting an additional problem with its 
sequence. The analysis of the phosphorylation of the downstream signalling pathway 
components has shown that Erk1/2 phosphorylation was mostly unchanged apart from 
an upregulation of pErk1 in sample SH2 and of pErk2 in samples SH1 and SH4. Stat3 
phosphorylation was not meaningfully affected. Akt phosphorylation was possibly not 
affected as well. The phosphorylation of Trk Y785 was upregulated in all samples, 
when detected with the pTrk** antibody, and upregulated in samples SH1-3 but 
decreased in samples SH4-5, when detected with the pTrk* antibody. The cells looked 
very healthy and their morphology remained unchanged in all samples in comparison to 
the mock control sample (Figure 6.6E).  
 Together these findings show a possible downregulation of pTrk Y785 in all 
samples apart from SH2 in the first experiment, but an upregulation in the second 
experiment, when using the same pTrk** antibody. An explanation for the contradicting 
outcomes might be the difference in the culturing systems (+/- growth inhibitors).  
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Figure 6.5. Effects of Ptpro knockdown in murine E13.5 sensory neurons. Experiment 1.  
The experiment was carried out with five shRNA (SH1-5) targeting Ptpro and a non-targeting 
control (ctrl) lentiviruses and without mitotic inhibitors for 3 days. The effects on gene 
expression and protein phosphorylation were analysed. A) qPCR analysis of gene expression of 
Ntrk1-3, Ptpro and Ptprr. Results were normalized to Psmb2 as a HKG and the difference in 
ΔCT values between cells infected with shRNA targeting Ptprs and the non-targeting control 
(ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT %). In contrast to the 
Ptprf and Ptprs knockdown experiments no error bars (SD) were available as samples from all 
wells were pooled and analysed together. B) Representative WB and C) densitometry analysis. 
Results were compared to protein expression in cells infected with the ctrl virus. In the case of 
phospho-antibodies, expression was normalized to the protein amount (with the exception of 
pAkt, as the Akt antibody was not available). Several technical repeats were performed. And 
when data were available for the antibody from more than one western blot, standard errors 
were calculated and included in the graphs. pTrk** = pTrkB Y816 antibody detecting 
phosphorylated TrkA, TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. E) Cell 
morphologies. Scale bar = 10 µm. 
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Figure 6.6. Effects of Ptpro knockdown in murine E13.5 sensory neurons. Experiment 2.  
The experiment was carried out with five shRNA (SH1-5) targeting Ptpro and a non-targeting 
control (ctrl) lentiviruses and without mitotic inhibitors for 4 days. The effects on gene 
expression and protein phosphorylation were analysed. A) qPCR analysis of gene expression of 
Ntrk1-3, Ptpro and Ptprr. Results were normalized to Psmb2 as a HKG and the difference in 
ΔCT values between cells infected with shRNA targeting Ptprs and the non-targeting control 
(ctrl) virus, were used to generate percentage expression levels (2^-ΔΔCT %). In contrast to the 
Ptprf and Ptprs knockdown experiments no error bars (SD) were available as samples from all 
wells were pooled and analysed together. B) Representative WB and C) densitometry analysis. 
Results were compared to protein expression in cells infected with the ctrl virus. In the case of 
phospho-antibodies, expression was normalized to the protein amount (with the exception of 
pAkt, as the Akt antibody was not available). Several technical repeats were performed. And 
when data were available for the antibody from more than one western blot, standard errors 
were calculated and included in the graphs. pTrk* = pTrkA Y794 antibody detecting 
phosphorylated TrkA and TrkC Y785 sites, pTrk** = pTrkB Y816 antibody detecting 
phosphorylated TrkA, TrkB and TrkC Y785 sites. D) Knockdown (kd) efficiencies. E) Cell 
morphologies. Scale bar = 10 µm. 
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No particular changes in Erk1/2, Akt or Stat3 phosphorylation correlated with any other 
observation. The most striking result in both Ptpro knockdown experiments was the 
strong downregulation of Ntrk1 gene expression in all five knockdown samples and to 
some extent also Ntrk2 and Ntrk3. However, these changes were mostly not reflected on 
the protein levels. 
 
6.4. Discussion 
The knockdown experiments in this study provided interesting insights into the possible 
function of the three analysed RPTPs LAR, RPTPσ and RPTP-BK in Trk signalling 
pathways and their potential role in DRG regeneration and development. But before I 
will discuss the findings in this chapter, it is important to address several important 
issues concerning the experimental set-up and the cells used in this study. 
 In general knockdown experiments are a powerful tool to analyse the 
physiological function of proteins. But they can harbour several pitfalls and thus have to 
be interpreted carefully. As the mRNA level might not reflect actual protein levels, the 
knockdown efficiency should be assessed on the protein level. But this requires specific 
antibodies, which were unfortunately not available to us for the RPTPs, as mentioned 
earlier. Thus we can only speculate at this point, whether the phenotypes we observe 
can be really attributed to a deficiency of the RPTP of interest. However, the 
knockdown efficiency on the mRNA level was repeatedly higher than 45% and mostly 
above 50% for several small hairpin constructs in each experiment. Further, the 
experiments in this study have been conducted for 3-4 days, which was an appropriate 
amount of time to induce a successful knockdown on the protein level in previous 
studies. For instance in the case of LAR, an siRNA-induced knockdown resulted in a  
45% decrease in protein expression after 3 days and lead to molecular changes  
(Yang et al., 2006). One might argue that the experiments should be carried out for a 
longer period of time especially since the half-life time of the proteins is unknown. But 
long-term studies might suffer from compensatory effects caused for instance by 
functional redundancy of other RPTPs or an upregulation of compensatory proteins or 
even pathways and feedback mechanisms and thus will not reveal an RNAi phenotype 
of the particular RPTP.  
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 Additionally, before any conclusions can be drawn from the current knockdown 
study some thoughts should be assigned to the cell system used in this study. DRGs are 
commonly used in neuroscience research as a primary cell system due to many 
advantages (see introduction section 1.5). Nevertheless, it is in fact a complicated 
system due to its diverse cell composition of glia cells and at least 20 different subtypes 
of sensory neurons. In general, it is believed that embryonic DRG cultures display 
characteristics of a regeneration assay due to the axotomy of the axons. For instance in 
TG, which contain like DRGs sensory neurons, several changes in gene expression of 
Trk receptors were observed in dissociated cultures compared to ganglia in vivo and 
explant cultures (Friedel et al., 1997). Further, in culture experiments of dissociated rat 
E15 TG (corresponding to E13.5 in mouse) the cells showed altered Trk expression and 
responsiveness to NTs, whereas explant cultures rather resembled an in vivo model. 
Interestingly, all TG neurons coexpressed all three Trk receptors and survival rates were 
independent of whether cells were cultured with one or several NTs (Genc et al., 2005). 
 In regard to the documented responsiveness of sensory neurons to all NTs, I 
have also not observed any changes on the gene or protein level in the current 
experiment, which could have been attributed to the lack of NT-3 in one of the LAR and 
RPTPσ experiments. In this thesis I have performed gene expression analysis on DRGs 
in vivo (chapter 3) and on dissociated DRG cultures (chapter 5), which allowed us a 
broad comparison of both systems. Trk gene expression showed a consistent proportion 
of the TrkA, TrkB and TrkC receptors both in dissociated DRGs and in vivo (Figures 
3.2 and 5.4). It is possible though that neurons express in addition to their specific 
dominant Trk receptor, smaller amounts of the other two receptors, which would not 
skew the expression profile in general, but allow a survival response mediated by all 
NTs. Moreover, I have compared the expression of RPTP genes between DRGs in vivo 
and in dissociated cultures and detected substantial differences (Figures 3.4 and 5.4). 
The gene expression of four of the five analysed RPTPs LAR, RPTPσ, RPTP-BK and 
especially RPTPα was greatly elevated in dissociated cultures when compared to Trk 
expression. The expression levels of LAR and RPTPσ were broadly threefold and in the 
case of RPTPα tenfold higher than in vivo. Expression levels of all three RPTPs were 
above TrkA levels in dissociated cultures, but only LAR was expressed at higher levels 
than TrkA in vivo. RPTP-BK expression was fivefold increased and higher than the 
expression of TrkB and TrkC, although its expression in vivo was at a similar level as 
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TrkB expression. RPTPR expression was by tenfold decreased and below the 
expression level of TrkC in dissociated cultures unlike in vivo.  
 In previous studies on adult rat DRGs and sciatic nerves after injury RPTPσ 
mRNA was increased by 50% during regeneration in vivo, whereas both LAR and 
RPTPα were decreased by 50 and 20% respectively after 3 days. The gene expression 
of RPTP-BK remained unchanged (Haworth et al., 1998, McLean et al., 2002). 
However, in another study, LAR protein expression was increased in DRGs upon sciatic 
nerve crush in vivo (Xie et al., 2001). In contrast to these studies, our experiments were 
performed on embryonic DRG cultures, which might explain the differences in gene 
upregulation.  
 Together, these findings demonstrate that dissociated DRG cultures show a 
different gene expression profile especially of RPTPs compared to DRGs in vivo. The 
observed changes in gene expression might be caused for instance by axotomy followed 
by regeneration of the neurons in culture or it may be a specific effect of the 
disaggregation of the neurons in culture. Nevertheless, keeping this in mind this model 
system is still a good starting point to decipher the implication of RPTPs in Trk 
signalling in an endogenous environment and in fact represents an interesting study of 
regeneration. 
 
The knockdown experiments in this study showed that a likely downregulation of LAR 
upon Ptprf knockdown resulted in a possible upregulation of Trk Y785 
phosphorylation. These findings therefore support our hypothesis of a likely regulation 
of the Trk-mediated PLCγ pathway by LAR and hint towards a possible inhibitory 
effect of LAR on the Trk-Y785-PLCγ-pathway. However, this is in contrast to a 
previous report, in which augmented LAR function lead to an increase in PLCγ 
phosphorylation in hippocampal neurons (Yang et al., 2005a). The differences between 
published data and our results might be attributed to the action of LAR on different Trk 
subtypes, as our cultures contained predominantly TrkA neurons, whereas hippocampal 
neurons express almost exclusively TrkB. This is similar to the previously shown 
opposite effects of LAR on Trk Y490 phosphorylation in TrkB+ hippocampal neurons 
and TrkA+ PC12 cells (Yang et al., 2005a, Yang et al., 2006, Xie et al., 2006).  
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 The analysed downstream signalling pathways were mostly not affected in these 
knockdown experiments but the MAPK pathway was possibly slightly downregulated 
in the second experiment. No changes in Akt phosphorylation were detected. Taking 
into account that more glia cells (around 80%) were present in the first experiment 
(around 60% in the second experiment), which also signal through the MAPK and Akt 
pathways, the effects in the neurons might have been masked in the first experiment and 
LAR deficiency might in fact lead to a downregulation in the MAPK pathway in 
neurons as observed in the second experiment. This supports therefore an augmenting 
role of LAR on the MAPK pathway in these cells possibly through Src as previously 
suggested in similar studies (Yang et al., 2006). However, this finding is somewhat 
unexpected, if compared to the results on the Trk-Y785 phosphorylation described 
above, since it agrees with the effect of LAR in TrkB+ hippocampal cells and not in 
TrkA+ PC12 cells (Yang et al., 2005a, Xie et al., 2006). Then again different 
mechanisms exist in different cell types, which might explain the observed differences. 
In addition the signalling mechanisms controlling neurite outgrowth are largely 
unknown and also MAPK-independent pathways exist. Moreover, Trks are not the only 
LAR substrate, and so the effects on the MAPK pathway might be attributed to other 
growth factor receptors in these cells. And this might explain the controversy.  
 Together, a possible implication of LAR in the PLCγ pathway mediated through 
direct dephosphorylation of Trk Y785 (Figure 6.7) is therefore likely and represents an 
interesting new aspect and a good starting point for further investigations. 
 
The Ptprs knockdown experiments showed also an increase in the phosphorylation state 
of Trk Y785, which could lead to the activation of the PLCγ-1/PKCδ-pathway and 
subsequently to MAPK-independent neurite outgrowth or could activate the  
PLCγ-1/Ca2+ pathway and lead to synaptogenesis. This was previously not reported and 
agrees with our hypothesis.  
 Similar to the LAR experiments, the Akt pathway was not affected, whereas the 
MAPK pathway was downregulated in the second experiment, but remained unaltered 
in the first experiment. As mentioned above, signalling in glia cells and through other 
growth factor receptors might have masked the changes in neurons induced by Trk 
phosphorylation in the first experiment. The potential downregulation of the MAPK 
pathway might be attributed to an augmenting role of RPTPσ, and similar to LAR might 
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be mediated via Src. However, Src was not yet identified as a substrate of RPTPσ. 
Instead, many other kinases and growth factor receptors are dephosphorylated by 
RPTPσ such as EGFR in vitro (Suarez Pestana et al., 1999), which might be responsible 
for the effects in the downstream signalling pathways in DRGs upon Ptprs knockdown.  
 Together these findings might display a possible new role of RPTPσ in 
synaptogenesis and/or neurite outgrowth mediated through the Trk Y785-PLCγ-
pathway (Figure 6.7), which is an interesting question for future research.  
 
 
 
 
Figure 6.7. Possible function of LAR and RPTPσ  in Trk signalling in sensory neurons. 
LAR and RPTPσ might both dephosphorylate the Y785 residue and thus negatively affect the 
PLCγ-pathway and subsequently synaptic plasticity and MAPK-pathway mediated functions 
such as differentiation including neurite outgrowth, proliferation and cell survival. These effects 
might be most probably attributed to TrkA receptors, which are predominantly expressed in 
neurons in dissociated DRG cultures. 
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The results from the Ptpro knockdown experiments were very surprising. A 
dephosphorylation of TrkC by RPTP-BK was previously shown in overexpression 
systems (Hower et al., 2009). This might also be the case under physiological 
conditions and in fact also true for TrkA and TrkB. Our findings in the analysis of the 
effects of a decrease in RPTP-BK on Trk phosphorylation however were most 
contradictory between the two experiments and do not allow a conclusion. Whereas in 
the first experiment a possible downregulation of pTrk Y785 was observed in the 
majority of samples, in the second experiment Trk Y785 phosphorylation was 
upregulated. No particular changes were observed in Erk1/2 or Akt phosphorylation in 
both experiments. A possible explanation for this controversy might be the different 
culturing techniques between experiments. Subsequent studies are required to draw 
conclusions from this analysis.  
 One striking and unexpected finding in this study was the significant 
downregulation of Ntrk1 gene expression and to some extent also of Ntrk2 and Ntrk3 
upon Ptpro knockdown. This was reproducible in both experiments and was caused by 
all shRNAs, suggesting a specific, not off-target effect. These changes were not 
reflected on the protein level, but this might be due to compensation on the translational 
level or a decrease in Trk degradation. Thus, the question arises, how can RPTP-BK 
influence the gene expression especially of TrkA?  
 Our data are of particular interest in regard to the phenotype of RPTP-BK-/- 
mice, which display nociceptive abnormalities such as the loss of the response to 
thermal pain (Gonzalez-Brito and Bixby, 2009). These mice in fact showed a 
downregulation of GCRP on TrkA+ neurons by 50%, but with no significant changes in 
the total amount of neurons in DRGs. In our experiments we also did not observe an 
obvious increase in cell death or a change in Akt signalling. But this requires further 
experimental assessment. Based on the observations that overexpression of Runx1, 
which controls the expression of TrkA in neurons during DRG development and 
represses the generation of TrkB+ neurons, resulted in a similar phenotype as observed 
in the RPTP-BK-/- mice (Chen et al., 2006b, Dykes et al., 2010) an antagonizing effect 
of RPTP-BK on the TF Runx1 was suggested (Gonzalez-Brito and Bixby, 2009). This 
is supported by the phenotype of Runx1-/- animals, which show an increase in the 
amounts of TrkA+, TrkC+ and CGRP+ neurons (Yoshikawa et al., 2007) (see also 
chapter 4, discussion and chapter 8). However, it is important to note that Runx1 
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function differs at early and late developmental stages. Early on it initiates TrkA 
expression and suppresses TrkB expression, whereas after approximately E17 it 
suppresses TrkA expression in favour of Ret expression (Molliver and Snider, 1997, 
Molliver et al., 1997, Chen et al., 2006b). Therefore a comparison between the 
phenotype of knockout mice and the results in our study has to be made with caution. In 
our experiments RPTP-BK seems to play an agonistic role on Runx1 function, as it 
suppresses Ntrk1 expression consistent with a late function of Runx1 although the 
cultures were obtained from E13.5 embryos.  
 RPTP-BK-/- mice also display neurite guidance defects of proprioceptive 
neurons, similar to the phenotype observed in Runx3-/- mice (Arber et al., 2000, Inoue et 
al., 2002). It is known that Runx3 drives the generation of TrkC+ neurons and represses 
the generation of TrkB+ neurons (Kramer et al., 2006, Inoue et al., 2007, Dykes et al., 
2010). Thus a possible regulation of RPTP-BK expression by Runx3 or a collaboration 
of these two proteins in the regulation of other proteins was also suggested. In our Ptpro 
knockdown experiments a possible regulation of the TrkC and TrkB gene and protein 
expression were also observed. However, these changes were subtler compared to TrkA 
gene regulation.  
 Finally the question arises, how can RPTP-BK influence the expression of Ntrk1 
to such an extent, when it is expressed only in a small proportion of TrkA+ neurons in 
vivo? In my gene expression analysis (chapters 3 and 4) I have observed additionally to 
the strong expression of Ptpro in a small subset of neurons, lower staining in other 
neurons similar to reported findings in rat E14 and E18 DRGs (Haworth et al., 1998). 
Therefore a low level of Ptpro in the majority of neurons in DRGs cannot be excluded. 
Additionally, the gene expression in dissociated DRG cells is fivefold upregulated in 
comparison to the in vivo state (see above). But it is still much smaller compared to the 
expression of Ntrk1. One other possible explanation for the impact of RPTP-BK on 
Ntrk1 gene expression might be the translational control of RPTP-BK, which might 
compensate for the smaller amount of RPTP-BK mRNA. However, in an 
immunohistochemical analysis the amount of Ptpro and RPTP-BK roughly agreed with 
each other in E16 mouse DRGs in vivo (Beltran et al., 2003). It will be of great 
importance to address this question also in dissociated DRGs in future, possibly with 
immunocytochemistry, if antibodies become available. 
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 Together with findings from other groups our Ptpro knockdown study provides 
data, which might support a possible role of RPTP-BK in the transcriptional regulation 
of Trk expression. These findings represent interesting starting points for a possible 
analysis of RPTP-BK function in the specification of sensory neurons. 
 
In conclusion, the results in this chapter suggest a potential role of LAR and RPTPσ in 
the inhibition of Trk Y785 phosphorylation (Figure 6.7), the major mediator of the 
PLCγ-1 signalling pathway. Additionally, both phosphatases might potentially have an 
augmenting effect on the MAPK pathway. However, especially since the changes on the 
MAPK pathway are rather marginal, a compensatory effect by one another, which was 
often suggested, is possible. It will be interesting in the future to further investigate the 
possible activation of the PLCγ-1/PKCδ pathway by LAR and RPTPσ for instance by 
analysing PLCγ phosphorylation and its effects on neurite outgrowth and possibly 
synapse plasticity. The effect of RPTP-BK on the phosphorylation state of Trk Y785 
was most controversial and it might not be involved in these regulatory processes. 
RPTP-BK might be instead involved in the control of Trk gene expression, since 
especially Ntrk1 expression was highly decreased in these experiments. We have also 
observed a possible control of Trk expression by another RPTP. In an analysis of Trk 
gene expression in DRGs from different knockout mice, we detected a downregulation 
of all Trk receptors in RPTPγ-/- mice and to some extent in RPTPζ-/-/RPTPγ-/- double 
knockouts (Appendix, Figure 6). As anatomical abnormalities in DRGs were not 
reported in these mice, these findings further support a possible role of RPTPs in the 
regulation of Trk gene expression.  
 
Together our findings provide a good platform for further experiments to decipher the 
role of these phosphatases in DRG development and regeneration and particularly in the 
control of Trk function and possibly expression. However, any future such experiments 
must address several issues that have complicated the interpretation of the results in our 
study.  
 First, dissociated DRG cells are a mixed population of cells including glia cells 
and different neuronal subtypes, which complicates the read-out of the experiments. A 
physical separation of different cell subtypes would be therefore desirable, but in our 
study such an approach was not possible, as sensory neurons consist of many different 
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subpopulations of cells and no marker can be used currently to select a specific 
subpopulation for instance by separation using FACS sorting. Not only will the selected 
population of neurons, which might express a common marker such as Trk receptors, 
still differ in the composition of other receptors etc., but it would also be very difficult 
to generate an appropriate amount of cells for a molecular study like the one presented 
in this work. Additionally this is complicated by the apparent changes in gene 
expression in dissociated sensory ganglia cultures (Genc et al., 2005). Further, the 
presence of non-neural cells in the culture also complicates the analysis. In my study, I 
did use mitotic inhibitors to reduce the amount of glia cells in the culture to improve the 
read-out of the effects on neurons, and this may have lead to more reliable data. 
However, glia cells play crucial roles for instance in the control of the neuronal 
microenvironment and clearing of apoptotic cells, and are involved in chronic pain and 
can thus direct neuronal function (Hanani, 2005, Wu et al., 2009, Hanani, 2010b, 
Hanani, 2010a). Their reduction after mitotic inhibition might have affected the 
signalling responses in neurons including Trk signalling. Therefore although this cell 
model of primary cells with endogenously expressed Trk and RPTP proteins still has 
more advantages than an overexpression system, it will be of added benefit if future 
studies could be performed on a specific, selected population of neurons. For this 
purpose a generation of Trk expressing cells using embryonic stem cells like in other 
studies on Trk receptors (Nikoletopoulou et al., 2010) would be a good alternative.  
 The second major obstacle in my study was the lack of RPTP-specific antibodies 
and good antibodies against Trk phosphorylation sites. RPTP-specific antibodies are 
especially important for the assessment of an actual knockdown on the protein level, 
and this could be alternatively assessed in over-expression studies of tagged-RPTPs for 
instance in HEK293T cells. The phospho-Trk antibodies were especially difficult to use 
on lysates from a limited amount of primary cells despite enormous efforts to improve 
WB conditions. Possibly an increase in cell material might improve these issues as 
several of the antibodies worked on over-expressed samples but not on lysates from 
primary cells (data not shown). These Trk-specific antibodies are especially important 
because many of the Trk downstream signalling pathway components such as Erk, Akt, 
PLCγ, and PI3K etc. are also used by other growth factors and cytokines etc. For 
instance FGFR stimulation leads to increased activation of the MAPK, PI3K, PLCγ and 
Akt pathways (Huang and Reichardt, 2003) and FGF is also involved in neurite 
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outgrowth in PC12 cells (Togari et al., 1985). For this reason in order to test whether 
the effect of RPTP knockdown is mediated through Trks and not FGFR, EGFR etc., 
inhibitors against FGF/EGF etc. receptors could be used in addition to Trk specific 
antibodies. However, the selectivity of some inhibitors is questionable and has to be 
tested extensively first.  
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Analysis of the interaction of Trk receptors and RPTPs 
using a Bimolecular Fluorescent Complementation Assay 
(BiFc) 
7.  
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7.1. Introduction 
Protein-protein interactions (PPIs) describe a physical association between different 
proteins, which is essential for their function (Papin et al., 2005). Thus it is important 
for the characterization of the function of these proteins to identify their binding 
partners. Therefore in order to understand a possible direct function of RPTPs on Trk 
receptors their interaction has to be examined. For this reason the aim of this chapter 
was to establish an assay to analyse the direct interaction of RPTPs and Trk receptors. 
 Several different assays have been developed for the analysis of PPIs, such as 
yeast two-hybrid (Y2H) assays and co-immunoprecipitation (co-IP), or the direct 
visualization of protein interactions in vivo using Förster resonance energy transfer 
(FRET) assays or protein fragment complementation assays (PCAs). The latter is a 
simple direct visualization technique, which is based on the split of a reporter protein 
into two non-functional fragments linked to two possibly interacting proteins. When the 
proteins associate with each other, the two reporter fragments come together and  
form a functional reporter molecule. Depending on the reporter molecule such as  
β-galactosidase, ubiquitin, luciferase or fluorescent proteins (FPs), different PCA assays 
have been developed (Kerppola, 2008, Morell et al., 2009).  
 One such PCA assay is the Bimolecular fluorescent complementation (BiFc) 
assay, which utilizes as a reporter molecule a split FP such as the enhanced yellow 
fluorescent protein (EYFP) or its less temperature-sensitive mutant Venus (Hu and 
Kerppola, 2003, Shyu et al., 2006). The principle behind BiFc is very simple. The two 
proteins of interest are both covalently linked to a complementary FP fragment that 
upon interaction of the proteins associate with each other and form a functional FP, 
which can be simply detected with an inverted fluorescent microscope in living cells 
(Hu et al., 2002). BiFc assays can be used in a plethora of applications to answer many 
different questions. It is possible to use BiFc assays to detect PPIs in vitro and in vivo in 
almost any cell type and in specific subcellular compartments, and it allows the 
detection of interactions in response to developmental, environmental etc. changes. 
 BiFc assays have also many advantages compared to other protein interaction 
assays such as the Y2H assays, Co-IPs and the other in vivo method FRET. For instance 
Y2H assays would have the disadvantage of potential false post-translational 
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modifications of mammalian proteins as it is carried out in Saccharomyces cerevisiae, 
which might affect their interactions with other proteins. Co-IP, another widely 
accepted method to analyse protein interactions, depends on high affinity of the 
interacting proteins with each other and on the availability of specific antibodies. This 
problem can be overcome by introducing covalently bound tags such as HA or myc, 
which however might interfere with protein folding or might become inaccessible for 
the antibodies. Additionally cell lysis and mixing of contents from different subcellular 
compartments might change protein interactions. In contrast to this, since a BiFc assay 
is performed in living cells, not only is the environment of the proteins accounted for 
but also experimental manipulations, which can alter the results, are minimized (Hu et 
al., 2002). Especially the endogenous environment of the proteins is of great importance 
since proteins have specific functions in different cell types and respond differently to a 
variety of extracellular signals, in different subcellular localizations, and at different 
developmental stages of the cell, which all determine the availability of interacting 
partners. However, like any other technique, the BiFc assay has its limitations. One 
main disadvantage is the delay between the interaction of the proteins and the time 
when fluorescence can be detected due to the slow folding of the protein fragments and 
the autocatalytic cyclization reactions required to produce a functional fluorophore  
(12-24 hours). Therefore detection of real-time interaction is not possible with BiFc. 
Additionally, this reaction is irreversible and does not allow the detection of association 
and dissociation of the interacting proteins. However, because of this permanent 
interaction, this assay is very sensitive and can detect even very weak transient 
interactions between proteins (Kerppola, 2008).  
 BiFc assays have been successfully used to demonstrate different PPIs and were 
also expanded to visualize multiple protein interactions to detect competition between 
different interaction partners based on the formation of fluorescent complexes with 
different spectra. The majority of these BiFc studies however analysed interaction of 
cytoplasmic proteins or receptor-type proteins in combination with cytoplasmic 
proteins. Very few studies have been documented with receptor-type proteins only like 
RPTPs and Trks. For instance one study has used BiFc to monitor homodimerization of 
the α1b-adrenoceptor and its mislocalisation due to introduced mutations (Lopez-
Gimenez et al., 2007). Another study analysed the formation of the adenosine A2A and 
the dopamine D2 receptors in neuronal cells using multicolour BiFc (Vidi et al., 2008). 
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And an earlier study has also shown the interaction of the amyloid precursor protein 
(APP) with Notch receptors. It was reported that these heterodimers produced the 
strongest fluorescence signals in comparison to weaker signals of the APP homodimers 
and almost no signals of the Notch homodimers. This is in agreement with findings that 
APP but not Notch receptors form homodimers and these were therefore used as 
positive and negative controls (Chen et al., 2006a). Additionally, another PCA method 
was used to successfully detect and analyse dimerization and activation of 
erythropoietin receptors (EpoRs) upon ligand-binding using the dehydrofolate reductase 
(DHFR) as a reporter (Remy et al., 1999). These studies demonstrate that it is indeed 
possible to perform successful BiFc or other PCA assays also on receptor-type proteins 
such as RPTPs and Trks under topological constrains. 
 
A direct and selective interaction of RPTPs with Trk receptors has been previously 
shown using co-IPs. For instance RPTPσ but not RPTPα was demonstrated to 
selectively and strongly bind to TrkA and C, but only weakly to TrkB (Faux et al., 
2007). Further, also LAR co-immunoprecipitates with TrkA and TrkB either via direct 
interaction or in a complex for instance with Src, as Src knockdown prevented  
TrkB-LAR co-immunoprecipitation (Xie et al., 2006, Yang et al., 2006). Apart from the 
fact that co-IPs have several disadvantages as pointed out above, more than one assay 
has to be used in order to prove a genuine PPI. Therefore in these experiments we have 
assessed the functionality and specificity of a BiFc assay to analyse the potential 
interactions of RPTPs with Trk receptors.  
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7.2. Experimental procedures 
7.2.1. Cloning of BiFc constructs 
7.2.1.1. Cloning strategy  
The host plasmids pEYFP1 or pEYFP2 containing an N-terminal YFP 1 or a C-terminal 
YFP2 fragment in pcDNA3.1 were used for cloning of the negative controls (RPTPα 
and CD34) and the TrkA constructs. These plasmids were modified versions of the 
zipper-EYFP plasmid kindly provided by JF Paradis in SW Michnick’s lab. The zipper 
between the NotI and ClaI RE sites in front of the linker was deleted and an XbaI RE 
site was introduced for non-directional cloning. The XbaI site following the YFP 
fragment was deleted. The flexible linker consists of 12 glycines and serines 
(GGGGSGGGGSSG). The RPTP or TrkA sequences were PCR amplified with primers 
containing an XbaI site and ligated into the host plasmids in reading frame with the 
linker and the YFP fragment. Their expression was driven by the cytomegalovirus 
(CMV) promoter. I will refer in this thesis to YFP1 as VNT and YFP2 as VCT in 
respect to plasmids provided by Dr. Radu Aricescu (see below). YFP1/VNT and 
YFP2/VCT interact with each other and form a functional fluorophore. 
 
 
 
 
 
 
 
 
 
Figure 7.1. Schematic representation of truncated BiFc constructs.  
TM = transmembrane domain (~ 24 aa), ECD = extracellular domain, linker consisting of 12 aa, 
VNT/YFP1 and VCT/YFP2 are N- and C-terminal Venus or eYFP fragments respectively. 
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7.2.1.2. BiFc constructs  
Two types of constructs were generated. They contained either a cDNA sequence 
encoding the full-length TrkA or RPTP protein, or a truncated version, which mostly 
contained the ECD and the TMD. To design the truncated BiFc constructs the RPTP or 
TrkA annotated sequences were retrieved from the NCBI database 
(http://www.ncbi.nlm.nih.gov/nucleotide/) and examined thoroughly to identify the 
Kozak consensus sequence and the TMD using primarily the program Protean 
Lasergene® (DNASTAR) and entries from a variety of databases such as 
UniProtKB/Pfam (http://pfam.sanger.ac.uk/) as references. The Kozak consensus 
sequence is a short recognition sequence that greatly facilitates the initial binding of 
eukaryotic mRNAs to the small subunit of the ribosome. The consensus sequence for 
initiation of translation in vertebrates is known to be (GCC)RCCAUGG with R 
representing a purine (A or G) and contains the start codon AUG (Kozak, 1987). The 
TMD consists mostly of hydrophobic amino acids (aa) and was identified using the 
Kyte-Doolittle-hydrophobicity plot. Once these sequence regions were located PCR 
primers were designed upstream the Kozak sequence and 11 aa downstream of the 
TMD. The 11 aa bridging the TMD and the linker were included in the sequence design 
to match further constructs kindly provided by Dr. Radu Aricescu (see below).  
 
 pEYFP-TrkA-TM-VNT/VCT and -FL-VNT/VCT constructs 
For the generation of the target constructs TrkA-FL- and TrkA-TM-VNT or -VCT a 
template plasmid containing a chimera of a mouse and rat TrkA sequence was used for 
PCR amplification (pSP72-TrkA, originally provided by Dr. Elspeth in Dr. S. Meakin’s 
lab, Roberts Research Institute, Ontario, Canada). The first 220 bp of the TrkA 
sequence corresponded to mouse TrkA (NM001033124), whereas the rest was a rat 
TrkA sequence (NM021589). The mouse sequence encoded the signalling peptide (bp 
62-164), which is usually cleaved off after the transport of the mRNA to its target 
location, and the first amino acid of the TrkA protein, which was a valine instead of a 
threonine. The TrkA-TM-construct covers bp 56-1429 and the TrkA-FL construct 
covers bp 56-2455 of rat TrkA cDNA (NM021589). 
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 pEYFP-RPTPα-TM-VNT/VCT constructs 
pSG-HA-RPTPα-P135-C and pSG-HA-RPTPα wild type plasmids containing the 
murine Ptpra cDNA sequence (NM_008980) in-frame with an N-terminal 
Haemagglutinin (HA)-tag at bp 25-79 were used as templates for the PCR reaction 
(kindly provided by Prof. J. den Hertog). pSG-HA-RPTPα-P135-C plasmid contains a 
functional mutant of RPTPα, which was generated by site-directed mutagenesis of the 
Phe residue at position 135 in the ECD to a Cys residue, resulting in a disulfide bridge 
between monomers and thus constitutive dimerization of the molecule and consequently 
its inactivation (Jiang et al., 1999). The TMD was located at bp 711-785. The final 
constructs contained bp 272-818 of the RPTPα cDNA (NM_008980). 
 
 pEYFP-CD34-TM-VNT/VCT constructs 
The plasmid MPSVleader71tCD34scTKhz containing the human CD34 cDNA kindly 
provided by Dr. Hong in Dr. Kenth Gustafson’s lab (MIU, ICH) was used as a template. 
The human CD34 gene encodes two protein isoforms due to alternative splicing: 
isoform CD34-F, the “canonical” sequence, and CD34-T, which lacks the aa 329-385 
and encodes GEDP instead of ELEP at aa 321-328. The provided CD34 encodes CD-F 
but the first 12 aa are missing in the signalling peptide. The TMD corresponds to  
bp 1129-1191. The PCR product covered bp 295-1230 of the hCD34 cDNA 
(NM_001025109). 
 
 pHLsec-CD45/RPTPσ /LAR-TM/FL-VNT/VCT constructs 
Several constructs (Table 7.1) contained human or chick truncated or full-length CD45, 
RPTPσ or LAR sequences in the pHLsec plasmid and were kindly provided by  
Dr. Radu Aricescu (University of Oxford, UK). The pHLsec vector is based on the 
pLEXm backbone and contains additionally a Kozak sequence, a secretion signal 
sequence and a Venus fragment either VNT154 or VCT155 followed by a Lys-His6-tag. 
The RPTP sequences were introduced between the AgeI and KpnI sites and were under 
the transcriptional control of the chick β-actin promoter with an additional CMV 
enhancer (Aricescu et al., 2006). 
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BIFC CONSTRUCT PROTEIN SPECIES REGION PLASMID 
 
rTrkA-TM-VNT TrkA rat ECD+TM pEYFP1 A.S. 
rTrkA-TM-VCT  TrkA rat ECD+TM pEYFP2 V.T. 
rTrkA-FL-VCT TrkA rat full length pEYFP2 A.S. 
hRPTPσ-FL-VCT/VNT RPTPσ human full length pHLsec R.A. 
hRPTPσ-TM-VCT/VNT RPTPσ human ECD+TM pHLsec R.A. 
Cryp-TM-VCT/VNT RPTPσ chick ECD+TM pHLsec R.A. 
Cryp-TM-mV RPTPσ chick ECD+TM pHLsec R.A. 
Cryp-FL-mV RPTPσ chick full length pHLsec R.A. 
hLAR-TM-VCT/VNT LAR human ECD+TM pHLsec R.A. 
mRPTPα-HA-TM-VNT/VCT (Cys-
mut) RPTPα mouse ECD+TM pEYFP1/2 V.T. 
mRPTPα-HA-TM-VNT/VCT (wt) RPTPα mouse ECD+TM pEYFP1/2 V.T. 
CD45 (RO)-TM-VNT/VCT CD45 human ECD+TM pHLsec R.A. 
hCD34-TM-VNT/VCT CD34 human ECD+TM pEYFP1/2 V.T. 
EYFP1 (YFP1/VNT)    pEYFP1 A.S. 
EYFP2 (YFP2/VCT)    pEYFP2 A.S. 
 
Table 7.1. BiFc constructs.  
The constructs were cloned by Dr. Andrew Stoker (A.S.), Dr. Radu Arcescu (R.A.) and Viktoria 
Tchetchelnitski (V.T.). EYFP1=VNT154, EYFP2=VCT155. 
 
7.2.1.3. Cloning techniques 
All general cloning techniques were described in section 1.1. 
Briefly, 5 µg of the host plasmid were digested with XbaI and purified using the 
QIAquick PCR purification Kit, then treated with AP to prevent self-ligation and 
purified again. The RPTP or Trk sequence was PCR amplified with specifically 
designed primers containing an XbaI restriction site (Table 7.2) using plasmids 
described above as templates. The PCR product was gel purified, digested with XbaI 
and then purified using QIAquick PCR purification Kit and finally ligated into the 
digested host plasmid. Recombinant plasmids were subjected to analytical RE digest to 
confirm the predicted maps. Finally the plasmids were sequenced with custom primers, 
which annealed to the XbaI site (F, forward primer) and the VNT or VCT (R, reverse 
primer) for all products, apart from TrkA-FL, which needed additional sequencing 
primers in the middle of the sequence (Table 7.3). 
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Table 7.2. Cloning primers. 
 
 
Table 7.3. Sequencing primers. 
 
7.2.2. Transfection of HEK293T cells with BiFc constructs 
HEK293T cells were seeded at a density of 50% the day before transfection in a  
12-well-plate. The cells were transfected with 1 or 0.5 µg of each BiFc plasmid per well 
using CaPO4 as described in 2.5.1.3. Pictures were taken 48 h after transfection as 
described in section 2.6. The exposure times for eGFP were 2, 1, 0.5 and for BF 
0.25 sec and 8 msec. 
 
 
 
 
PRIMER SEQUENCE (5’   3’) TM (°C) 
mRPTPα–TM F GG-TCTAGA-TCTTGTCCTGTTTGGCAGTG 60.5 
mRPTPα-TM R GG-TCTAGA-ATGACTCCCAGCTTGCTTGT 61.9 
rTrkA-FL  GG-TCTAGA-GATCCCAAATTTGCTCCTCTGTCCACA 61.9 
hCD34-TM F GG-TCTAGA-ATGCCGCGGGGCTGGACC 68.5 
hCD34-TM R GG-TCTAGA-CAGCCTTTCTCCTGTGGG 62.1 
PRIMER SEQUENCE (5’   3’) TM (°C) 
F EYFP1/2 CCAAGCTGGCTAGCGTTTA 52.6 
R EYFP2 (VCT) CGATGTTGTGGCGGATCT 55.6 
R EYFP1 (VNT) TCCAGCTCGACCAGGATG 61.1 
TrkA FL iF TCTCCTTCAGTGCCTTGACA 57.3 
TrkA FL iR CAAGAAGAATGTGACGTGCTG 57.3 
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7.3. Results 
7.3.1. Design of BiFc plasmids and experiments 
The workflow of a BiFc assay is rather straightforward. Constructs, which contain a 
complementary FP fragment covalently bound to the protein of interest, are transfected 
into living cells such as HEK293T cells and fluorescence is detected with an inverted 
fluorescent microscope after a certain time.  
 The most challenging part for a successful BiFc experiment is the design of the 
constructs. Several important criteria have to be met. For instance the linkers between 
the protein of interest and the FP fragments are crucial, as they determine whether an 
interaction will occur and whether it is specific. These linkers usually consist of a 
flexible serine and glycine sequence of around 10-12 aa and are empirically chosen. The 
positioning of the FP fragments at the N- or C-terminals of the proteins of interest 
depends on the expected association of the binding partners. Further, it is important to 
express the fusion proteins close to endogenous levels, since high expression levels 
might result in non-native interactions, complex mislocalisation or spontaneous 
reassembly of the FP fragments. This can be achieved by using weak endogenous 
promoters or alternatively transfection with low amounts of plasmid DNA. It is 
especially important to control for the specificity of the assay using negative controls. 
Such controls could be the substitution of the protein partners with a known  
non-binding polypeptide or the introduction of mutations, which reduce or eliminate 
protein interaction. It is also important to swap the FP fragments in the constructs to 
ensure this does not cause any changes in the read-out. Finally, it has also to be 
established whether the YFP fragments interfere with the folding of the proteins by 
changing the position of the fragments in the fusion proteins (Kerppola, 2006, Morell et 
al., 2009).  
7.3.2. Interaction of BiFc constructs in HEK293T cells 
In this study we have assessed the interaction of rat TrkA receptors with chick, mouse 
or human RPTPs and other receptor proteins in HEK293T cells. We used either full-
length (FL) proteins or truncated (TM) versions containing only the ECD and the TMD 
with a C-terminally bound YFP/Venus fragment (Figures 7.1 and 7.2). As positive 
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controls LAR and RPTPσ constructs were used, based on previously reported 
homodimerization and interaction of these RPTPs with Trk proteins (see previous 
chapters). This allowed us to assess the functionality of this assay. Further, to assess the 
specificity of the assay, we used RPTPα, CD45 and CD34 as negative controls with no 
previous records of an interaction with Trk receptors. In fact, RPTPα was previously 
even shown not to interact with TrkA directly in a co-IP study (Faux et al., 2007). In 
this study, we have used a constitutively dimerized mutant (Jiang et al., 1999, van der 
Wijk et al., 2005) as well as a wild type form of RPTPα. The leukocyte common 
antigen CD45 is expressed exclusively in hematopoietic cells, where it is involved for 
instance in the regulation of the activity of the SFKs Lck in T cells and Lyn in B cells 
(Trowbridge and Thomas, 1994). In this study we used the shortest isoform, CD45RO, 
which is specifically located on T cells (Tonks et al., 1990, Lammers et al., 1993, Way 
and Mooney, 1994). CD34 is a monomeric cell surface glycophosphoprotein and 
adhesion molecule that is expressed on early lympho-hematopoietic stem and progenitor 
cells, embryonic fibroblasts and small-vessel endothelial cells (Krause et al., 1996).  
 
 
 
Figure 7.2. Different combinations of truncated and full-length BiFc constructs.  
Displayed are representative combinations of a) full-length and b-g) truncated TrkA, different 
types of RPTPs (both were described in more detail in Figures 1.1 and 1.2) and the heavily 
glycosylated CD34 receptors, which were used in the BiFc assay. VNT/YFP1 and VCT/YFP2 
are N- and C-terminal Venus or eYFP fragments respectively. 
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7.3.2.1. The positive controls RPTPσ  and LAR do interact with TrkA 
The RPTPσ-FL- or TM-VNT/VCT and LAR-TM-VNT/VCT constructs formed 
homodimers in our BiFc assay as expected (summarized in 1.2.1) (Figure 7.2G-L). The 
transfected cells looked healthy and very bright fluorescent signals localized to the 
plasma membrane were visible. In contrast to this, fluorescent cells transfected only 
with TrkA-TM constructs were mostly small in size and their frequency was very low 
(Figure 7.2I). Our experiments were performed without NGF and therefore although a 
high level of Trk expression usually leads to their ligand-independent dimerization and 
activation, this does not occur frequently. This could explain the low abundance of 
fluorescent cells (Hempstead et al., 1992). The differences in fluorescence intensities 
between TrkA and RPTPσ or LAR constructs could be additionally caused by the 
different promoters that drive their expression and thus control the amount of expressed 
proteins. We have used constructs with either a very strong chick β-actin promoter with 
an additional CMV enhancer in the case of RPTPσ and LAR, but a weaker CMV 
promoter for TrkA. Additionally to fluorescence localized to the plasma membrane, in 
some cells the fluorescent clusters were visible in intracellular compartments. This is 
most probably due to unspecific interaction of excess proteins in constrained spaces 
such as the Golgi apparatus or the endoplasmatic reticulum after translation. When we 
reduced the amounts of plasmid DNA used for transfection from 1 µg to 0.5 µg, this 
unspecific interaction was minimized. All transfections with a single plasmid were 
negative as expected (data not shown). 
 Rat TrkA-TM and human and chick RPTPσ-TM or human LAR-TM constructs 
interacted with each other in the plasma membrane (Figure 7.2A-C). Interestingly also 
the full-length TrkA interacted with truncated RPTPσ or LAR proteins (Figure 7.2E-F). 
The interaction of full-length TrkA with full-length RPTPσ was also observed  
(Figure 7.2D). However the fluorescence signal was very weak and only detectable at 
higher exposure times (1-2 sec longer). An interaction was also not detectable in every 
performed experiment. Similar to the observations made with the TrkA-TM constructs 
alone, the majority of cells transfected with TrkA-FL constructs in different 
combinations with other proteins were detected at low frequency and the cells were 
small in size. The reason for this poor interaction might be the stereochemistry of the 
proteins. Especially in the case of TrkA-FL interaction with RPTPσ-FL the D2 PTP 
domain and the TrkA catalytic domain may point away from each other. This issue was 
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Figure 7.3. Positive BiFc controls: Interaction of RPTPs with TrkA.  
Interaction of A-C) rTrkA-TM-VNT with chick or human RPTP-TM-VCT constructs (exposure 
time 0.7 sec). Interaction of rTrkA-FL-VCT with D) hRPTPσ-FL-VNT constructs and with  
E-F) RPTP-TM-VNT constructs (exposure times 2.5 sec). G-K) Homodimerization of 
truncated TrkA and RPTP or full-length RPTPσ constructs (exposure time 0.7 sec).  
L) Representative bright field picture. C = chick, h = human, r = rat, BF = bright field. Scale  
bar = 5 µm. Arrows point to staining in the plasma membrane and arrow heads to intracellular 
staining. 
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previously an apparent problem in FRET experiments (personal communication from 
Prof. Jeroen den Hertog and Dr. Andrew Stoker). Interestingly, similar to our analysis 
the interaction of APP with the truncated form of Notch was much stronger than with its 
full-length form. The authors suggested two reasons, the different length of the ICD of 
the proteins or an interference of the YFP fragments with the binding (Chen et al., 
2006a). 
 In summary, these results show that all tested constructs formed homodimers, 
and that the TrkA-TM constructs interacted strongly with the RPTPσ- and LAR-TM 
constructs. Additionally, TrkA-FL constructs interacted with RPTPσ- and LAR-TM and 
RPTPσ-FL constructs, however, at lower frequency. Taken together this data 
demonstrate the functionality of the BiFc assay. 
7.3.2.2. The negative controls RPTPα, CD45 and CD34 interact with TrkA  
In order to assess whether the BiFc assay is specific, we have carefully assessed the 
interaction of TrkA with the putative negative control plasmids expressing RPTPα, 
CD45 and CD34. In our experiments the RPTPα- and CD45-TM constructs formed 
homodimers and were thus functional in the BiFc assay (Figure 7.3F, I and J). CD34 
does not normally form homodimers and fluorescence was mostly undetectable in the 
transfected cells (Figure 7.3C). The detected fluorescence in very few cells might 
indicate an unspecific interaction of the YFP fragments on their own due to an  
over-expression of the CD34 constructs. A transient interaction of the YFP halves might 
trap them in a conformation able to form a functional fluorescent protein.  
 When we co-transfected these control constructs with TrkA-TM or TrkA-FL, we 
detected fluorescent cells in every possible combination. However, whereas the positive 
controls RPTPσ and LAR formed very bright fluorophores with TrkA-TM constructs, 
the interaction of RPTPα-TM Cys mutant or wild type form with TrkA-TM was much 
weaker and only detectable at a higher exposure of more than 2 sec compared to 0.5 sec 
for the positive controls. The differences in frequencies and fluorescent signal strengths 
detected might be due to higher amounts of proteins present in transfections with the 
positive controls and CD45 constructs, which had another backbone with a stronger 
promoter than the negative controls RPTPα and CD34. An additional indication for the 
higher protein amounts was also reflected by the presence of cytoplasmic staining  
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Figure 7.4. Negative controls: Interaction of CD45, RPTPα  and CD34 with TrkA.  
Interaction of A-C) hCD34-TM-VNT full-length or truncated rTrkA constructs and homo-
dimerization (exposure time 2 - 2.5 sec), D-F) hCD45-TM-VNT/VCT with full-length or 
truncated TrkA constructs and homodimerization (exposure times 2.5, 2 and 1.4 sec 
respectively), G-J) mRPTPα wt/Cys-TM-VNT/VCT with rTrkA-TM-VCT/VNT constructs or 
homodimerization (exposure time 2.5 sec). K) Representative bright field picture. h = human, m 
= mouse, r = rat, BF = bright field, Cys = cysteine mutation, wt = wild type. Scale bar = 5 µm. 
Arrows point to staining in the plasma membrane and arrow heads to intracellular staining. 
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in cells transfected with the positive control constructs especially in contrast to RPTPα- 
TM. However, specific fluorescent signals localized to the plasma membrane could be 
seen in all transfections with the negative control plasmids and TrkA fusion proteins. 
7.3.2.3. Interaction of RPTP receptors with each other  
When we tested the interaction of all RPTPs and the CD34 receptor in different 
combinations with each other, we observed an interaction of all these constructs (Figure 
7.4). Not only did all TM-constructs interact with each other but also RPTPσ-FL 
interacted with LAR- and CD45-TM (Figure 7.4D and L) and with CD34-TM (data not 
shown). Cells transfected with all of these constructs apart from RPTPσ-FL and  
CD45-TM showed a normal and healthy morphology. In comparison to the interaction 
of CD45-, RPTPσ- and LAR-constructs among each other, all interactions with the 
RPTPα and CD34-constructs were detected at 1-2 sec higher exposure times. Therefore 
once again the constructs driving transgene expression with the strong β-actin promoter 
showed brighter signals possibly due to higher amounts of proteins in the transfected 
cells as mentioned above. 
 
7.4. Discussion 
In this short study I have shown clearly that the BiFc assay does work well with type I 
transmembrane proteins that are known to dimerize such as RPTPσ and LAR and to 
interact with TrkA. However, all tested BiFc constructs, the full-length and truncated 
forms of TrkA receptors, the RPTPs LAR, RPTPα, RPTPσ and further negative 
controls CD45 and CD34, interact with each other in any combination, even though 
with differing fluorescence intensities. This was a disappointment, and at this point it is 
not possible to draw a final conclusion, whether these detected PPIs are specific and 
genuine under the experimental conditions or an artefact due to the current design of the 
assay, or whether these receptor-type molecules are generally unsuitable targets for 
BiFc assays. In order to find an answer to these questions, improvements to the design 
of the BiFc assay must be made.  
 On the one hand, the observed PPIs might be genuine and the analysed proteins 
including the negative controls might indeed interact with each other indirectly or 
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Figure 7.5. Interaction of RPTPs with each other.  
Interaction of A-F) hCD45-TM-VNT with full-length or truncated RPTP constructs (exposure 
times A-E: 0.7-1 sec, F: 2.7 sec), E-J) mRPTPα wt/Cys -TM-VCT with RPTP-TM-VNT 
constructs (exposure times F-J 2.7 sec), K, L) hLAR-TM-VNT/VCT with full-length or 
truncated RPTPσ constructs (exposure times 0.7 sec), M-O) hCD34-TM-VNT with truncated 
RPTP constructs (exposure times M: 1.5 sec, N-O: 2.7 sec). C = chick, h = human, m = mouse, 
r = rat, BF = bright field. Scale bar = 5µm. Arrows point to staining in the plasma membrane 
and arrowheads to intracellular staining. 
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directly. Fluorescence complementation does not require direct interaction of the 
proteins, but only that the YFP fragments are brought close enough together to associate 
and form a mature fluorophore. Therefore it is possible that depending on the design of 
the BiFc assay, an interaction of proteins, which are for instance localized in the same 
complex and/or bound to the same scaffold, might be detected. The intensity of the 
fluorescence has been shown by others to be proportional to the strength of the 
interaction and thus a possible indicator for a direct or indirect interaction. Hereby 
stronger fluorescence levels suggest a direct or close interaction, whereas lower levels 
indicate an interaction within a complex (Morell et al., 2007). For instance in our assay 
the fluorescence intensity from an interaction of RPTPσ and TrkA was high, whereas 
the intensity from the interaction between RPTPα and TrkA was much weaker. In a 
previous study RPTPσ was shown to co-IP with TrkA possibly via a direct interaction, 
whereas RPTPα did not (Faux et al., 2007). The BiFc assay is more sensitive than  
co-IPs and so the interaction between TrkA and RPTPα might be genuine but indirect 
and therefore the signal intensity was much lower. However, the fluorescence intensity 
in our assay should be considered carefully, as we have used constructs with either a 
very strong chick β-actin promoter with an additional CMV enhancer or with a weaker 
CMV promoter. In this respect it was difficult to compare the signals from the 
interactions with the positive controls to the interactions with CD34 and RPTPα, as the 
weaker signals for the latter two might be caused by smaller protein amounts. However, 
the constructs of CD45 or RPTPσ were similar and their interaction with TrkA showed 
equally strong fluorescence levels. CD45 and in this context also CD34 are not 
expressed in the nervous system and a physiological interaction between TrkA and 
these receptors was never reported. Nevertheless, they are in fact coexpressed with 
TrkA in hematopoietic stem cells (Trowbridge and Thomas, 1994, Krause et al., 1996, 
Mulloy et al., 2005). An interaction in our BiFc assay between these receptors may 
therefore possibly be a physiological interaction, although it is unlikely, and might be 
direct.  
 Further, the observed interactions such as the RPTP heterodimerisation might 
also be direct regardless of the intensity of the signals due to the aforementioned 
reasons. In fact heterodimers between different vertebrate RPTPs were previously 
shown and several mechanisms were suggested. For instance an interaction between the 
D2 and D1 domains was proposed (Blanchetot and den Hertog, 2000). However, as we 
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have replaced the entire ICD with the YFP fragments in the majority of the BiFc 
constructs, a direct interaction between different RPTP molecules and other receptors 
might be in fact attributed to the binding of their ECDs or TMDs. In a genetic screening 
system in E.coli, which allows identification and quantitative analysis of TMD 
oligomerization, all 19 analysed human RPTPs formed homodimers through their TMD 
with different strengths (Chin et al., 2005). Similar results were also obtained prior to 
the mentioned study for RPTPα, RPTPσ, RPTP-BR7 and CD45 (Kitamura et al., 1995, 
Jiang et al., 2000, Tertoolen et al., 2001b, Chin et al., 2005, Lee et al., 2007, Noordman 
et al., 2008). The interaction of receptor proteins through their TMD was also suggested 
for homodimerization of ErbB tyrosine kinase receptors, integrins, and TrkA with one 
of its substrates the ankyrin-rich membrane spanning protein (ARMS) (Mendrola et al., 
2002, Arevalo et al., 2004). Additionally, in a co-IP study in our lab RPTPσ and TrkA 
were suggested to interact with each other through their TMD and the immediate 
juxtamembrane regions (Faux et al., 2007). In a recent analysis an interaction of RPTPs 
with Trks was also assessed using a binding assay in COS cells. In this study a soluble 
form of the ECD of RPTPσ interacted with a soluble TrkC-ECD, but not TrkA- or 
TrkB-ECD. This interaction was attributed to the binding between the Ig domain in the 
ECD of RPTPσ and the LRR and Ig1 domains in the ECD of TrkC. Additionally, 
RPTPσ-ECD did not bind in a homophilic manner or to a soluble form of LAR or 
RPTPδ in this assay (Takahashi et al., 2011). If the TMD is in fact responsible for the 
binding between some of the phosphatases and Trks, as previously suggested, the lack 
of an interaction in these experiments might be attributed to the lack of a TMD in the 
constructs. This would support our hypothesis and in addition would point out 
differences in the interaction mechanisms between RPTPs with different Trks. First, in 
our assay, we show an interaction of the TMD-containing TrkA- and RPTPσ-constructs, 
whereas an interaction just between the ECDs of these receptors did not occur in the 
described study. And second, the mechanisms between RPTPσ-TrkA and RPTPσ-TrkC 
interactions seem to involve different domains. And in addition, the RPTPσ-TrkC 
interaction was shown to be trans-synaptic, whereas the RPTPσ-TrkA interaction in our 
BiFc assay occurs in the same cell. But as mentioned above at this point we do not 
know, whether all of our observed interactions are genuine. 
 On the other hand, the detected interactions between different RPTPs, CD34 and 
TrkA might be non-specific and are caused by topological constraints and/or an 
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overexpression of the proteins. Due to the localization of all constructs in the plasma 
membrane at potentially high densities, the target proteins might then come close 
enough together to cause the association of the YFP fragments. Additionally a self-
assembly of the YFP fragments might be independent from the interaction of the target 
proteins causing a background signal, which is a known issue with some BiFc assays 
and new fluorescent proteins are currently being developed to minimize this problem 
(Shyu and Hu, 2008). Generally in order to minimize nonspecific interactions, weak 
promoters should be used to ensure that the target proteins are not over-expressed 
(Cabantous et al., 2005). In our study we have used a very strong and a weaker 
promoter and reduced the amount of plasmid DNA for transfections. However, this was 
still not enough to eliminate possibly unspecific intracellular interactions for some 
constructs. Additionally, the length of the flexible linker (currently 12 aa) could be 
shortened to reduce the chance of a possible self-association of the YFP fragments. This 
could also reduce BiFc detection of proteins, which do not interact directly but are 
localized within a complex (Shyu and Hu, 2008). And at last, additional negative 
controls should be used, such as plasmids with mutations in the potential interaction 
sites in order to prove specific interactions. This would also improve the measurements 
of fluorescent signals as indicators of the strength of the interactions, which might be 
skewed, if different constructs are used. Improving the current design of the BiFc assay 
might then solve the problem of possibly false positives due to unspecific interactions. 
Due to time constraints, I was not able to make these amendments.  
 Independent from our studies and in agreement with our results, Charlotte Coles 
in Dr. Radu Aricescu’s group (University of Oxford, UK) was also performing a BiFc 
assay using some of the same constructs, but with an automated read-out using a 
fluorescence plate reader to measure the intensity of the signals. She has additionally 
performed a dilution curve of DNA amounts to analyse whether there is a specific 
threshold for negative and positive controls. However despite all efforts, she also came 
to the conclusion that it is not possible to distinguish between specific and unspecific 
PPIs using the BiFc assay in its current design (personal communication).  
 To sum up, the current design of the BiFc assay has to be improved in order to 
possibly use this assay for the analysis of the interaction of RPTPs with Trk receptors. 
Also further negative controls should be used. Once the specificity of the assay is 
established, it could have a great potential to be expanded to a high-throughput study, to 
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a competitive analysis using multicolour assays, and also to search for ligands, which 
cause dimerization of RPTPs and similar applications.  
 Alternatively, FRET another promising technique could be used, which similar 
to BiFc also allows direct visualization of PPIs in living cells. It is based on the energy 
transfer between two spectrum-overlapped fluorophores. A donor fluorophore such as 
CFP is linked to a bait protein and an acceptor fluorophore such as GFP is linked to the 
prey molecule. Once the fluorophores come into proximity, which allows FRET, the 
emitted light of one fluorophore activates the other fluorophore, which is visualized by 
the colour of the fluorophore. One of the great advantages of FRET is the possible 
detection of real-time complex formation and dissociation, which is not possible with 
BiFc assays. However, it suffers from several disadvantages such as background signals 
or photo bleaching. The proteins also have to be expressed at very high levels and the 
design of the FRET constructs might be very challenging, as the two fluorophores have 
to be as close together as 100Å for a successful FRET. This requires prior detailed 
knowledge about the structure of the proteins, which is often not available (Jares-
Erijman and Jovin, 2003, Sekar and Periasamy, 2003). In a previous study in Stoker’s 
and also in den Hertog’s labs a FRET approach with RPTPσ or RPTPα constructs was 
not successful due to lack of knowledge about their confirmation (personal 
communication with Dr. Andrew Stoker). However several years later and with more 
information available on the protein structures it might be possible to establish a 
successful FRET assay to determine the interaction of RPTPs with Trk receptors. 
 In the end, all mentioned methods in this study such as BiFc, FRET, Y2H and 
co-IP not only vary in their sensitivity but might also provide different results. 
Therefore in order to prove a real interaction between proteins more than one assay has 
to be employed. Several methods can also be combined with each other such as BiFc 
and FRET for instance to analyse oligomerization of proteins (Vidi and Watts, 2009). 
Nevertheless, all of these PPI assays are based on over-expression of the proteins of 
interest and their actual coexpression and interaction has to be confirmed under 
physiological conditions such as in animal models. 
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The story of NTs began over half a century ago, when Levi-Montalcini, Cohen and 
Hamburger discovered NGF. This groundbreaking finding was crowned with the Nobel 
Price in Physiology or Medicine in 1986 and started a long history of NT research. The 
role of NTs remains of most importance in the nervous system, where they control cell 
survival, precursor proliferation, commitment, and axon and dendrite growth and 
guidance of neurons as well as synapse formation, function and plasticity in the 
developing and adult PNS and CNS. Additionally, they also have important 
immunotrophic and metabotrophic functions and play a crucial role for instance in 
cardiac development, neovascularisation and the immune system. Their relevance is 
most apparent from their implication in the manifestation of several human genetic, 
neurodegenerative, and inflammatory, cardiovascular or metabolic diseases and 
carcinogenesis. The discovery of Trks several decades after the identification of their 
ligands, the NTs, stimulated this research area greatly. However, despite extensive 
studies on Trk-NT signalling, many questions remain unanswered and this reflects the 
complexity of this subject.  
 For instance one of the most important aspects is the implication of 
phosphatases, the counter-partners of kinases, in Trk signalling pathways. This remains 
poorly understood. A role of several PTPs in Trk signalling has been suggested in the 
literature and an interaction and direct dephosphorylation of Trks by these PTPs has 
been shown. However, because most of these analyses were performed in over-
expression systems, their physiological relevance remains to be demonstrated. 
Unfortunately work with phosphatases is not a trivial task and the progress is obstructed 
by the nature of these PTPs. Not only do they show a promiscuity towards substrates in 
vitro, but the lack of antibodies against these enzymes and a possible compensation by 
other related phosphatases, as well as lack of knowledge about their physiological 
substrates and ligands, all complicate the research and, as a consequence, their 
implication in Trk signalling.  
 Nevertheless, the importance of some phosphatases in Trk signalling is 
unquestionable especially since several PTP knockout mice show mild to severe sensory 
abnormalities. The two main goals of this thesis were hence to identify RPTPs that 
could potentially interact with Trks, and to characterize their function in Trk signalling 
in a knockdown study using a primary cell model of sensory neurons from embryonic 
DRGs.  
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The expression of PTPs and Trks in the same tissue and possibly in the same cells is a 
prerequisite for their interaction. Therefore I have performed an extensive analysis of 
the gene expression of 94 of the 106 known PTPs using qPCR arrays on murine 
embryonic DRGs. I have identified several PTP members with high expression levels 
and noted some interesting temporal expression patterns. Although my further analysis 
was concentrated on RPTPs, an investigation of several other highly interesting PTPs in 
future will be worthwhile. The detailed analysis of the spatiotemporal expression 
patterns of RPTPs in comparison to Trk receptors during development, as well as the 
analysis of the coexpression of these receptor families, was a starting point to select 
candidate RPTPs for further functional analysis.  
 I could clearly show that 13 of the total 21 RPTPs are present in DRGs at 
relatively high levels during organogenesis (E12.5-14.5). Eleven of these RPTPs 
encoded by Ptpra, Ptprd, Ptprf, Ptprg, Ptprj, Ptprk, Ptprm, Ptpro, Ptprr, Ptprs and 
Ptprz1 were in fact previously implicated in neuronal processes in different species in 
the CNS and/or PNS.  
 The spatiotemporal expression patterns of all candidate genes and a further  
in-depth coexpression analysis of the seven strongest candidate RPTPs with Trk 
receptors in murine E13.5 DRGs revealed unique patterns for all analysed phosphatases. 
Among these, the six RPTP genes Ptpra, Ptprd, Ptprg, Ptprr, Ptprf and Ptprs were 
strongly and ubiquitously expressed in almost all Trk+ DRG neurons. Interestingly, in 
contrast to previous reports by other groups, I could also clearly show that Ptprd is 
expressed in DRGs. A small, yet uncharacterised subpopulation of TrkA+ neurons did 
not coexpress Ptprr, Ptprs, Ptprg and Ptprf, and the proportion of TrkA+/Ptprr– was 
particularly high. Over 20 different subtypes of sensory neurons exist in DRGs and it 
would be interesting to analyse which specific subpopulations of TrkA+ neurons lack 
expression of these RPTPs and whether it is actually one subpopulation that does not 
express any of these RPTPs.  
 Together these findings suggest that these phosphatases could feasibly be 
implicated in the signalling pathways of all Trk types. The role of the phosphatases 
RPTPσ, LAR, RPTPR and RPTPγ in Trk signalling was in fact already looked at, but in 
contrast to previous assumptions an interaction with all Trk types is likely, based on 
their coexpression with all Trk receptors in my study. However, especially in regard to a 
lack of an expression in a specific subpopulation of TrkA+ neurons, one might speculate 
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that these RPTPs are also expressed in DRGs for additional reasons not directly related 
to Trk signalling. The data also strongly suggest a functional redundancy in RPTP 
action, since arithmetically most Trk neurons must express a significant cohort of RPTP 
family members.  
 RPTP-BK revealed the most striking gene expression and coexpression patterns 
as it was found in a specific, small subpopulation of DRG neurons unlike any other 
RPTP. The coexpression analysis revealed its presence in all TrkB+ neurons, the 
majority of TrkC+ neurons and around 5% of TrkA+ neurons in E13.5 DRGs. A 
comparison to a previous study by Beltran et al. in E16 DRGs has also unveiled an 
interesting dynamic expression pattern (Beltran et al., 2003). Whereas the TrkC+/Ptpro+ 
population remained constant at around 50%, the TrkB+/Ptpro+ population decreased 
and the TrkA+/Ptpro+ population increased during development. I have also observed a 
similarity in the amount of Ptpro+/TrkA+ and the amount of TrkB/TrkA and 
TrkC/TrkA-coexpressing cells. But the expression pattern of Ptpro is further 
complicated by differences in the amounts of mRNA molecules in different neurons 
(Haworth et al., 1998). It will be of great interest to further analyse the dynamics of the 
coexpression pattern of this RPTP with Trks over its major expression period from  
E12 to E16 in DRGs. Together, these findings hint towards an interesting mechanism 
possibly in the regulation of sensory neuron specification and Trk expression by  
RPTP-BK (see below).  
 Together, this is the first such analysis of the gene expression of almost the 
entire family of PTPs and in particular of eleven RPTPs in murine embryonic DRGs, 
and a comparison of their expression patterns to Trk receptors. The further unique 
coexpression analysis of seven candidate RPTPs with Trk receptors revealed rather 
unexpected coexpression with all three kinases. My investigation also demonstrated that 
many Trk+ neurons express most of these RPTPs, hinting towards a possible functional 
redundancy possibly within an RPTP subgroup as suggested above. On the other hand 
not all RPTPs were expressed in DRGs and this also shows some degree of specificity. 
 In my analysis I have shown the expression of all or the most common neuronal 
isoforms of Trk and RPTP receptors. An even more complete picture of gene expression 
and coexpression would benefit from an analysis of the different isoforms of Trk 
receptors and RPTPs, since these isoforms are differentially expressed and have 
different functions (Forrest et al., 2006).  
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Since coexpression is a prerequisite, but not an ultimate proof for an interaction of 
proteins, I have further analysed the function of the RPTPs LAR, RPTPσ and RPTP-BK 
in Trk signalling in primary dissociated E13.5 DRG cultures. For this, I developed an 
efficient lentivirus-mediated shRNA-induced knockdown assay for silencing particular 
RPTPs in these primary neurons. LAR and RPTPσ are the highest expressed PTPs in 
DRGs and were previously both analysed as possible interaction partners of Trk 
receptors and my expression analysis showed a clear coexpression of these RPTPs with 
all Trk receptors. However, apart from a study of LAR and TrkB in hippocampal 
neurons, the majority of these experiments was performed in over-expression systems 
or PC12 cells, hence these data may lack some physiological relevance. In this respect 
my lentiviral study of endogenous proteins performed in primary DRG cultures may 
have one advantage.  
 The knockdown of LAR and RPTPσ in these cells suggested an inhibitory role 
of LAR and RPTPσ in Trk Y785 dephosphorylation, and in both cases possibly an 
augmenting effect on the MAPK pathway but no effect on the Akt pathway  
(Figure 6.7). This suggests an involvement of both RPTPs in the control of the Trk-
mediated PLCγ signalling pathway, possibly leading to the control of synaptogenesis or 
MAPK- and Akt-independent neurite outgrowth. However, these signalling mechanisms 
remain largely unknown and my findings represent a good starting point for further 
investigation. Interestingly, while the similarities in the effects of the knockdown of 
both phosphatases suggest potential functional redundancy, they also show that removal 
of single RPTPs is still sufficient to moderately perturb the system. It would therefore 
be worthwhile to analyse a double knockdown of both RPTPs, especially since no  
LAR/ RPTPσ double-knockout mice are available, to address this very important issue. 
 The important role of RPTP-BK in Trk+ sensory neurons is undoubted since 
RPTP-BK-/- mice clearly display proprioceptive (TrkC) and nociceptive (TrkA) 
abnormalities and neurite guidance defects (Gonzalez-Brito and Bixby, 2009).  
RPTP-BK was also previously suggested to interact with Trks and particularly it was 
shown to dephosphorylate TrkC receptors (Hower et al., 2009). My coexpression study, 
however, clearly shows a coexpression of this phosphatase with all three Trk receptors, 
which makes an interaction with all Trk types possible. The results from my knockdown 
study showed contradicting effects on the dephosphorylation of Trk Y785 by this 
phosphatase and no effects on the MAPK or Akt pathways. Subsequent studies are 
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required to draw conclusions from this analysis concerning an implication of RPTP-BK 
in the Trk signalling cascade.  
 One striking and unexpected finding in these knockdown experiments was the 
very strong downregulation of Ntrk1 gene expression and to some extent also of Ntrk2 
and Ntrk3 upon very efficient Ptpro downregulation with five different small hairpins. 
Although these changes were not reflected on the protein level, but this might be caused 
by compensating translational mechanisms and requires some additional research. 
Together with my results from the coexpression analysis of RPTP-BK with Trk 
receptors, these data fit the hypothesis of a potential regulation of Trk expression and 
therefore sensory neuron specification by RPTP-BK. This raises a whole lot of new 
questions and with additional findings from many independent previously reported 
studies my results represent pieces of a puzzle that creates a possible picture of  
RPTP-BK function and strengthens its case in the specification of Trk neurons  
in DRGs.  
 The first piece of the puzzle comes from the comparison of the phenotypes of 
RPTP-BK -/- mice and other mouse models. RPTP-BK-/- mice display proprioceptive 
and nociceptive abnormalities such as neurite guidance defects and the loss of the 
response to thermal pain and an additional downregulation of the calcitonin gene-related 
peptide (CGRP) on TrkA+ neurons by 50%, but with no significant changes in the total 
amount of neurons in DRGs (Gonzalez-Brito and Bixby, 2009). In comparison, mice 
with abnormal expression of the TFs Runx1 and Runx3 revealed similar nociceptive 
and proprioceptive defects (Gonzalez-Brito and Bixby, 2009). For instance an 
overexpression of Runx1 resulted in a similar phenotype as observed in the RPTP-BK-/- 
mice (Chen et al., 2006b, Dykes et al., 2010) and Runx1-/- animals show an increase in 
the amounts of TrkA+, TrkC+ and CGRP+ neurons displaying a negative regulation of 
TrkA and TrkC expression in DRGs by Runx1 (Yoshikawa et al., 2007). Therefore an 
antagonizing effect of RPTP-BK on Runx1 was suggested (Gonzalez-Brito and Bixby, 
2009). However, Runx1 function differs at early and late stages of development. At 
early embryonic stages it does in fact initiate TrkA expression and suppresses TrkB 
expression, whereas approximately after E17 Runx1 suppresses TrkA expression in 
favour of Ret expression (Molliver and Snider, 1997, Molliver et al., 1997, Chen et al., 
2006b). Further, RPTP-BK-/- mice display a similar phenotype as Runx3-/- mice in terms 
of neurite guidance defects of proprioceptive neurons (Arber et al., 2000, Inoue et al., 
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2002), but RPTP-BK-/- mice show also defects in neurite guidance of nociceptive 
neurons. Runx3 drives the generation of TrkC+ neurons and represses the generation of 
TrkB+ neurons (Kramer et al., 2006, Inoue et al., 2007, Dykes et al., 2010) and 
interestingly, Runx3-/- mice show a decrease in the amounts of TrkA+, TrkC+ and 
CGRP+ neurons (Nakamura et al., 2008). Therefore RPTP-BK might also play an 
agonistic effect on Runx3.  
 The second piece of the puzzle comes from the comparison of the previously 
reported expression patterns of Runx genes with Ptpro and my coexpression data of 
Ptpro with Trk receptors in E13.5 DRGs. Ptpro expression begins at E12 and shows a 
peak between E16 until P3 (Van Vactor, 1998). Runx3 expression in DRGs has an onset 
at E10.5 and a decline from E16 on. And in contrast to Ptpro no coexpression with 
TrkB was detected, which is not surprising as it represses TrkB expression (Levanon et 
al., 2002). In contrast to this, Runx1 expression begins at E12.5 and in addition to TrkA 
neurons it is also expressed in TrkB and TrkC neurons (Chen et al., 2006b). And so 
Runx1 suggests the highest similarity in gene expression to RPTP-BK. To confirm 
these assumptions, a coexpression analysis of RPTP-BK with Runx1 and Runx3 could 
be performed.  
 The third piece of the puzzle comes from my knockdown analysis. A possible 
downregulation of Ntrk1 upon Ptpro knockdown but not to such an extent of Ntrk2 and 
Ntrk3 also hints mainly towards a regulation of Runx1 expression or function by  
RPTP-BK. However, in contrast to the comparison of the knockout animals above, in 
this scenario RPTP-BK would rather hint towards an agonistic role to Runx1. This 
might be explained by the different functions of Runx1 at early and late stages.  
 Several further pieces of the puzzle support a general role of RPTP-BK in 
sensory neuron specification. For instance Ptpro was identified as a target gene of  
Wnt signalling, with Wnt3a as a possible ligand for RPTP-BK (Kim et al., 2010). The 
Wnt/β-catenin pathway is known to drive NCCs towards a sensory fate (Le Douarin and 
Kalcheim, 1999) and might so implicate RPTP-BK in this process. 
 Recently another puzzle piece was found when Met, a HGFR kinase, was shown 
to be required for Runx1 extinction and differentiation of peptidergic CGRP+ 
nociceptors together with TrkA, whose expression is downregulated in RPTP-BK-/- 
mice. Additionally, Runx1 represses Met expression in non-peptidergic neurons 
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(Gascon et al., 2010). Met is a kinase and a substrate for some RPTPs such as DEP-1 
(Palka et al., 2003) and LAR (Kulas et al., 1996) and could as well be a substrate of 
RPTP-BK. It will be intriguing to analyse Met as a potential substrate and link of 
RPTP-BK to Runx and thus the control of sensory neuron specification.  
 And at last Runx (Kaminker et al., 2002, Kramer et al., 2006) and RPTP-BK 
(Desai et al., 1996, Krueger et al., 1996, Sun et al., 2000b, Stepanek et al., 2001) were 
both implicated in axon targeting and guidance in many different studies and knockout 
mice of either protein also show defects in neurite guidance (Arber et al., 2000, Inoue et 
al., 2002). Hence these proteins were once again implicated in the same processes. 
 In this respect my results provide one or two valuable and testable puzzle pieces 
for this complex research field, which is however still controversial in some aspects. 
 
In conclusion, this thesis has provided valuable insights into the potential role of RPTPs 
in Trk signalling, possibly pointing towards roles in controlling synaptogenesis, neurite 
outgrowth and also neuronal specification. Further studies will be able to expand this 
analysis and contribute to the understanding and possible control of Trk signalling. The 
very efficient lentiviral knockdown approach, with some important improvements as 
discussed in chapter 6, provides a very valuable tool in this respect. Nevertheless, 
research on the function of RPTPs still remains challenging. My findings further 
support the possibility of a degree of redundancy among some RPTPs, but also some 
specificity. This is especially important if RPTPs are considered as potential drug 
targets possibly to control Trk function, which is deregulated in many different diseases. 
Especially the possibility of the control of Trk gene expression by RPTP-BK opens 
many new doors. Understanding the transcriptional regulation of Trk receptor 
expression is not only of importance to decipher neuronal cell fate specification 
mechanisms, but could in fact also provide new strategies for therapeutic implications 
for the treatment of neurodegenerative diseases, chronic pain, neuropathies, cancers etc. 
For instance Runx3 is a tumor suppressor and TrkB is an oncogene in several tumor 
types including neuroblastoma. Since Runx3 represses TrkB expression in DRGs it 
would be interesting to find out what controls Runx3 function (Inoue et al., 2007) and in 
this context RPTP-BK might be a good candidate. Further, Runx1 controls the 
development, survival and function of the majority of nociceptive neurons by 
controlling for instance the expression of TrkA and many ion channels (Chen et al., 
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2006b, Marmigere et al., 2006) and RPTP-BK may well be implicated in the control of 
Runx1 expression and/or function. It is therefore of great importance to decipher these 
transcriptional pathways for instance in regard to future pain therapies.  
 This thesis thus provides novel data about the potential functional interactions 
and co-expression dependencies of RPTPs and Trk enzymes in primary sensory neurons 
and suggests several starting points for further research that will lead to an 
understanding of the complex, functional interactions between Trks and RPTPs and 
their possible implication in disease. 
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Chapter 2 
 
 
 
 
 
 
Figure 1. Specificity of Trk antibodies on WBs.  
The antibodies against TrkA, TrkB and TrkC ECDs detected all isoforms of TrkA, TrkB or 
TrkC receptors respectively in transfected HEK293T cells on WBs.  No cross-reaction with any 
of the other Trk receptors was detected. The panTrk antibody detected the ICD and hence only 
the full-length isoforms of all three Trk receptors. M = marker. 
 
 
Appendix 
 
  280 
 
 
 
 
 
Figure 2. Cross-reaction of pTrk antibodies on WBs.  
The antibody pTrk* = pTrkA recognizes phosphorylated Y785 on TrkA and TrkC and  
pTrk** = pTrkB recognizes phosphorylated Y785 on all three Trk receptors. M = marker,  
SH = small hairpin, kd = knockdown. See chapter 6 for more explanations. 
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  PROTEIN NAME GENE NAME ID NUMBER 
 MKP1 Dusp1 QT00288638 
 PAC1 Dusp2 QT00248283 
 MKP2 Dusp4 QT00140357 
 hVH3 Dusp5 QT01065617 
 MKP3 Dusp6 QT00101997 
 PYST2 Dusp7 QT00155337 
 hVH5 Dusp8 QT00118650 
 MKP4 Dusp9 PPM25836A 
 MKP5 Dusp10 QT00152257 
 MKP7 Dusp16 QT00097272 
M
KP
s 
 MK-Styx Styxl1 PPM34884A 
 FMDSP Dusp1 not existing 
 VHR Dusp3 QT00138467 
 PIR1 Dusp11 QT00104867 
 HYVH1 Dusp12 QT00124600 
 TMDP Dusp13b QT00168882 
 MKP6 Dusp14 QT00284424 
 VHY Dusp15 QT00171605 
 LMW DSP20 Dusp18 QT00119322 
 SKRP1 Dusp19 QT00169624 
 LMW DSP21 Dusp21 QT00267064 
 JSP1 Dusp22 QT00158431 
 MOSP/VHZ Dusp23/25 QT01075487 
 MKP8 Dusp26 QT00112630 
 FMDSP/DUPD1 Dusp27 QT01064378 
 LAFORIN Epm2a QT00261842 
 PTPMT1 Ptpmt1 QT00114772 
 MCE Rngtt QT00151564 
aty
pic
al 
DS
Ps
 
 Styx Styx QT01531992 
 SSH1 Ssh1 QT00165011 
 SSH2 Ssh2 QT00101199 SS
Hs
 
 SSH3 Ssh3 QT00150227 
 PTEN Pten QT00141568 
 TPIP Tpte QT00161126 
 TENSIN-1 Tns1 PPM33341A 
 TENSIN-3 Tns3 QT01557437 PT
EN
s 
 TENSIN-2, C1-TEN Tenc1 QT01066800 
 PRL1 Ptp4a1 QT00156464 
 PRL2 Ptp4a2 QT00143332 
PR
Ls
 
 PRL3 Ptp4a3 QT00138243 
 Cdc14a Cdc14a QT01051764 
 Cdc14b Cdc14b QT01079148 
 KAP1 Cdkn3 QT01561763 CD
C1
4s
 
 PTP 9q22 Ptpdc1 QT00161973 
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continued 
  PROTEIN NAME GENE NAME ID NUMBER 
 MTM1 Mtm1 QT01066079 
 MTMR1 Mtmr1 QT00147070 
 MTMR2 Mtmr2 QT00144795 
 MTMR3 Mtmr3 QT01068655 
 MTMR4 Mtmr4 QT00148757 
 MTMR5 Sbf1 QT01549450 
 MTMR6 Mtmr6 QT00147994 
 MTMR7 Mtmr7 QT00175868 
 MTMR9 Mtmr9 QT00102305 
 MTMR10 Mtmr10 QT01067675 
 MTMR11 Mtmr11 QT00157318 
 MTMR12 Mtmr12 QT00132384 
M
yo
tu
bu
lar
ins
 
 MTMR13 Sbf2 QT00125951 
 CDC25a Cdc25a QT01058778 
 CDC25b Cdc25b QT00127806 
CD
C2
5s
 
 CDC25c Cdc25c QT01055222 
 PTP1B Ptpn1 QT00166418 
 TCPTP Ptpn2 QT01063573 
 PTPH1 Ptpn3 QT00264649 
 MEG1 Ptpn4 PPM35219A 
 STEP Ptpn5 QT01063580 
 SHP1 Ptpn6, Hcph QT00155967 
 HePTP Ptpn7 QT01073611 
 LyPTP Ptpn22/Ptpn8 QT00103943 
 MEG2 Ptpn9 QT00170520 
 SHP2 Ptpn11 QT00103362 
 PEST Ptpn12 QT00168126 
 PTPBAS Ptpn13 QT00097244 
 PEZ Ptpn14 QT01553097 
 BDP1 Ptpn18 QT00097027 
 PTPTyp Ptpn20 PPM25464A 
 PTPD1 Ptpn21 QT00197862 
NP
TP
s 
 HDPTP Ptpn23 QT01560692 
  LMW PTP Acp1 QT00135135 
 GPS1 Gps1 QT00120113 
 HPRT1 Hprt1 QT00166768 
 PSMB2 Psmb2 QT00113701 HK
Gs
 
 UBC Ubc QT00245189 
 TrkA Ntrk1 QT01046143 
 TrkB Ntrk2 QT00132111 Tr
ks
 
 TrkC Ntrk3 QT00146153 
  
 Table 1. qPCR primers used on the qPCR array. 
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Figure 3. ISH with sense Trk and RPTP riboprobes on transverse E13.5 mouse 
cryosections.  
Pictures with corresponding anti-sense probes are displayed in Figures in chapters 3 and 4.  
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Figure 4. ISH on transverse murine E14.5 embryo sections retrieved from GenePaint 
databank.  
Figures of ISH with RPTP and Trk anti-sense probes on sagittal murine E14.5 embryos were 
retrieved from the GenePaint database (www.genepaint.org). Ngfr = p75NTR gene. 
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 TrkA+ neurons TrkB+ neurons TrkC+ neurons 
IHC 75.2 +/- 12.4% (7236) 6.5 +/- 1.5% (2502) 8.1 +/- 3.3% (2984) 
ISH 60.2 +/- 9.7% (1164) 4.5 +/- 1.9% (4454) 9.6 +/- 4% (5297) 
 
Table 2. Percentage of Trk+ neurons in E13.5 mouse DRGs.  
Trk+ and DAPI+ neurons were counted on pictures and the mean percentage and SD of 
unambiguously stained neurons was determined. Total number of neurons counted is included 
in brackets. Displayed in form of a graph in Figure 4.6. 
 
 
 
 
Double ISH (DISH) IHC and ISH 
TrkA+ neurons   
       TrkA+/TrkB+ 1.8+/- 1.5% (805) 1.7 +/- 1.1% (1176) 
       TrkA+/TrkC+  3.0 +/- 1.0% (526) 3.3 +/- 2.1% (1510) 
TrkB+ neurons   
       TrkB+/TrkA+ 33.3 +/- 13.3% (805) 26.7 +/- 13.1% (1176) 
       TrkB+/TrkC+  25.0 +/- 6.7% (214)  
TrkC+ neurons   
       TrkC+/TrkA+ 28.6 +/- 15.3% (526) 26.1 +/- 11.1% (1510) 
       TrkC+/TrkB+  14.3 +/- 3.9% (214)  
 
Table 3. Percentage of Trk coexpression in E13.5 mouse DRG neurons.  
For calculations Trk+ and DAPI+ neurons were counted on pictures and the mean percentage of 
neurons unambiguously stained for the Trk receptors was determined. Mean percentage of Trk 
coexpressing neurons among TrkA+, TrkB+ or TrkC+ neurons and SD were determined for each 
staining technique separately. Total number of neurons counted is displayed in brackets. 
Displayed in form of a graph in Figure 4.6. 
 
 
Table 4. Percentage of RPTP+ neurons in E13.5 mouse DRGs.  
Mean percentages and SD of unambiguously stained neurons from coexpression counting and 
their median (lowest row). Displayed in form of a graph in Figure 4.10. 
Ptpra Ptprd Ptprf Ptprg Ptpro Ptprr Ptprs 
93.2 +/- 2.2 91.5 +/- 2.6 79.3 +/- 14 88.4 +/- 5.5 12.1 +/- 3.4 65.9 +/- 14 92.1 +/- 5.4 
92.5 +/- 1.9 82.1 +/-9.5 95.3 +/- 2.9 94.5 +/- 3 11.9 +/- 1.9 69.6 +/- 6.3 96.7 +/- 0.6 
94.5 +/- 3.1 90.6 +/- 6.2 81.6 +/- 7.5 93.7 +/- 6.2 9.3 +/- 2.8 68.9 +/- 9.3 97.2 +/- 1 
93.2 +/- 2.2 90.6 +/- 6.2 81.6 +/-7.5 93.7 +/- 5.5 11.9 +/- 2.8 68.9 +/- 9.3 96.7 +/- 1 
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Trk+/Rptp+ neurons TrkA+ neurons TrkB+ neurons TrkC+ neurons 
TrkX+/Ptpra+ 98.2 +/- 2.1% 100% 100% 
Ptpra+ /TrkX+ 86.7 +/- 6.1% 3.5 +/- 0.6% 11.8 +/- 2% 
Total neurons 80.8 +/- 5.9% 
(710) 
3.2 +/- 0.5% 
(502) 
11.2 +/- 2.1% 
(567) 
TrkX+/Ptprd+ 97.4 +/- 4.5% 74.2 +/- 21.2% 100% 
Ptprd+ /TrkX+ 84.0 +/- 7.8% 2.7 +/- 1.6% 12.4 +/- 5.5% 
Total neurons  76.8 +/- 7.8% 
(924) 
2.2 +/- 1.3% 
(520) 
11.2 +/- 5% 
(568) 
TrkX+/Ptprf+ 93.3 +/- 3.7% 100% 100% 
Ptprf+ /TrkX+ 81.2 +/- 9.7% 4.3 +/- 0.7% 7.9 +/- 3.1% 
Total neurons 66.1 +/- 10.6% 
(470) 
4.1 +/- 0.7% 
(389) 
6.3 +/- 2.1% 
(534) 
TrkX+/Ptprg+ 91.0 +/- 4.3% 100% 100% 
Ptprg+ /TrkX+ 75.0 +/- 12.5% 5.0 +/- 1.5% 4.2 +/- 0.6% 
Total neurons 64 +/- 7.9% 
(868) 
4.7 +/- 1.2% 
(479) 
3.9 +/- 0.7% 
(533) 
TrkX+/Ptpro+ 5.3 +/- 2.4% 99.0 +/- 3% 78.0 +/- 10.9% 
Ptpro+ /TrkX+ 28.4 +/- 8.4% 56.3 +/- 19% 48.6 +/- 10.7% 
Total neurons 3.5 +/- 1.6%  
(1373) 
6.5 +/- 1.9% 
(996) 
4.6 +/- 1.7% 
(1184) 
TrkX+/Ptprr+ 79.3 +/- 8% 100% 98.7 +/- 4.3% 
Ptprr+ /TrkX+ 90.5 +/- 6.9% 5.6 +/- 2.9% 15.4 +/- 4.3% 
Total neurons 59.1 +/- 11.1% 
(470) 
3.8 +/- 1.8% 
(282) 
10.5 +/- 2.7% 
(1244) 
TrkX+/Ptprs+ 94.1 +/- 2.2% 100% 100% 
Ptprs+ /TrkX+ 77.4 +/- 6.5% 5 +/- 0.2% 7.4 +/- 5.8% 
Total neurons 71.2+/- 6.3% 
(619) 
4.8 +/-0.2% 
(249) 
7.3 +/- 5.7% 
(613) 
 
Table 5. Percentage of Trk and RPTP coexpressing neurons in E13.5 mouse DRGs. 
Trk+, RPTP+ and DAPI+ neurons were counted on pictures and the mean percentage of neurons 
unambiguously stained for Trk receptors and RPTP genes was determined. Mean percentage of 
coexpressing neurons among TrkA+, TrkB+ or TrkC+ neurons and SD were determined. Total 
number of neurons counted is displayed in brackets. A graphical representation of these data can 
be seen in Figure 4.10. 
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Table 6. Transduction efficiency of seven different lentiviral pseudotypes on murine E13.5 
DRG neurons.  
HIV1-derived replication deficient eGFP-lentiviruses (pLNT/SFFV-eGFP-WPRE) were 
pseudotyped with envelop glycoproteins of seven different viruses: Murine Leukaemia Virus – 
Ecotropic (MLV-E), Vesicular Stomatitis Virus (VSVg), Murine Leukaemia Virus – 
Amphotropic (MLV-A), Ross River Virus (RRV), Ebola Zaire (EboZ), Baculovirus gp64 
(gp64), or Hanta virus. The primary sensory neurons were infected with these pseudotyped 
lentiviruses at an MOI of 25, 50 and 100. To determine the transduction efficiency  
165-330 neurons were counted on pictures using Openlab software. Displayed in Figure 5.2. 
 
 
 
 
 
 
 
 
 
MOI  MLV-E VSVg MLV-A RRV EboZ gp64 Hanta 
Total neurons 249 205 189 243 275 331 165 
GFP+ neurons 218 123 0 1 1 5 0 25 
Efficiency % 87.5 60 0 0.4 0.4 1.5 0 
Total neurons 272 224 201 187 181  232 
GFP+ neurons 258 149 0 0 2  0 50 
Efficiency % 94.9 66.5 0 0 1.1  0 
Total neurons 224 216 177 217 215 262 187 
GFP+ neurons 212 172 0 0 2 4 1 100 
Efficiency % 94.6 79.6 0 0 0.93 1.5 0.5 
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Figure 4. Dissociated murine embryonic DRG cultures with and without mitotic 
inhibitors.  
Dissociated DRG cultures from murine E13.5 embryos were cultured either with mitotic 
inhibitors floxuridine (FdUrd; 50 mM) and Uridine (150 mM) or without for 3 or 4 days. The 
amount of neurons and non-neural cells is based on cell counts of 3 to 4 pictures for each 
condition. Upper panel: ICC on dissociated E13.5 DRG cells with a TuJ antibody, which 
recognizes β III-tubulin and thus detects all neurons in the mixed cell culture. This was used as 
a reference to identify the neurons in the cultures.  
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Figure 6. WB on DRG samples from knockout mice.  
DRG samples from knockout mice for WB were kindly provided by Dr. Sheilla Harroch. 
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